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Preface 
This Thesis compiles the work done during my doctoral studies that started in 
2008 at the Instituto de Medicina Molecular (IMM), Faculdade de Medicina, 
Universidade de Lisboa. I gladly joined the Biomembranes Unit, headed by Prof. 
Nuno C. Santos, the supervisor of this Thesis, after I completed one year of 
research training with him, for my 4-years License degree in Biochemistry. I 
received a PhD fellowship from Fundação para Ciência e Tecnologia, Ministério da 
Educação e Ciência (SFRH/BD/42205/2007) which provided me the necessary 
funding to enroll in the Lisbon Academic Medical Centre Doctoral Program in 
Biomedical Sciences at the institution mentioned above. 
The studies done at IMM relate to the membrane action of HIV-1 fusion 
inhibitor peptides using fluorescence spectroscopy methodologies. This theme was 
a common interest with another research unit at IMM, the Physical Biochemistry, 
led by Prof. Miguel Castanho, which we have always interacted closely. This body 
of work is contained in Chapter II. However, my research evolved to explore other 
aspects of viral entry besides the peptide inhibitors and I was fortunate to foster 
collaborations that allowed to do part of my studies abroad. Prof. Ricardo 
Gutiérrez Gallego accepted me in his lab in Barcelona, at the Institut Hospital del 
Mar d'Investigacions Mèdiques (IMIM), to explore interaction of HIV-1 
glycoprotein with glycosaminoglycans. For this I used a surface plasmon 
resonance equipment, a technique that was not available in my lab at the time. The 
results related to his collaboration are presented as a submitted manuscript, in 
Chapter III. In order to seek expertise with a Virology group, I went to Prof. 
Gregory Melikyan’s lab, at the Emory Children’s Center, Emory University 
(Atlanta, USA). Here I studied the actual viral fusion in supported lipid bilayers 
and also with cells, using live confocal microscopy imaging. This work was 
incorporated in Chapters IV and V. 
Overall, my doctoral studies have resulted in the following peer-reviewed 
publications: 
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 Matos PM, Andreu A, Santos NC*, Gutiérrez-Gallego R*. Structural requirements 
of glycosaminoglycans for the interaction with HIV-1 envelope glycoprotein 
gp120. (2013) Submitted for publication (*Co-corresponding authors). 
 Matos PM, Marin M, Ahn B, Lam W, Santos NC, Melikyan GB. Anionic lipids are 
required for Vesicular Stomatitis Virus G protein-mediated single particle fusion 
with supported lipid bilayers. J. Biol. Chem. 288:12416-12425 (2013). Journal IF: 
4.773; Citations: 0 (ISI), 2 (Google Scholar). 
 Hollmann A*, Matos PM*, Augusto MT, Castanho MARB, Santos NC. 
Conjugation of cholesterol to HIV-1 fusion inhibitor C34 increases peptide-
membrane interactions potentiating its action. PLoS ONE 8:e60302 (2013). 
(*Contributed equally to this work). Journal IF: 4.092; Citations: 0 (ISI), 0 (Google 
Scholar). 
 Padilla-Parra S, Matos PM, Kondo N, Marin M, Santos NC, Melikyan GB. 
Quantitative imaging of endosome acidification and single retrovirus fusion with 
distinct pools of early endosomes. Proc. Natl. Acad. Sci. U.S.A. 109:17627-17632 
(2012). Journal IF: 9.681; Citations: 2 (ISI), 5 (Google Scholar). 
 Matos PM, Freitas T, Castanho MARB, Santos NC. The role of blood cell 
membrane lipids on the mode of action of HIV-1 fusion inhibitor sifuvirtide. 
Biochem. Biophys. Res. Commun. 403:270-274 (2010). Journal IF: 2.484; Citations: 
5 (ISI), 7 (Google Scholar). 
 Matos PM, Castanho MARB, Santos NC. HIV-1 Fusion inhibitor peptides 
enfuvirtide and T-1249 interact with erythrocytes and lymphocytes membranes. 
PLoS ONE 5:e9830 (2010). Evaluated “Recommended” by Faculty of 1000 
(http://f1000.com/2953959). Journal IF: 4.092; Citations: 12 (ISI), 16 (Google 
Scholar). 
Reviews: 
 Domingues MM, Matos PM, Carvalho FA, Santos NC. Protein-Biomembrane 
interactions as therapeutic targets. Canal BQ (Journal of the Portuguese 
Biochemical Society), 8:4-11 (2011). 
 
v
 Matos PM, Franquelim HG, Castanho MARB, Santos NC. Quantitative 
assessment of peptide-lipid interactions: Ubiquitous fluorescence methodologies. 
Biochim. Biophys. Acta. 1798:1999-2012 (2010). Journal IF: 3.990; Citations: 15 
(ISI), 19 (Google Scholar). 
 Matos PM, Gonçalves S, Santos NC. Interaction of peptides with biomembranes 
assessed by potential sensitive fluorescent probes. J. Pept. Sci. 14:407-415 (2008). 
Journal IF: 1.799; Citations: 11 (ISI), 16 (Google Scholar). 
Book chapter: 
 Franquelim HG, Matos PM, Veiga S. “HIV vs. HIV: Turning HIV-Derived 
Peptides into Drugs” in Peptide drug discovery and development – Translational 
research in Academia and Industry (2011), Castanho MARB and Santos NC (eds.), 
Wiley-VCH, Weinheim, Germany. Citations: 1 (Google Scholar). 
The four central chapters in this Thesis (II-V) are based on the inclusion of 
the respective article(s), preceded by a small overview explaining their context and 
declarations of authorship. I considered here the articles to be autonomous units, 
in the sense that they have their own sections, figure numbering and references. 
All the content of this book outside the articles or manuscripts are continuous, one 
sequence for figures, tables and reference numbering. All the references are at the 
end of the Thesis. 
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Summary 
Enveloped virus attachment and fusion into the host cells constitutes the first 
and crucial step for the life cycle of a virus and is mediated by the envelope 
glycoproteins. This Thesis aimed to clarify some important factors that influence 
this process and the mechanism of action at the molecular level of drugs that 
inhibit it.  
First, the mode of action of HIV-1 fusion inhibitor peptides at the membrane 
level was studied using fluorescence spectroscopy. Interaction of these peptides 
with human cell membranes was assessed by dipole potential sensitive probes. 
C34-cholesterol, one of the latest generation fusion inhibitors had the highest cell 
membrane affinity, followed by T-1249, enfuvirtide and sifuvirtide. Sifuvirtide 
however showed strong preference for rigid membrane domains, mimicked by 
dipalmitoylphosphatidylcholine (DPPC), while C34-cholesterol strongly 
partitioned to cholesterol and sphingomyelin-rich model membranes. The overall 
results establish a relationship between these drugs antiviral activity and their 
membranotropism towards raft-like membrane compositions, following the trend 
C34-cholesterol > T-1249 > enfuvirtide. The capacity of the peptides to 
concentrate on lipid rafts microdomains, near the cell receptors for the virus, 
would make them more available to bind the viral gp41 in its exposed 
conformation. 
We then focused on another aspect of the HIV-1 entry related to envelope-
receptor interactions, namely with glycosaminoglycans. Their general structural 
requirements of that enable the binding to gp120 were determined by surface 
plasmon resonance. Binding was found to be dependent on sequence type and size, 
preferring heparin and heparan sulfate, with an extension of at least 12 monomers. 
Sulfate groups were essential for the interaction. These results help to understand 
some basic mechanisms of viral attachment.  
Although envelope-receptor interactions play a pivotal role in the viral entry, 
lipids are also relevant. The role of acidic lipids in the viral fusion kinetics of 
vesicular stomatitis pseudoviruses (VSV) was assessed by single-particle imaging 
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on supported lipid bilayers. Phosphatidylserine (PS) and 
bis(monoacylglycero)phosphate (BMP) greatly enhanced the efficiency of 
hemifusion and enabled full fusion. The lag between lipid and content mixing 
defining the lifetime of a hemifusion intermediate were significantly shorter for 
BMP-containing compared to PS-containing bilayers. BMP is a late endosome-
resident lipid and its effect on promoting VSV fusion makes it an important 
modulator on the outcome of viral entry through endocytosis. 
Evolving from model membranes to cells, the internalization and fusion of a 
retrovirus through endocytosis was imaged. A pH-sensor consisting of two fused 
fluorescent proteins mTFP1-eYFP was incorporated in the envelope of an avian 
sarcoma and leucosis virus (ASLV). The pH values were quantified along the virus 
track and varied from 5.6 to 6.5 in early endosomes. Single-virus tracking showed 
that ASLV, upon internalization, are sorted into distinct pools of early endosomes 
with different dynamics, depending on using the two receptor isoforms, TVA800 
or TVA950. 
Overall, this Thesis sheds light on important host factors that influence 
enveloped virus entry and fusion, establishing lipid binding as a key player in the 
action of peptide fusion inhibitors. 
Keywords 
Avian sarcoma and leucosis virus Human immunodeficiency virus 
Confocal microscopy Membrane fusion 
Enveloped viruses Single virus imaging 
Fluorescence spectroscopy Surface plasmon resonance 
Fusion inhibitors Vesicular stomatitis virus 
Glycosaminoglycans Viral entry 
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Sumário 
O ciclo de vida dos vírus depende da sua capacidade de reconhecer as células 
do hospedeiro, ligar-se à sua superfície através de receptores específicos e transferir 
o seu conteúdo genético para o interior dessas células. Deste modo, os 
componentes virais apropriam-se da maquinaria intracelular de modo a 
replicarem-se. Para isso, os vírus envelopados têm de fundir a membrana lipídica 
que os envolve com a membrana da célula hospedeira. As glicoproteínas do 
envelope viral são responsáveis pelo reconhecimento do(s) receptor(es) celular(es) 
e pela mediação desta fusão. No entanto, os mecanismos pelos quais a entrada e 
fusão viral se processam ainda não estão totalmente compreendidos, por exemplo, 
ao nível das interacções envelope-receptor, dos intermediários de fusão e das vias 
de entrada para o interior das células. 
Esta Tese explora detalhes moleculares da aderência, fusão e entrada de vírus 
envelopados usando sistemas modelo de membranas e receptores, além de 
mecanismos de acção de péptidos inibidores do vírus da imunodeficiência humana 
tipo 1 (HIV-1).  
No primeiro capítulo, a influência das membranas no modo de acção de 
péptidos inibidores de fusão do HIV-1 foi estudada usando espectroscopia de 
fluorescência. Estes péptidos inibem as alterações conformacionais da gp41, 
proteína do envelope que permite a fusão da membrana do vírus com a da célula 
hospedeira. Deste modo, o vírus fica impedido de entrar na célula e prosseguir 
com o seu ciclo de vida. O enfuvirtide é o único fármaco deste tipo aprovado até 
agora para uso clínico. No entanto, estudámos também outros péptidos inibidores 
de fusão, mais potentes mas ainda experimentais: o T-1249, o sifuvirtide e o C34-
colesterol, listados por ordem crescente de potência antiviral. Em estudos 
anteriores dos grupos de investigação onde estive inserido, foi estudada a 
interacção dos péptidos enfuvirtide, T-1249 e sifuvirtide com modelos de 
membrana (vesículas lipídicas) de composições definidas. Nós estendemos esse 
conhecimento para estudos com células sanguíneas humanas, eritrócitos e 
linfócitos, usando sondas fluorescentes de membrana sensíveis ao potencial 
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dipolar. Nos primeiros estudos, o T-1249 revelou-se como aquele que interage 
mais com as membranas das células, seguido do enfuvirtide, sendo o sifuvirtide o 
que apresentava menor afinidade. No entanto, estudos adicionais de potencial 
dipolar em vesículas confirmaram a preferência do sifuvirtide para domínios de 
membrana rígidos, mimetizados por modelos de membranas do lípido 
dipalmitoilfosfatidilcolina (DPPC). O membranotropismo de largo espectro, em 
vesículas e células, do T-1249 pode ser um dos factores que explicam a sua mais 
actividade em relação ao enfuvirtide. No caso do sifuvirtide, a alta especificidade 
para domínios rígidos de membrana, as chamadas jangadas lipídicas (lipid rafts), 
pode contribuir também para a sua potência, dado que são os locais onde a fusão 
viral é mais provável de ocorrer a nível das membranas das células.  
O C34-colesterol é um dos inibidores de fusão de última geração, mais 
potente que os referenciados anteriormente. Trata-se de um conjugado formado 
pelo péptido C34 ligado a uma molécula de colesterol. Para este fármaco, foi 
efectuado um estudo completo em sistemas modelo de membranas e células 
humanas. O C34-colesterol teve uma partição substancialmente mais alta para 
vesículas lipídicas e células, comparado com a forma não conjugada, C34. O 
conjugado apresentava uma preferência para composições lipídicas ricas em 
colesterol e esfingomielina, típicas das jangadas lipídicas. De entre todos os 
péptidos estudados, o C34-colesterol apresentava a maior afinidade para as 
membranas das células: em linfócitos, 14 e 115 vezes maior afinidade que o T-1249 
e o sifuvirtide, respectivamente. Ao longo destes estudos da acção dos péptidos a 
nível da membrana, podemos estabelecer uma relação entre actividade antiviral e a 
apetência para ligação às membranas e às jangadas lipídicas, seguindo a ordem 
C34-colesterol > T-1249 > enfuvirtide. Esta correlação pode ser explicada pela 
capacidade destes fármacos se concentrarem ao nível das jangadas lipídicas, onde a 
interacção vírus-receptor, e consequente fusão, é mais provável de ocorrer. A 
grande disponibilidade do péptido nesse local facilita a subsequente interacção do 
péptido com a conformação exposta da glicoproteína gp41.  
Outro aspecto da entrada do HIV-1 relacionado com interacções envelope-
receptor é apresentado no capítulo 2. Este processo, mediado pela glicoproteína do 
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envelope gp120 depende não só do receptor principal CD4 e co-receptores 
CCR5/CXCR4 mas também de receptores adjuvantes que melhoram a aderência 
do vírus às células. Neste caso, foi estudado a interacção da gp120 com 
glicosaminoglicanos, os componentes glicídicos dos proteoglicanos. Estes 
proteoglicanos, principalmente os de sulfato de heparano à superfície das células, 
são muito relevantes na dispersão e patogénese do vírus num contexto de infecção 
do organismo. Determinaram-se genericamente os requisitos estruturais dos 
glicosaminoglicanos que permitem a ligação à gp120, através da técnica de 
ressonância de plasmão de superfície ou espectroscopia de onda evanescente (SPR, 
Biacore). Esta ligação foi identificada como dependente do tipo de sequência do 
glicosaminoglicano, com preferência pela heparina e sulfato de heparano e menor 
ligação aos sulfatos de condroitano e dermatan. A extensão mínima de heparina 
necessária para a ligação foi definida como 12 monómeros, nas nossas condições. 
Também de relevância foi o facto dos grupos sulfatos serem essenciais para 
promover esta ligação, sendo que glicosaminoglicanos parcialmente ou totalmente 
desulfatados não apresentavam ligação. Estes estudos são relevantes para melhor 
compreender os mecanismos básicos de aderência do HIV às células, antes da 
interacção com o receptor principal, CD4. 
A interacção envelope receptor tem um papel fundamental na fusão e entrada 
dos vírus envelopados. No entanto outros factores do hospedeiro podem modular 
este processo, nomeadamente os próprios lípidos das membranas celulares. No 
terceiro capítulo, o papel dos fosfolípidos aniónicos na cinética de fusão do vírus 
da estomatite vesicular (VSV, vesicular stomatitis virus) foi avaliado através de 
visualização de partículas individuais sobre bicamadas lipídicas suportadas. Foi 
utilizado uma câmara contendo dois canais microfluídicos sobre uma lamela de 
vidro, previamente tratada com dextrano. Nestes microcanais, as bicamadas 
lipídicas foram formadas sobre o dextrano. Após isto, os vírus aderiam e puderam 
ser observados ao microscópio. Estes vírus incorporavam duas sondas 
fluorescentes: um marcador lipofílico de membrana e uma proteína fluorescente 
no interior do vírus, acoplada à nucleocápside. Esta dupla marcação permitia a 
detecção da mistura dos lípidos do vírus e da bicamada aquando da hemifusão, e 
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também da libertação do conteúdo viral, confirmando a fusão. Estas observações 
revelaram que a presença de fosfatidilserina (PS) e de bis(monoacilglicero)fosfato 
(BMP) aumentam a eficiência da hemifusão e permitiam a progressão para fusão 
completa, ao contrário de membranas contendo apenas o lípido zwitteriónico 
fostatidilcolina (PC). Adicionalmente, o tempo entre o início da hemifusão e a 
libertação do conteúdo viral (isto é, o tempo de vida do passo intermediário de 
hemifusão) era significativamente mais curto para o caso do BMP, em comparação 
com a PS. O BMP é de facto um lípido que se encontra em abundância 
especificamente nos endossomas tardios e nos corpos multivesiculares das células, 
onde a fusão do VSV é mais provável de ocorrer. O BMP pode constituir um factor 
importante que permite a fusão completa do vírus quando este é internalizado. 
No último capítulo, evoluímos da fusão de vírus em sistemas modelo de 
membranas para células e visualizámos a viagem intracelular de um retrovírus, 
contendo uma sonda de pH, pela via endossomal. Este sensor consistia em duas 
proteínas fluorescentes fundidas (mTFP1-eYFP) que foram incorporadas no 
envelope de um vírus da leucose e sarcoma aviário (ASLV, avian sarcoma and 
leukosis virus). Através de transferência de energia (FRET) entre estas duas 
proteínas foi possível quantificar o pH à medida que o endossoma onde se 
encontrava o vírus ia acidificando. Este retrovírus requer dois estímulos 
sequenciais para fundir com a membrana do endossoma: ligação ao receptor de 
membrana e pH acídico. O receptor utilizado por este vírus existe em duas 
isoformas: o TVA950 que é transmembranar e o TVA800 que é ancorado por um 
grupo glicosilfosfatidilinositol (GPI). Os valores de pH quantificados variavam ao 
longo do percurso de 6.5 a 5.6. A fusão foi observada pela libertação de uma 
proteína fluorescente associada à nucleocápside. As células que expressavam 
TVA950 distribuíam os vírus para endossomas que se moviam mais lentamente, 
ao contrário das células TVA 800 que eram indiferentes. Adicionalmente, as 
TVA950 suportavam uma fusão mais rápida que as TVA800, apesar dos valores de 
pH parecidos nos endossomas. Os resultados mostraram que após internalização, 
o ASLV é distribuído em diferentes grupos de endossomas, que se distinguem por 
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terem diferentes dinâmicas de mobilidade e que modulam a fusão de modo 
distinto. 
Em suma, esta tese tratou de esclarecer alguns factores importantes que 
influenciam a fusão e entrada de vírus envelopados, nomeadamente ao nível 
lipídico e das interacções envelope-receptor. Estabelecemos ainda que a apetência 
de ligação às membranas dos péptidos inibidores de fusão do HIV-1 é um factor 
importante no seu modo de acção e deve ser tido em consideração no design de 
novos fármacos deste tipo. 
Palavras-chave 
Entrada viral Microscopia confocal 
Espectroscopia de fluorescência Microscopia de vírus individuais 
Espectroscopia de onda evanescente Vírus da estomatite vesicular 
Fusão membranar Vírus da imunodeficiência humana 
Glicosaminoglicanos Vírus da leucose e sarcoma aviário  
Inibidores de fusão Vírus envelopados 
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ASLV avian sarcoma and leukosis virus 
BBB blood brain barrier 
BMP bis(monoacylglycero)phosphate 
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Chol. Cholesterol 
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1. General considerations on enveloped viral fusion and 
entry into host cells 
Viruses are nano-sized infectious agents composed of structurally organized 
and functional biomolecules (nucleic acids, proteins and, in some cases, lipids) 
that require a living cell in order to replicate themselves. They are in fact obligate 
intracellular parasites. There is a vast diversity of viruses, with distinct sizes, 
shapes, structural orders and host requirements. However, the studies presented in 
this Thesis will comprise only enveloped viruses that infect animal cells, being 
focused on a particular step of their lifecycles: the attachment and entry in the host 
cells. 
Enveloped viruses have a lipid bilayer membrane that covers and protects 
their capsid structures and nucleic acids. Infection of the host cells by the viruses 
requires their content, that is, their genome and associated viral proteins, to be 
delivered into the cytosol. To achieve this goal, enveloped viruses have membrane 
protein(s) at their surface. Envelope fusion glycoproteins have two crucial roles in 
the viral infection [1-4]: i) attach the virus to the specific host cell type it can infect, 
by a receptor or other cell surface molecular entities, and ii) promote the fusion 
between the host cell and virus membranes, in order to deliver the viral content to 
cytosol. Hence, we can say that viral envelope glycoproteins are also fusogenic 
proteins.  
The merging of two membranes implies a very high kinetic and 
thermodynamic barrier, and the fusion proteins work to lower it [5]. This is done 
by conformation changes that occur upon certain triggers that drive the 
membranes together [3] (Fig. 1). The fusion between the two membranes most 
likely proceeds through an hemifusion intermediate, also designated fusion stalk 
[6]. This implies that the outer leaflets of the opposing membranes would merge 
first, allowing lipid exchange between these leaflets [6]. Only after this step, the 
distal leaflets merge by expansion of the fusion stalk and the pore is created, 
allowing content mixing between the virus and cell cytoplasm [6]. The viral 
membranes fusion proteins catalyze this process (Fig. 1). 
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Figure 1 – Structure and mechanism of action of enveloped viruses fusion glycoproteins. (A-C) Possible 
models for the conformational changes of viral glycoproteins that mediate the fusion between the host cell and 
viral membranes. Similar steps govern the fusion process despite the structural diversity presented by class I (A), 
class II (B) and class III (C) fusion proteins. Interaction of the envelope glycoprotein with host cell receptor 
and/or contact to endosomal low pH exposes the fusion domain that is projected towards the host cell membrane, 
bridging the two membranes after insertion. Subsequently, the glycoprotein folds back in order to approximate 
the N and C-terminus and such rearrangement induces the two membranes to fuse. At the end, the two 
membrane anchors stay in the same continuous membrane. Adapted from [1]. (D) Post-fusion ribbon structures 
of representatives of the three classes of fusion glyproteins, positioned in relation to the host membrane. From left 
to right: HIV-1 gp41 core structure (class I); Flavivirus protein E (class II) and VSV protein G (class III). Black 
and red arrows represent the positions of the fusion peptide and the transmembrane (TM) domain, respectively. 
Reprinted from [4]. 
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The diverse viral fusion proteins can be classified in three classes that are 
distinguished mostly by their structural motif and spatial rearrangements [7-9]. 
However their functional logic is similar. A transmembrane region in the C-
terminus docks the protein to the viral membrane. A hydrophobic domain, the 
fusion peptide or loop, is present at the N-terminal region, which interacts with 
the host membrane in order to form a bridge between the two membranes. This 
fusion active conformation may be triggered by binding to the host cell receptor 
and/or activated by low pH, the latter when the viruses are internalized by 
endocytosis and fuse with the endosome membrane instead of the plasma 
membrane. After the binding to the host membrane, the fusion protein suffers a 
dramatic rearrangement in which the structure folds back or collapses, bringing 
the two opposing membranes together (Fig. 1A-C). The fusion proteins convert to 
a trimer of hairpins, in which the C and N-terminal parts are brought together. 
This fusion active trimeric structure is also a hallmark of the different viral fusion 
proteins [3].  
Class I fusion proteins are those from, for example, Human 
immunodeficiency virus (HIV) and Influenza. They have two heptad repeat (HR) 
domains with α-helical secondary structure, between the transmembrane domain 
and the fusion peptide (Fig. 1D). They are trimers in their pre-fusion state, and 
their HR domains form a six-helix coiled coil bundle as a post-fusion 
conformation [7]. Class II fusion proteins are dimeric in their pre-fusion state and 
have high β-sheet content and lay low parallel to the viral surface. The fusion 
domains are loops at the tips of β-sheets domains and buried in the dimeric 
structure. They realign in trimers and project towards the host cell when primed 
for fusion [7] (Fig. 1D). Examples of viruses bearing class II fusion proteins are 
Dengue, Tick-borne encephalitis and Semliki forest viruses. More recently 
discovered, class III fusion proteins share characteristics between the two other 
classes. They are trimers in their pre-fusion state and have a central α-helical coiled 
coil; however, their fusion domains are loops in tips of β-sheet domains [10]. 
Vesicular stomatitis virus (VSV) and Herpes simplex virus type 1 (HSV-1) are 
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prime examples of this class (Fig. 1D). In order to summarize the characteristics 
that distinguish the spectrum of viral fusion proteins, refer to Table 1. 
After fusion successfully occurs, either at the plasma membrane, or at the 
endosome level, the viral content is delivered and infection of the cell starts, with 
the virus taking over the cellular machinery to replicate itself.  
Table 1 – Comparison of properties between the different classes of enveloped 
viruses fusion proteins. Adapted from [7]. 
Property Class I Class II Class III 
Examples 
Influenza HA, 
Paramyxovirus F, HIV-1 
gp41 
Tick-borne encephalitis 
virus E, Semliki Forest 
virus E1/E2 
VSV G, Herpes simplex 
virus type 1 gB 
Requires proteolytic 
processing to generate 
fusion competent form 
Yes (of fusion protein)a 
Yes (of accessory 
protein) 
No 
Metastable on virion Yes Yes Nob 
Orientation with respect 
to viral membrane 
Perpendicular (projected 
as a spike) 
Parallel (close to viral 
membrane) 
Perpendicular (VSV G), 
HSV-1 gB not known. 
Major secondary 
structure (of native 
fusion subunit) 
α-helix β-sheet α-helix and β-sheet 
Oligomeric structure of 
native fusion protein 
Trimer Dimer 
Trimer (VSV G). HSV-1 
gB not known.c 
Location of fusion 
peptide in native fusion 
protein 
Buried in subunit 
interface 
Masked in trimer 
interface, at tip of 
extended β-strands 
Exposed, at tips of 
extended β-strands (VSV 
G). HSV-1 gB not known. 
Location of fusion 
peptide in primary 
sequence 
At or near N-terminus Internal Internal (bipartite) 
Activated to fusogenic 
form by 
Low pH, receptor(s), or 
receptor followed by low 
pH 
Low pH 
VSV G, Low pH; HSV-1 
gB, Receptorsd 
Oligomeric structure of 
fusion-active form 
(membrane-embedded 
prehairpin and bundles) 
Trimer Trimer Trimer 
Structure of the post-
fusion form 
Trimer-of-hairpins 
(central α-helical coiled-
coil, 6HB) 
Trimer-of-hairpins 
(mainly β-structure) 
Trimer-of-hairpins 
(central α-helical coiled-
coil and significant β-
structure) 
 
a) May not be necessary for infection. 
b) VSV G is not metastable. Studies on low pH effect on HSV-1 gB also observed reversibility [11]. 
c) HSV-1 gB native and presumed pre-fusion structure is not yet determined. 
d) In some conditions and with some strains low pH may also be required for HSV-1 gB [11-14]. 
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2. Human Immunodeficiency Virus entry 
2.1. HIV-1 envelope mediated entry and fusion 
The HIV-1 envelope glycoprotein (gene designation Env) is constituted by 
two not covalently associated proteins: gp120 (surface subunit, SU) and gp41 
(transmembrane subunit, TM). They form a trimer of dimers complex at the virus 
surface, with gp41 anchoring the complex to the viral membrane and gp120 
covering it, making the outer shell [15]. gp120 is responsible for the attachment of 
the virus to the host cell and for the engagement with the entry receptors for HIV-
1 (Fig. 2A-B). gp41 is the actual fusion protein that contains the fusion peptide, 
which anchors to the host cell membrane and drives the approximation of the 
membranes [16] (Fig. 2C). In the native state, gp120 holds gp41 in a metastable 
conformation, and only when gp120 binds to the receptors it allows the fusion 
competent conformation of gp41 to be presented [17,18].  
The preferential host cells for HIV-1 are the CD4+ T lymphocytes. Viruses can 
reach these cells either directly, or via transfer of the intact virus from one cell to 
another, a process called trans-infection. Some molecules or receptors can 
contribute to this process, such as adhesion molecules or heparan sulfate 
proteoglycans [19], which will be covered later in this section. These attachment 
helpers can maintain the virus at the cell surface before it reaches their prime 
receptors: CD4 [20-22] and the co-receptors CCR5 [23,24] or CXCR4 [25]. The 
first engagement occurs through the binding of gp120 to CD4, which triggers a 
conformation change that exposes a binding site to the co-receptor [26] (Fig. 2B). 
The preference for CCR5 or CXCR4 depends on the virus tropism. Double 
engagement leads to structural changes necessary to expose gp41 [27,28], which 
extends its fusion domain towards the host cell membrane. As a class I fusion 
protein, gp41 is composed of two helical heptad repeat domains, the C- and N-
terminal heptad repeats (CHR and NHR, respectively). To catalyze membrane 
fusion, the two domains fold into each other, ending in a packed 6-helix bundle (6-
HB) structure (Fig. 2B). This gp41 folding was discovered to be inhibited by 
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peptides derived from either CHR or NHR, competing with the binding sites for 
the formation of the 6-HB [29] (Fig 2B-D). 
The viral site of fusion as long been believed to occur at the plasma membrane 
due to the need for receptor interaction and no requirements of low pH [33-35]. 
However, a recent study concluded that HIV-1 preferential route of entry is by 
endocytosis and fusion with endosomes [36]. Using real-time single virus imaging, 
the authors observed that at the plasma membrane, fusion did not progress beyond 
Figure 2 – HIV-1 entry and its inhibition by gp41 derived peptides. (A) HIV-1 life cycle showing the entry, 
intracellular replication and budding of new virions out of the host cell. The majority of the steps are now targeted 
by antiviral drugs (pink boxes) that impede the life cycle to progress beyond the indicated points. Reprinted from 
[30]. (B) Interaction of gp120 with the entry receptors CD4 and CCR5 or CXCR4. These binding steps induce 
conformational changes that expose gp41, which in turn will mediate membrane fusion through a hairpin or 6-
helix bundle structure. Peptides derived from gp41 heptad repeat regions prevent this process and hence inhibit 
fusion. Adapted from [31]. (C) Schematic structure and domains of the extended conformation of gp41 when 
interacting with the host cell membrane, together with the numbering of amino acid residues (HXB2 strain). 
MPER stands for membrane-proximal region. Adapted from [32]. (D) Sequences of fusion inhibitor peptides 
derived from gp41 CHR domain. Colored-shading denotes the more hydrophobic and Trp-rich regions of the 
peptides referred in the text as pocket-binding domain (PBD, in blue) and lipid binding domain (light magenta). 
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lipid mixing and that complete fusion occurred at the endosomes. Moreover, this 
fusion process was dependent on dynamin, a GTPase that is involved in the 
scission of clathrin-coated pits from the plasma membrane. Further studies 
supported this notion by failing to force the virus to fuse at the plasma membrane 
[37].  
2.2. HIV-1 fusion inhibitor peptides 
In the early 1990s, when more knowledge became available regarding the 
structure and function of envelope glycoproteins of HIV-1 [15], researchers 
realized that small oligopeptides (up to 6-mer) derived from gp41 sequences were 
able to inhibit HIV-induced cell fusion [38] (Fig. 2C-D). Soon after, in 1992, an 
inhibitory 38-mer peptide derived from the NHR region was developed, named 
DP-107 [29]. In the following year two new potent inhibitory peptides were 
discovered, peptide (637-666) [39] and DP-178 [40,41], this time derived from 
CHR heptad repeat region (LAI strain). 
While still in their infancy regarding possible clinical applications, these gp41 
derived peptides came as valuable research tools to better understand the HIV-1 
entry mechanisms. Two synthetic peptides, N36 and C34, from NHR and CHR, 
respectively, were selected by limited proteolysis of gp41, showing optimal 
thermodynamic properties for interactions [42]. The complex of these two 
peptides in solution was crystalized, which revealed a trimer of heterodimers with 
a complete helical structure [42]. This gave the most important insight in the 
understanding of the coiled coil structure of the gp41 core. Inhibitory peptides 
such as DP-178 could interfere with a fusion active conformation of gp41 [43]. As 
such, the mechanism of action of these fusion inhibitor peptides was regarded as 
interfering with the formation of the 6-helix bundle that brings the membrane of 
the virus and host cells together. 
DP-178, meanwhile renamed T-20, progressed successfully into a clinical 
proof of concept of in vivo efficacy in humans [44]. With the large scale clinical 
trials [45,46], T-20 became the first and, until now, only HIV-1 fusion inhibitor 
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peptide to be approved for clinical use, as enfuvirtide (brand name Fuzeon®) [47] 
(Fig. 2D). 
The success of enfuvirtide prompted for the development of new peptide 
drugs of this kind. Until enfuvirtide, the sequence used in the peptides was native 
of the reference strain HIV-1LAI gp41. Rational design of sequences became crucial 
to this development. A second generation inhibitor developed by the same 
companies that led enfuvirtide to clinical trials (Roche and Trimeris) was named 
T-1249. Its sequenced is based not only on HIV-1 but also HIV-2 and Simian 
immunodeficiency virus (SIV) [48] (Fig. 2D). It is more potent in vitro than 
enfuvirtide and active against enfuvirtide-resistant viruses [48]. Although it did 
not progress in the clinical trials due to formulation problems [49], it is still tested 
in animal models as a component of microbicides (topical gels) to prevent HIV-1 
infection [50-52]. 
Sifuvirtide, developed by the Chinese company Fusogen, is another second 
generation fusion inhibitor peptide, one of the latest drugs of this kind to complete 
phase IIb clinical trials, with promising results until now [53-55]. In April 2012, 
the Chinese State Food and Drug Administration (SFDA) approved phase III 
clinical trials [56]. It is a prime example of ration design, in which its sequence, 
based on the same C34 derived region, was modified to increase stability of the α-
helix and binding to the deep pocket region of gp41 [53] (Fig. 2D). It is more 
potent than enfuvirtide in a range of primary HIV-1 isolates [53,57] and the half-
life is also longer, which would require less frequent applications than enfuvirtide 
[53,54]. Recently, its topical gel formulation was also been proved to be safe and 
effective to be used as a microbicide [58].  
For more information on HIV-1 fusion inhibitor peptides and how they 
evolved, please read the designated Book Chapter A included at the end of this 
Introduction section. 
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2.2.1. C34-cholesterol and other antiviral lipopeptides 
The latest HIV-1 fusion inhibitor peptide to be studied in the context of this 
thesis was actually a conjugate between the C34 peptide and cholesterol, 
designated as C34-cholesterol [59] or L’644 [60] (Fig. 2D). This new compound 
was designed in line with previous attempts to conjugate a peptide with a 
lipophilic moiety, which generally improved their potency [61-63]. These lipid 
moieties should function as an anchor for the peptides to be displayed at the cell 
membrane. This way, they should be more readily available when the gp41 is 
exposed upon rearrangement of the HIV-1 envelope. This strategy is also sensitive 
to the orientation of the peptide anchoring [61]. A C-terminal derivatization of a 
CHR based peptides anchors the peptide in the optimal orientation for antiparallel 
binding to the gp41 NHR that is extended towards the host cell membrane [61]. 
In order to optimize such lipid anchor for inhibitory peptides, Ingallinella et 
al. [59] chose the cholesterol moiety to attach to the C34 peptide. The main reason 
was the importance of lipid rafts in the HIV-1 entry [64,65]. These cholesterol and 
sphingomyelin enriched membrane microdomains also cluster receptors at the cell 
surface and influence several membrane-related processes [66]. The reported 
evidences that lipid rafts are a preferential site of HIV-1 docking and entry 
[65,67,68] suggest that targeting fusion inhibitors to these sites could enhance their 
potency. As previously studied, T-1249 naturally adsorbs to cholesterol rich 
membranes, which can be one of the factors contributing for its higher activity 
when compared to enfuvirtide or C34 [69]. 
C-terminal derivatization of C34 indeed produces a very potent fusion 
inhibitor, with two or more orders of magnitude more potent than C34, 
enfuvirtide and T-1249, across multiple HIV-1 isolates [59]. An N-terminal 
derivatization had lower potency and lower degree of binding to the gp41 derived 
coiled coil 5-helix. Moreover, the use of palmitic acid instead of cholesterol 
rendered the conjugate with even lower activity compared to the native C34. 
Importantly, C34-cholesterol had an extended circulatory half-life when tested in 
mice, being detectable up to 24 h in the plasma when compared to 6 h of C34. This 
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is also a consequence of the fact that C34-cholesterol is much more resistant to the 
digestion by proteinase K, when compared with C34 and enfuvirtide [70]. 
The efficacy of C34-cholesterol as a microbicide was also evaluated against a 
panel of other fusion inhibitors, including C34, enfuvirtide and T-1249 [60]. This 
constituted a major study for preclinical evaluation of these inhibitors, using 
human mucosal tissue explants that included colorectal, penile and cervical tissues. 
C34-cholesterol was generally the most active fusion inhibitor across all tissues. 
Most importantly, protection provided by C34-cholesterol to the tissues was 
resistant to washing after pre-incubation with the inhibitors. T-1249 also 
presented some resistant to washing and, together with C34-cholesterol, were the 
only ones to have meaningful activity in penile explants [60]. This characteristic of 
the conjugate to offer a sustainable protection at the mucosal tissue level makes 
C34-cholesterol a good candidate to be used as a topical gel formulation to prevent 
HIV-1 infections during intercourse. This new development comes at a right time 
when several microbicide formulations, mainly based in polyanonic polymers, 
failed to have success in clinical trials [71]. Only recently the CAPRISA 004 trial 
showed efficacy of a 1% vaginal gel formulation of tenofovir, a reverse 
transcriptase inhibitor, with 39% reduction of HIV-1 infections overall. However, 
a year later a large scale trial for women at risk (VOICE) was cancelled 
prematurely due to lack of demonstrated efficacy [72]. 
The cholesterol tagging strategy of fusion inhibitor peptides was more 
recently applied to other viruses. A sequence of the C-terminal heptad repeat of 
the F protein of Human parainfluenza virus type 3 (HPIV3) gained 100-fold 
potency when C-terminally tagged with cholesterol to inhibit in vitro viral 
infection [73]. Moreover it could also inhibit two other paramyxovirus, Nipah 
virus (NiV) and Hendra virus (HeV), which cause lethal central nervous diseases 
[73]. An improved paramyxovirus peptide inhibitor was sequence optimized and 
cholesterol tagged, yielding potent anti-HPIV3 and NiV activity [74]. This tagged 
peptide was also efficacious against NiV encephalitis in an animal model, 
demonstrating the capability of the conjugate to cross the blood brain barrier [74]. 
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Influenza virus was also susceptible to cholesterol conjugates of 
hemagglutinin derived inhibitory peptides [43]. This virus is well known to 
undergo low pH dependent fusion at the endosomes, demonstrating that lipophilic 
fusion inhibitors can be internalized with the virus in order to achieve intracellular 
inhibition. 
New inventive ways to improve peptide fusion inhibitors continue to thrive. 
One of the latest efforts in the cholesterol conjugated family of inhibitors 
consisting of attaching two fusion inhibitor peptides to a single cholesterol moiety 
[75]. This strategy improved paramyxovirus inhibitors although for HIV the 
potency was equivalent to the monomer. 
In line with the diversification of lipophilic moieties attached to peptide 
fusion inhibitors, the latest strategy applied by Ashkenazi et al. [76] consisted in 
using a sphinganine moiety (dihydrosphingosine) to tag these peptides. An HIV-1 
gp41 NHR derived peptide N17 was endowed with antiviral activity only in its 
sphingopeptide form. Conjugation with palmitic acid, cholesterol and tocopherol 
had no effect in providing N17 antiviral activity. These results point to the fact that 
different peptides may require distinct lipophilic moieties for optimal potency. 
2.2.2. Interaction of HIV-1 fusion inhibitor peptides with membranes 
The function of gp41 is intimately tied with its membrane environment. As 
such, investigation of membrane interactions from gp41 derived peptides helped 
shed light on its function [77]. The first studies regarded the fusion peptide and 
how it interacts, destabilized and inserts in planar membranes and lipid vesicles 
[78,79]. However, the HR domain derived peptides that can inhibit the 6-HB 
formation and hamper fusion were also probed for direct membrane interactions 
in order to understand the role of the membrane in their mode of action. We will 
focus on CHR derived fusion inhibitor peptides, since these are the ones studied in 
this Thesis.  
Enfuvirtide (DP-178) and C34 were first compared in their ability to bind 
with phosphatidylcholine (PC):cholesterol and PC:phosphatidylserine 
(PS):cholesterol using a Förster resonance energy transfer (FRET) based assay 
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between the Trp residues of the peptides and 5-dimethylaminonaphthalene-1-
sulfonyl (DNS)-labeled lipid in the vesicles [80]. Energy transfer was detected in 
the case of enfuvirtide, contrary to C34 that showed no binding. However in small 
unilamellar vesicles (SUV) of PC:PS (1:1), 7-nitro-2-1,3-benzoxadiazol-4-yl 
(NBD)-labeled peptides interact with the membranes, with enfuvirtide having 10-
fold higher surface partition coefficient when compared to C34. Moreover, 
enfuvirtide also formed oligomers at the membrane level. This was the first 
indication that membranes affect these peptides behavior and that they could 
influence their action. Enfuvirtide binding to PC:sphingomyelin 
(SM):phosphatidylethanolamine (PE):cholesterol (4.5:4.5:1:1) was also detected via 
surface plasmon resonance [61]. 
However a more complete study on enfuvirtide [81] and T-1249 [69] 
interactions with lipid vesicles was conducted by Veiga et al., whom used the Trp 
fluorescence of the peptide as reporter. Enfuvirtide and T-1249 partitioned to fluid 
phase zwitterionic lipid vesicles containing POPC, with partition constant of (1.6 
±0.1) × 103 and (5.1 ± 0.7) × 103, respectively. Enrichment in cholesterol 
significantly decreased partition for both peptides. However, a more detailed study 
for T-1249 using FRET (dehydroergosterol (DHE) acceptor of Trp fluorescence in 
the membrane) revealed that T-1249 significantly adsorbed in to cholesterol-rich 
POPC lipid vesicles [69], contrary to enfuvirtide. The peptides location was also 
determined to be in a shallow position, at the level of the phospholipids head-
groups [69,81].  
A study using isothermal titration calorimetry also showed interaction of 
enfuvirtide with POPC vesicles, while the C36 peptide showed no binding (similar 
to C34) [82]. However, mutation of the tryptophan rich region of enfuvirtide at its 
C-terminus (WNWF to ANAA) completely abrogated the ability to bind 
membranes. This domain is then essential for lipid binding, and can be designated 
as lipid binding domain (LBD). The sequence of C34 does not have this domain, 
having instead a WMEW motif in the N-terminus, which is important to bind to 
an hydrophobic pocket in the NHR domain, competing for the 6-HB formation 
[42]. A subsequent calorimetric study analyzed the function of these domains 
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using a designed heptad repeat sequence (EEYTKKI) unrelated to gp41 [83]. A 
peptide containing only the pocket binding domain (PBD), as the case of C34 and 
sifuvirtide, was designated PBD-4HR. The peptide with only the lipid binding 
domain was designated 4HR-LBD, equivalent to enfuvirtide, and a peptide 
containing the two domains PBD-4HR-LBD would be equivalent to T-1249. 
Membrane binding for POPC vesicles was residual for PBD-4HR, while binding 
constants of 6.80×104 and 1.27×104 were obtained for 4HR-LBD and PBD-4HR-
LBD, respectively [83]. This was in agreement with the also previously determined 
higher partition of T-1249 for POPC, relative to enfuvirtide and C34. As for T-
1249, PBD-4HR-LBD also had the highest antiviral activity among the three 
studied peptides [83]. 
Sifuvirtide was also studied in detail regarding its behavior in model 
membranes. Contrary to enfuvirtide and T-1249, sifuvirtide did not partition to 
POPC vesicles, instead preferring rigid, gel-like, DPPC membranes [84]. It 
localizes in a very shallow position, indicating more adsorption to these lipids 
rather than insertion. Its selectivity for rigid domains is limited to 
phosphatidylcholines, instead of sphingomyelins, and is also highly dependent on 
NaCl concentration [85]. Sifuvirtide is significantly more potent than enfuvirtide 
[53], and these studies shed light on the importance of targeting fusion inhibitors 
to rigid membrane domains, or lipid rafts, where receptors are clustered and viral 
entry and fusion are more likely to occur. 
2.3. Role of HSPG in HIV entry and pathogenesis 
In order for HIV to reach its prime receptors, is has been well established that 
other alternative receptor entities at the cell surface help the virus to approach and 
attach to the host cells, before it engages with CD4 [19]. These receptors consist of 
adhesion molecules, lectins, heparan sulfate proteoglycans (HSPG) and the 
glycolipid galactosylceramide (GalCer) [19]. For example, HIV can naturally 
incorporate the intercellular adhesion molecule 1 (ICAM-1) that increases 
infectivity for lymphocyte function-associated antigen 1 (LFA-1) bearing T CD4+ 
lymphocytes [86,87]. Also, dendritic cell-specific intercellular adhesion molecule-
3-grabbing non-integrin (DC-SIGN), is able to bind and retain HIV virus and 
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facilitates trans-infection to CD4+ cells [88]. Importantly, HSPG also have a role 
similar to DC-SIGN; however, due to its ubiquitous presence in the body they end 
up having a major effect on spreading of the viral infection, contributing to the 
pathogenesis [89]. 
HSPG are membrane or secreted proteins that have glycosaminoglycans 
(GAG) chains attached, mainly heparan sulfate and chondroitin sulfate. These 
GAG are linear polysaccharides consisting of repeating dissacharide units of 
hexosamine and uronic acid, which are often sulfated [90]. Hence, GAG differ on 
their repeating dissacharide unit, and glycosidic linkage, to produce distinct 
sequences (Fig. 3A).  
Cell surface proteoglycans, the ones that are membrane bound, exist in two 
forms: syndecans and glypicans (Fig. 3B). Syndecans are transmembrane 
molecules and have an extended ectodomain, with the heparan sulfate (HS) chains 
mainly attached in a distal position from the membrane [91]. Glypicans are 
glycosylphosphatidylinositol (GPI)-anchored to the plasma membrane and they 
form a globular ectodomain structure by disulfide links. Contrary to syndecans, 
glypicans have the HS chains attached in to the region proximal to the membrane 
[91] (Fig. 3B). However, only syndecans have been shown to be implicated in HIV 
pathogenesis [89].  
In vitro studies of glycosaminoglycans-protein interactions usually rely on the 
soluble heparin as a GAG model. Heparin and HS have been shown to bind in 
vitro to HIV-1 gp120 [92,93]. The binding sites of gp120 to heparin were mapped 
and essential residues for this interaction were identified, included in the V2 and 
V3 loops, in the C-terminal domain and in the CD4-induced co-receptor binding 
site [94,95]. Also, the V3 loop was found to be essential to bind to the different 
types of syndecans [96]. Residues implicated in these interactions are often 
arginines and lysines, basic aminoacids that can interact electrostatically with 
negatively charged heparin. 
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Figure 3 – Structures of glycosaminoglycans and proteoglycans. (A) Chemical structures of the typical 
disaccharide units that compose the different glycosaminoglycans. Colored text refers to enzymes that catalyze 
modifications to these chains, mainly sulfations (in balloons) but also epimerizations in the case of dermatan 
sulfate and heparan sulfate. Abbreviations: C4ST, chondroitin sulfate-4O-sulfotransferase; C6ST, chondroitin 
sulfate-6O-sulfotransferase; CS/DS2ST, chondroitin sulfate/dermatan sulfate-2O-sulfotransferase; CS/DS5epi, 
chondroitin sulfate/dermatan sulfate-C5-epimerase; Gal, galactose; GalNAc, N-acetyl-galactosamine; GlcA, 
glucuronic acid; GlcNAc, N-acetyl-glucosamine; GlcNAc6ST, N-acetyl-glucosamine-6O-sulfotransferase; HS2ST, 
heparan sulfate-2O-sulfotransferase; HS3ST, heparan sulfate-3O-sulfotransferase; HS6ST, heparan sulfate-6O-
sulfotransferase; IdoA, iduronic acid; KSGal6ST, keratan sulfate-galactose-6O-sulfotransferase; NDST: N-
deacetylase-N-sulfotransferase. Reprinted from [97]. (B) Schematic representation of the cell surface heparan 
sulfates syndecan (right) and glypican (left). Glypicans associate to the membrane via GPI anchor and its 
ectodomain is globular due to disulfide bonds. Syndecans have a transmembrane domain and an extended 
ectodomain. Heparan sulfate chains attach to syndecans in a distal position from the membrane, contrary to 
glypicans that have the chains proximal to the membrane. Reprinted from [98]. 
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Regarding the influence of proteoglycans in in the viral infection, it was first 
observed that cells treated with heparitinase [99] or knocked out for GAG 
production [100] have much lower levels of viral attachment and infection than 
their wt counterparts. In fact, in the case of macrophages, syndecans are crucial as 
attachment receptors for HIV-1, as they compensate for the lower levels of CD4 of 
these cells, relative to T CD4+ cells [101]. Syndecan-3 was also identified as a 
specific attachment receptor in the case of dendritic cells [102]. Importantly, the 
blood-brain-barrier (BBB) crossing by HIV-1 was shown to be mediated, at least in 
part, by proteoglycans present in the brain microvascular endothelial cells 
[103,104]. 
Proteoglycans are ubiquitously present, especially in the epithelial, endothelial 
and dendritic cells, as well as in macrophages. All these cell types and formed 
tissues (mucosas, endothelium) can capture HIV virions, protecting them and 
facilitating trans-infections via syndecans to the T lymphocytes in a very efficient 
way [8]. The endothelium can function as a major in trans reservoir, as it can keep 
virions bound to syndecans in an infectious state [89]. 
Strategies have already been devised to block HIV entry by taking advantage 
of this gp120-proteglycans interaction. A syndecan-Fc (fragment crystallizable) 
hybrid molecule showed potent and broad-range antiviral activity and prevented 
trans-infection [105]. It was effective when applied 2 h before infection, when 
diluted in genital fluids and at low pH, making it a promising candidate to use as a 
microbicide [105]. A synthetic CD4-mimetic peptide linked to an HS chain was 
designed taking into account that HS binds also to the CD4 induced co-receptor 
binding site [106]. Another version of this compound was also made with the HS 
chain substituted with a peptidomimetic [107]. These hybrid molecules had 
nanomolar antiviral activity against both CCR5- and CXCR4-tropic HIV-1 strains, 
making it another promising entry inhibitor [106,107]. 
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3. Avian Sarcoma and Leukosis Virus entry 
The Avian Sarcoma and Leukosis Virus (ASLV) is an alpharetrovirus that, 
contrary to lentiviruses (such as HIV), has a simpler genome with the Gag-Pol and 
Env genes, but without the accessory ones (Vif, Vpr, Tat, Rev, Vpu and Nef) [108]. 
These ones allow lentiviruses to replicate on non-dividing cells [108]. Its envelope 
fusion protein is also class I, as usual in retroviruses, and forms a 6-HB as a post-
fusion conformation. There are 10 viral subgroups classified, named A-J [108], 
however we will focus on ASLV-A. The receptor for this virus was discovered to be 
TVA, a membrane protein related to the low-density lipoprotein (LDL) receptor 
[109,110]. Indeed, soluble forms of TVA (sTVA) pre-incubated with the virus 
could inhibit its infection [111,112]. Moreover, the soluble receptor was also able 
to induce infection in cells that do not express the cognate receptor [113], 
suggesting that sTVA can induce the conformational changes necessary for 
priming the envelope for fusion. However, in a rare case among viruses, ASLV 
requires not only the interaction with the receptor but also a second low pH trigger 
to fully activate the fusion protein [114]. ASLV two-step entry proceeds first with 
the interaction with the cognate receptor, which induces conformational changes 
that exposes the fusion peptide, still at neutral pH, and mediates its internalization 
[115]. Acidification of the endosomal compartment leads to the completion of the 
fusion reaction with the delivery of the viral contents to the cytoplasm [115,116]. 
As a class I fusion protein, this entry process is also inhibited by ASLV CHR-
derived peptides that inhibit the formation of the 6-HB post fusion structure 
[117,118]. Another unusual characteristic of the viral envelope is the stability of 
the receptor-primed intermediate that can remain in this state for long periods of 
time compared to other pH-dependent viruses [114,119]. 
The TVA receptor exists in two different isoforms that originate from 
alternative splicing: TVA950 is a transmembrane receptor with a single membrane 
spanning domain, while TVA800 is a GPI-anchored protein. This has implication 
on the entry pathways of ASLV [119]. TVA800 was shown to be associated with 
lipid rafts (defined as detergent-resistant membranes), contrary to TVA950 [119]. 
Receptor usage influenced the rate at which viruses were uptaken and 
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internalization via TVA800 rendered the viruses more resistant to ammonium 
chloride arrest, a feature dependent on lipid raft association [119]. More robust 
imaging techniques with fluorescent labeled viruses and pH sensitive fluorophores 
allowed a more detailed dissection on the entry routes of ASLV-A [120,121]. 
Internalization of viruses was faster with TVA950; however, fusion of internalized 
viruses was delayed compared with TVA800 expressing cells. TVA950 supported 
more robust pores and higher efficiencies of infection [120]. These two receptors 
also likely redirect the viruses to distinct sub-cellular compartments. Viruses 
internalized via TVA950 are more likely to fuse at intermediate endosomes, while 
TVA800 internalized ones are likely to fuse in intraluminal vesicles trapped in 
multivesicular bodies, with the liberation of the core to the cytoplasm dependent 
on a second back-fusion process [121]. Recently, a cryo-EM study allowed the 
direct visualization of ASLV attached to liposomes in its sTVA-bound and fusion 
competent state [122]. 
4. Vesicular Stomatitis Virus entry 
Vesicular stomatitis virus belongs to the Rhabdoviridae family of enveloped 
viruses with single stranded negative-sense RNA genome [123]. These viruses have 
also a distinct bullet shape, with a flat base and a round tip. The envelope 
glycoprotein is designated as G protein, a class III fusion protein forming trimers 
at the viral surface [124]. It enters and infects cells via endocytosis and is 
dependent on the low pH to trigger fusion (Fig. 4). The virus should attach or 
enter via a receptor that until very recently was not identified. Phosphatidylserine 
(PS) has been shown to promote VSV fusion and entry into cells and with model 
membranes [125-128], but it is unlikely to be the primary receptor for this virus 
[129]. The chaperon protein gp96 was identified as essential for VSV infection, as 
cells without this protein were unable to bind VSV [130]. Due to its location at the 
endoplasmic reticulum, gp96 is likely to act as a chaperone for a putative 
membrane receptor for VSV, allowing its correct folding [130]. Very recently, 
Finkelshtein et al. seem to have identified the low-density lipoprotein receptor 
(LDLR) and its family members as the cellular receptors for VSV [131]. To support 
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this claim, they presented experiments such as inhibition of VSV binding and 
infectivity with a soluble form of LDLR, affinity measurements of the G protein 
with LDLR and competition of LDL and VSV for the same binding site, among 
other evidences. 
Rhabdovirus G protein also has a unique property among low pH dependent 
fusion proteins: its conformational changes due to low pH are reversible when 
returning to neutral pH [132]. Other pH sensitive viruses when exposed to low pH 
in the absence of a target membrane undergo irreversible inactivation [133]. This 
Figure 4 – Entry pathways of vesicular stomatitis virus (VSV) in the host cell. VSV should bind to the cell 
membrane via one or more putative receptors or attachment molecules, being internalized via partially coated 
clathrin vesicles. Upon arrival to early endosomes the virus can fuse in these compartments upon sufficient 
acidification of the lumen (a). However, should the virus progress to multivesicular bodies and late endosomes, 
the probability of fusion with internal vesicle is higher, releasing the capsid inside them (b). This would require a 
second fusion event (back-fusion) to occur in late endosomes in order to release the capsid to the cytosol. Rab5 
(magenta) and Rab7 (green) are small GTPases that are present in early and late endosomes, respectively. 
Reprinted from [123]. 
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reversibility allows the protein to pass through the acidic compartments of the 
Golgi apparatus and recover its native conformation when incorporated in the 
virions [134]. Other viruses require chaperones to protect these fusion proteins 
from undergoing irreversible changes in the Golgi. 
Internalization of the virus is dependent on clathrin and dynamin-2, a 
GTPase involved in the release of nascent vesicles during endocytosis [135] and 
viruses were indeed observed inside coated vesicles [136]. Fusion was previously 
observed to occur within minutes in early endosomes [135], and VSV infection 
was dependent on Rab5 (maturation factor for early endosomes) but not Rab7 
(maturation factor for late endosomes) [137]. However a recent study proposed 
that VSV can also fuse with intralumenal vesicles, inside multivesicular bodies 
[138] (Fig. 4). Such pathway requires a second back-fusion event with the limiting 
membrane of late endosomes in order to release the capsid to the cytosol. This step 
is dependent on the late endosome-specific lipid bis(monoacylglycero)phosphate 
(BMP) [138], also referred to as lysobisphosphatidic acid (LBPA) [139]. Tsg101, 
which is part of the endosomal sorting complexes required for transport (ESCRT), 
and its partner Alix were also demonstrated to regulate this late fusion step of viral 
capsid release [140]. Moreover, in vitro experiments with liposomes enriched with 
BMP also favored lipid mixing with VSV [141]. BMP was also shown to function 
as a co-factor in the fusion of dengue virus with late endosomes [142]. These 
examples of VSV and Dengue virus show that specific lipids can influence the 
entry and fusion process of enveloped viruses. 
5. Methodological and technical approaches 
5.1. Fluorescence-based evaluations of peptide-membrane 
interactions 
In this Thesis we made use of fluorescence spectroscopy in order to measure 
interactions between peptide and membranes, either of cells or lipid vesicles. These 
methods were extensively reviewed in the Review Articles A and B at the end of 
this Introduction section. 
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5.2. Surface plasmon resonance 
Surface plasmon resonance (SPR) is a technique that provides label-free, real-
time detection of biomolecular interactions [143]. It is used to characterize the 
binding equilibrium and kinetics of a ligand immobilized on a thin gold surface 
with a binding partner in solution (analyte) [143]. This is an optical technique 
based on the evanescent wave phenomenon that arises from a surface of a metallic 
film when incident light is totally reflected, which happens above a critical angle 
[144] (Fig. 5A). The resonance is a result of energy and momentum being 
transformed from incident photons to surface plasmons. It is sensitive to the 
refractive index of the medium on the opposite side of the film. The changes in 
mass occurring at the surface, due to molecular interactions and increased local 
concentration of the analyte, lead to changes in the refractive index within the 
evanescent wave penetration range. The angle of incidence required associated 
with the SPR phenomenon is altered due to this refractive index change, and is this 
angle alteration that is measured as the response signal [144] (Fig. 5A). 
SPR instruments for biomolecular interactions (in the case of this Thesis, 
Biacore, from GE Healthcare) usually rely on microfluidic channels to deliver 
small amounts of sample to the flow cells, which are in contact with the gold film 
surface of the chip [145] (Fig. 5A). This way, solution exchange and washing is 
easier, allowing the delivery of the ligand for immobilization, and the binding 
partners of interest. Usually, two or more flow cells are available for simultaneous 
measurements, with one serving as control. 
The immobilization of a biomolecule on the chip surface can be done either 
covalently or non-covalently. Covalent attachment is usually done with a carboxyl 
presenting surfaces, than can react with proteins by different chemical strategies 
(Fig. 5C). Non-covalent attachment explore strategies such as the high-affinity of 
streptatividin-biotin pair, the 6-His sequence chelation of Ni2+ or the hydrophobic 
interactions for the case of lipids [146] (Fig. 5D). 
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Figure 5 – Principles of surface plasmon resonance binding experiments. (A) Detection of intermolecular 
binding events in the flow channel of an SPR equipment (e.g., Biacore), in which the changes of mass due to 
binding have an effect on the reflected angle of the light associated to the surface plasmon effect. (B) Typical 
sensorgram obtained for an SPR binding experiment. The resonance signal increases as the surface mass also 
increases (association). After ending the infection of the analyte, the buffer flow induces the dissociation of the 
molecules, decreasing the signal. Finally, regeneration procedures can return the signal to the baseline, with the 
surface ready for another use. (C) Chemical conjugation possibilities to covalently immobilize proteins to a 
carboxymethyl matrix chip via a reactive N-hydroxysuccinimide (NHS) ester. This can readily react with an 
amino group to form an amide linkage. Hydrazine allows coupling with aldehyde groups. Coupling via disulfide 
bonds can also be achieved using pyridinyldithioethanamine (PDEA) and cystamine routes. (D) Non-covalent 
methods to immobilize biomolecules in SPR chips: streptavidin-presenting surfaces can bind to biotin derivatized 
molecules (top); monoclonal antibodies immobilized through amine coupling can specifically bind proteins or 
other biomolecules with the respective epitopes (middle); nitrilotriacetic acid (NTA) bearing chips immobilize 
proteins engineered to display a 6-His sequence tag (bottom). Adapted from [146]. 
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The need for immobilizing one of the binding partners, which can potentially 
hide binding sites, remains the main disadvantage of this technique. However, that 
can be circumvented in many cases by putting a tag (6-His or biotin) in a specific 
site, or using antibodies against a specific epitope as an immobilization 
intermediate, in order to control the immobilization orientation. 
After a successful immobilization, the surface is ready to be tested with the 
desired analyte(s). When the analyte binds to the ligands at the surface, it induces a 
response signal that is recorded along the time, constituting the sensorgram [144] 
(Fig. 5B). During the binding phase, or association phase, the response increases 
until the binding sites are saturated and equilibrium is reached. When the analyte 
injection is stopped and the flow substituted by the running buffer, the analyte 
dissociation causes the response to decrease. In this way, association and 
dissociation kinetics, as well as affinity constants can be extracted from these time-
course measurements data [144]. After each run, the surface is usually regenerated, 
typically using a solution with modifications in pH, salts or other compounds that 
accelerated the dissociation of the analyte and brings the response signal back to 
the original baseline. This allows the chip to be reused for several individual runs 
until it wears off. 
For binding reactions that occur at 1:1 stoichiometry, we can represent as the 
following chemical equation: 
  
(1)
 
The rate equations that characterize the association and dissociation kinetics, 
respectively, are [147]: 
      BAAB a  kdt
d  (2) 
    ABAB d  kdt
d  (3) 
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The net equation is: 
        ABBAAB da  kkdt
d  (4) 
When the reaction reaches equilibrium, the rate of association is the same as 
the rate of dissociation: 
      ABBA da  kk  (5) 
The equilibrium constants are defined by: 
Equilibrium association constant:      BA
AB
d
a
A  k
kK  (6) 
Equilibrium dissociation constant:     AB
BA
a
d
D

k
k
K  (7) 
All these kinetic and affinity constants can be quantified by this technique. 
Surface plasmon resonance based sensors can be very versatile, characterizing 
the binding over a range of biomolecules. It has been possible for a while to also 
run relatively high throughput screenings in which this technique is valuable to 
identify high affinity drugs or antibodies to a specific target [148,149]. 
Technological advances should drive a more applied use of these sensors in 
medicine, where they could serve as rapid and efficient diagnostic tools in 
laboratories [150]. 
5.3. Imaging viral entry and fusion in model membranes and cells 
Virus life cycles are a complex sequence of steps that are challenging to study 
and follow. Viruses intimately interact with the cellular structures of their host 
cells to carry out replication. In the past two decades, microscopy techniques have 
advanced in order to allow the discrimination of single virus interactions with cells 
and dissect the pathways of the infection process [151]. In practical terms, viral 
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and cellular structures must be fluorescently labeled and the microscope powerful 
enough for the detection of single viruses or viral components in real time. As 
such, two main technical aspects are crucial: the fluorescent labeling, and the 
imaging instrument and configuration. 
Virus labeling can be done either with chemical probes or genetically 
engineered fluorescent proteins. Covalent labeling with fluorescent chemical 
probes is a very versatile method, as an array of amine reactive dyes (fluoresceins, 
rhodamines, Alexas and BODIPY, among others) can be attached to viral surface 
proteins. Viral membranes can be labeled with lipophilic dyes that incorporate in 
the bilayer leaflets. Nucleic acids intercalating dyes such as acridine orange or 
neutral red [152] can label viral genomes, although only recently the use of Syto82 
allowed for live replication imaging [153]. Indirect labeling when virus 
components are already inside the cell is also possible with the use of biarsenical 
dyes [154] that bind tetracystein motifs engineered in the proteins of interest 
[155,156].  
The advent of the genetically encoded fluorescent proteins, starting with the 
development of the green fluorescent protein (GFP) variants [157,158], greatly 
expanded the capabilities of imaging specific proteins in biological systems. Since 
then, an array of fluorescent proteins of all colors is available [159,160]. These 
fluorescent proteins can be fused to structural proteins of the virus (usually matrix 
or capsid proteins), with more than one copy per virus, in order to improve 
detection by the microscope. 
Microscopy equipment and configuration is the other important factor in 
these viral imaging experiments. The objective is to reduce the background as 
much as possible and detect the labeled viral particles, which are nanometric in 
scale. Conventional widefield epifluorescence microscopy collects light emitted by 
the entire depth of the sample [161]. This is usually not suited for viruses due to 
higher background and poor distinction of detailed structures. However, applying 
deconvolution techniques greatly improves image quality by computational 
removal of out of focus light, while still retaining the advantage of fast acquisition 
of widefield [162]. Confocal systems remove this out of focus light through a 
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pinhole before the light reaches the detector, producing sharper images [161]. In 
these systems, with the use of laser excitation lines that allow higher flexibility on 
multicolor imaging, defined specific regions for illumination (useful for 
photobleaching experiments) and increased technological advances in detectors 
over time, confocal is now a widespread method in fluorescence imaging for 
biological sciences. If one wants to visualize events at the membrane level, or 
structures close to the coverglass, TIRF (total internal reflection fluorescence) 
microscopy allows for sensitive and reduced background detection [163]. This is 
done by illuminating the glass at a critical angle for total internal reflection, 
producing an envanescent wave of limited depth that will excite the nearby 
fluorophores (similar to what was explained earlier in this introduction for SPR 
instrumentation). 
The resolution limit of these optical microscopies is around 200 nm, which is 
derived from the inherent diffraction effect of light, described by the Abbe 
equation [164,165]: 
  

sin2  nd  (8) 
in which d is the resolution, λ the light wavelength, n the refractive index and 
θ the converging angle of the light (n sin θ is also defined as the numerical 
aperture, NA). 
Most viruses sizes are below that value, which limits the way these viral 
structures can be distinguished when imaged. In the recent years, sub-diffraction 
imaging technologies have been developed that brought the resolution down to 10 
nm, in what is called super-resolution microscopies [165,166]. This encompasses 
techniques such as SIM (structure illumination microscopy), STED (stimulated 
emission depletion), PALM (photoactivated localization microscopy) and STORM 
(stochastic optical reconstruction microscopy) [166]. These methods still have to 
mature in order to provide fast, real time imaging, although significant progress 
has already been made [167].  
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Early studies with labeled viruses provided the first glimpses on how they 
enter and traffic inside the cell, mainly in the endosomes. Semliki forest virus and 
reovirus serotype 1, chemically labeled with rhodamine or fluorescein, were among 
the first viruses to be used in this kind of approach [168,169]. Application of GFP 
in virus labeling was first done with herpes simplex type 1 by fusing it either with 
capsid or matrix protein components [170,171], enabling to follow the structural 
components of the virus after fusion. Viral trafficking studies also helped to 
uncover novel cell biology concepts related, for example, with microtubules 
dynamics via Texas red labeled adenovirus [172] or a new, caveolae and actin 
dependent, entry pathway for SV40 [173,174]. Also, GFP-labeled HIV-1 imaging 
in cells clarified the implications of the microtubules and dynein in the 
intracellular trafficking of the virus [175]. As the technology advanced, single 
molecule detection and computational tracking capabilities allowed for higher 
sensitivity of detection and quantitative characterization of the entry pathways and 
motion of single viruses [176]. Enveloped viruses trafficking together with fusion 
events observation was achieved using influenza virus labeled with the lipophilic 
dye 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine (DiD) [177]. The 
fusion after acidification was detected when dye dequenching and redistribution 
occurred upon lipid mixing. Using different labeling for outer and inner leaflets of 
the viral membrane (DiD and palmitoylated yellow fluorescent protein (YFP)), the 
fusion process of ALSV was characterized in terms of kinetics and pH dependence 
[178]. Observing HIV-1 fusion in live cells was possible using DiD labeled virions 
together with fluorescent protein marked nucleocapsid [179]. This kind of robust 
double-labeled, single virus tracking in live cells was also the base to unveil the 
previously unknown entry pathway of HIV-1 through fusion at the endosome 
level, instead of the plasma membrane [36]. HIV-1 spreading via virological 
sinapses, cell-cell adhesions that facilitate viral transfer, was also directly observed 
via Gag labeling using high speed 3D video microscopy [180]. ASLV entry 
pathways and the two step entry process dependent on low pH and receptor 
binding were dissected via single virus live imaging using pH sensitive markers, 
allowing to distinguish the sorting of the virions in distinct intracellular 
compartments [120,121]. As super-resolution paves the way for the future of 
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imaging, more detailed viral structures can be distinguished in infected cells, such 
as the conical shaped HIV-1 capsid, and if the virus is mature or immature [181]. 
However, when we want to look at details on how specific molecules 
modulate the fusion process, it is useful to simplify the system and use minimal 
components to mimic and isolate the phenomenon under study. For long, virus 
fusion requirements were also studied with membrane model systems, such as 
lipid vesicles, that offered a simple mean of manipulating lipid composition and 
buffer conditions (salt and pH), in order to identify specific requirements or 
dependences. For imaging, however, only recently virus-membrane fusion was 
directly imaged using supported lipid bilayers (SLB) in glass supports [182,183] 
(Fig. 6). SLB consist of a single phospholipid bilayer on top of a clean planar 
surface, in an aqueous environment [184]. An ideal SLB should be uniform and 
fluid, allowing lateral mobility of the phospholipids. It can be formed by lipid 
vesicle rupture at the surface (Fig. 6C) or using a Langmuir–Blodgett trough to 
compress monolayers on a water surface that can be transferred to the glass surface 
[184]. Wessels et al. reported direct influenza and Sindbis viruses fusion with glass 
supported lipid bilayers [183]. The viruses were membrane labeled with octadecyl 
rhodamine (R18) at self-quenching concentrations and the fusion was observed by 
the dequenching and radial spreading of the dye upon lipid mixing. Floyd et al. 
improved this technique by using double labeled influenza virus (membrane dye 
and content dye) to measure the kinetics of lipid mixing and content release, 
providing a full picture of fusion kinetics [182]. The same methodology was later 
modified to use proton uncaging by UV for lowering the pH, instead of buffer 
exchange [185]. Such methods allow to measure single particle fusion kinetics and 
detail the mechanism in levels difficult to obtain when using live cells. 
Virus imaging studies are now essential to understand the full picture of the 
viral life cycles. New technological advances will certainly benefit the field as they 
also become increasingly accessible to researchers. 
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Figure 6 – Model membranes for biophysical studies. (A) Schematic representation of the general steps for 
the formation of the lipid vesicles used in this Thesis for peptide-membrane interactions and formation of 
supported lipid bilayers. Adapted from [186,187] (B) Lipid bilayer supported on a solid planar surface, in an 
aqueous environment. A water sheet remains between the bilayer and the support, allowing for some degree of 
lipid mobility. Reprinted from [184]. (C) Possible mechanisms of SLB formation by successive events of vesicle 
adsorption, deformation, fusion and rupture. Reprinted from [188]. 
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6. Review articles and book chapter 
In order to complement this introduction, we present a book chapter related 
to HIV-1 fusion inhibitor peptides and two review articles that explain the 
methodological approaches based on fluorescence to study peptide-membrane 
interactions. 
Book Chapter A 
Franquelim HG, Matos PM, Veiga S. “HIV vs. HIV: Turning HIV-Derived Peptides 
into Drugs” in Peptide drug discovery and development – Translational research in 
Academia and Industry (2011), Castanho MARB and Santos NC (eds.), Wiley-VCH, 
Weinheim, Germany. 
Review Article A 
Matos PM, Gonçalves S, Santos NC. Interaction of peptides with biomembranes 
assessed by potential sensitive fluorescent probes. J. Pept. Sci. 14:407-415 (2008). 
Review Article B 
Matos PM, Franquelim HG, Castanho MARB, Santos NC. Quantitative assessment of 
peptide-lipid interactions: Ubiquitous fluorescence methodologies. Biochim. Biophys. 
Acta. 1798:1999-2012 (2010). 
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HIV vs. HIV: Turning HIV-Derived Peptides into Drugs
Henri G. Franquelim, Pedro M. Matos, and A. Salome Veiga
10.1
Introduction
Human immunodeﬁciency virus (HIV) is the causative agent of the acquired
immunodeﬁciency syndrome (AIDS). There are two types of HIV: HIV-1 and
HIV-2, HIV-1 being the most virulent [1]. HIV can be transmitted by blood
and blood products, vertically (from mother to child), or through sexual activity. By
the end of 2009, the United Nations Programme on AIDS (UNAIDS)/World
Health Organization (WHO) epidemic update estimated 33.4 million (31.1–35.8
million) people worldwide living with HIV [2]. Despite much effort, no curative
treatment or effective vaccine has yet been achieved.
The rational design of anti-HIV-1 therapeutics is based on detailed knowledge of
the biology of the virus. Combination therapy with reverse transcriptase and
protease inhibitors is the most common current treatment of HIV-1 infection [3].
Despite the success of this therapy, namely by reducing morbidity and mortality of
HIV-1 infected patients [4], it has adverse effects and drug resistant HIV-1 strains
have emerged [5]. This demands the development of new classes of drugs targeting
different stages of the viral life cycle. A new class of antiviral agents in develop-
ment, the entry inhibitors, exhibits promising inhibition proﬁles. Unlike reverse
transcriptase and protease inhibitors, which target post-entry steps inside the host
cells, entry inhibitors act extracellularly preventing viral entry into target cells [6].
10.2
HIV-1 Envelope Protein
HIV-1 is an enveloped virus that infects CD4þ T cells, dendritic cells, and mac-
rophages [1]. The HIV-1 envelope glycoprotein is the protein responsible for the
viral entry into the target cells. It is expressed on the surface of the viral membrane
as a trimer [7]. It is composed of two subunits noncovalently associated: the gp120
subunit, a globular-shaped subunit at the surface of the membrane that interacts
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with cellular receptors, and the gp41 transmembrane subunit, responsible for the
fusion between the viral and cellular membranes (reviewed in [6, 8, 9]).
gp41 is composed of an ectodomain (extracellular domain), a transmembrane
domain (TM) and an endodomain (intracellular domain or cytoplasm tail (CT)).
Several functional domains have been identiﬁed in the ectodomain. The fusion
peptide (FP) is located at the ectodomain N-terminal. This region, hydrophobic
and rich in glycine residues, interacts with the target cell membrane and plays an
important role in membrane fusion (reviewed in [10]). Two heptad repeat regions
((HR(), with the tendency to form a-helical coiled-coils [11], are also present: the
ﬁrst (NHR or HR1) near the N-terminal is adjacent to the FP; the second (CHR or
HR2) is located at the ectodomain C-terminal. Peptides derived from them are
referred to as N- and C-peptides, respectively. The two HR are separated by a loop
region (LR) that contains an intramolecular cysteine bridge. At the C-terminal
between the CHR and the TM is located a Trp-rich domain (TRD), the membrane
proximal external region (MPER), which also seems to play an important role
during the viral membrane fusion [12]. As several monoclonal antibodies bind to
this region, the MPER is seen as the major target for vaccine development
(reviewed in [13]).
Protein dissection combined with biophysical analysis has demonstrated that
the two HR regions within gp41 form a helical trimer of antiparallel dimers [14].
The crystal structures of portions of the ectodomain [15, 16] conﬁrmed that the
gp41 core tends to form a trimer of hairpins (also called trimeric coiled coil or six-
helix bundle (6HB)). A central trimeric coiled coil formed by the N-peptide region
is surrounded by three helical C-peptides that bind to conserved hydrophobic
grooves on the coiled-coil surface in an antiparallel orientation. This structure
represents the fusion-active conformation of gp41.
10.3
HIV Entry and Its Inhibition
HIV-1 entry into target cells is believed to be a multi-step and complex process
(reviewed in [6, 8]). The ﬁrst step is the binding of gp120 to the target cell surface
molecule CD4, which serves as the main receptor for HIV-1 [17]. However, CD4
alone is not sufﬁcient for HIV-1 to fuse with the cells [18, 19]. Two chemokine
receptors, known as CCR5 and CXCR4, are the major HIV-1 coreceptors and all
viral strains can use one (R5 and X4 viruses) or both (R5X4 viruses). The gp120-
CD4 binding induces conformational changes in gp120 leading to the exposure or
the formation of the coreceptor binding site. gp120 binding to the CD4 and cor-
eceptor results in further conformational changes that lead to gp41 activation into
its fusion-active state. The gp41 conformational changes lead to the insertion of its
FP into the target cell membrane and the formation of an extended prehairpin
intermediate that bridges the viral and cellular membranes. Subsequent chan-
ges within the gp41 ectodomain involve the interaction of CHR and NHR, and
a 6HB structure is formed. The hairpin formation brings the viral and cell
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membrane into close proximity, allowing fusion of the membranes and then
entry of the virus.
Each of the HIV-1 entry steps can be a target for entry inhibitors. The ones
currently under development fall into one of three categories: gp120-CD4 binding
inhibitors (or attachment inhibitors), gp120-coreceptors binding inhibitors (or
chemokine coreceptors inhibitors), and fusion inhibitors (reviewed in [20, 21]).
Several molecules that block gp120 binding to CD4 receptor and coreceptors have
been identiﬁed and are reviewed elsewhere. This chapter reviews the molecular
bases of fusion inhibition and the involvement of gp41. As such, the discussion
will focus on peptide-based fusion inhibitors (Figure 10.1).
Fusion inhibitors, such as enfuvirtide (also known as DP-178, T-20, or Fuzeon)
and T-1249 (Tifuvirtide), both from Trimeris, Inc. and Hoffmann-La Roche, Inc.,
are peptides whose mode of action involves binding to gp41. They interfere with
the conformational changes that lead to the 6HB formation and membrane fusion.
These kinds of inhibitors are the leading compounds, enfuvirtide being approved
by the FDA since 2003 [23, 24]. Enfuvirtide remains the standard in HIV fusion
inhibitor peptides as the only drug to complete the whole development track up
to clinical use.
10.4
HIV-1 Fusion Inhibitors: from Bench to Clinical Administration
The initial development of HIV-1 fusion inhibitors was based on peptides that
were derived from the HR regions of gp41, mainly obtained by protein dissection
strategies. Some synthetic C-peptides, such as C34 and enfuvirtide, are highly
potent inhibitors of HIV-1 infection at low nanomolar range [25, 26]. It has been
proposed that these C-peptides act by interfering with the formation of the 6HB in
a dominant negative fashion, by binding to the NHR region of gp41 exposed in the
prehairpin intermediate [8, 14, 27].
Synthetic N-peptides also exhibit inhibitory activity against HIV. They are less
potent inhibitors (micromole range) than the C-peptides [14, 28, 29]. It was pro-
posed that one of the main reasons for this behavior is their tendency to aggregate
in solution [14]. N36 and DP107 are examples of N-peptide inhibitors. In their
mode of action, N-peptides may either target the CHR region [14] or intercalate
with the NHR region [30].
A critical aspect of the inhibition by HR-derived peptides is the propensity of the
central NHR core to form a highly stable helical 6HB complex with CHR peptides.
Structural analysis of gp41 indicated that the NHR core formed deep hydrophobic
pockets. A complementary speciﬁc region of CHR, named the pocket binding
domain (PBD), packs into those domains on the NHR core faces enabling effective
interactions within the helical complex [31].
C34, a 34 amino acid residues peptide, was the C-peptide used to discover the
trimeric coiled coil structure of gp41 [15]. It can be used as a fusion inhibitor and is
one of the most potent early-discovered fusion inhibitors. This peptide overlaps the
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CHR region, including the PBD region, which is essential for its antiviral effec-
tiveness [31]. In terms of activity, it showed an increased in vitro activity. At a
molecular level, C34 forms highly stable helical complexes with N-peptides, such
as N36 [29]. Considering the mode of action, evidence (using the C34-like 36
residues inhibitor T649) suggests that the hydrophobic pocket domain and the
LLSGIV sequence of the NHR are both preferential docking sites for this peptide,
explaining its increased inhibition efﬁcacy [32]. Nevertheless, despite being more
potent, C34 is not a good drug candidate due to its low solubility [33].
Enfuvirtide is a 36 amino acid residues peptide that was developed as a novel
anti-HIV drug [26, 34]. It is currently the more advanced fusion inhibitor drug
approved for clinical application. Since 2003, enfuvirtide has been licensed by the
FDA for the treatment of HIV patients who failed to respond to current anti-
retroviral therapeutics [23].
Enfuvirtide shares 24 identical residues with C34, but lacks the PBD at the
N-terminal. In terms of molecular interaction, unlike C34, enfuvirtide does not
form stable helical complexes with N36 [35]. Despite the reduced helicity, it pos-
sesses high antiretroviral activity. Crucial for this inhibitory effect are the
C-terminal residues not included in C34 [36]. Mutations and deletions of the
C-terminal domain have been shown to impair the antiretroviral activity of enfu-
virtide [35]. This region overlaps the TRD and is responsible for efﬁcient lipid
membrane binding [37, 38]. Lipid membranes play an important role during HIV
inhibition, since the fusion process must occur in extreme conﬁnement between
the viral envelope and the cellular plasma membrane [39]. Membranes participate
in enfuvirtide’s action, by increasing its concentration at its site of action. It was
demonstrated that enfuvirtide incorporates extensively into neutral liquid-crystal
lipid membranes and occupies a shallow position in the lipid membrane [40]
(Figure 10.2).
The mode of action by which enfuvirtide inhibits viral fusion is still not com-
pletely clear and is rather complex. Several proposals have been presented invol-
ving different target sites in gp41, gp120, and at the membrane level. The most
currently accepted mechanism is the one proposed for C-peptides in general,
involving interaction with the gp41 NHR region, thus preventing the conforma-
tional changes that lead to the fusion-active arrangement [26, 41, 42].
However, accumulated evidence suggests that this assumption may be too
simplistic. Due to the lack of the PBD region, it was suggested that enfuvirtide
binding afﬁnity to the NHR region cannot justify its strong inhibitory activity and
the peptide should have at least two different interactions modes with gp41 [43].
In addition, Kliger et al. [44] showed that enfuvirtide can bind to membranes
and oligomerize on their surface. The involvement of lipids in the mechanism of
interaction of enfuvirtide, by contrast with C34, has also been reported by Jiang
and coworkers [37]. Therefore, two possible enfuvirtide target sites in gp41 can
be proposed, both contributing to fusion inhibition: interaction with the NHR
region in aqueous solution prevents the formation of the 6HB structure, while
interaction with gp41 in the membrane environment inhibits fusion pore
formation [43–45].
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Less accepted, but also proposed modes of action for enfuvirtide involve its
binding to the gp41 FP, preventing the insertion of the latter into the target cell
membrane and thus membrane fusion [46], and binding to the gp120 subunit, as
an additional target site contributing to its inhibitory activity [47].
During pre-clinical and clinical trial phases, enfuvirtide was demonstrated to be
effective against a broad spectrum of HIV-1 strains. Maximum efﬁcacy and safety
were achieved with a dose of 90 mg injected subcutaneously twice daily [48].
Though it possess potent anti-HIV activity, enfuvirtide has several pitfalls, such as
a short half-life in vivo, local side effects and induction of drug-resistant strains.
Based on the knowledge gathered on the structure, activity, and function of
fusion inhibitors such as enfuvirtide or C34, several modiﬁed peptides have been
created, in an attempt to achieve better antiretroviral activity in vivo (reviewed
in [35]).
One of these new molecules is the rationally designed second generation fusion
inhibitor T-1249. This 39 amino acid residues peptide is composed of sequences
derived from HIV-1, HIV-2, and simian immunodeﬁciency virus (SIV) [49], and
incorporates both PBD and TRD regions, which explains the efﬁcacy enhance-
ment. Despite the need for clariﬁcation, it is believed that, in its mechanism of
action, T-1249 acts like most C-peptides, interacting with the NHR region and
preventing 6HB formation [23]. It is also able to concentrate on lipid membranes.
At variance with enfuvirtide, T-1249 adsorbs on the surface of raft-like platforms in
lipid membranes, this difference being one possible explanation for its improved
activity. Pre-clinical and clinical studies have demonstrated that this peptide is
more potent (2 to 100-fold increase in activity in vitro [35]) and has a higher half-life
than enfuvirtide, thus enabling a once-daily subcutaneous dose. Furthermore,
WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL
YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF
FP NHR CHR TM CT
SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL
C34
Enfuvirtide
N36
Figure 10.2 Peptide fusion inhibitors and respective gp41 domains. Schematic
representation of the location of the N- and C-terminal heptad repeats domains (NHR and
CHR, respectively) on gp41 and the sequences from which three ﬁrst-generation fusion
inhibitors are derived: N-peptide N36 (residues 546–581) and C-peptides C34 (residues 628–
661) and enfuvirtide (residues 638–673). The underlined and bold sequence in C34 represents
the pocket-binding domain (PBD), whereas the underlined and italic sequence in enfuvirtide
represents the Trp-rich domains (TRD). FP – fusion peptide, TM – transmembrane domain,
CT – cytoplasmic tail.
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T-1249 has been demonstrated to be active against enfuvirtide resistant HIV-1
isolates [50]. Nevertheless, in spite of these optimistic results, the clinical devel-
opment of T-1249 was discontinued due to formulation difﬁculties [35, 48].
Another peptide that has recently completed phase IIb clinical trials
(http://www.fusogen.com/en/news.asp?id=146) is Sifuvirtide. This 36 aa peptide
designed by FusoGen Pharmaceuticals Inc. has been engineered using 3D
structure information of HIV-1 gp41 and computer modeling analysis [51]. Sifu-
virtide has 16 different residues compared to C34 and 22 compared to enfuvirtide.
Like C34, it maintains the PBD region and lacks the TRD region important for
membrane binding [52]. Its mode of action is believed to be similar to C34.
Nevertheless, it was demonstrated that this peptide adsorbs selectively on the
surface of rigid phosphatidylcholine membranes [53, 54]. Sifuvirtide can form a
stable 6HB structure with the N-peptide N36 and has potent inhibitory activity
against enfuvirtide-resistant strains. Phase Ia clinical studies demonstrated that
this peptide has a better safety proﬁle, tolerability, and pharmacokinetic properties
than enfuvirtide [52, 55]. This peptide presents low injection side reactions, a
longer half-life in vivo and a 20-fold higher potency in vitro, which enables the
administration of a lower once-daily dose compared to enfuvirtide [52, 55]. This
peptide was modiﬁed by introducing several salt bridges, which favored its solu-
bility, a-helicity, durability and antiviral potency [52]. In the next section new
modiﬁcations of the C- and N-peptides, as those applied in Sifuvirtide, will be
discussed in more detail.
10.5
New Strategies for Creating New HIV Fusion Inhibitor Peptides
Understanding the trimeric gp41 structure and the putative interaction of the
CHR and NHR explained why peptides derived from sequences of gp41 inhibited
HIV infection of cells. This unlocked a new wave of research that aimed to discover
new peptide drugs that target gp41-mediated fusion. In fact, the peptide nature of
these drugs gives the researcher a particularly ﬂexible framework with deﬁned
rules, which can be played in a myriad of ways. Also, exploring these diverse
combinations gives important information on the factors that are most important
for the effectiveness of these drugs. In this setting, and not surprisingly, the
majority of the fusion inhibitor peptides that were or will be described did not
proceed to clinical trials nor were intended to. Hence, many of the peptides were
created for research purposes only, as intermediates or precursors for possible
future drugs.
In this section we will describe new fusion inhibitor peptides and the strategies
behind their design to improve their activity. The starting point is always the wild
type (wt) sequence of gp41 (HXB2) or an already modiﬁed gp41-based peptide. The
rational design of new sequences for these types of drugs usually takes into
account factors such as binding to native gp41, secondary structure (helicity),
solubility, oligomerization, isomerism, or even lipophilicity.
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10.5.1
Increasing Helicity and Binding to gp41
One of the ﬁrst practical rationalizations in order to improve enfuvirtide activity
was to increase the helicity of the peptide in solution [56]. Enfuvirtide does not
have a deﬁned secondary structure in solution [26], but assumes an a-helical
structure when bundled with a corresponding gp41 N-terminal peptide [14].
Hence, forcing a helical conformation in solution could reduce the energy
necessary for the interaction to occur. For this, HIV35, a shorter derivative of
enfuvirtide in which the hydrophobic C-terminal TRD (KWASLWNWF) is absent,
was used. Ablation of this domain actually results in a peptide with substantially
decreased antiviral activity. Covalent crosslinks between aminoacids at positions i
and iþ 7 were used to lock the a-helical conformation. Peptides derived from
HIV35 with one (HIV24) or two (HIV31) cross-links were prepared, and circular
dichroism studies conﬁrmed the increased helicity of these forms. The cross-
linking in HIV24 partially restored the activity of the truncated peptide, while in
HIV31 it increased it to levels similar to enfuvirtide. This proved the importance of
the secondary structure in determining the binding with gp41, even when an
important domain for activity is ablated.
A similar approach was used with other short C-peptides that were targeted to
the hydrophobic pocket region [57]. The a-helix was stabilized via chemical
crosslinking with a diaminoalkane group linking two Glu residues at i and iþ 7
and with the use of an unnatural aminoacid that favors helicity (a-aminoisobutyric
acid). The sequence C14wt (gp160 HXB2 626–639) showed very weak antivi-
ral activity, measured by cell–cell fusion assay. The highest antiviral activity was
obtained for the version of the peptide cross-linked in the middle at positions 629
and 636 (C14linkmid) followed by an unlinked version but with those positions
substituted by a-aminoisobutyric acid (C14Aib). For this case, an important
binding site, targeting the hydrophobic pocket, was maintained, and the short
sequences used proved to be sufﬁcient for inhibition but modiﬁcations to achieve
helical constrain were mandatory.
A possible disadvantage of this kind of approach is that cross-linking strategies
are not favorable to large scale manufacturing, if a peptide of this kind is able to
reach broad clinical use.
Besides these two examples of peculiar use of chemical crosslinking, the
majority of the approaches for modifying this kind of peptide involves aminoacid
residue changes, rearrangements, and shortening/elongation.
A good example of rational design by modifying the aminoacid sequence was
done for C34. It is less soluble than enfuvirtide which is one of the reasons why
C34 never progressed in a clinical setting. Otaka et al. [33] modiﬁed C34 with the
following rationale: (i) maintenance of the aminoacids responsible for the inter-
action with gp41, when represented in a helical-wheel diagram against a trimer of
N36; (ii) substitution of non-conserved aminoacids of the solvent accessible site by
Glu and Lys that should form ions pairs at positions i and iþ 4. This would
enhance solubility and helicity due to formation of intrahelical salt bridges [58].
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Two main peptides were derived, SC34 and SC34EK, with the latter neglecting the
maintenance of some conserved aminoacids in favor of more salt bridges to sta-
bilize the helix. These two peptides had signiﬁcantly higher antiviral activity in
vitro than enfuvirtide, SC34EK being a little more potent than SC34. An extreme
version of these peptides (SC35EK) was also synthesized in the form Z-EE-ZZ-KK
(with Z representing an arbitrary aminoacid), maintaining the interactive site
while the solvent accessible was exclusively Glu and Lys, with activity still com-
parable with the other peptides. The stable structure of SC34EK with N36 was later
conﬁrmed by X-ray crystallography [59]. This shows that increasing helicity by
aminoacid substitution while maintaining the residues that interact with gp41
NHR is a successful strategy to increase the activity of fusion inhibitor peptides
(Figure 10.3).
The same approach was taken for enfuvirtide, by introducing the same motif
Z-EE-ZZ-KK resulting in an increase in the antiviral activity [60]. Shorter versions
of SC35EK were also produced with 29 (SC29EK) and 22 (SC22EK) aminoacids by
truncation at the C-terminal region [61]. Only SC29EK maintained activity similar
to SC34EK and also inhibited enfuvirtide-resistant strains of HIV.
In an effort to screen for the next generation fusion inhibitor that would follow
enfuvirtide and T-1249, scientists from Trimeris designed a new set of peptides to
improve helical propensity and afﬁnity to gp41 NHR that self-associate to stable
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Figure 10.3 Design and structure of SC34EK. (a) The C34 sequence was modiﬁed by
introducing EK (i, iþ 4) motif in the solvent accessible site, while maintaining the aminoacid
residues (Z) of the interactive site. (b) Side and top views of the structure of the 6HB formed
by N36/SC34EK (gray), superimposed by the gp41 native core structure (black). (c) Stick
model representation of SC34EK modeled in interaction with part of a N36/SC34EK bundle
(gray structure). The location of the N-terminal Trp rich domain is indicated by a circle (TRD).
Adapted from [59].
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oligomers in solution and are active against enfuvirtide-resistant strains [62]. The
starting peptide was named T-2410, a wt sequence from gp41 CHR that included
the hydrophobic pocket binding sequence. Residues that could be changed with-
out compromising antiviral activity and 6HB stability were selected by Ala scan-
ning. Charged aminoacids Glu and Arg were introduced in spaced positions i and
iþ 4 in order to favor formation of salt bridges. To further increase helicity, some
noncritical aminoacids not participating in salt bridges were substituted by Ala, an
aminoacid with high helical propensity. Up to 15 peptides were obtained with this
rational design, from which we will highlight T-2635. This peptide was found, by
circular dichroism, to be 75% helical, compared with the starting point of only 7%
for T-2410 (enfuvirtide is 12%). It oligomerizes in solution, being a trimer in the
concentration range from 50 to 1000 mM and a mixture of trimer and monomer
below 50 mM. Its in vitro activity can be up to >3600-fold greater than enfuvirtide in
certain strains. Importantly, it takes much longer for the virus to aquires muta-
tions to resist these peptides than with enfuvirtide and they have improved
pharmacokinetics in cynomolgus monkeys, including extended half-life. Besides
the usual structural reﬁnements, this work also emphasizes the role of the oli-
gomerization state in the antiviral activity.
Although the majority of the peptides described here contain the pocket binding
sequence and/or the TRD lipid binding domain, He et al. identiﬁed a new motif
upstream of the pocket binding domain important for the stabilization of gp41
6HB (621QIWNNMT627) [63]. A series of peptides containing this sequence was
obtained, from which we will highlight CP621–652. This peptide was able to
interact with a counterpart NHR peptide in a more stable way than C34. Moreover,
improved activity was observed compared to enfuvirtide and the peptide
also inhibited strains resistant to enfuvirtide and C34. Based on CP621–652, a new
peptide was designed by introducing Lys and Glu in order to create ion pairs, and
the ﬁrst residue at the C-terminal was changed to Val to enhance hydrophobic
interaction with the NHR counterpart [64]. This new peptide, CP32M, had
improved characteristics over its predecessor and we can emphasize the high
potency in low picomolar amounts against enfuvirtide- and C42-resistant strains.
These peptides do not rely on the 547GIV549 motif to interact with NHR, a
sequence previously shown to be a major determinant of resistance to enfuvirtide
and C34 [65].
However, creating peptides that are effective against resistant strains should not
be more difﬁcult. Single aminoacid residue modiﬁcation of enfuvirtide or C34 can
overcome such resistance. Izumi et al. [66] took into account that the CHR
mutations S138A and N126K enhance resistance to enfuvirtide and C34, respec-
tively, and created a peptide with modiﬁed aminoacids on those positions. For
enfuvirtide, substitution with all natural aminoacids was tried, resulting in the fact
that only T-20S138A inhibited replication of enfuvirtide-resistant virus as efﬁ-
ciently as the wt clone. Other efﬁcient substitutions were for smaller hydrophobic
residues (Ala, Leu, Ile) or more ﬂexible ones (Met, Thr). The same happened
for a C34 modiﬁed through the mutation N126K, which became active against
the respective resistant strain. This case highlights the importance of having
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resistance information in order to speciﬁcally tailor the peptides to overcome such
barrier.
Another example of an innovative approach comes from the creation of C34coil,
a derivative of C34 grafted into a GCN4 Leu zipper [67]. In this case, residues of
C34 critical for binding to NHR are transferred to a GCN4 sequence, functioning
as a scaffold. After that, the C34-GCN4 peptide was disulﬁde linked to a GCN4
peptide only in order to form a coiled coil dimer. This resulted in a more stable and
structurally deﬁned peptide, with enhanced solubility and helicity. Importantly,
C34coil was 1000 times more resistant to proteolytic degradation than C34 itself.
This new peptide is not more potent than C34; however, IC50 values for cell–cell
fusion and infectivity assays are within an order of magnitude.
We should also not forget that computational biology is nowadays a major tool to
design new drugs tailored to a speciﬁc molecular target. The computation power
available makes the simulation of structures and interactions increasingly acces-
sible and informative. A series of 10 variants of C34 (KYK01 to 10) was designed
based on molecular dynamics simulations of 6HB stability to increase the binding
to the gp41 NHR region [68]. KYK01, KYK02, and KYK03 were more efﬁcient in
inhibiting virus replications than the original C34; however, they were inactive
against enfuvirtide-resistant viruses. To overcome this, KYK02 was modiﬁed to
carry the previously mentioned S138A substitution. For this case more than one
strategy was applied in order to design a truly efﬁcient drug.
10.5.2
Isomeric Peptides and Resistance to Proteolysis
To speciﬁcally tackle the problem of the oral bioavailability of these drug peptides,
due to rapid preoteolytic degradation in the gastrointestinal tract, the main
strategy that emerged was to design peptides with different chirality from the
natural ones: D-peptides. Using once again the pocket binding site as a target,
a D-peptide IQN17 was designed to properly present this target to serve as a
template for the new peptides [69]. Using mirror-image phage display, several D-
peptides were identiﬁed (D10-p1 through D10-p12). They presented a 10 residues
consensus sequence to the binding of the pocket region. Cys ﬂanking the con-
sensus sequence generated an intramolecular disulﬁde bond to yield a cyclic
peptide. Lys were added at the N-terminus to increase solubility. These peptides
were capable of inhibiting HIV-1 entry into cells in the micromolar concentra-
tion range. This kind of approach was reﬁned in a later study [70] in which the
authors locked the consensus residues and randomized the other ones in
the phage-display rounds. The new peptides were more potent than those obtained
in the ﬁrst studies and were active against laboratory-adapted strains (HXB2) and
primary isolates.
In another attempt to create proteolysis resistant fusion inhibitors, the C34
sequence was modiﬁed by introducing D-aminoacid point substitutions at sites
not directly involved in 6HB integrity [71]. These modiﬁcations were able to create
stable and helical peptides with similar activity to C34.
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10.5.3
Bacterially Expressed Peptides
From the pharmaceutical point of view, even if a peptide is very potent, it may not
be feasible for commercialization if its manufacturing is difﬁcult and costly. To
address the problem of large scale manufacturing, Deng et al. tried, for the ﬁrst
time, to express a fusion inhibitor peptide, C52L in E. coli [72]. This peptide spans
the sequence of enfuvirtide and C34, containing at the C-terminus a heptad reg-
ister of three residues from the N-terminus of GCN4-pII isoleucine trimer to
enhance helicity. The peptide was produced by extraction from insoluble bacterial
inclusion bodies. It possessed broad activity, inhibiting infection of all clades of
HIV-1 group M and also enfuvirtide resistant variants. This was the ﬁrst and only
time that this kind of production was tried, aiming at a solution for getting more
affordable drugs of this type.
10.5.4
Modiﬁcation of Peptides by Derivatization with Lipids or Proteins
In the constant search for ways to optimize and increase the effectiveness of HIV
fusion inhibitor peptides, sometimes it takes more than just residue substitutions
to achieve a better result. In this section we will describe how HIV fusion inhibitor
peptides can be modiﬁed by covalently attaching another molecular entity to
increase potency.
An unconventional approach was taken by Hildinger et al. by expressing a
membrane-anchored version of enfuvirtide [73]. In this case enfuvirtide was
expressed fused with a membrane protein, so that the peptide was displayed at the
surface of a T-helper cell line. In this way, the peptide potently inhibited viral
replication in these transduced cell lines. In contrast, a construct that attached
enfuvirtide to a secreted protein instead of a membrane spanning one, did not
inhibit the replication. This indicates that attachment of the drug to the cell
membrane, where viral fusion occurs, increases the efﬁcacy of the drug.
Following different observations of the enhanced efﬁcacy of membrane asso-
ciated peptides, Peisajovich et al. [74] synthesized SIV-derived enfuvirtide peptides
acylated at their C-terminus. Octylation of enfuvirtide rendered the peptide sig-
niﬁcantly more potent than the peptide itself. The same did not happen for propyl
and hexyl variations and for N-terminal acylation. Moreover, an inactive enfuvir-
tide mutant in which part of the TRD, GNWF, was substituted by ANAA, was
rescued when octylated. The acylation seemed to mimic the role of the hydro-
phobic C-terminal region of the peptide. This C-terminal modiﬁcation to the
peptide could direct the peptide to the cell membranes in order to be readily
available if the virus infects the cell, and with the favorable orientation to interact
with gp41 NHR. This membrane association effect is similar to the previously
presented case of enfuvirtide covalently attached to a membrane spanning
protein.
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A series of enfuvirtide peptides was truncated at this region to arrive at a
minimal inhibitory sequence, named DP [75]. In this version, the entire region
containing the three C-terminal Trp residues was removed. This peptide was then
attached to fatty acids of 8, 12, or 16 carbons to assess the effect of chain length.
Indeed, the higher the length the more potent was the conjugate in inhibiting viral
fusion. N-terminal conjugation did not lead to similar improved efﬁcacy, hence the
importance of the orientation of the peptide. The hydrophobic anchor of these
modiﬁed peptides permitted higher potency, presumably due to membrane tar-
geting and concentration effects.
Trimeris, the company behind enfuvirtide and T-1249, also developed a peptide
conjugated with fatty-acid. TRI-999 is a peptide that includes the pocket binding
domain regions but not the C-terminal hydrophobic tail. Instead, a C18 fatty acid is
attached to the only Lys residue near the C-terminus through a PEG3 linker [76].
This peptide was more potent than enfuvirtide, having an IC50 up to 250-fold
lower. Importantly, the pharmacokinetics clearance values were up to sixfold
slower than enfuvirtide, showing a slow and steady release of the drug [77].
In an effort by scientists of Merck Research Laboratories to increase the efﬁcacy
of C34, a new type of conjugate was synthesized with a cholesteryl moiety attached
[78]. The rationale for the use of cholesterol instead of a fatty acid was the higher
afﬁnity towards membranes and targeting of the drug to the receptor-rich mem-
brane microdomains (lipid rafts) where HIV-cell fusion is likely to occur. This
modiﬁcation increases the antiviral activity from 15-fold to 300-fold compared to
enfuvirtide and T-1249, and increases signiﬁcantly the half-life of the peptide in
vivo. Moreover, the activity is retained in vitro if pre-treated host cells are washed.
Contrary to C34, the addition of cholesterol to enfuvirtide does not have the same
effects of enhancing potency, probably due to the existence of the lipid binding
domain already. Interestingly, this cholesterol tagging strategy was also later used
for fusion inhibitor peptides of paramoxyvirus [79].
Beside these lipopeptide conjugates that turned out to be quite successful,
protein conjugates were recently considered. The C34 fusion inhibitor peptide was
conjugated with human serum albumin and tested for in vitro and in vivo action
[80]. A maleimido-C34 derivative was reacted with cysteine 34 of HSA, the only
cysteine of this protein, resulting in a 1 : 1 complex, named PC-1505. The potency
of this conjugate was still similar to C34 and enfuvirtide, indicating that the
accessory protein did not prevent the peptide from reaching gp41 in the pre-fusion
state. More importantly, the PC-1505 activity in vivo was 3 times higher than the
unconjugated form and was more sustained, resulting in an improved pharma-
cokinetic proﬁle. A similar approach was taken by Xie et al. [81], where they
modiﬁed a C34 peptide in order to carry a maleimido group in Lys 13 (FB006M).
When injecting this modiﬁed peptide in SCID/hu mouse model the peptide
reacted with Cys 34 of albumin in the blood, generating a 1 : 1 complex which
prolonged the half-life of the drug while maintaining its efﬁcacy.
Another interesting approach was taken by Ji et al. [82]. They created a construct
CD4-BFFI which consists of two HIV-1 fusion inhibitor peptides T-651 [62] fused
to the Fc (fragment, crystallizable) end of a humanized anti-CD4 monoclonal
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antibody. This antibody part would direct the conjugate to the CD4 receptor
making the peptides available at the exact site of viral attachment. CD4-BFFI
presented improved antiviral activities over nonconjugated T-651, as well as
improved serum stability and pharmacokinetics, with a half-life of several days.
This demonstrates once again the utility of using peptide conjugates to improve
the pharmacological proﬁles of these kinds of peptide drugs.
10.6
Drug-Resistance and Combination Therapy
The emergence of drug-resistant HIV-1 variants in patients under fusion inhibitor
therapy is one of the aspects that should be taken into consideration in the
development of novel compounds. Resistance to enfuvirtide has been observed
both in vitro and during clinical studies and is governed by changes in the NHR
region, especially in and around the GIV motif (amino acids 35–45 of gp41)
(reviewed in [83]). Those mutations have been shown to reduce the level of
enfuvirtide binding and sensitivity, but at a ﬁtness cost. These mutations interfere
in the interaction between the viral NHR and CHR domains, thus decreasing viral
bundle stability, which may alter fusion kinetics, pathogenicity, replicative ﬁtness,
and other aspects of the viral fusion process. Nevertheless, the virus may further
evolve to repair its ﬁtness loss by introducing a compensatory mutation, normally
in the CHR domain. For instance, Baldwin and Berkhout reported that, for the
V38A mutated virus, the compensatory mutation N126K promoted a drug-
dependent phenotype [83]. Alternatively, Bai et al. [84] and Tolstrup et al. [85]
reported the E137K mutation that partially compensated the loss of stability at the
helical bundle level for N43D-mutated viruses and further increased its resistance
to enfuvirtide.
A way to delay the emergence of drug resistance and/or take advantage of the
loss of replicative ﬁtness of drug-resistant strains could be the use of combination
therapy. The simultaneous use of antiretroviral drugs with different targets is able
to increase the antiviral potency because of the synergistic effect resulting from the
combination. For instance, strong synergistic activity was reported when entry
inhibitors targeting gp120 (e.g., PRO 542), gp41 (e.g., enfuvirtide), and the cor-
eceptor, CXCR4 (e.g., AMD3100) or CCR5 (e.g., SCH-C), were used in combina-
tion [86–88]. Additionally, some studies demonstrated that combination of fusion
inhibitors targeting different sites would also result in a similar phenomenon.
Hrin et al. demonstrated that a combination of enfuvirtide and (CCIZN17)3, a
trimer of N-peptides targeting the CHR domain, worked synergistically in inhi-
biting the entry of primary HIV-1 isolates in an in vitro infectivity assay [89]. The
combinations of enfuvirtide with other C-peptides have also demonstrated potent
synergistic effects. For instance, the combination of enfuvirtide (which possesses
the TRD) and Sifuvirtide (which presents the PBD) exhibited strong synergic
activity against laboratory-adapted and primary HIV-1 strains [90]. More recently,
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Pan et al. tested the combination of enfuvirtide with both second-generation
T-1249 and next-generation fusion inhibitor T-1144 (drug similar to T-2635)
against HIV-1 induced cell–cell fusion [91]. The double combination exhibited
strong synergism, leading to two orders of dose reduction. Exceptional synergistic
activity was retrieved using the triple combination, where a three-order dose
reduction was demonstrated. Furthermore, combination therapy with enfuvirtide,
T-1249 and T-1144 led also to strong synergism against enfuvirtide- and T-1249-
resistant HIV-1 variants. Enfuvirtide, T-1249 and T-1144, and also Sifuvirtide,
contain different functional domains and present distinct primary binding sites.
The binding of one of those C-peptides to the viral gp41 NHR domain may extend
the temporal window period of the already transient fusion intermediate, which
would then become more accessible to the other C-peptides, resulting in a potent
synergism [51].
To conclude, synergistic strategies may provide higher efﬁcacy with lower
antiretroviral doses, overcoming limitations of a one-drug therapy to patients, such
as ineffectiveness against resistant-strains, requirement of high doses per injection
and serious injection side effects. In the end, the use of a combination of fusion
inhibitors may result in lower costs and lower rejection of the antiretroviral
therapy.
10.7
Concluding Remarks
The notions underlying the HIV-1 membrane fusion process and the contribution
of gp41 fusion intermediate are nowadays well accepted among the scientiﬁc
community. The discovery of the structure of the gp41 hairpin, prior and after
gp41 NHR and CHR reorganization, contributed signiﬁcantly to the development
of new strategies to inhibit HIV-1. To ensure a competent viral and plasma
membrane fusion, the CHR and NHR domains of the viral protein gp41 must
interact to form a trimeric hairpin structure. The inhibition of this viral process is
the basis of the mode of action, potency, efﬁcacy and selectivity of fusion inhibi-
tors. Since the early 1990s, when the ﬁrst peptide inhibitors were discovered,
major advances have occurred in the way we understand and design these peptidic
compounds. The development of more potent and novel fusion inhibitors is being
addressed, understanding the contribution of structural features and speciﬁc
domains that are needed for a stronger and efﬁcient interaction with gp41.
Enfuvirtide is still the only licensed and FDA-approved drug of the fusion inhibitor
class, but other drugs are now in pre-clinical or clinical development. Moreover,
new insights on the mechanism of resistance and tolerance of these compounds
have been discovered and several strategies involving synergistic approaches are
being tested. Therefore, we can expect better outcomes and more compounds to
appear in the near future, thus providing new hope for the treatment not only of
AIDS but also of other viral diseases.
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Abstract: Peptide–membrane interaction is an important step to be evaluated in a study of the activity and mode of action
of several bioactive peptides. A variety of methods are available; however, few of them satisfy the criteria of being sensitive,
biocompatible, versatile, easy to perform, and allowing real-time monitoring as the use of potential-sensitive fluorescent probes.
Here we review methods for detecting the effects of membrane-active peptides, even those that are not intrinsically fluorescent, on
the different types of membrane potentials, with a special emphasis on studies conducted with living cells. FPE is a probe sensitive
to surface potential and detects electrostatic interactions at the water-lipid interface. Di-8-ANEPPS is sensitive to dipole potential
and detects membrane incorporations. Transmembrane potential changes reveal major membrane destabilizations, such as in
pore formation. The combination of the information obtained from the three potential variations can lead to a more elucidative
picture of the mechanisms of the interaction of relevant peptides with biomembranes. Copyright  2008 European Peptide Society
and John Wiley & Sons, Ltd.
Keywords: biomembranes; bioactive peptides; fluorescent probes; surface potential; dipole potential; transmembrane potential
INTRODUCTION
The cell membrane is the interface between the
cytoplasm and the outer environment, where all
the exchanges and interactions take place, allowing
cells to obtain nutrients and energy, export, attach,
communicate and sense, with the aid of a myriad
membrane-associated proteins. The numerous roles
of membranes are indicative of its extraordinary
functional flexibility.
Interaction of peptides with lipid bilayers, either
cell membranes or artificial vesicles, is an expanding
research field, as peptides are a very versatile and
heterogeneous group of molecules. Depending on
the peptide sequence, charge, hydrophobicity and
secondary structure, it can be prone to interact
with lipid bilayers by simple electrostatic surface
interaction, incorporation due to the hydrophobic effect,
translocation or pore formation. All of this brings
consequences for membrane structure, namely on lipid
organization and packaging, induction of events such
as fusion, aggregation or content leakage.
Measuring these types of interactions can help to
unveil the mode of action of these membrane-active
peptides. These studies are particularly important
in drug research, where interaction with membrane
*Correspondence to: Nuno C. Santos, Unidade de Biomembranas,
Instituto de Medicina Molecular, Faculdade de Medicina da Univer-
sidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal;
e-mail: nsantos@fm.ul.pt
‡ This article is part of the Special Issue of the Journal of Peptide Science
entitled ‘‘2nd workshop on biophysics of membrane-active peptides’’.
lipids can determine the drug effects, delivery, and
bioavailability [1,2]. Even for peptides whose targets
are membrane proteins, the membrane can act as
a catalyst in the reaction, the so-called ‘membrane
catalysis model’, as it is much more probable that the
peptide establishes contact first with the membrane
and not directly with the receptor [3]. Studies on
peptides can also serve as a simple model to understand
interactions at higher levels of complexity, such as the
interaction of proteins with the membrane [4].
Fluorescence methods are very sensitive, relatively
simple to perform and can provide reliable results. In
the specific case of the use of simple mimetic sys-
tems of biological membranes (lipid vesicles) and if the
peptide have intrinsic fluorescent amino acid residues,
especially tryptophan, the peptide–membrane binding
can be followed by fluorescence spectroscopy due to
microenvironment induced changes on quantum yields,
spectral changes, fluorescence anisotropy or fluores-
cence lifetimes of these residues [5]. However, this
technique is not suitable for peptides lacking fluores-
cent aminoacid residues and/or if we want to study
the interaction with biomembranes, where other pro-
teic components are already present. In order to face
these limitations, alternative strategies were developed
to indirectly measure peptide interactions with mem-
branes. This can be achieved by monitoring the effects
of these interactions on the different types of membrane
potentials, using membrane incorporated fluorescent
Copyright  2008 European Peptide Society and John Wiley & Sons, Ltd.
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probes. This is a minimally invasive method and avoids
the necessity of peptide derivatization, which modifies
its native structure and can potentially lead to biased
results.
In this article, we will focus onmethods for measuring
the interaction of peptides with membrane-model
systems and cell membranes based on the use of
fluorescent dyes that are sensitive to different types
of membrane potential, namely, surface, dipole and
transmembrane potentials.
SURFACE POTENTIAL
The surface potential arises from the net excess charges
that accumulate in the outer surface of the membrane,
in contact with the external medium (Figure 1). It
is therefore the potential difference between the
membrane surface and the bulk medium. The sources
of these charges are mainly charged lipid head-groups
and ions electrostatically interacting with them [6–8].
Any interaction of a charged entity with the membrane
surface is likely to alter the surface potential and hence
it is susceptible to be detected by a fluorescent probe.
Fluorescein phosphatidylethanolamine (FPE) is a
probe sensitive to surface potential (Figure 2) [9]. It
was first used to measure pH changes in the internal
compartment of lipid vesicles due to the variation
of its quantum yield with the protonation state of
the fluorescein (increased fluorescence with increased
deprotonation) [10]. Later it was described more
generically for the measure of pH at the water/lipid
interface [11], a property that permits, for instance,
the assessment of a proton pump activity [12,13].
During these experiments it was realized that changes
in the medium ionic strength could compromise the
pH measurements, which led to studies concerning the
Figure 1 Electrical potential profile across a phospholipid
bilayer. The surface potential (ψs) arises from charge accumu-
lation at the membrane surface, the dipole potential (ψd) is
a consequence of the alignment and distribution of lipid and
water dipoles, and the difference in charge concentration in
the two bulk mediums separated by the membrane constitutes
the transmembrane potential (�ψ ).
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Figure 2 Structures of the membrane potential probes FPE and di-8-ANEPPS, incorporated in a phosphatidylcholine membrane
leaflet.
effect of peptides in lipid membrane surface potentials
[9].
When incorporated into lipid membranes, the fluo-
rescein moiety of this probe stands precisely in the
water–lipid interface, and hence it has the ability to
detect pH or charge distribution changes at the mem-
brane surface [9]. FPE behavior can be explained by the
Handersen–Hasselbach equation, taking into account
the surface potential [14]:
log
(
cF
cHF
)
= pH−
(
pK − Fψs
RT ln10
)
(1)
where cF and cHF are the concentrations of the
dissociated and protonated forms, respectively, of the
fluorophore located at the membrane surface, and the
expression pK − Fψs/(RT ln 10) is the apparent pK,
where ψs is the surface potential. It can be easily
understood that for the fluorescein moiety of FPE,
standing at the membrane surface, changes in the
surface potential at constant bulk phase pH, will affect
its apparent pK and consequently, its protonation state,
resulting in changes in the quantum yield [9,15]. The
simplest test to verify the correct incorporation and
responsiveness of FPE in vesicles or cells is the addition
of calcium ions to the medium, which will lead to an
increased surface potential and consequently decreased
fluorescein apparent pK, increased deprotonation,
and increased fluorescence intensity [9]. A possible
interference factor is the adsorption of proteins, which
may change the dielectric constant in the vicinity of the
fluorescent probe, so that fluorescence changes may
not only reflect surface potential alterations.
The first experiments that used FPE to assess
peptide–membrane interactions were done with phos-
pholipid vesicles and involved the study of the pep-
tides pyrularia thionin (PT), CTX (Naja naja kaouthia
cardiotoxin), p25 (leader peptide of subunit IV of
cytochrome c oxidase) and melittin, known to be
membrane-active [9]. FPE was characterized in terms
of its fluorescence spectra in phospholipid vesicles and
pH titrations were done to determine the pKapp in dif-
ferent ionic conditions. The correct incorporation of
FPE in the outer leaflet of the vesicles was tested. PT
and CTX were shown to interact with phosphatidyl-
choline/phosphatidylserine (PC/PS) phospholipid vesi-
cles, as addition of each peptide caused an increase
in the fluorescence of membrane-bound FPE. Melit-
tin and p25 had a slightly different behavior: they
also caused an increase in the fluorescence inten-
sity upon addition (increase in electropositivity of the
membrane surface) but followed by a slow decrease
until saturation (Figure 3). This biphasic interaction
was more clearly observed using a stopped-flow rapid
mixing technique, as it allowed resolving of the ini-
tial fluorescence increase in the millisecond time-scale.
The final decrease can be explained by the insertion
of regions of the peptides, or even its translocation,
placing the positive charges away from the membrane
surface, no longer affecting its potential. Melittin has a
short hydrophobic N-terminal helix bearing two posi-
tive charges (in a total of six) that can insert into the
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lipid bilayer [16]. This is in agreement with the results
mentioned above [9], because the extent of the signal
decrease following the insertion event is approximately
1/3 of the initial change, as stated by the original
authors. For the case of p25, it has been reported that
the N-terminal region of the peptide, containing posi-
tive charged aminoacid residues, inserts into the lipid
bilayer with its axis perpendicular to the membrane
surface [17]. Pore-formation and peptide translocation,
which can also explain the decreased number of positive
charges in contact with the surface upon peptide-
membrane interaction, have actually been reported for
melittin [18], and can be advanced as a hypothesis
for the case of p25. Titrating FPE-labeled PC/PS vesi-
cles with p25 held a hyperbolic binding curve with an
approximate half saturation point of 4 µM.
A more systematic study of the interaction of p25
with membrane vesicles was done later [19]. Relying on
the stopped-flow technique, fluorescence changes were
recorded over time and the dependence of fluorescence
change with the p25 concentration was found to be
described by a cooperative model (sigmoidal curve).
It was the first time that a cooperative behavior was
identified in a signal-sequence peptide and denotes the
complexity of peptide–membrane interactions.
FPE labeling of living cells is also possible and
was done, for the first time, with erythrocytes and
lymphocytes [15]. Systematic studies for B-lymphocytes
were carried out with BSA. Serial additions of this
protein caused a decrease in fluorescence intensity,
as expected, considering BSA negative net charge
at the pH of the experiment (pH 7.5). Changes on
fluorescence upon BSA addition were plotted and
analyzed according to a single binding site model,
resulting in a Kd of 2.85± 0.48 µM (Figure 4). The
choice of this specific fitting model can be controversial.
However this does not imply that there is only one
Figure 3 Time-course variation of FPE-labeled PC vesicles
fluorescence during mixing with p25 at the concentrations
(µM) indicated in each trace. Traces were offset for clarity and
for each one, two experimental traces were combined covering
time periods with different scales. Reprinted with permission
from [19]. Copyright 1996 American Chemical Society.
possible molecular explanation for the process. The
majority of the peptide–membrane interactions actually
follow a simple water–membrane partition [5] but
this cannot be quantified directly by these methods.
For assessing the response of FPE to protein–ligand
interactions at the membrane level, assays were
done using MHC class II monoclonal antibodies
and a fluorescence decrease was observed. By the
opposite, testing with an antibody that lacks binding
site in B-lymphocyte membranes, GaM-IgG, showed
no alterations in fluorescence. For studying peptide
interactions with FPE-labeled erythrocyte membrane,
melittin, poly-L-lysine, and BSA were chosen. The
first two macromolecules, being positive at the pH
of the experiments, should increase membrane-bound
FPE fluorescence. However, the opposite was observed
instead. Only when FPE-labeled erythrocytes were
previously treated with neuraminidase, the expected
fluorescence increases were observed. It seems that
for the specific case of erythrocytes, the abundant
negatively charged sialic acid residues of membrane
glycoproteins affects the response of FPE. It can be
speculated that binding of melittin or poly-L-lysine
to these moieties may alter its organization and
disposition in such a way that their influence on the
microenvironment on the close vicinity of the membrane
surface would change the FPE response, explaining the
decrease in fluorescence.
HIV-1 infection of T-lymphocytes involves the inter-
action of its membrane glycoprotein gp120 with CD4
receptors and co-receptors. When that happens, gp41
is exposed and its fusion peptide domain is inserted
in the target cell membrane [20]. The interaction of
this 16 residues gp41 fusion peptide (gp41FP) with
Figure 4 Effect of serial additions of BSA on the fluorescence
of FPE-labeled B-lymphocytes. Fluorescence decreases over
time as BSA has a net negative charge at pH of the assay (7.5).
The inset represents the absolute fluorescence changes as a
function of BSA concentration, in which solid lines represent
the fittings to a single binding site and a cooperative model [15].
Reproduced with permission of the Company of Biologists.
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T-lymphocyte membranes was assessed using FPE [21].
Assays with FPE-labeled PC vesicles show increased
fluorescence in the presence of this peptide and a coop-
erative behavior on the variation of fluorescence with
peptide concentration. These results were confirmed
using Jurkat T-lymphocytes. Moreover, the effects of
interleukin 8 (IL-8), heparitinase, heparin, and hep-
aran sulfate were also investigated. The presence of
IL-8 or heparan sulfate in soluble forms, or treatment
of the cells with heparitinase, significantly decreased
the interaction between the peptide and the cell mem-
brane. Heparin apparently affects the interactions in a
much lower extent. These results indicate that gp41FP
interacts specifically with heparan sulfate in the cell
surface, revealing that the latter may have an important
role in the virus attachment to the cell and subsequent
membrane fusion.
FPE was also used to study the interaction between
fibronectin, an extracellular matrix protein, and the
osteoblast membranes [22]. The variation profile of the
fluorescence against fibronectin concentration followed
a single binding site hyperbolic model, yielding an
affinity constant of 120 nM. Treating osteoblasts with
heparitinase reduced the binding capacity of fibronectin
to almost 50%. In the presence of the RGD peptide,
which sequence is involved in the binding of fibronectin
to integrin α5b1, the binding capacity is also reduced,
but at a lesser extent. Cell-surface proteoglycans are
then an essential way by which fibronectin binds to the
osteoblast membrane and not only to the integrins.
The versatility of FPE extends also to prokaryotic
cells. A successful labeling of Escherichia coli and
Helicobacter pylori was reported, after inactivation
with heat or UV light [23]. Although requiring some
optimizations, the authors managed to obtain an
adequate response with calcium ions and poly-L-lysine.
The interaction of the VacA (H. pylori vacuolating toxin)
p37 subunit with H. pylori membrane was studied and
a Kd value of 1.7 nM was obtained by a cooperative
binding model. The interaction of this peptide with FPE-
labeled PC/PS vesicles (model system of eukaryotic
cell membranes) was also studied [23], showing a
much lower affinity. This indicates that the preferential
interaction of p37 with the bacterial membrane can be
due to its particular lipid composition or to the existence
of a specific receptor.
DIPOLE POTENTIAL
The dipole potential of lipid membranes, or alter-
ations to it, can also reveal interactions at the mem-
brane level. This type of potential originates from the
alignment of dipolar residues of lipids (polar head-
groups and glycerol–ester regions) and oriented water
molecules hydrating the outer surface of the mem-
brane (Figure 1) [24,25]. Various methods are described
to measure dipole potentials in planar lipid bilay-
ers and lipid vesicles [26]. In terms of lipid vesicles
and cells, the easier to use, the most biocompati-
ble and allowing real-time monitoring and imaging is
the method using voltage-sensitive fluorescent dyes.
Such dyes are di-8-ANEPPS (4-[2-[6-(dioctylamino)-
2-naphthalenyl]ethenyl]-1-(3-sulfopropyl)-pyridinium)
(Figure 2) [27] and RH421 (N-(4-sulfobutyl)-4-[4-
[4-(dipentylamino)phenyl]butadienyl]-pyridinium) [28].
Beside the aliphatic chains, these probes possess a con-
jugated structure (the chromophore region), therefore
providing an extensive degree of electron delocaliza-
tion, a reason for its fluorescence and relatively high
stokes shift. They incorporate in the outer leaflet of
the membranes and the chromophore group stays near
the lipid head-group region, sensing the local electric
field derived from the dipoles [27]. The mechanism by
which di-8-ANEPPS, and RH421 and other aminos-
tyry1pyridinium dyes operate in order to sense dipole
potential is believed to be electrochromic [29]. Absorp-
tion and emission peaks shift in response to a nearby
electrical field that differentially interacts with the
ground-state and excited-state dipole moments of the
chromophore [30,31]. Therefore these kinds of probes
suggest a dual wavelength ratiometric measurements
strategy, similar to what is done with some ion indica-
tors, such as for Ca2+ [32]. This approach has several
advantages because the signal is independent of probe
or cell concentration and avoids photobleaching arti-
facts [27].
Emphasis will be put in di-8-ANEPPS, the most
used dye for dipole potential measurement. Although
the vast majority of the work with di-8-ANEPPS
relies on the excitation spectrum shift to measure
dipole potential, only recently a systematic study was
done to compare excitation and emission ratiometric
fluorescence methods for this dye, concluding that
only the former can be used [33]. Membrane fluidity is
another aspect for concern and has been addressed in
previous papers. Gross et al. [27] states that membrane
microviscosity does not significantly influence the
fluorescence excitation ratio and Clarke and Kane [34]
suggested that in order to eliminate the possible effects
of membrane fluidity, fluorescence should be detected
at the red-edge of the emission spectra, at 670 nm. It is
also relevant to refer that the use of a fluorescent probe
is not the most adequate method to measure absolute
values of dipole potential, mainly because a rigorous
calibration method has not been established yet. An
equation for converting fluorescence excitation ratio to
voltage is available [35], but is based on potential values
calculated on previous and distinct papers, by different
methods. However, in the presented cases, the use of
absolute values of dipole potential is not relevant.
The influence of dipole potential on p25 interaction
with lipid vesicles was studied with di-8-ANEPPS along
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with the above-mentioned FPE measurements for sur-
face potential [36]. In the presence of p25, the dipole
potential of di-8-ANEPPS labeled PC vesicles decreased,
as indicated by the decrease of the ratio of the flu-
orescence intensities at two excitation wavelengths,
460 and 520 nm, for the same emission wavelength
of 580 nm, with the increase of peptide concentration.
The dipole potential of PC vesicles was also manipu-
lated adding phloretin and 6-ketocholestanol (6-KC),
previously known to decrease and increase the dipole
potential, respectively [27,37]. The results showed that
the larger the initial dipole potential, the larger is
its decrease caused by the interaction of the peptide
with the membrane (Figure 5). Kinetic studies using
stopped-flow technique and the comparison with the
kinetic results obtained from FPE experiments also led
to the conclusion that the decrease in dipole potential
occurs when the peptide inserts into the membrane
rather than during the initial binding event.
A similar study was done for assessing the inter-
action between the fusion peptide from simian
immunodeficiency virus (SIV) gp32 with phosphatidyl-
choline/phosphatidylethanolamine (PC/PE) vesicles
[38]. Addition of the SIV fusion peptide to the vesicles
suspension caused a decrease in the dipole potential,
and the larger the initial dipole potential, the larger
the magnitude of the decrease, as for p25. The influ-
ence of the magnitude of the dipole potential in the
peptide-dependent membrane fusion was assessed by
a fluorescence resonance energy transfer (FRET) based
Figure 5 Variation of the ratio of the di-8-ANEPPS fluo-
rescence intensities at two excitation wavelengths, 460 and
520 nm, R(460/520), as a function of p25 concentration. The
emission wavelength was kept at 580 nm. Each trace refers
to a different vesicle composition: ž, pure PC vesicles;
°
,
phloretin-enriched PC vesicles; , 6-KC enriched PC vesicles
[36]. Reproduced with permission of the Biophysical Society.
lipid-mixing fusion assay. It was clearly demonstrated
that increasing dipole potential with 6-KC enhanced the
fusion process and the opposite was true for phloretin.
The HIV-1 gp41 fusion peptide interaction with PC/PE
vesicles was also studies with FPE and di-8-ANEPPS
[39]. Apart from demonstrating once again that 6-KC
and, at a lesser extent, cholesterol increases membrane
dipole potential, the authors related the Kd derived
from FPE kinetic studies with the dipole potential of
vesicles with different cholesterol/6-KC compositions.
The fusion peptide had a higher affinity for membranes
with higher dipole potential. As a high-dipole potential
enhances fusion and cholesterol has an increased pro-
portion on SIV and HIV membrane [40,41], the results
of these two studies shed some light on the impor-
tance of membrane lipid composition for the infectivity
of SIV/HIV.
The modulation of membrane dipole potential can
bring new possibilities in the drug delivery research
area. With this in mind two different studies are pre-
sented involving the drugs saquinavir and bacitracin.
Saquinavir is a peptidomimetic inhibitor of HIV
protease and its interaction with Caco-2 cell membrane
was studied [42]. The human intestinal epithelial
cell line Caco-2 is often used to assess intestinal
permeability of drugs [43]. The shift in the excitation
spectra of di-8-ANEPPS, indicative of alterations in
the dipole potential, revealed that saquinavir decreases
this potential when binding to Caco-2 cell membranes
and, at a lower extent, to PC/PS vesicles. Analyzing
the dependence of the ratio with the saquinavir
concentration, it was shown that for Caco-2 cells
the data followed a cooperative binding profile, in
contrast with the results obtained for vesicles, which
followed a hyperbolic single binding site model. This
is indicative that a receptor-mediated process may
take place besides the membrane binding per se, as
it is known to be a substrate of the P-glycoprotein,
the product of MDR1 gene [44]. Membrane dipole
potentials were modulated by 6-KC or phloretin,
yielding a larger decrease of the fluorescence ratio for
6-KC, both for Caco-2 and lipid vesicles. Moreover,
the binding capacity of saquinavir for cholesterol
depleted cell membranes was also assessed and
found to be decreased relative to normal ones. It
is shown that increasing membrane dipole potential
enhances saquinavir binding to Caco-2 cells. Such
dipole potential modulation can be a strategy to
increase intestinal absorption.
The interaction of bacitracin with PC vesicles was
studied in the context of enhancing the transdermal
delivery of this cyclic peptide antibiotic [45]. The red
shift in the excitation spectra of di-8-ANEPPS labeled
vesicles showed that bacitracin binding decreases
the membrane dipole potential. With 6-KC enriched
vesicles, the dipole potential decreased at a higher
extent in the presence of bacitracin. The opposite
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effect was observed for phloretin. The variation of the
surface potential over time was also measured using
FPE, upon adding bacitracin to PC vesicles suspension.
Those enriched with 6-KC yielded an increased signal.
All these studies were done to help to interpret the
initial experiment in which FITC-labeled bacitracin
penetrated more deeply in epidermis pretreated with
6-KC-enriched PC vesicles, as visualized by confocal
microscopy. The more efficient binding of bacitracin to
6-KC enriched membranes suggests a new and more
efficient way of delivering this peptide for the treatment
of skin infections.
Although di-8-ANEPPS has been the most used
probe for measuring dipole potential, recently developed
probes based on the 3-hydroxyflavone fluorescent
moiety promise better detection [46]. The probes F4N1
and BPPZ were synthesized and tested for their ability
to sense dipole potential. These probes have the
particularity of undergoing excited-state intramolecular
proton-transfer (ESIPT), yielding two tautomeric forms,
revealed by the presence of two emission peaks in
the fluorescence spectrum. The presence of a nearby
electrical field not only originates a shift in the
absorption and emission bands, but also alters the
intensity ratio of the two emission peaks. These two
types of ratios, using two wavelengths at each side of
the excitation band and using the two emission peaks,
correlated well with the typical excitation ratio used
for di-8-ANEPPS. The fact that emission ratios can be
used facilitates fluorescence microscopy imaging of the
dipole potential in membranes, as for a single excitation
wavelength the emission of the probes can be collected
on two separate detectors at the same time. This is
a very useful approach for visualizing dipole potential
distribution in membranes of living cells [47].
TRANSMEMBRANE POTENTIAL
The last member of the membrane potential club
is the transmembrane potential. As it is the most
well-known and well-studied type of potential, just a
contextualization in this case will be given. In simple
terms, it is defined as the potential difference between
the intra and extracellular aqueous phases (Figure 1).
This is a consequence of the selective nature of the
membrane, that allows the flux of specific charged
solutes (e.g. ions), creating a concentration gradient.
Measuring the transmembrane potential in a con-
text of a peptide–membrane interaction is especially
important for antimicrobial peptides, which usually
form pores or channels in membranes, enabling the
dissipation of an established potential, or for cell-
penetrating peptides, whose mode of action may depend
on this potential [48,49]. In fact, membrane poten-
tial tests are routinely used to assay the membrane
potential alterations that occur when these types of pep-
tides are added to a vesicle or cell suspension. There
are several fluorescent dyes available for the detec-
tion of transmembrane potential alterations, from slow
response carbocyanines (DiI, DiS, and DiO derivatives)
and oxonols (DiBAC and DiSBAC) to fast response styryl
dyes (ANEP and RH dyes) [50].
The majority of the studies test the ability of a cer-
tain peptide to alter the transmembrane potential in
vesicles or even bacteria, using slow-response dyes.
In vesicles, a transmembrane potential is achieved by
adding valinomycin to vesicles prepared in a KCl buffer
and suspended in NaCl buffer. Some peptides are able
to dissipate the potential [51–53] while others simply do
not [54], depending on the degree of membrane disrup-
tion. Moreover, monitoring transmembrane potential of
bacteria when they are exposed to antimicrobial pep-
tides often reveals membrane depolarization [55–57].
CONCLUDING REMARKS
There is no doubt that when certain peptides have
the ability to interact with membranes they alter some
of their properties, and membranes potentials are no
exception. For the three types of membrane potential,
there are different types of fluorescent dyes capable
of measuring each of them. This is an advantage, as it
permits the establishment of similar protocols, based on
the same concept of fluorescent dye detection, in order
to build a combined study, with readily comparable
results. Such combined studies, involving the different
membrane potentials, permit a wider vision of what is
happening at the membrane level when certain peptides
are present.
Alterations in surface potential sensed by FPE can
reveal the very first electrostatic binding events at
the membrane surface and even peptide insertion or
translocation. Di-8-ANEPPS is the most used probe for
measuring dipole potential and allows the monitoring of
insertion events, as these tend to change the disposition
of the molecular dipoles of membrane phospholipids.
It has the advantage of being sensitive to uncharged
molecules. A study of the effect of transmembrane
potential is important to find out if a more extensive
disruption is made on the membrane by the peptide,
such as pore or channel formation.
These tools, although available for a while, can be
more extensively explored, especially in the context
of in vivo environments, in conjunction also with
fluorescence imaging and real-time observation of the
interaction events.
Acknowledgments
This work was partially supported by the Fundac¸a˜o
para a Cieˆncia e Tecnologia (FCT) of the Portuguese
Ministry of Science, Technology and Higher Education
(MCTES).
Copyright  2008 European Peptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2008; 14: 407–415
DOI: 10.1002/psc
65
414 MATOS, GONC¸ALVES AND SANTOS
REFERENCES
1. Burton PS, Conradi RA, Ho NF, Hilgers AR, Borchardt RT. How
structural features influence the biomembrane permeability of
peptides. J. Pharm. Sci. 1996; 85: 1336–1340.
2. Fahr A, van Hoogevest P, May S, Bergstrand N, Leigh MLS.
Transfer of lipophilic drugs between liposomal membranes and
biological interfaces: consequences for drug delivery. Eur. J. Pharm.
Sci. 2005; 26: 251–265.
3. Castanho MA, Fernandes MX. Lipid membrane-induced optimiza-
tion for ligand-receptor docking: recent tools and insights for the
‘‘membrane catalysis’’ model. Eur. Biophys. J. 2006; 35: 92–103.
4. Killian JA, Nyholm TK. Peptides in lipid bilayers: the power of
simple models. Curr. Opin. Struct. Biol. 2006; 16: 473–479.
5. Santos NC, Prieto M, Castanho MA. Quantifying molecular
partition into model systems of biomembranes: an emphasis on
optical spectroscopic methods. Biochim. Biophys. Acta 2003; 1612:
123–135.
6. McLaughlin S. The electrostatic properties of membranes. Annu.
Rev. Biophys. Biophys. Chem. 1989; 18: 113–136.
7. Langner M, Kubica K. The electrostatics of lipid surfaces. Chem.
Phys. Lipids 1999; 101: 3–35.
8. Cevc G. Membrane electrostatics. Biochim. Biophys. Acta 1990;
1031: 311–382.
9. Wall J, Golding CA, Van Veen M, O’Shea P. The use of fluorescein
phosphatidylethanolamine (FPE) as a real-time probe for peptide-
membrane interactions. Mol. Membr. Biol. 1995; 12: 183–192.
10. Thelen M, Petrone G, O’Shea PS, Azzi A. The use of fluorescein-
dipalmitoylphosphatidylethanolamine for measuring pH-changes
in the internal compartment of phospholipid vesicles. Biochim.
Biophys. Acta 1984; 766: 161–168.
11. Soucaille P, Prats M, Tocanne JF, Teissie J. Use of a fluorescein
derivative of phosphatidylethanolamine as a pH probe at
water/lipid interfaces. Biochim. Biophys. Acta 1988; 939: 289–294.
12. Yuanbo C, Fan Z, Jiachang Y. Detecting proton flux across
chromatophores driven by F0F1-ATPase using N-(fluorescein-5-
thiocarbamoyl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethano
lamine, triethylammonium salt. Anal. Biochem. 2005; 344:
102–107.
13. Thelen M, O’Shea PS, Petrone G, Azzi A. Proton translocation
by a native and subunit III-depleted cytochrome c oxidase
reconstituted into phospholipid vesicles. Use of fluorescein-
phosphatidylethanolamine as an intravesicular pH indicator. J.
Biol. Chem. 1985; 260: 3626–3631.
14. O’Shea P. Intermolecular interactions with/within cell membranes
and the trinity of membrane potentials: kinetics and imaging.
Biochem. Soc. Trans. 2003; 31: 990–996.
15. Wall J, Ayoub F, O’Shea P. Interactions of macromolecules with the
mammalian cell surface. J. Cell Sci. 1995; 108: 2673–2682.
16. Bechinger B. Structure and functions of channel-forming peptides:
magainins, cecropins, melittin and alamethicin. J. Membr. Biol.
1997; 156: 197–211.
17. Chupin V, Leenhouts JM, de Kroon AI, de Kruijff B. Cardiolipin
modulates the secondary structure of the presequence peptide of
cytochrome oxidase subunit IV: a 2D 1H-NMR study. FEBS Lett.
1995; 373: 239–244.
18. Matsuzaki K, Yoneyama S, Miyajima K. Pore formation and
translocation of melittin. Biophys. J. 1997; 73: 831–838.
19. Golding C, Senior S, Wilson MT, O’Shea P. Time resolution of
binding and membrane insertion of a mitochondrial signal peptide:
correlation with structural changes and evidence for cooperativity.
Biochemistry 1996; 35: 10931–10937.
20. Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998; 93:
681–684.
21. Cladera J, Martin I, O’Shea P. The fusion domain of HIV gp41
interacts specifically with heparan sulfate on the T-lymphocyte cell
surface. EMBO J. 2001; 20: 19–26.
22. Sim B, Cladera J, O’Shea P. Fibronectin interactions with
osteoblasts: identification of a non-integrin-mediated binding
mechanism using a real-time fluorescence binding assay. J.
Biomed. Mater. Res. A 2004; 68: 352–359.
23. Fitchen N, O’Shea P, Williams P, Hardie KR. Electrostatic sensor
for identifying interactions between peptides and bacterial
membranes. Mol. Immunol. 2003; 40: 407–411.
24. Gawrisch K, Ruston D, Zimmerberg J, Parsegian VA, Rand RP,
Fuller N. Membrane dipole potentials, hydration forces, and the
ordering of water at membrane surfaces. Biophys. J. 1992; 61:
1213–1223.
25. Zheng C, Vanderkooi G. Molecular origin of the internal dipole
potential in lipid bilayers: calculation of the electrostatic potential.
Biophys. J. 1992; 63: 935–941.
26. Clarke RJ. The dipole potential of phospholipid membranes and
methods for its detection. Adv. Colloid Interface Sci. 2001; 89–90:
263–281.
27. Gross E, Bedlack RS, Loew LM. Dual-wavelength ratiometric
fluorescence measurement of the membrane dipole potential.
Biophys. J. 1994; 67: 208–216.
28. Zouni A, Clarke RJ, Holzwarth JF. Kinetics of the solubilization of
styryl dye aggregates by lipid vesicles. J. Phys. Chem. 1994; 98:
1732–1738.
29. Fluhler E, Burnham VG, Loew LM. Spectra, membrane binding,
and potentiometric responses of new charge shift probes.
Biochemistry 1985; 24: 5749–5755.
30. Loew LM, Bonneville GW, Surow J. Charge shift optical probes of
membrane potential. theory. Biochemistry 1978; 17: 4065–4071.
31. Bublitz GU, Boxer SG. Stark spectroscopy: applications in
chemistry, biology, and materials science. Annu. Rev. Phys. Chem.
1997; 48: 213–242.
32. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+
indicators with greatly improved fluorescence properties. J. Biol.
Chem. 1985; 260: 3440–3450.
33. Vitha MF, Clarke RJ. Comparison of excitation and emission
ratiometric fluorescence methods for quantifying the membrane
dipole potential. Biochim. Biophys. Acta 2007; 1768: 107–114.
34. Clarke RJ, Kane DJ. Optical detection of membrane dipole
potential: avoidance of fluidity and dye-induced effects. Biochim.
Biophys. Acta 1997; 1323: 223–239.
35. Clarke RJ. Effect of lipid structure on the dipole potential of
phosphatidylcholine bilayers. Biochim. Biophys. Acta 1997; 1327:
269–278.
36. Cladera J, O’Shea P. Intramembrane molecular dipoles affect the
membrane insertion and folding of a model amphiphilic peptide.
Biophys. J. 1998; 74: 2434–2442.
37. Franklin JC, Cafiso DS. Internal electrostatic potentials in bilayers:
measuring and controlling dipole potentials in lipid vesicles.
Biophys. J. 1993; 65: 289–299.
38. Cladera J, Martin I, Ruysschaert JM, O’Shea P. Characterization
of the sequence of interactions of the fusion domain of the simian
immunodeficiency virus with membranes. Role of the membrane
dipole potential. J. Biol. Chem. 1999; 274: 29951–29959.
39. Buzon V, Cladera J. Effect of cholesterol on the interaction of the
HIV GP41 fusion peptide with model membranes. Importance of the
membrane dipole potential. Biochemistry 2006; 45: 15768–15775.
40. Aloia RC, Jensen FC, Curtain CC, Mobley PW, Gordon LM. Lipid
composition and fluidity of the human immunodeficiency virus.
Proc. Natl. Acad. Sci. U.S.A. 1988; 85: 900–904.
41. Aloia RC, Tian H, Jensen FC. Lipid composition and fluidity of the
human immunodeficiency virus envelope and host cell plasma
membranes. Proc. Natl. Acad. Sci. U.S.A. 1993; 90: 5181–5185.
42. Asawakarn T, Cladera J, O’Shea P. Effects of the membrane dipole
potential on the interaction of saquinavir with phospholipid
membranes and plasma membrane receptors of Caco-2 cells. J.
Biol. Chem. 2001; 276: 38457–38463.
43. Shah P, Jogani V, Bagchi T, Misra A. Role of Caco-2 cell
monolayers in prediction of intestinal drug absorption. Biotechnol.
Prog. 2006; 22: 186–198.
44. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M,
Jeang KT, Ambudkar SV, Pastan I, Dey S. HIV-1 protease
Copyright  2008 European Peptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2008; 14: 407–415
DOI: 10.1002/psc
66
PEPTIDE EFFECTS ON MEMBRANE POTENTIALS 415
inhibitors are substrates for the MDR1 multidrug transporter.
Biochemistry 1998; 37: 3594–3601.
45. Cladera J, O’Shea P, Hadgraft J, Valenta C. Influence of molecular
dipoles on human skin permeability: Use of 6-ketocholestanol to
enhance the transdermal delivery of bacitracin. J. Pharm. Sci. 2003;
92: 1018–1027.
46. Klymchenko AS, Duportail G, Mely Y, Demchenko AP. Ultrasensi-
tive two-color fluorescence probes for dipole potential in phos-
pholipid membranes. Proc. Natl. Acad. Sci. U.S.A. 2003; 100:
11219–11224.
47. Shynkar VV, Klymchenko AS, Duportail G, Demchenko AP,
Mely Y. Two-color fluorescent probes for imaging the dipole
potential of cell plasma membranes. Biochim. Biophys. Acta 2005;
1712: 128–136.
48. Deshayes S, Plenat T, Charnet P, Divita G, Molle G, Heitz F.
Formation of transmembrane ionic channels of primary
amphipathic cell-penetrating peptides. Consequences on the
mechanism of cell penetration. Biochim. Biophys. Acta 2006; 1758:
1846–1851.
49. Terrone D, Sang SL, Roudaia L, Silvius JR. Penetrating and related
cell-penetrating cationic peptides can translocate across lipid
bilayers in the presence of a transbilayer potential. Biochemistry
2003; 42: 13787–13799.
50. Haugland RP. Probes for membrane potential. The Handbook – A
Guide to Fluorescent Probes and Labelling Technologies. Invitrogen
Molecular Probes: Eugene, OR, 2005; 973–986.
51. Moll GN, Brul S, Konings WN, Driessen AJ. Comparison of
the membrane interaction and permeabilization by the
designed peptide Ac-MB21-NH2 and truncated dermaseptin S3.
Biochemistry 2000; 39: 11907–11912.
52. Rintoul MR, de Arcuri BF, Morero RD. Effects of the antibiotic
peptide microcin J25 on liposomes: role of acyl chain length
and negatively charged phospholipid. Biochim. Biophys. Acta 2000;
1509: 65–72.
53. Ibrahim HR, Sugimoto Y, Aoki T. Ovotransferrin antimicrobial
peptide (OTAP-92) kills bacteria through a membrane damage
mechanism. Biochim. Biophys. Acta 2000; 1523: 196–205.
54. Tiriveedhi V, Butko P. A fluorescence spectroscopy study on the
interactions of the TAT-PTD peptide with model lipid membranes.
Biochemistry 2007; 46: 3888–3895.
55. Zhu WL, Lan H, Park IS, Kim JI, Jin HZ, Hahm KS, Shin SY.
Design and mechanism of action of a novel bacteria-selective
antimicrobial peptide from the cell-penetrating peptide Pep-1.
Biochem. Biophys. Res. Commun. 2006; 349: 769–774.
56. Nuding S, Fellermann K, Wehkamp J, Mueller HA, Stange EF. A
flow cytometric assay to monitor antimicrobial activity of defensins
and cationic tissue extracts. J. Microbiol. Methods 2006; 65:
335–345.
57. Yang ST, Shin SY, Kim JI. Interaction mode of a symmetric Trp-
rich undeca peptide PST11-RK with lipid bilayers. FEBS Lett. 2007;
581: 157–163.
Copyright  2008 European Peptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2008; 14: 407–415
DOI: 10.1002/psc
67

 
69
Review Article B 
Declaration of authorship 
I, Pedro Miguel Baptista de Matos, declare that the manuscript preparation 
and writing was carried out by me, Henri Franquelim, Prof. Miguel A. R. B. 
Castanho and Prof. Nuno S. Santos. 
I, Nuno C. Santos, as supervisor of Pedro Matos and as corresponding author 
of the article mentioned above, hereby acknowledge and confirm that the 
information above is correct. 
 
 
 
 Pedro M. Matos Nuno C. Santos 
 
 

Review
Quantitative assessment of peptide–lipid interactions.
Ubiquitous ﬂuorescence methodologies
Pedro M. Matos, Henri G. Franquelim, Miguel A.R.B. Castanho, Nuno C. Santos ⁎
Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisbon, Portugal
a b s t r a c ta r t i c l e i n f o
Article history:
Received 27 March 2010
Received in revised form 13 July 2010
Accepted 13 July 2010
Available online 18 July 2010
Keywords:
Peptide
Protein
Lipid
Membrane
Fluorescence
Partition
Peptide–membrane interactions have been gaining increased relevance, mainly in biomedical investigation, as
the potential of the natural, nature-based and synthetic peptides as new drugs or drug candidates also expands.
These peptides must face the cell membrane when they interfere with or participate in intracellular processes.
Additionally, several peptide drugs and drug leads actions occur at the membrane level (e.g., antimicrobial
peptides, cell-penetrating peptides and enveloped viruses membrane fusion inhibitors). Here we explore
ﬂuorescence spectroscopy methods that can be used to monitor such interactions. Two main approaches are
considered, centered either on the peptide or on the membrane. On the ﬁrst, we consider mainly the
methodologies based on the intrinsic ﬂuorescence of the aminoacid residues tryptophan and tyrosine. Regarding
membrane-centric approaches, we reviewmethods based on lipophilic probes sensitive tomembrane potentials.
The use of ﬂuorescence constitutes a simple and sensitive method to measure these events. Unraveling the
molecular mechanisms that govern these interactions can unlock the key to understand speciﬁc biological
processes involving natural peptides or to optimize the action of a peptide drug.
© 2010 Elsevier B.V. All rights reserved.
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1. Introduction
The interaction of peptides with lipid bilayers is attracting the
attention of a growing community of scientists. Innovative applications
of atomic force microscopy, NMR and ﬂuorescence spectroscopy [1], for
instance, allow detailed information on peptide conformation, orienta-
tion and association in the conﬁned space of the bilayer to be obtained.
Along with academic interest, industry (mainly pharmaceutical) has
been achieving important milestones on the development of peptide
products. Enfuvirtide (T-20) is a 36-aminoacid peptide HIV-1 fusion
inhibitor in clinical use. Other clinically relevant peptides may follow,
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not only in the ﬁeld of antimicrobials, but also on central nervous
system-targeted drugs [2–5]. In the long term, cell-penetrating peptides
(CPP) may also play an important role in gene therapy [6].
Many of the peptides that gather academic and industrial interest
are membrane-active (i.e., lipid-interactive) peptides (Fig. 1), but
while antimicrobial peptides (AMP) target bacterial membranes,
others (such as enfuvirtide [7,8]) may bind lipids in a pre-stage for
receptor docking. This concept was put forward in 1986 [9] and has
been reﬁned over the years (for a review see [10]). The lipid palisade
inﬂuences the peptide concentration, conformation, location, and
orientation in ways that improve peptide ligand–receptor interaction
relative to free solution. The ﬁrst conceptualization [9] considered the
docking of a ligand to amembrane receptor to be a three-step process:
(i) adsorption of the ligand to the membrane and formation of an
accumulation layer; (ii) insertion in the membrane for which binding
sites were considered to exist; and, (iii) receptor docking in the
membrane matrix. Whilst electrostatic accumulation in adsorption is
important, as shown by the fact that receptor-binding kinetics may be
105 times faster than in its absence [9], steady-state considerations
can be made clearer considering the bulk aqueous medium vs.
membrane concentration balance. Fig. 2 depicts the equilibria
involved in membrane-mediated ligand–receptor docking in a more
simpliﬁed way. Membrane insertion is accounted for in a single step
and no membrane binding sites for insertion are evoked, because this
membrane binding sites have an elusive physical counterpart. There
are however other frameworks that account for multi-step binding
processes of peptides to membranes, taking into account water–lipid
interfacial regions and also the folding of the peptide or protein itself
[11,12].
The concentrating effect of the membrane is expected to increase
the occupied-to-unoccupied receptor-binding sites ratio by a partition
coefﬁcient (Kp) factor (see below) that combines adsorption and
insertion in the lipid palisade [10]. The ratio of bound to unbound
receptors is:
LR½ �m
R½ �m
= KpKb L½ �w ð1Þ
where [LR]m is the concentration of the ligand–receptor complex in
the membrane, [R]m is the concentration of the receptor in the
membrane, Kb is the binding constant and [L]w is the ligand
concentration in aqueous environment. In the absence of membranes,
the ratio of bound to unbound receptors would be Kb[L]w.
Typical moderate values of Kp are 103–104 in the absence of an
electrostatic contribution and 105–106 when an electrostatic attrac-
tion is present [7,8,13]. Thus, the extent of ligand–receptor binding
can be improved up to several orders of magnitude. However, the
power of membranes to concentrate the ligand is not effective unless
receptor-binding site and ligand are located at the same depth in the
membrane. Three main methods exist to estimate the depth or depth
distribution of ﬂuorophores in the membrane. The Parallax Method
[14] adapts the common simple methodology of the three-dimen-
sional quenching sphere-of-action model to two dimensions. The
underlying concept of static (non-diffusive) quenching [15] remains
unchanged. This assumption conﬁnes the appropriate applicability of
themodel to few experimental cases, although it is often usedwithout
checking for this premise. The Distribution Analysis of Depth-
Dependent Fluorescent Quenching (Distribution Analysis, in short)
is an alternative that overcame these limitations [16]. For instance,
compared to the Parallax Method, the Distribution Analysis yields
additional valuable information on the ﬂuorophore's transverse
heterogeneity and lipid exposure and it can be used to evaluate
wide ranges of membrane penetrations [17]. A second alternative to
overcome some of the formal weaknesses of the Parallax Method [18]
applies the simple diffusional quenching concepts to the restricted
dimensionality of a bilayer, which is treated as a slab where
ﬂuorophores and quenchers locate, having a certain in-depth
distribution. Single-molecule Brownian Dynamics simulations were
carried out to ascertain the quencher statistical location distributions.
Pairs of quenchers (either brominated or doxyl-derivatized acyl
chains in fatty acids or phospholipids) are then used to quench the
ﬂuorophore. The relative degree of quenching between them depends
on the known distributions of the quenchers and on the ﬂuorophore
distribution to be determined. This methodology was applied to study
the location of the HIV fusion inhibitors enfuvirtide (T-20), T-1249
and sifuvirtide, which were proposed to use membrane-mediated
steps in theirmechanism of action [7,8,19]. A shallow average position
of the Trp residueswas determined, which helps to position thewhole
molecular ensemble in the lipid bilayer.
Along with concentration and conformation modulation, the most
important role of membranes is the modulation of the ligand
orientation. The most common spectroscopic methods used to
determine the orientation of foreign molecules in membranes were
reviewed in reference [20]. These include IR spectroscopy, UV–Vis
linear dichroism, time-resolved ﬂuorescence anisotropy decays,
Raman spectroscopy, Surface Plasmon Resonance and NMR. UV–Vis
linear dichroism methodologies have been applied in a large number
of studies involving different classes of molecules, including multi-
functional peptides [21,22].
An eventual advantage in membrane mediation relates to the
reduction of dimensionality from 3D to 2D. Adam and Delbrück [23]
theorized that reaction rates between ligands and surface bound
receptors would be increased by non-speciﬁc ligand adsorption and
2D diffusion towards receptors. This effect is referred to as reduction
of dimensionality (RD) reaction rate enhancement. Since then, several
theoretical models attempted to describe the relevance of underlying
factors to this behavior [24–28]. However, as justly referred by
Fig. 1. Outline of peptide–membrane interactions. Peptides in contact with membranes
may change conformation, which may facilitate proper binding to a receptor. Peptides
may also exert local speciﬁc effects, such as disorder or permeabilization (e.g.,
antimicrobial peptides). Other peptides have the ability to translocate across the
membrane, having no apparent effect in the lipid bilayer. Reprinted from [10].
Fig. 2. Simpliﬁed scheme for membrane-mediated ligand–receptor interaction, where
no membrane binding sites are considered and partition is described by a single
equilibrium step. Kp and Kb are equilibrium constants for partition into the membrane
and binding to receptor, respectively (Lw refers to ligand L in the bulk aqueous phase;
Lm refers to ligand in the membrane; R — receptor). Reprinted from [10].
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Martins et al. [29], caution must be exerted when comparing a 2D
reaction with a 3D counterpart, namely not disregarding the clause
“other factors being equal”. When going from 3D to 2D some factors
will face changes inherent to the reduction of dimensionality, as it
happens for the diffusion coefﬁcient. While there is RD enhancement
in most cases for reaction-limited processes, for diffusion limited
processes there is a disadvantage in conditions plausible to occur in
biological systems [10].
This review is focused on methods to monitor membrane
interaction that avoid chemical modiﬁcation of the peptides and
proteins involved in the study, as this may change their membrane
binding properties (e.g., [30,31]). This is achieved mainly by taking
advantage of the intrinsic ﬂuorescence of the peptides and the use of
membrane ﬂuorescent probes to indirectly monitor perturbations
caused by peptide interaction. However, it is important to mention
that in many cases of peptides that are not intrinsically ﬂuorescence,
the derivatization with a suitable ﬂuorophore can be a valuable
solution to measure their interaction with membranes, provided that
it does not signiﬁcantly alter the peptide structural and functional
properties. This labeling may also enable the use of other ﬂuores-
cence-based techniques, such as microscopy imaging and ﬂuores-
cence correlation spectroscopy (FCS) [32,33]. Moreover, this can also
be useful to obtain more insightful information regarding peptide
orientation in membranes [34,35].
2. Quantiﬁcation of the partition of a peptide to a membrane
using intrinsic ﬂuorescence
2.1. Basic concept
The partition constant or partition coefﬁcient of a solute between
an aqueous and a lipid phase can be deﬁned, based on the free energy
of transfer of the solute between the two phases, as:
Kp;x =
nS;L
nL + nS;L
nS;W
nW + nS;W
ð2Þ
where nW and nL are the moles of water and lipid, and nS,i are the
moles of solute present in each phase (i=W, aqueous phase; i=L,
lipid phase). As under most experimental conditions the quantities of
water and lipid are considerably higher than the quantity of solute on
the aqueous and lipid phases, respectively, the equation is usually
simpliﬁed to:
Kp;x≈
nS;L
nL
nS;W
nW
ð3Þ
However, in most of the literature the partition coefﬁcient is
presented as a function of the volumes of the phases, Vi, instead of
using the quantity of lipid and water:
Kp =
nS;L
VL
nS;W
VW
ð4Þ
This parameter, sometimes named Nernst partition coefﬁcient, can
be related with the previous one by the expression:
Kp = Kp;x
γW
γL
ð5Þ
where γi is the molar volume of water (i=W) or lipid (i=L).
A different way to describe the interaction of a solute with a
membrane is by considering a binding mechanism. In this case, a
chemical equilibrium between the solute and one or more lipid
molecules is considered, and a conventional binding isotherm is
obtained (e.g., [36,37]), in which two parameters describe the
process: a dissociation constant, Kd (or an association constant) and
the number of lipid molecules that are associated with a solute
molecule. The main disadvantage of this option relatively to the
partition formalisms is that there is no molecular counterpart for
describing those binding sites in the membrane, as if some kind of
receptors for the solute would exist. In fact, the membrane is a
supramolecular system and the solute interaction is controlled by the
lipid ensemble.
The partition quantiﬁcation has been previously extensively
reviewed elsewhere [38], including the use of several optical
spectroscopies and non-optical techniques. Experimental artifacts,
practical limitations and the determination of membrane inter-
domain partitions are also discussed in that review.
2.2. Determination of Kp by intrinsic ﬂuorescence parameters
For most of the cases, the partition coefﬁcient of a molecule
between a lipid and an aqueous phase can be evaluated by
ﬂuorescence spectroscopy as long as: (i) there is a difference in a
ﬂuorescence parameter (e.g., quantum yield, ﬂuorescence anisotropy
or ﬂuorescence lifetime) of the partitioning molecule when in
aqueous solution and after incorporation in the membrane or, (ii)
the incorporation of the molecule in the membrane leads to a change
on a ﬂuorescence property of a membrane probe. The ﬁrst situation
will be treated in this section.
The intrinsic ﬂuorescence of peptides containing tryptophan (Trp)
or tyrosine (Tyr) residues is a valuable tool to quantify their insertion
on lipid membranes. Due to the strong dependence of the ﬂuores-
cence of these aromatic amino acids (specially Trp) on the physical
properties of their micro-environment, the insertion of the peptide on
a lipid membrane can lead to substantial changes on the quantum
yield, wavelength of the emission maximum, ﬂuorescence anisotropy
and ﬂuorescence lifetime [39].
As long as there is a signiﬁcant difference between the quantum
yield of the peptide in the aqueous environment and in the lipid
membrane, its partition constant can be determined by conducting
ﬂuorescence intensity, I, measurements with a ﬁxed concentration of
peptide and increasing lipid concentrations ([L]). This usually yields a
hyperbolic-like I vs. [L] variation proﬁle, which can be ﬁtted using
[40,41]:
I =
IW + KpγL L½ �IL
1 + KpγL L½ �
ð6Þ
where γi is the molar volume of water (i=W) or lipid (i=L). Ideally, I
should be the integrated ﬂuorescence emission intensity but, if no
signiﬁcant spectral shifts occur upon increasing [L], Imay be measured
at a chosen emission wavelength. Typical examples of the use of this
equation on the quantiﬁcation of the interaction of peptides with
membranes are the studies of the lipid selectivity of the previously
mentioned different HIV-1 membrane fusion inhibitors [7,8,19].
To use the steady-state ﬂuorescence anisotropy, r, to calculate the
partition coefﬁcient of a ﬂuorescent molecule, it is not only necessary
that this parameter has a signiﬁcant change between the lipid and
aqueous phases, but also the ﬂuorescence intensity from both phases
must be comparable. Using an experimental design identical to that
indicated for the ﬂuorescence intensity-based methodology, the data
should be ﬁtted using [42]:
r =
rW γL L½ �ð Þ−1−1
 
+ rLKpεLϕL = εWϕWð Þ
γL L½ �ð Þ−1−1 + KpεLϕL = εWϕWð Þ
ð7Þ
where ϕ is the ﬂuorescence quantum yield and ε is the molar
absorption.
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In addition to the steady-state ﬂuorescence spectroscopy
methodologies, partition coefﬁcients can also be obtained by time-
resolved ﬂuorescence spectroscopy. When carrying out a time-
resolved ﬂuorescence spectroscopic study of the interaction of a
ﬂuorescent molecule with a membrane system, ideally two
exponentials would describe the experimental ﬂuorescence inten-
sity decay, one corresponding to the molecules in aqueous media
and the other to the molecules in the lipid environment:
IðtÞ = aW expð−t = τWÞ + aL expð−t = τLÞ ð8Þ
(where t is time and τi is the ﬂuorescence lifetime of the molecules in
each phase). In this ideal case, the relative concentration of each
specie could be calculated from the pre-exponential factors ratio (aL/
aW), if the radiative rate constants and absorption coefﬁcient ratios in
both phases are known [43]. However, in most of the cases (including
intrinsically ﬂuorescent peptides), the decays both in the aqueous
phase and on the membrane are complex. Thus, the total decay must
be described by a sum of exponentials, mixing up all the contributions.
Therefore, an average of the ﬂuorescent lifetime should be used. The
average ﬂuorescence lifetime of a ﬂuorophore, bτN, is given by (e.g.,
[44]),
hτi =∑aiτ
2
i
∑aiτi
ð9Þ
However, if bτN is used for Kp determination, a complex equation
would be attained, where steady-state and transient-state data must
be combined [40]:
τh i = τh iW + τh iL− τh iW
  KpγL L½ �
KpγL L½ � + εWϕWεLϕL
ð10Þ
Therefore, it is more convenient to calculate the variation of the
ﬂuorescence lifetime averaged by the pre-exponentials, Pτ,
Pτ =
∑aiτi
∑ai
ð11Þ
leading to the formalism for the determination of Kp [40],
Pτ =
PτW + KpγL L½ �PτL
1 + KpγL L½ �
ð12Þ
This simpler equation is similar to Eq. (6) because both Pτ and I
are additive parameters. These cases can be assigned to the same
general equation [38]:
p =
pW + KpγL L½ �pL
1 + KpγL L½ �
ð13Þ
where p stands for any additive parameter, such as I or Pτ. If
εWϕW≈εLϕL and γL[L]≪1 (a condition present in most experimental
conditions) are assumed in Eq. (7), then p may also stand for r.
2.3. Complex partition curves
As an exception to the general rule of the increase of I, r and τ of a
ﬂuorophore upon incorporation in a membrane system, Vermeir et
al. [45] reported a decrease on the ﬂuorescence intensity of the
partitioning molecule when in the membrane. This quenching
process was used as a simple methodology to obtain the value of
the partition coefﬁcient, by a linear ﬁt:
IW
I
= 1 + KpγL L½ � ð14Þ
This equation is in fact a special case of Eq. (6) for a situation in
which it is assumed that IL=0. More recently, in a study of the
membrane and environmental parameters that inﬂuence the activity
of the cell-penetrating peptide pep-1 [46], a less strict model was
proposed to quantify the partition constants of systems in which
ﬂuorescence quenching (usually self-quenching) can occur upon
insertion in the membrane (Fig. 3):
I =
KpγL L½ �IL
1 + KpγL L½ � + k2KpIL
+
IW
1 + KpγL L½ �
ð15Þ
where,
k2 =
kq
εlkf
ð16Þ
l is the optical path, kq is the kinetic constant of the quenching process,
kf is the radiative ﬂuorescence constant and ε is the molar absorption.
Pina et al. adapted this model to a more complex and speciﬁc
situation, in which there is a combined effect of the partition of the
Shiga toxin B-subunit to the bulk lipid membrane, with self-
quenching, and the subsequent binding of the protein to its speciﬁc
ligand (a glycolipid) with an increase on the quantum yield [47].
Other types of deviations from the normal hyperbolic behavior of
partition curves were reported on the study of the interaction of the
antimicrobial peptide omiganan with biomembrane model systems
with different lipid compositions [3]. Upon titration of the peptide
solution with some of the lipid vesicles, a spike was registered,
deviating from the hyperbolic-like behavior just on a restrict range of
lipid concentrations (Fig. 4). This critical-point was explained by a
model, tested by curve simulation, where a sequence of events is
taken into account, in which it is considered that the apparent Kp is
dependent on peptide concentration: ﬁrstly, at high peptide/lipid
ratios, a saturated regime in which the local concentration of the
peptide in the membrane is constant and independent of the
concentration of the peptide in solution. In this situation, the constant
parameter that describes the system, instead of Kp, is the local
peptide/lipid ratio in themembrane, σ. Secondly, at low peptide/lipid
ratios, the excess of lipid enables the use of the previously described
common partition formalisms, with a constant Kp. On the critical-
Fig. 3. Fluorescence emission intensity of pep-1 (6.88 μM), normalized by dividing by
IW, upon titration with large unilamellar vesicles of palmitoyloleoylphosphatidylcho-
line (POPC; circles; normal hyperbolic increase of I) or dipalmitoylphosphatidylcholine
(DPPC; squares; system where self-quenching occurs). Eqs. (6) and (15), respectively,
were used for data ﬁtting and Kp quantiﬁcation. Reprinted from [46].
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points, both σ and Kp are valid to describe the system. These points
can be identiﬁed from the partition curves experimentally obtained
with different peptide concentrations and ﬁtted by:
P½ �s =
σ
KpγL
+ σ L½ � ð17Þ
where [P]s is the peptide concentration at the saturation point for a
concentration of lipid, [L]. On a study of the membrane insertion of a
possible dengue virus fusion peptide [48], the use of this formalism
was further extended to systems in which peptide oligomerization
occurs, driven by its local high concentration in the membrane, but
not strictly resulting from saturation (Fig. 5).
2.4. Adsorption quantiﬁcation by Förster Resonance Energy Transfer
methodologies
As previously shown, the evaluation of the interaction of
ﬂuorescent peptides and proteins with lipid membranes can be easily
followed by recording the changes on the ﬂuorescence properties of
the aromatic amino acid residues. Nevertheless, generally, the
adsorption of peptides or proteins on the surface of lipid membranes
will not induce signiﬁcant changes in the ﬂuorescence parameters or
will lead to changes not large enough to allow a correct determination
of a partition coefﬁcient. Therefore, it can be advantageous to follow
the interaction of ﬂuorescent peptides with lipid membranes adding
molecules that will perturb the ﬂuorescence properties of the
aromatic residues of the peptides. Simple dynamic quenching
approaches, as recently described [49], or even Förster Resonance
Energy Transfer (FRET) methodologies can be used with this purpose.
For instance, FRET methodologies can be a quite powerful approach,
yielding information about the extent and the topological range of the
molecular interaction of peptides with membranes [39,44].
FRET is the process in which a molecule in the excited state
(donor) returns to the ground state by transferring its energy to
another molecule (acceptor) without the emission of a photon or
contact between molecules. The extent of the energy transfer is
determined by the distance between donor and acceptor and the
overlap of the donor's ﬂuorescence emission spectrum and the
acceptor's adsorption spectrum [39]. An important parameter to
describe this phenomenon is the Förster radius, R0, which can be
calculated from the spectroscopic data of the donor and acceptor,
using:
R0 = 0:2108 κ
2ϕDn
−4J
h i1=6 ð18Þ
where κ2 is a factor that depends on the relative orientation of donors
and acceptor (the value κ2=2/3, relative to the dynamic isotropic
limit, is usually assumed [50]), ϕD is the donor quantum yield in the
absence of the acceptor and n is the refractive index (n=1.4 is used as
refractive index within lipid vesicles [51]). The parameter J represents
the spectral overlap integral between the emission spectrum of the
donor and the absorption spectrum of the acceptor:
J = ∫
∞
0
I λð Þε λð Þλ4dλ ð19Þ
where I(λ) is the normalized donor emission spectrum and ε(λ) is the
acceptor molar absorption spectrum, in the interval of wavelengths
centered in λ and with width dλ. The numerical constant in Eq. (18)
implies the use of λ is in nm, ε in M−1 cm−1, and R0 in Å.
The efﬁciency of energy transfer, E, is deﬁned as the fraction of the
energy of the photons absorbed by the donor that is transferred to the
acceptor, and is given by,
E =
kT
kT + τ
−1
D
=
R60
R60 + R
6 ð20Þ
kT represents the rate of energy transfer from a donor to an acceptor
separated by a distance R. Therefore, the Förster radius, R0, represents
the distance for which the efﬁciency of energy transfer is 0.5.
Experimentally, the efﬁciency of energy transfer, E, can be calculated
using the equation:
E = 1−
PτDA
PτD
= 1− IDA
ID
ð21Þ
where PτDA and
PτD are the ﬂuorescence lifetimes averaged by the pre-
exponential factors (Eq. (11)) and IDA and ID are the ﬂuorescence
Fig. 4. Partition curves of the antimicrobial peptide omiganan to lipid vesicles of
palmitoyloleoylphosphatidylglycerol (POPG; triangles) and dipalmitoylphosphatidyl-
glycerol (DPPG; circles). Fluorescence emission intensities were normalized by dividing
by IW. The peptide concentration was 7.7 μM. Reprinted from [3].
Fig. 5. Partition of a possible dengue virus fusion peptide to lipid vesicles of POPC:POPG
(4:1) at pH 5.5 (ﬁlled squares) and pH 8.0 (open squares). Fluorescence emission
intensities were normalized by dividing by IW. The peptide concentration was 18 μM.
Reprinted from [48].
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emission intensities of the donor in the presence and absence of the
acceptor, respectively.
Here, we will use the interaction of HIV gp41 derived peptides
with lipid bilayers to illustrate FRET applications on the quantiﬁcation
of adsorption. The HIV fusion process mediated by the gp120–gp41
complex occurs in an extreme conﬁnement between the viral
envelope and the cell membrane [52]. The ability of certain domains
and regions of these proteins to interact withmembranes is important
for various steps of the entry and even for the inhibition of the fusion
process. As previously referred, some HIV gp41 derived peptides have
a peculiar interaction with lipid model systems, which can be related
to their molecular mode of action [7,8,19]. In all the examples that will
be given, the donor groups are the Trp residues of the peptides,
whereas the acceptor molecules are localizedwithin the lipid bilayers.
Kliger et al. studied the binding of a recombinant protein
corresponding to the ectodomain of gp41 [53] and HIV-1 fusion
inhibitor peptides (enfuvirtide and C34 [54]) with lipid membranes
by measuring the energy transfer from the Trp residues of these
proteins and peptide to dansyl (DNS) chromophores incorporated
into lipid vesicles. They detected the binding by measuring the
increase in the sensitized DNS ﬂuorescence emission upon excitation
of Trp (Fig. 6).
Other studies using ﬂuorescence spectroscopy methodologies
[7,8,19] found a correlation between membrane-interaction proper-
ties of HIV fusion inhibitor peptides and their efﬁcacy. The adsorption
of T-1249 to cholesterol-rich membranes and the adsorption of
sifuvirtide to DPPC gel phase membranes were demonstrated by
several ﬂuorescence approaches and conﬁrmed by FRET, using as
acceptors dehydroergosterol (DHE), an intrinsically ﬂuorescent
cholesterol analogue, and 1,6-diphenylhexatriene (DPH), a rigid
rod-like ﬂuorescent probe that partitions deeply within the core of a
lipid bilayer [55], respectively.
Using a speciﬁc FRET methodology to describe the adsorption
events, it was possible to quantify the fraction of molecules that was
adsorbed on the surface of the bilayers. The formalism [7,19,51]
assumes several planes parallel to the bilayer surface (Fig. 7A): two
acceptor planes and a donor plane (Trp residues) at a distanceWi from
that of the acceptors, in the case of T-1249, for instance. Firstly, the
decay of the donor ﬂuorescence intensity in the absence of acceptor is
given by:
ID tð Þ = AWID;W tð Þ + 1−AWð Þ⋅ID;L tð Þ ð22Þ
where ID,W and ID,L are the ﬂuorescence decays of the donor in the
buffer and adsorbed to the lipid vesicles, respectively, and AW is the
fraction of the molecules in aqueous solution. For T-1249 in the
presence of the acceptor in the membrane, the ﬂuorescence decay of
the sub-population in solution is not affected, but the adsorbed
donor's ﬂuorescence is extinct by acceptors localized in two parallel
planes (Fig. 7A). The donor ﬂuorescence decay, in the presence of the
acceptor is:
ID;A tð Þ = AWID;W tð Þ + 1−AWð Þ⋅ID;L tð Þ⋅ρ1 tð Þ⋅ρ2 tð Þ ð23Þ
The ρi(t) functions denote the FRET rates to acceptors located on
the planes W1 and W2 away from the donor, respectively, and are
given by [51]:
ρi tð Þ = exp −2
Wi
R0
� �2
nπR20 ∫
1
0
1− exp − thτi
� � R0
Wi
� �6
α6
� �
α3
dα
8><>:
9>=>; ð24Þ
Fig. 6. Detection of peptide binding to the membrane by FRET. Fusion inhibitors enfuvirtide (A) or C34 (B) at 0.45 μM, were added to phosphatidylcholine/phosphatidylserine/
cholesterol/DNS-phosphatidyletanolamine (8:8:2:1 (w/w), 68 μM) lipid vesicles. Excitation at 280 nm and emission at 518 nm. Reprinted from [54].
Fig. 7. Detection of the binding of T-1249 to cholesterol-enriched membranes by FRET.
(A) Diagram representing the donor–acceptor geometry in the lipid bilayer: T-1249
adsorbed at the surface and DHE in both leaﬂets of the membrane. (B) Energy transfer
efﬁciency from Trp residues of T-1249 (donor) to DHE (acceptor) in POPC/cholesterol
vesicles. The boundaries AW=0.2 and AW=0.4 are also represented (dashed lines).
Reprinted from [7].
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where n is the acceptor density (molecules/unit area), which was
computed from:
n =
½DHE�
½POPC�⋅ aPOPC + 12 achol−b
  ð25Þ
where aPOPC and achol are the areas per POPC and the cholesterol
molecule on the bilayer plane, respectively, and b is the condensation
effect of cholesterol on the bilayer area. In this equation, the area of
cholesterol is divided by 2 due to the fact that the POPC:cholesterol
mixture ratio used in that original work was 2:1. R0 was calculated
using Eq. (18) and the FRET efﬁciency according to Eq. (21), where ID
and IDA were obtained by the numerical integration of the theoretical
decay laws:
ID = ∫
∞
0
iD tð Þdt ð26Þ
ID;A = ∫
∞
0
iD;A tð Þdt ð27Þ
AW, was obtained from the non-linear regression analysis of
experimental data (Fig. 7B). It is worth of notice that the interactions
of T-1249 and sifuvirtide with the lipid vesicles for which there is
peptide adsorption were difﬁcult to quantify by the ﬂuorescence
spectroscopy approaches mentioned in the previous sections, because
these peptide–membrane interactions only cause minor changes in
the Trp ﬂuorescence parameters [7,19]. Overall, the use of a FRET
methodology allowed retrieving detailed information (Fig. 8) and
revealed a correlation between the efﬁcacy and membrane domain
selectivity among HIV fusion inhibitor peptides [7,19].
3. Peptide–lipid interactions studied using membrane
potential-sensitive probes
In many cases, it is not possible to rely on the intrinsic ﬂuorescence
of peptides or proteins due to the lack of ﬂuorescent amino acids.
Moreover, on the study of cell systems, interference of other cellular
proteic components makes Trp and Tyr ﬂuorescence a useless tool.
However, when a molecule is interacting with a lipid membrane, it
alters some of the intrinsic properties of the membrane, such as the
different types of membrane potentials, lipid ﬂuidity, curvature,
polarity or packing. Lipophilic ﬂuorescent probes sensitive to these
properties can be used to indirectly report parameters of protein–
membrane or peptide–membrane interactions. We will focus on the
use of potential-sensitive ﬂuorescent probes, as ﬂuidity and polarity
probes are more commonly used to study membrane properties
themselves [56]. This strategy also avoids the necessity of peptide or
protein derivatization, which can modify native structures and lead to
biased results. This advantage is particularly important when peptides
are used. The use of these probes has also been recently reviewed
elsewhere [57].
3.1. Membrane surface potential perturbation
The surface potential is a consequence of the net excess charges
that accumulate in the outer surface of the cell membrane, in contact
with the external medium (Fig. 9). It is therefore the potential
difference between the membrane surface and the bulk medium. The
sources of these charges are mainly ionized lipid head-groups and
ions electrostatically interacting with them [58–60]. Hence, the
approach of a charged entity, such as a peptide or protein, to the
membrane outer surface is likely to alter the surface potential by itself
or altering the ion distribution.
Fluorescein phosphatidylethanolamine (FPE) has been the main
probe used to detect alterations in the membrane surface potential
[61].When incorporated into lipidmembranes, the ﬂuoresceinmoiety
of this probe stands precisely in the water–lipid interface, and hence it
has the ability to detect pH or charge distribution changes at the
membrane surface (Fig. 10) [61]. FPE behavior can be explained by the
Fig. 8. Putative modes of action at the membrane level of T-1249 and sifuvirtide,
revealed after combining overall partition and more detailed FRET approaches. (A)
Schematic representation of the involvement of lipid membranes in T-1249 inhibition
mechanism, as described in [7], displaying the adsorption on cholesterol-enriched
membrane domains. The translocation of the peptide is prevented due to charge
repulsion of negatively charged phospholipids of the inner leaﬂet. The term raft refers
to cholesterol-rich liquid-ordered membrane microdomains. (B) Schematic represen-
tation of the adsorption of sifuvirtide on the surface of DPPC gel phase membranes in
the presence of physiological NaCl concentration, as described in [49]. Reprinted from
[7,49].
Fig. 9. Schematic representation of the three types of membrane potential by tracing
the electrical potential proﬁle across the membrane. Surface potential (ψs) arises from
the accumulation of charges at the membrane surface. Dipole potential (ψd) derives
from the sum of the dipolar components of the phospholipids and interface water. Ion
concentration gradients account for transmembrane potential (Δψ). Reprinted from
[57].
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Henderson–Hasselbalch equation, taking into account the surface
potential [62]:
log
cF
cHF
 
= pH− pK− Fψs
RTln10
 
ð28Þ
where cF and cHF are the concentrations of the dissociated and
protonated forms of the ﬂuorophore located at themembrane surface,
respectively, and the expression pK−Fψs/(RT∙ln10) is the apparent
pK, where ψs is the surface potential. Changes in the surface potential
at constant bulk phase pH affect the apparent pK of FPE and,
consequently, its protonation state, resulting in changes in the
quantum yield [61,62]. The simplest test to verify the correct
incorporation and responsiveness of FPE in vesicles or cells is the
addition of calcium ions (cation to which the membranes are
impermeable) to the medium, which will lead to an increased surface
potential (accumulation of positive charges at the surface) and,
consequently, decreased ﬂuorescein apparent pK, increased deproto-
nation and increased ﬂuorescence intensity [61]. This effect is
observed not only for negatively charged phospholipids that attract
the calcium ions, but also for the zwitterionic ones, which complex the
calcium ions via the phosphate groups [63,64] or even possibly
through the carbonyl oxygens [65]. The dielectric environment
appears not to inﬂuence signiﬁcantly the probe [66]. However, this
is a possible interference factor, as protein adsorption may alter the
dielectric environment of the probe and not only the surface potential.
As a lipophilic dye, FPE is suitable for labeling both lipid vesicles
and cell membranes. Lipid vesicles are usually obtained by extrusion
methods, and the incorporation of FPE can be done by two different
experimental approaches: (i) co-solubilizing the probe in the lipid
mixture prior to the extrusion, or (ii) labeling the vesicles after they
are formed, by incubating them with the probe, followed by gel
ﬁltration to remove unbound ﬂuorophore [61]. The ﬁrst option is a
simpler and faster method, but both inner and outer leaﬂets of the
bilayers get labeled. In most of the cases where just the interaction
with the outer leaﬂet is concerned, the labeled inner leaﬂet does not
interfere (provided that translocation of the interacting molecule to
the vesicle interior and changes in the inner leaﬂet environment are
not signiﬁcant). Cell membranes can be easily labeled by incubating
them with FPE. There is no need for gel ﬁltration, as the unbound
probe can be removed by centrifugation and washing with fresh
buffer. In some speciﬁc cases of its application to studies with cells, the
response of FPE may not be the expected due to complex membrane
features, such as the extensive glycocalix in erythrocytes [67,68] or
the extracellular matrix of B12 microglial cells [67]. Successful FPE
changes could be observed after treatment with neuraminidase and
collagenase, respectively, to remove such features.
The interactions of the peptides melittin (component of the bee
venom) and p25 (leader sequence of subunit IV of cytochrome c
oxidase) with membrane model systems were among the ﬁrst
experiments to use FPE as surface potential reporter [61]. When p25
or melittin was added to a FPE-labeled vesicles suspension, an
immediate increase of ﬂuorescence intensity was observed as a
consequence of their overall positive charge, followed by a slower
decrease in ﬂuorescence until stabilization. This biphasic response
was better observed using stopped-ﬂow rapid mixing method, as it
allowed resolving the initial ﬂuorescence increase event in the
millisecond time scale [61,69]. The most plausible explanation for
this kinetic proﬁle, advanced by the original authors, is that the
cationic peptide reaches themembrane surface, increasing the surface
potential and consequently the probe ﬂuorescence. After that, a
partial insertion into the membrane would bury positive charges,
which would no longer contribute to the potential and hence a
ﬂuorescence decrease would be observed. The dependence of FPE
Fig. 10. Structural representation of different potential sensitive probes in the membrane leaﬂet environment. FPE and di-8-ANEPPS are the main probes for use in the detection of
surface and dipole potential, respectively. DiSC3(5) is depicted as an example of slow response transmembrane potential probe that partitions to themembrane. The structures of the
probes are represented as inserted in a portion of a phosphatidylcholine (PC) lipid layer.
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ﬂuorescence change with p25 concentration was also shown to follow
a cooperative binding model, never demonstrated before for a free
signal-sequence peptide [69].
The prion protein (PrP) is a cell membrane-associated protein that
can be converted, via post-translational modiﬁcations, to a pathogenic
scrapie form, which causes spongiform encephalopathies [70].
Interaction with membranes can have a role in this conversion. The
binding of Syrian hamster prion protein, which closely resembles
human prion protein, to biomembrane model systems was assessed
with FPE [70]. The interaction with POPG vesicles follows a complex
kinetic in which a rapid ﬂuorescence intensity increase is observed
due to initial interaction events, followed by a ﬂuorescence decrease,
probably due to protein partial insertion, and a third slower phase of
less perceptible ﬂuorescence increase, hypothesized as being caused
by lipid rearrangements. However, for the POPC:POPG mixture 70:30
(molar ratio), only the initial binding phase was observed, but with a
slower kinetics. This is an example of how FPE can dissect the different
stages of a peptide–membrane interaction.
FPE was also used to study the interaction between the
extracellular matrix protein ﬁbronectin and the membranes of
osteoblast, cells responsible for bone formation [71]. Upon addition
of ﬁbronectin to FPE-labeled osteoblasts, an immediate increase on
ﬂuorescence is observed (Fig. 11A, inset), revealing that an interaction
occurred rapidly. These ﬂuorescence variations were analyzed as a
function of protein concentration, enabling the calculation of a
dissociation constant (Kd) of 120 nM. The treatment of these cells
with heparitinase previously to the interaction experiments lead to a
50% decrease in binding (Fig. 11B), indicating that cell surface heparan
sulfate proteoglycans are partly responsible for the binding. More-
over, in the presence of the integrin-binding motif RGD peptide,
ﬁbronectin membrane binding was also reduced, due to competition
with integrin receptors. Therefore, ﬁbronectin appetence for osteo-
blasts is modulated by cell surface integrins and proteoglycans.
3.2. Membrane dipole potential perturbation
Dipole potential is another type of membrane potential, originat-
ing from the sum of the dipolar residues of lipids (polar head-groups
and glycerol-ester regions) due to its rather aligned organization and
oriented water molecules hydrating the surfaces of the membrane
(Fig. 9) [72,73]. Macromolecules interacting with the membrane can
destabilize this organization and/or contribute with their own dipoles
to the membrane dipole potential; hence, the detection of alterations
on this property can be used to report such interactions. The ﬁrst
ﬂuorescent membrane probes described as sensitive to dipole
potential were di-8-ANEPPS (4-[2-[6-(dioctylamino)-2-naphthale-
nyl]ethenyl]-1-(3-sulfopropyl)-pyridinium) [74] and RH421 (N-(4-
sulfobutyl)-4-[4-[4-(dipentylamino)phenyl]butadienyl]-pyridinium)
[75]. They possess a considerably conjugated chromophore region
(high stokes shift) in which two aliphatic chains are attached to
facilitate the incorporation of the probe in a phospholipid layer. The
chromophore stays near the lipid head group and glycerol backbone,
sensing the local electric ﬁelds derived from the dipoles [74]. The
mechanism by which di-8-ANEPPS and RH421 sense the dipole
potential is believed to be electrochromical [76]. Absorption and
emission peaks shift in response to a nearby electrical ﬁeld that
differentially interacts with the ground-state and excited-state dipole
moments of the chromophore [77]. Thus, changes in dipole potential
are measured in terms of spectral shifts of the lipid bilayer
incorporated probe. Therefore, this type of probes is specially suitable
for a dual wavelength ratiometric measurements strategy, similar to
what is done with some ion indicators, such as for Ca2+ [78]. This
approach is very advantageous because the signal is independent of
probe or cell concentration and avoids photobleaching-induced
artifacts [74].
In this section, we present some examples regarding only the use
of di-8-ANEPPS, as it is the most commonly used dye for dipole
potential-related interaction studies (Fig. 10). Although the vast
majority of the work conducted with di-8-ANEPPS relies on the
measurement of excitation spectrum shifts, only recently a systematic
study was carried out to compare excitation and emission ratiometric
ﬂuorescence methods for this dye, concluding that only the former
can be used [79]. Shifts in the excitation spectra can be better
observed by transforming data in differential spectra, that is,
subtracting the normalized excitation spectra of the probe without
the molecule of interest from the normalized excitation spectra of di-
8-ANEPPS in the presence of the interacting molecules. This typically
yields a sinusoidal curve crossing the abscissa axis with onemaximum
and one minimum. A blue shift is denoted when the minimum occurs
at a lower wavelength than themaximum and the opposite for the red
shift. However, one has to know what this means in terms of dipole
potential variation. This is revealed bymodulating the dipole potential
of phospholipid vesicles with phloretin and 6-ketocholestanol (6-KC)
[74], previously shown to decrease and increase the membrane dipole
potential, respectively [80]. A blue shift is induced by 6-KC, meaning
that blue shifts indicate the increase in dipole potential, and the
opposite for phloretin. In addition, the ratio of the ﬂuorescence
intensity produced at the wavelengths of the maximum and
minimum of the differential spectra (the value at lower wavelength
divided by the value at higher wavelength) is a quantitative
parameter that can be used for the same purpose. Addition of 6-KC
to di-8-ANEPPS labeled vesicles increased the ratio, while such
parameter was decreased by phloretin [74]. To summarize, increasing
the dipole potential leads to a blue shift in the excitation spectrum and
Fig. 11. Interaction of ﬁbronectin with osteoblast membranes. (A) FPE-labeled osteoblasts ﬂuorescence intensity variation proﬁle with concentration, upon serial addition of
ﬁbronectin. A typical time course variation of ﬂuorescence intensity at the addition moment is shown in the inset. The data was ﬁtted to a single binding site model. (B) Heparitinase
treatment reduced the binding signiﬁcantly. Comparison of the ﬂuorescence changes between FPE-labeled osteoblasts (○) with those previously treated with heparitinase (□) that
removes cell surface heparan sulfate. The experiments were conducted at 37 °C with a cell concentration of 5×104/mL. Reprinted from [71].
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increase of the ratio value; at variance, decreasing of this potential
leads to a red shift and decrease of the ratio (Fig. 12).
A problem that may arise is the fact that di-8-ANEPPS, as other fast
response voltage sensitive probes, is also sensitive to transmembrane
potential variations [81] and hence it is advised that, during
measurements, transmembrane potential, if any, should be kept
constant. Membrane ﬂuidity is another aspect for concern. Gross et al.
[74] stated that membrane microviscosity does not signiﬁcantly
inﬂuence the ﬂuorescence excitation ratio, and Clarke and Kane [82]
suggested that, in order to eliminate the possible effects of membrane
ﬂuidity, ﬂuorescence should be detected at the red-edge of the
emission spectra.
The inﬂuence of dipole potential on p25 interaction with lipid
vesicles was studied with di-8-ANEPPS, along with the above
mentioned FPE measurements for surface potential [83]. This peptide
induced a decrease in the dipole potential of phosphatidylcoline lipid
vesicles, as evaluated by the di-8-ANEPPS differential spectrum. The
excitation ratio of this probe was also measured for different
concentrations of p25, yielding a Kd of 2.8 μM. The initial dipole
potential of lipid vesicles was also modulated via phloretin or 6-KC,
changing the maximum extension of binding for the peptide. These
results, together with those from stopped-ﬂow ﬂuorescence mea-
surements with FPE, elucidated that p25 rapidly interacts with the
membrane surface before inserting into the membrane, affecting the
dipole potential only in this latter step.
The propensity of HIV-1 fusion inhibitor peptides enfuvirtide and
T-1249 to interact with blood cell membranes was also evaluated
using di-8-ANEPPS, as a Trp ﬂuorescence-based approach would be
impracticable with cells [84]. Human isolated erythrocytes and
peripheral blood mononuclear cells with their membranes labeled
with the probe were incubated with either one of the peptides.
Differential excitation spectra were obtained in order to observe the
probe response, showing that the presence of the peptides decreased
the dipole potential of the membrane in a concentration-dependent
manner (Fig. 13A). The kinetics of this interaction could be followed
by measuring the excitation ratio in real-time (Fig. 13B). To quantify
the afﬁnity of these peptides to the cell membranes, the variation of
the ratio with the peptide concentration was analyzed using a
hyperbolic binding curve, in order to obtain the peptide–biomem-
brane dissociation constants (Fig. 13C). T-1249 was shown to have an
approximately eight-fold higher afﬁnity when compared with
enfuvirtide. This enhanced interaction of T-1249 with cell membranes
correlates with its higher efﬁcacy in vivo, due to a possible effect of
membrane-enhanced drug transfer to the membrane-associated gp41
in its pre-fusion conformation.
Besides di-8-ANEPPS, other probes have been shown to be
sensitive to dipole potential. Variants of NBD-labeled lipids were
tested for their sensitivity to membrane dipole potential [85]. The
probes relative ﬂuorescence intensity had a linear dependency on the
dipole potential of the labeled vesicles. No shifts or broadening of the
probe spectrum were observed when the dipole varied; hence, no
ratiometric approach can be used. Probes derived from 3-hydroxy-
ﬂavone, such as F4N1 (N-[(4′-dimethylamino)-3-hydroxy-6-ﬂavonyl]
methyl-N,N-trimethyl ammonium bromide) and BPPZ (3-(4-{4-[4′-
(3-Hydroxybenzo[f]ﬂavonyl)phenyl]piperazino}-1-pyridiniumyl)-1-
propanesulfonate), were more recently developed [86]. These probes
have the particularity of undergoing excited-state intramolecular
proton-transfer (ESIPT), yielding two tautomeric forms, revealed by
the presence of two peaks on their ﬂuorescence emission spectra.
Excitation spectrum shifts were observed for both probes and, more
importantly, the intensity ratio of the two emission bands also
changed as a response to potential variations. These two types of ratio,
at two wavelengths of the excitation spectrum edges and at the two
emission peaks, correlated very well with di-8-ANEPPS excitation
ratio, proving the usefulness of these new probes for detecting dipole
potential. The two-band emission ratio is also very useful for
microscopy, as the emissions can be collected from two emission
ﬁlters corresponding to the bands, enabling the production of ratio
images.
3.3. Transmembrane potential perturbation
The transmembrane potential can be deﬁned, in simple terms, as
the difference of potentials between the intra and extracellular
aqueous phases. This is a consequence of the selective nature of the
membrane, which may allow the ﬂux of speciﬁc charged solutes (e.g.,
ions), creating a concentration gradient (Fig. 9).
There are many ﬂuorescent probes available to detect changes in
the transmembrane potential. They can be divided in two major
groups, depending on their slow or fast response [87]. The slow
response probes include carbocyanins, such as its indo-(DiI), thio-
(DiS) and oxo-(DiO) derivatives, and oxonols, including bis-barbituric
acid (DiBAC) and bis-thiobarbituric acid (DiSBAC) derivatives. The
mode of detection of this type of probes may vary depending on the
molecule, but it is often based on the partition equilibrium between
the membrane and the aqueous medium, or through a Nernst
equilibrium-dependent translocation to the cell or mitochondria
interior [88]. On the other hand, fast response probes (that include
ANEP and RH families) sense potential alterations by electrochromic
mechanisms and intramolecular charge rearrangements, as
Fig. 12. Sensing the membrane dipole potential with di-8-ANEPPS. The excitation spectrum of membrane-bound di-8-ANEPPS shifts in response to changes in the dipole potential.
The differential spectra help to visualize these shifts and to determine the wavelengths of maximal variation, in order to deﬁne the ratio R.
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previously explained for di-8-ANEPPS. Such electronic changes are
much faster than molecular translocations, justifying the
nomenclature.
The monitoring of alterations in transmembrane potential during
the interaction of macromolecules with membranes is important in
cases where major membrane destabilizations (such as pore forma-
tion or loosening of the lipid matrix) take place, dissipating ionic
gradients. The most representative examples are from antimicrobial
peptides, which often form pores or channels in bacterial membranes,
in order to induce leakage and, consequently, cell death. Additionally,
cell-penetrating peptides, able to translocate cargo molecules inside
the cell without major membrane disruption, can depend on
transmembrane potential for their mode of action [30,89].
The antimicrobial family of microcins consists of low molecular
weight peptides synthesized mainly by Escherichia coli [90]. The
interaction of the peptide Microcin J25 (MccJ25) with membrane
vesicles was assessed by various methods, including transmembrane
potential monitoring with the slow response probe DiSC3(5) (3,3′-
dipropylthiadicarbocyanine iodide, Fig. 10) [91]. A transmembrane
potential was achieved by adding valinomycin to vesicles prepared in
a KCl-containing buffer and suspended in a NaCl-containing buffer. In
the presence of MccJ25, the preformed potential is signiﬁcantly
dissipated, as indicated by an increase in the ﬂuorescence of the
probe, both for vesicles of PC and PC/PG/CL (phosphatidylcoline/
phosphatidylglycerol/cardiolipin), a mixture that mimics bacteria
membrane (Fig. 14). Therefore, it was shown that the peptide is
Fig. 13. Interaction of HIV fusion inhibitor peptides with erythrocyte membrane. (A) Differential spectra showing the dipole potential changes in the presence of enfuvirtide or T-
1249. (B) The decrease in the dipole potential when the peptides are added can be followed through time by measuring the ratio (R) of ﬂuorescence intensities (I) at two excitation
wavelengths of maximum variation according to the differential spectra, R= I455nm/I525nm. (C) Quantiﬁcation of the afﬁnity of the two peptides towards the erythrocyte membrane
by ﬁtting the data to a hyperbolic binding model (single binding site). T-1249 dissociation constant (4.16 μM) is approximately eight times lower than for enfuvirtide (35.4 μM). For
peripheral blood mononuclear cells the variation trend was similar. Ratios were normalized for the initial value. Adapted from [84].
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capable of inducing membrane permeabilization. A similar study was
done with the rationally designed peptide PST11-RK, based on the
structural motifs of the antimicrobial peptide tritrpticin. The effect
that this peptide has on bacterial membranes was assessed via DiSC3
(5) ﬂuorescence for Staphylococcus aureus and E. coli [92]. In the
presence of PST11-RK, a ﬂuorescence increase was observed due to
bacterial membrane depolarization (dissipation of potential) in a
concentration-dependent manner. Membrane permeabilization
should then represent a major killing factor upon PST11-RK
application.
4. Conclusions
Visualizing, monitoring and understanding biological and biophy-
sical processes in real-time are of key importance for life sciences
research. Focusing on processes that occur at the cell membrane level,
it has been described how intrinsic features of peptides and proteins,
namely ﬂuorescence, can help to observe their behavior towards this
important cell structure.
The interaction of proteins or peptides with the cell membrane or
membrane model systems can be conveniently followed using
ﬂuorescence spectroscopy. This can be regarded simply as a
qualitative tool, but themain advantages of ﬂuorescence spectroscopy
application at this level are related with its use for quantitative
purposes, on the direct evaluation of peptide–membrane and
protein–membrane interactions, together with the elucidation of
the factors that inﬂuence the extension of the process. The changes in
some of the intrinsic ﬂuorescence parameters of peptides containing
ﬂuorescent amino acid residues can be easily used to measure the
insertion of a peptide on a membrane, without the need of peptide
labeling (a process that can lead to signiﬁcant changes on the
structure and properties of the molecule and consequent biased
observations). Additionally, the ﬂuorescent amino acid residues of a
protein can also be used as energy transfer donors, enabling the
quantiﬁcation of the extension even of the weak interactions
associated with most of the membrane adsorption processes.
Many studies are centered in the interacting macromolecule,
meaning that it is such the entity that produces the ﬂuorescence
signal, whether it has intrinsic ﬂuorescent amino acid residues or it is
derivatized with a ﬂuorophore. However it can be more advantageous
to perform membrane-centered studies, in which a property of the
membrane is monitored by means of a lipophilic ﬂuorescent probe
while the interaction is occurring. We reviewed how probes sensitive
to the different types of membrane potential can translate such
interactions. FPE is the main probe sensitive to surface potential and
can report interactions of charged macromolecules with the mem-
brane surface. It is capable of distinguishing different moments of
interaction, such as initial binding events and insertion, allowing
multiphasic kinetics to be observed. The membrane dipole potential
sensor di-8-ANEPPS detects interactions of molecules that do not
need to be charged and is particularly sensitive to molecules rich in
dipole chemical groups. It reports insertions in the lipid layer or
surface interactions that disturb the organizations of dipolar residues
of the phospholipids. Transmembrane potential probes are useful to
assess interactions that lead to membrane disruption, causing
potential dissipation and eventually content leakage or lysis. Real-
time imaging with membrane potential sensitive probes is becoming
a reality and it will be very interesting to follow the evolution of these
techniques to enable the mapping of interaction events at the
membrane level.
Several studies use more than one of these experimental
approaches in order to obtain more information about the interaction
events. All these methodologies, as well as their combination provide
molecular level information useful in the ﬁelds of drug development,
cell signaling, trafﬁcking and interactomics.
Acknowledgments
This work was partially supported by projects PTDC/QUI/69937/
2006 and PTDC/QUI-BIQ/104787/2008 from Fundação para a Ciência
e Tecnologia of the Portuguese Ministery of Science, Technology and
Higher Education (FCT-MCTES). PMM and HGF also thank FCT-MCTES
for grants SFRH/BD/42205/2007 and SFRH/BD/39039/2007,
respectively.
References
[1] M. Castanho (Ed.), Structure and function of membrane-active peptides,
International University Line Publishers (IUL Press), La Jolla, CA, 2010.
[2] S.C.D.N. Lopes, A. Fedorov, M.A.R.B. Castanho, Chiral recognition of D-kyotorphin
by lipidic membranes: relevance toward improved analgesic efﬁciency, Chem-
MedChem 1 (2006) 723–728.
[3] M.N. Melo, M.A.R.B. Castanho, Omiganan interaction with bacterial membranes
and cell wall models. Assigning a biological role to saturation, Biochim. Biophys.
Acta 1768 (2007) 1277–1290.
[4] M.N. Melo, D. Dugourd, M.A.R.B. Castanho, Omiganan pentahydrochloride in the
front line of clinical applications of antimicrobial peptides, Recent Patents Anti-
Infect, Drug Disc. 1 (2006) 201–207.
[5] V.J. Hruby, W. Kazmierski, A.M. Kawasaki, T.O. Matsunaga, Peptide pharmaceu-
ticals, in: D.A. Ward (Ed.), Synthetic Chemistry and the Design of Peptide-based
Drugs, Open University Press, Buckingham, UK, 1991, pp. 135–184.
[6] J.S. Wadia, M. Becker-Hapak, S.F. Dowdy, Protein transport, in: Ü. Langel (Ed.),
Cell-penetrating Peptides— Processes and Applications, CRC Press, Boca Raton, FL,
2002, pp. 365–375.
[7] A.S. Veiga, N.C. Santos, L.M. Loura, A. Fedorov, M.A.R.B. Castanho, HIV fusion
inhibitor peptide T-1249 is able to insert or adsorb to lipidic bilayers. Putative
correlation with improved efﬁciency, J. Am. Chem. Soc. 126 (2004) 14758–14763.
[8] S. Veiga, S. Henriques, N.C. Santos, M. Castanho, Putative role of membranes in the
HIV fusion inhibitor enfuvirtide mode of action at the molecular level, Biochem. J.
377 (2004) 107–110.
[9] D.F. Sargent, R. Schwyzer, Membrane lipid phase as catalyst for peptide–receptor
interactions, Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 5774–5778.
Fig. 14. Perturbation of lipid membranes by the antimicrobial peptide microcin J25.
Transmembrane potential monitoring with the probe DiSC3(5) for K+-loaded lipid
vesicles of PC (solid line) or PC:PG:CL 7:2:1 (dotted line) in Na+-containing buffer.
Addition of valinomycin induced a transmembrane potential that was dissipated with
the addition of the peptide. Reprinted from [91].
2010 P.M. Matos et al. / Biochimica et Biophysica Acta 1798 (2010) 1999–2012
82
[10] M.A.R.B. Castanho, M.X. Fernandes, Lipid membrane-induced optimization for
ligand–receptor docking: recent tools and insights for the “membrane catalysis”
model, Eur. Biophys. J. 35 (2006) 92–103.
[11] S.H. White, W.C. Wimley, Hydrophobic interactions of peptides with membrane
interfaces, Biochim. Biophys. Acta 1376 (1998) 339–352.
[12] S.H. White, W.C. Wimley, Membrane protein folding and stability: physical
principles, Annu. Rev. Biophys. Biomol. Struct. 28 (1999) 319–365.
[13] S.T. Henriques, M.A.R.B. Castanho, Consequences of nonlytic membrane pertur-
bation to the translocation of the cell penetrating peptide pep-1 in lipidic vesicles,
Biochemistry 43 (2004) 9716–9724.
[14] A. Chattopadhyay, E. London, Parallax method for direct measurement of
membrane penetration depth utilizing ﬂuorescence quenching by spin-labeled
phospholipids, Biochemistry 26 (1987) 39–45.
[15] M.A.R.B. Castanho, M.J.E. Prieto, Fluorescence quenching data interpretation in
biological systems. The use of microscopic models for data analysis and
interpretation of complex systems, Biochim. Biophys. Acta 1373 (1998) 1–16.
[16] A.S. Ladokhin, Distribution analysis of depth-dependent ﬂuorescence quenching
in membranes: a practical guide, Methods Enzymol. 278 (1997) 462–473.
[17] E. London, A.S. Ladokhin,Measuring the depth of amino acid residues inmembrane-
inserted peptides by ﬂuorescence quenching, Curr. Top. Membr. 52 (2002) 89–115.
[18] M.X. Fernandes, J. Garcia de la Torre, M.A.R.B. Castanho, Joint determination by
Brownian dynamics and ﬂuorescence quenching of the in-depth location proﬁle
of biomolecules in membranes, Anal. Biochem. 307 (2002) 1–12.
[19] H.G. Franquelim, L.M. Loura, N.C. Santos, M.A.R.B. Castanho, Sifuvirtide screens
rigid membrane surfaces. establishment of a correlation between efﬁcacy and
membrane domain selectivity among HIV fusion inhibitor peptides, J. Am. Chem.
Soc. 130 (2008) 6215–6223.
[20] S.C.D.N. Lopes, M.A.R.B. Castanho, Overview of common spectroscopic methods to
determine the orientation/alignment of membrane probes and drugs in lipidic
bilayers, Curr. Org. Chem. 9 (2005) 889–898.
[21] S.C.D.N. Lopes, A. Fedorov, M.A.R.B. Castanho, Cholesterol modulates maculo-
sin's orientation in model systems of biological membranes. Relevance towards
putative molecular recognition, Steroids 69 (2004) 825–830.
[22] S.C.D.N. Lopes, A. Fedorov, M.A.R.B. Castanho, Lipidic membranes are potential
“catalysts” in the ligand activity of the multifunctional pentapeptide neokyotor-
phin, Chembiochem 6 (2005) 697–702.
[23] G. Adam, M. Delbrück, Reduction of dimensionality in biological diffusion
processes, in: A. Rich, N. Davidson (Eds.), Structural Chemistry and Molecular
Biology, W. H. Freeman & Co., San Francisco, 1968, pp. 198–215.
[24] C. DeLisi, The biophysics of ligand–receptor interactions, Q. Rev. Biophys. 13
(1980) 201–230.
[25] N.D. Gershon, K.R. Porter, B.L. Trus, The cytoplasmic matrix: its volume and
surface area and the diffusion of molecules through it, Proc. Natl. Acad. Sci. U.S.A.
82 (1985) 5030–5034.
[26] M. Baldo, A. Grassi, A. Raudino, Diffusion-controlled reactions among ligands and
receptor clusters: effects of competition for ligands, J. Phys. Chem. 95 (1991)
6734–6740.
[27] J. Erickson, B. Goldstein, D. Holowka, B. Baird, The effect of receptor density on the
forward rate constant for binding of ligands to cell surface receptors, Biophys. J. 52
(1987) 657–662.
[28] R.I. Cukier, The effect of surface diffusion on surface reaction rates, J. Chem. Phys.
79 (1983) 2430–2435.
[29] J. Martins, E. Melo, K.R. Naqvi, Reappraisal of four different approaches for ﬁnding
the mean reaction time in the multi-trap variant of the Adam–Delbruck problem,
J. Chem. Phys. 120 (2004) 9390–9393.
[30] S.T. Henriques, J. Costa, M.A.R.B. Castanho, Re-evaluating the role of strongly
charged sequences in amphipathic cell-penetrating peptides: a ﬂuorescence
study using Pep-1, FEBS Lett. 579 (2005) 4498–4502.
[31] H.H. Szeto, P.W. Schiller, K. Zhao, G. Luo, Fluorescent dyes alter intracellular targeting
and function of cell-penetrating tetrapeptides, FASEB J. 19 (2005) 118–120.
[32] E. Rhoades, T.F. Ramlall, W.W. Webb, D. Eliezer, Quantiﬁcation of alpha-synuclein
binding to lipid vesicles using ﬂuorescence correlation spectroscopy, Biophys. J.
90 (2006) 4692–4700.
[33] L. Rusu, A. Gambhir, S. McLaughlin, J. Radler, Fluorescence correlation spectros-
copy studies of peptide and protein binding to phospholipid vesicles, Biophys. J.
87 (2004) 1044–1053.
[34] S. Haldar, H. Raghuraman, A. Chattopadhyay, Monitoring orientation and
dynamics of membrane-bound melittin utilizing dansyl ﬂuorescence, J. Phys.
Chem. B 112 (2008) 14075–14082.
[35] H. Raghuraman, A. Chattopadhyay, Orientation and dynamics of melittin in
membranes of varying composition utilizing NBD ﬂuorescence, Biophys. J. 92
(2007) 1271–1283.
[36] M.K. Jain, J. Rogers, L. Simpson, L.M. Gierasch, Effect of tryptophan derivatives on
the phase properties of bilayers, Biochim. Biophys. Acta 816 (1985) 153–162.
[37] A.S. Ito, A.M. Castrucci, V.J. Hruby, M.E. Hadley, D.T. Krajcarski, A.G. Szabo,
Structure–activity correlations of melanotropin peptides in model lipids by
tryptophan ﬂuorescence studies, Biochemistry 32 (1993) 12264–12272.
[38] N.C. Santos, M. Prieto, M.A.R.B. Castanho, Quantifying molecular partition into
model systems of biomembranes: an emphasis on optical spectroscopic methods,
Biochim. Biophys. Acta 1612 (2003) 123–135.
[39] N.C. Santos, M. Castanho, Fluorescence spectroscopy methodologies on the study
of proteins and peptides. On the 150th anniversary of protein ﬂuorescence,
Trends. Appl. Spectr. 4 (2002) 113–125.
[40] N.C. Santos, M. Prieto, M.A.R.B. Castanho, Interaction of the major epitope region
of HIV protein gp41 with membrane model systems. A ﬂuorescence spectroscopy
study, Biochemistry 37 (1998) 8674–8682.
[41] A. Coutinho, M. Prieto, Self-association of the polyene antibiotic nystatin in
dipalmitoylphosphatidylcholine vesicles: a time-resolved ﬂuorescence study,
Biophys. J. 69 (1995) 2541–2557.
[42] M.A.R.B. Castanho, M.J.E. Prieto, Fluorescence study of the macrolide pentaene
antibiotic ﬁlipin in aqueous solution and in a model system of membranes, Eur. J.
Biochem. 207 (1992) 125–134.
[43] W.L.C. Vaz, E. Melo, Fluorescence spectroscopic studies on phase heterogeneity in
lipid bilayer membranes, J. Fluoresc. 11 (2001) 255–271.
[44] J.R. Lakowicz, Principles of Fluorescence Spectroscopy, 2nd ed., Kluwer Academic/
Plenum Publishers, New York, NY, 1999.
[45] M. Vermeir, N. Boens, K.P. Heirwegh, Interaction of 7-n-alkoxycoumarins with
cytochrome P-450(2) and their partitioning into liposomal membranes. Assess-
ment of methods for determination of membrane partition coefﬁcients, Biochem.
J. 284 (1992) 483–490.
[46] S.T. Henriques, M.A.R.B. Castanho, Environmental factors that enhance the action
of the cell penetrating peptide pep-1 A spectroscopic study using lipidic vesicles,
Biochim. Biophys. Acta 1669 (2005) 75–86.
[47] D.G. Pina, L. Johannes, M.A.R.B. Castanho, Shiga toxin B-subunit sequential binding
to its natural receptor in lipid membranes, Biochim. Biophys. Acta 1768 (2007)
628–636.
[48] F. Stauffer, M.N. Melo, F.A. Carneiro, F.J. Sousa, M.A. Juliano, L. Juliano, R. Mohana-
Borges, A.T. Da Poian, M.A.R.B. Castanho, Interaction between dengue virus fusion
peptide and lipid bilayers depends on peptide clustering, Mol. Membr. Biol. 25
(2008) 128–138.
[49] H.G. Franquelim, A.S. Veiga, G. Weissmuller, N.C. Santos, M.A.R.B. Castanho,
Unravelling the molecular basis of the selectivity of the HIV-1 fusion inhibitor
sifuvirtide towards phosphatidylcholine-rich rigid membranes, Biochim. Biophys.
Acta (2010).
[50] R.E.Dale, J. Eisinger,W.E.Blumberg, Theorientational freedomofmolecularprobes. The
orientation factor in intramolecular energy transfer, Biophys. J. 26 (1979) 161–193.
[51] L. Davenport, R.E. Dale, R.H. Bisby, R.B. Cundall, Transverse location of the
ﬂuorescent probe 1, 6-diphenyl-1, 3, 5-hexatriene in model lipid bilayer
membrane systems by resonance excitation energy transfer, Biochemistry 24
(1985) 4097–4108.
[52] S. Bar, M. Alizon, Role of the ectodomain of the gp41 transmembrane envelope
protein of human immunodeﬁciency virus type 1 in late steps of the membrane
fusion process, J. Virol. 78 (2004) 811–820.
[53] Y. Kliger, S.G. Peisajovich, R. Blumenthal, Y. Shai, Membrane-induced conforma-
tional change during the activation of HIV-1 gp41, J. Mol. Biol. 301 (2000)
905–914.
[54] Y. Kliger, S.A. Gallo, S.G. Peisajovich, I. Munoz-Barroso, S. Avkin, R. Blumenthal, Y.
Shai, Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid
mixing stage, J. Biol. Chem. 276 (2001) 1391–1397.
[55] T. Le Doan, M. Takasugi, I. Aragon, G. Boudet, T. Montenay-Garestier, C. Helene,
Excitation energy transfer from tryptophan residues of peptides and intrinsic
proteins to diphenylhexatriene in phospholipid vesicles and biological mem-
branes, Biochim. Biophys. Acta 735 (1983) 259–270.
[56] R.M. Epand, R. Kraayenhof, Fluorescent probes used to monitor membrane
interfacial polarity, Chem. Phys. Lipids 101 (1999) 57–64.
[57] P.M. Matos, S. Goncalves, N.C. Santos, Interaction of peptides with biomem-
branes assessed by potential-sensitive ﬂuorescent probes, J. Pept. Sci. 14 (2008)
407–415.
[58] S. McLaughlin, The electrostatic properties of membranes, Annu. Rev. Biophys.
Biophys. Chem. 18 (1989) 113–136.
[59] M. Langner, K. Kubica, The electrostatics of lipid surfaces, Chem. Phys. Lipids 101
(1999) 3–35.
[60] G. Cevc, Membrane electrostatics, Biochim. Biophys. Acta 1031 (1990) 311–382.
[61] J. Wall, C.A. Golding, M. Van Veen, P. O'Shea, The use of ﬂuoresceinpho-
sphatidylethanolamine (FPE) as a real-time probe for peptide-membrane
interactions, Mol. Membr. Biol. 12 (1995) 183–192.
[62] P. O'Shea, Intermolecular interactions with/within cell membranes and the trinity
of membrane potentials: kinetics and imaging, Biochem. Soc. Trans. 31 (2003)
990–996.
[63] H. Binder, O. Zschornig, The effect of metal cations on the phase behavior and
hydration characteristics of phospholipid membranes, Chem. Phys. Lipids 115
(2002) 39–61.
[64] L. Herbette, C.A. Napolitano, R.V. McDaniel, Direct determination of the calcium
proﬁle structure for dipalmitoyllecithin multilayers using neutron diffraction,
Biophys. J. 46 (1984) 677–685.
[65] R.A. Bockmann, H. Grubmuller, Multistep binding of divalent cations to
phospholipid bilayers: a molecular dynamics study, Angew. Chem. Int. Ed Engl.
43 (2004) 1021–1024.
[66] P. Soucaille, M. Prats, J.F. Tocanne, J. Teissie, Use of a ﬂuorescein derivative of
phosphatidylethanolamine as a pH probe at water/lipid interfaces, Biochim.
Biophys. Acta 939 (1988) 289–294.
[67] J. Cladera, P. O'Shea, Generic techniques for ﬂuorescence measurements of
protein–ligand interactions; real time kinetics and spatial imaging, in: S.E.
Harding, B.Z. Chowdhry (Eds.), Protein–ligand Interactions, Oxford University
Press, Oxford, 2001, pp. 169–200.
[68] J. Wall, F. Ayoub, P. O'Shea, Interactions of macromolecules with the mammalian
cell surface, J. Cell Sci. 108 (1995) 2673–2682.
[69] C. Golding, S. Senior, M.T. Wilson, P. O'Shea, Time resolution of binding and
membrane insertion of a mitochondrial signal peptide: correlation with structural
changes and evidence for cooperativity, Biochemistry 35 (1996) 10931–10937.
[70] N. Sanghera, T.J. Pinheiro, Binding of prion protein to lipid membranes and
implications for prion conversion, J. Mol. Biol. 315 (2002) 1241–1256.
2011P.M. Matos et al. / Biochimica et Biophysica Acta 1798 (2010) 1999–2012
83
[71] B. Sim, J. Cladera, P. O'Shea, Fibronectin interactions with osteoblasts: identiﬁ-
cation of a non-integrin-mediated binding mechanism using a real-time
ﬂuorescence binding assay, J. Biomed. Mater. Res. A 68 (2004) 352–359.
[72] H. Brockman, Dipole potential of lipid membranes, Chem. Phys. Lipids 73 (1994)
57–79.
[73] R.J. Clarke, The dipole potential of phospholipid membranes and methods for its
detection, Adv. Colloid Interface Sci. 89–90 (2001) 263–281.
[74] E. Gross, R.S. Bedlack, L.M. Loew, Dual-wavelength ratiometric ﬂuorescence
measurement of the membrane dipole potential, Biophys. J. 67 (1994) 208–216.
[75] A. Zouni, R.J. Clarke, J.F. Holzwarth, Kinetics of the solubilization of styryl dye
aggregates by lipid vesicles, J. Phys. Chem. 98 (1994) 1732–1738.
[76] E. Fluhler, V.G. Burnham, L.M. Loew, Spectra, membrane binding, and potentio-
metric responses of new charge shift probes, Biochemistry 24 (1985) 5749–5755.
[77] L.M. Loew, G.W. Bonneville, J. Surow, Charge shift optical probes of membrane
potential. Theory, Biochemistry 17 (1978) 4065–4071.
[78] G. Grynkiewicz, M. Poenie, R.Y. Tsien, A new generation of Ca2+ indicators with
greatly improved ﬂuorescence properties, J. Biol. Chem. 260 (1985) 3440–3450.
[79] M.F. Vitha, R.J. Clarke, Comparison of excitation and emission ratiometric
ﬂuorescence methods for quantifying the membrane dipole potential, Biochim.
Biophys. Acta 1768 (2007) 107–114.
[80] J.C. Franklin, D.S. Caﬁso, Internal electrostatic potentials in bilayers: measuring
and controlling dipole potentials in lipid vesicles, Biophys. J. 65 (1993) 289–299.
[81] R.S. Bedlack Jr., M. Wei, L.M. Loew, Localized membrane depolarizations and
localized calcium inﬂux during electric ﬁeld-guided neurite growth, Neuron 9
(1992) 393–403.
[82] R.J. Clarke, D.J. Kane, Optical detection of membrane dipole potential: avoidance of
ﬂuidity and dye-induced effects, Biochim. Biophys. Acta 1323 (1997) 223–239.
[83] J. Cladera, P. O'Shea, Intramembrane molecular dipoles affect the membrane
insertion and folding of a model amphiphilic peptide, Biophys. J. 74 (1998)
2434–2442.
[84] P.M. Matos, M.A.R.B. Castanho, N.C. Santos, HIV-1 fusion inhibitor peptides
enfuvirtide and T-1249 interact with erythrocyte and lymphocyte membranes,
PLoS ONE 5 (2010) e9830.
[85] J.I. Alakoskela, P.K. Kinnunen, Control of a redox reaction on lipid bilayer surfaces
by membrane dipole potential, Biophys. J. 80 (2001) 294–304.
[86] A.S. Klymchenko, G. Duportail, Y. Mely, A.P. Demchenko, Ultrasensitive two-color
ﬂuorescence probes for dipole potential in phospholipid membranes, Proc. Natl.
Acad. Sci. U.S.A. 100 (2003) 11219–11224.
[87] R.P. Haugland, The Handbook — A Guide to Fluorescent Probes and Labelling
Technologies, 10th ed, 2005 Molecular Probes, Eugene, OR.
[88] J. Plasek, K. Sigler, Slow ﬂuorescent indicators of membrane potential: a survey of
different approaches to probe response analysis, J. Photochem. Photobiol. B 33
(1996) 101–124.
[89] S.T. Henriques, J. Costa, M.A.R.B. Castanho, Translocation of beta-galactosidase
mediated by the cell-penetrating peptide pep-1 into lipid vesicles and human
HeLa cells is driven by membrane electrostatic potential, Biochemistry 44 (2005)
10189–10198.
[90] C. Asensio, J.C. Perez-Diaz, A new family of low molecular weight antibiotics from
enterobacteria, Biochem. Biophys. Res. Commun. 69 (1976) 7–14.
[91] M.R. Rintoul, B.F. de Arcuri, R.D. Morero, Effects of the antibiotic peptide microcin
J25 on liposomes: role of acyl chain length and negatively charged phospholipid,
Biochim. Biophys. Acta 1509 (2000) 65–72.
[92] S.T. Yang, S.Y. Shin, J.I. Kim, Interaction mode of a symmetric Trp-rich undeca
peptide PST11-RK with lipid bilayers, FEBS Lett. 581 (2007) 157–163.
2012 P.M. Matos et al. / Biochimica et Biophysica Acta 1798 (2010) 1999–2012
84
 
85
7. General objectives 
The studies presented in this Thesis aim to clarify and improve the knowledge 
on molecular aspects of enveloped virus entry through membrane fusion and its 
inhibition, with a focus on the role of host factors. For this, we used optical based 
biophysical techniques, mainly fluorescence spectroscopy, single-particle 
microscopy and surface plasmon resonance. Overall, the objectives of this Thesis 
are: 
 Evaluate the interaction of HIV-1 fusion inhibitor peptides with model 
and cell membranes; 
 Correlate the antiviral activity of fusion inhibitor peptides with their 
membranotropic properties; 
 Determine the general structural requirements of glycosaminoglycans to 
bind the HIV-1 envelope glycoprotein gp120; 
 Visualize single enveloped virus fusion on supported lipid bilayers under 
the microscope; 
 Study the role of anionic lipids in modulating the VSV G protein mediated 
viral fusion in model membranes. 
 Clarify the entry pathway of ASLV in cells by simultaneous imaging of 
single virus fusion and quantification of endosomal pH along virus 
trafficking. 
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Overview 
This section presents 3 articles related to the studies of HIV-1 fusion inhibitor 
peptide interactions with model and cell membranes.  
Article A describes the peptide-membranes interactions detected by a dipole 
potential sensitive fluorescent probe. This allowed the quantification of membrane 
binding of enfuvirtide and T-1249 to human isolated blood cells, erythrocytes and 
lymphocytes. These studies were extended to sifuvirtide in Article B, a fusion 
peptide rationally designed in order to be more potent than enfuvirtide. 
A comprehensive membrane interactions study with model membranes and 
cells was done for the latest generation and highly potent peptide conjugate C34-
cholesterol, presented in Article C. The overall results for the fusion inhibitors 
studied emphasize the role of membrane interaction in their mode of action and as 
an important factor to take into account when designing drugs of this type. 
All these studies were performed at IMM in Lisbon. 
Article A 
Matos PM, Castanho MARB, Santos NC. HIV-1 Fusion inhibitor peptides enfuvirtide 
and T-1249 interact with erythrocytes and lymphocytes membranes. PLoS ONE 
5:e9830 (2010). 
Article B 
Matos PM, Freitas T, Castanho MARB, Santos NC. The role of blood cell membrane 
lipids on the mode of action of HIV-1 fusion inhibitor sifuvirtide. Biochem. Biophys. 
Res. Commun. 403:270-274 (2010). 
Article C 
Hollmann A*, Matos PM*, Augusto MT, Castanho MARB, Santos NC. Conjugation 
of cholesterol to HIV-1 fusion inhibitor C34 increases peptide-membrane 
interactions potentiating its action. PLoS ONE 8:e60302 (2013). (*Contributed equally 
to this work). 
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carried out by me, under the supervisions of Prof. Nuno C. Santos and the help of 
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I, Nuno C. Santos, as supervisor of Pedro Matos and as corresponding author 
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Abstract
Enfuvirtide and T-1249 are two HIV-1 fusion inhibitor peptides that bind to gp41 and prevent its fusogenic conformation,
inhibiting viral entry into host cells. Previous studies established the relative preferences of these peptides for membrane
model systems of defined lipid compositions. We aimed to understand the interaction of these peptides with the
membranes of erythrocytes and peripheral blood mononuclear cells. The peptide behavior toward cell membranes was
followed by di-8-ANEPPS fluorescence, a lipophilic probe sensitive to the changes in membrane dipole potential. We
observed a fusion inhibitor concentration-dependent decrease on the membrane dipole potential. Quantitative analysis
showed that T-1249 has an approximately eight-fold higher affinity towards cells, when compared with enfuvirtide. We also
compared the binding towards di-8-ANEPPS labeled lipid vesicles that model cell membranes and obtained concordant
results. We demonstrated the distinct enfuvirtide and T-1249 membranotropism for circulating blood cells, which can be
translated to a feasible in vivo scenario. The enhanced interaction of T-1249 with cell membranes correlates with its higher
efficacy, as it can increase and accelerate the drug binding to gp41 in its pre-fusion state.
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Introduction
The Human Immunodeficiency Virus type 1 (HIV-1) is a highly
pathogenic, evasive and difficult to eradicate agent that causes
Acquired Immunodeficiency Syndrome (AIDS). This discovery in
the early 1980s triggered major international scientific efforts in
antiviral drug discovery and development [1]. As a consequence,
many drugs are now available to manage this condition, allowing
the use of drug combination therapy known as HAART (highly
active antiretroviral therapy). The majority of the drugs inhibit the
different enzymes vital for the HIV-1 life cycle: reverse
transcriptase, integrase and protease. However, the entry inhib-
itors target steps before the viral content is released into the host
cell cytoplasm [2]. Infection of T CD4+ cells begins with the
binding of the viral envelope trimeric glycoprotein gp120 with the
CD4 receptor and a chemokine receptor (CCR5 or CXCR4) of
the host cell. This engagement triggers the exposure of the
hydrophobic N-terminal region of another envelope glycoprotein,
gp41. This fusion peptide anchors to the membrane of the host
cell, enabling the two gp41 helical heptad repeat domains, the C-
terminal (CHR or HR2) and the N-terminal (NHR or HR1), to
fold into each other to form a hairpin-like structure (6-helix
bundle). This approximates the cell and the viral membranes,
facilitating their fusion and the release of the viral content into the
cell [3].
Besides maraviroc, a recently approved CCR5 antagonist
blocking gp120 co-receptor engagement [4], enfuvirtide is the
other only entry inhibitor approved for clinical use [5]. Enfuvirtide
(formerly known as T-20 and DP-178) is a peptide drug selected
from chemically synthesized peptides derived from various regions
of gp41 [6]. The core structure of gp41 was only revealed later and
helped to understand the inhibitory activity of enfuvirtide [7]. The
peptide sequence (sequence 643–678 of HIV-1LAI [6]) corre-
sponded partially to the CHR region of gp41 and it would bind to
the opposite NHR region, preventing the formation of the hairpin
structure and consequently, the fusion. The same consortium that
led enfuvirtide to clinical approval (Trimeris, Inc. and Roche)
developed a second generation fusion inhibitor, T-1249. It is a 39-
mer peptide which sequenced was designed taking into account
the gp41 CHR sequences from HIV-1, HIV-2 and SIV (Simian
Immunodeficiency Virus) [8]. A successful short-term evaluation
of antiretroviral activity and safety in humans proved the potential
of this new drug [8], although further clinical development was put
on hold [9].
Since the first appearance of enfuvirtide, the search for peptide
drugs against HIV has been a growing field of research and several
candidates proved to be efficient in vitro [10]. As our knowledge of
HIV structure and function progresses, more sophisticated peptide
designs are developed in order to overcome viral resistance to
previous drugs. The initial view of the mechanism of action of
these peptides, that is, binding to NHR region and block 6-helix
bundle formation, has been refined over the years. Other factors
besides gp41-peptide binding can contribute to explain the mode
of action of these peptides. In fact enfuvirtide does not form stable
6-helix bundle structures with N36, a NHR derived peptide,
contrary to C34, another CHR derived peptide [11]. Moreover,
peptides derived from the membrane-spanning domain in gp41
and the co-receptor binding site in gp120 inhibited enfuvirtide
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antiviral activity [11], meaning that other sites in the viral
envelope could be targeted by enfuvirtide.
Membrane binding/tropism emerged as an important factor to
take into account concerning the mode of actions of these peptides.
Previous studies evaluated the preferences of enfuvirtide and T-
1249 to membrane model systems. Partition of these peptides to
fluid phase and cholesterol-rich lipid vesicles was followed by
intrinsic tryptophan fluorescence present in both peptides [12,13].
Both enfuvirtide [13] and T-1249 [12] partitioned to fluid phase
zwitterionic phospholipid vesicles (POPC, 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine) with partition constants (Kp [14]) of
1.66103 and 5.16103, respectively. However, regarding interac-
tion with cholesterol-rich POPC vesicles (up to 33% mol)
enfuvirtide showed residual association, while T-1249 binding
was significant, despite also presenting a low partition (membrane
insertion) [12]. T-1249 improved preference for lipid environment
correlated with its higher antiviral activity.
In this study, we aim to understand the nature of HIV-1 fusion
inhibitors-membrane interactions using human blood cells,
namely erythrocytes and PBMC (peripheral blood mononuclear
cells). We made use of an indirect reporter, the fluorescent
lipophilic probe di-8-ANEPPS, as direct measure of the peptide
intrinsic tryptophan fluorescence was impracticable with cells.
This probe incorporates in the outer leaflet of the cell membranes
and is sensitive to the local dipole potential by shifting its excitation
spectrum [15]. Interaction of peptides or other molecules with
membranes can change the lipid and interfacial water dipoles
organization. Moreover, the peptide dipoles themselves can
contribute to the potential. These overall dipolar changes
occurring at the membrane can then be translated by the probe
both qualitatively and quantitatively [16].
Results
Labeling of erythrocytes and PBMC with di-8-ANEPPS
membrane probe
Isolated human erythrocytes and PBMC membranes were
successfully labeled with di-8-ANEPPS. Confocal microscopy
images clearly show the delineated labeled membrane
(Fig. 1A,B). Importantly, no intracellular staining of di-8-ANEPPS
was observed. The emission and excitation spectra of the probe
were taken for the two cell types (Fig. 1C). Labeled erythrocytes
and PBMC had different spectral maxima (specially for the
emission) due to the probe sensitivity to the differences in the
composition and nature of the membrane lipids.
Enfuvirtide and T-1249 induce changes in the dipole
potential of cell membranes
Incubation of the labeled erythrocytes and PBMC with
enfuvirtide or T-1249, lead to changes in spectral properties of
the membrane-bound di-8-ANEPPS. Excitation spectra were
deviated to the red meaning that a decrease in the dipole potential
occurs. Differential spectra can be used in order to help the
visualization of the spectral shift (Fig. 2). In this case, the minimum
of the differential spectra comes at a lower wavelength than the
maximum, indicative of a decrease in the dipole potential (see
methods section). These changes depend on the peptide and its
concentration. T-1249 is more effective in decreasing the
membrane potential than enfuvirtide.
To follow the time course of the interaction, we used the ratio
between the approximate maximum and minimum of the
differential spectra (R = I455 nm/I525 nm), that correlates with
the dipole potential variations. After the addition of each peptide,
we observed a decrease on the dipole potential within the first
minutes for erythrocytes (Fig. 3) and lymphocytes.
Quantification of the membrane-peptide interaction for
erythrocytes and PBMC
In order to quantify the affinity of the peptides to the cell
membranes, we set to investigate the variation of the dipole
potential as a function of peptide concentration (Fig. 4). The ratio
R was measured for a range of concentrations of enfuvirtide and
T-1249. The decrease of the potential as a function of
concentration followed a hyperbolic curve. The data was analyzed
according to a single binding site model [17] to yield dissociation
constants (Kd) for each peptide (Table 1). For both cell types, the Kd
for T-1249 was much smaller (one order of magnitude),
accounting for a higher preference for the cell membrane. The
Figure 1. Visualization and spectral characterization of di-8-
ANEPPS labeled cells. Labeled erythrocytes (A) and PBMC (B) were
observed under a confocal fluorescence microscope to confirm that
only the plasma membrane was stained (shown in red). Additional
staining of the nucleus with Hoechst dye (blue) was performed for
PBMC, only for microscopy observation. Excitation and emission spectra
(C) were taken for each labeled cell type, differing on peaks due to
different membrane environments (blue trace for PBMC and red trace
for erythrocytes; filled line for excitation and dashed line for emission
spectra). Excitation at 465 nm for both cell types; emission at 600 nm
and 585 nm for erythrocytes and PBMC, respectively.
doi:10.1371/journal.pone.0009830.g001
HIV Inhibitors Membranotropism
PLoS ONE | www.plosone.org 2 March 2010 | Volume 5 | Issue 3 | e9830
94
relative behavior of the peptide towards the erythrocyte and
PBMC membrane seems to be maintained: the ratios Kd,ENF/Kd,T-
1249 are similar for both cell type (8.5 and 8.1 for erythrocytes and
PBMC, respectively).
Comparison of peptide-induced dipole changes in bio-
mimetic lipid vesicles
As stated earlier, interaction of enfuvirtide and T-1249 with
lipid vesicles has been previously studied by means of their
tryptophan residues fluorescence. For the sake of comparison with
the data obtained for the interaction with blood cells membranes
and in order to validate the comparison with previous data, we
used di-8-ANEPPS labeled lipid vesicles to assess the interaction of
these peptides, reported by changes on membrane dipole potential
(Fig. 5). The lipid vesicles were composed entirely of POPC, to
mimic most of the outer leaflets of mammalian cell membranes, in
the liquid disordered state, or a mixture of POPC with cholesterol
33% mol, as an approximation to the membrane microdomains in
the liquid ordered state (lipid rafts). This is especially relevant for
the erythrocyte membranes, which are particularly cholesterol-rich
[18]. Concerning the POPC vesicles, the binding of T-1249 was
again more pronounced than for enfuvirtide (Fig. 5). When the
vesicles are enriched with cholesterol, significant changes occur in
terms of peptide association to the membrane. Enfuvirtide binds
less extensively to membranes rich in cholesterol, while T-1249
increases the extension of membrane association (Fig. 5). This is in
agreement with previous results obtained for lipid vesicles [12], in
which the adsorption of T-1249 on cholesterol enriched domains
was identified, in contrast to enfuvirtide.
Discussion
Designing peptide drugs based in gp41 sequence to prevent viral
entry into host cells has been in focus in the antiretroviral research
field. Several factors related to their mode of action must be taken
into account in order to optimize efficacy. For the first time, we
addressed the interactions of HIV-1 fusion inhibitors with human
cell membranes to better understand their membranotropic
behavior in vivo. We made use of a dipole potential membrane
probe, di-8-ANEPPS, to indirectly assess the membrane binding of
enfuvirtide and T-1249 to erythrocytes and mononuclear
leukocytes. These peptides decreased the membrane dipole
potential of the two cell types, indicating that an interaction is
occurring. Quantitatively, T-1249 was found to have approxi-
mately 8 times more affinity towards these cell membranes than
enfuvirtide. Furthermore, studies with di-8-ANEPPS labeled
POPC vesicles corroborated this by showing higher binding of
T-1249 in comparison with enfuvirtide. Concerning POPC/
cholesterol vesicles, the relative binding affinity between the two
peptides was maintained. The presence of cholesterol reduced the
binding extension of enfuvirtide and had an opposite effect in the
case of T-1249, in agreement with our previous results that
followed the interaction by tryptophan fluorescence [12]. Due to
the fact that erythrocyte membranes contain significantly more
cholesterol than PBMC [18] it could be expected that peptide
binding characteristics for these two cell types would be more
distinct. However, these composition differences seem not to be
sufficient to change significantly the interaction behavior of the
Figure 2. Differential spectra of membrane-bound di-8-AN-
EPPS in the presence of HIV-1 fusion inhibitor peptides. The
shape of the difference spectra reveal spectral shift to the red, indicative
of a decrease in membrane dipole potential. For erythrocytes (top row)
and PBMC (bottom row), the higher the peptide concentration (150 mM
in blue, 40 mM in red and 10 mM in green), the higher the spectral shifts.
doi:10.1371/journal.pone.0009830.g002
Figure 3. Time course variation of dipole potential in response to the peptides. The effect of the addition of indicated concentrations (mM)
of enfuvirtide (A, red) and T-1249 (B, blue) to labeled erythrocytes was followed by measuring the ratio in real-time. Stepwise additions decreases the
ratio within minutes.
doi:10.1371/journal.pone.0009830.g003
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peptides, as we can see confronting POPC with POPC/cholesterol
(33% mol) vesicles. Other factors such as the diversity of lipidic,
proteic and glycidic components seem to superimpose to the effect
of differences in cholesterol content. In fact, we checked if
cholesterol depletion of erythrocytes membranes by methyl-b-
cyclodextrin would reflect on changes in peptide binding and no
significant alterations were detected (data not shown).
The membranotropism of these peptides can be explained in
molecular terms by their structure and aminoacid sequence. It has
been identified in the CHR and adjacent regions specific motifs
that account for different roles in the interaction with NHR and
membrane environment. Some of these regions also translate to
the CHR derived peptides. Towards the N-terminus of CHR,
there is a pocket binding domain (PBD, HIV-1LAI 628–635) that
binds to a hydrophobic groove in the NHR region [7]. It was
established that this PBD was a crucial region for the binding of
CHR and NHR in order to form the 6-helix bundle hairpin-like
structure [7]. Another region identified in the far C-terminus of
CHR is the lipid binding domain (LBD), a hydrophobic Trp-rich
region by which CHR derived peptides can apparently bind to
lipid membranes [19]. The sequence of enfuvirtide contains only
the LBD while T-1249 was designed to contain both LBD and
PBD (Fig. 6A). Thus, binding to cell and mimetic membranes is
related to this putative LBD. Interestingly, by mutating the LBD
region of enfuvirtide WNWF to ANAA, the antiviral activity of the
peptide was abrogated [20] as well as its ability to bind to POPC
vesicles [19]. Moreover, when an ANAA enfuvirtide mutant was
octylated, its inhibitory activity was restored to a level similar to
standard enfuvirtide [21]. This indicates the importance of the
LBD for the efficacy of enfuvirtide, as the octylation of enfuvirtide
also increased its potency. A similar result was obtained when
enfuvirtide and ANAA mutant were expressed attached to a
membrane protein in a T-helper cell line [22]. Another example
comes from the addition of a cholesteryl group to C34, another
peptide fusion inhibitor that lacks a LBP but contains the PBD
sequence [23]. The potency of the derivatized C34 increased
significantly; however, this effect was not observed when
cholesterol was attached to enfuvirtide, which already has a
LBD. TRI-999, another LBD lacking C-peptide, was synthesized
with an attached C18 chain [24], showing improved efficiency
over enfuvirtide.
All these findings that relate membrane binding to improved
efficiency of the peptides mean that this is a major factor to take
into account when rationally designing drugs of this type.
Enfuvirtide and T-1249 have membranotropic behavior towards
POPC lipid vesicles and now this study confirms that they both
Figure 4. Peptide affinity towards erythrocytes and PBMC cell membranes. The dependence of the ratio on the enfuvirtide (red) and T-1249
(blue) concentrations for erythrocytes (A) and PBMC (B) was analyzed by a single binding site model (dashed lines) in order to quantify the
dissociation constants (see Table 1). Ratio values were normalized for the initial value of zero peptide concentration. Plotted values represent the
mean 6 SEM (error bars not visible in erythrocytes due to small errors). N = 6 for erythrocytes and N=7 for PBMC.
doi:10.1371/journal.pone.0009830.g004
Table 1. Quantification of peptide binding.
Cells Peptide Rmin, norm Kd (mM) Kd, ENF/Kd, T-1249
Erythrocytes T-1249 20.8160.0063 4.1660.13 8.5
Enfuvirtide 20.9760.015 35.461.33
PBMC T-1249 20.7760.014 7.7160.61 8.1
Enfuvirtide 21.060.071 62.2610.2
Comparison of the values of the dissociation constant, Kd and the parameter
Rmin obtained by non-linear regression with equation (1). The values represent
mean 6 SEM.
doi:10.1371/journal.pone.0009830.t001
Figure 5. Interaction of the peptides with membrane model
systems. The binding profiles for enfuvirtide (red) and T-1249 (blue)
were obtained for large unilamellar vesicles composed of POPC (open
symbols) and POPC/cholesterol 33% mol (filled symbols).
doi:10.1371/journal.pone.0009830.g005
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also interact with circulating blood cells. These peptides have a
restricted temporal and spatial window of opportunity to bind to
their molecular target: the NHR region of gp41 in its extended
conformation when the virus and host cell are closely engaged.
This makes aqueous diffusion of the peptide to the target less
efficient. The capacity that these peptides have to bind to the cell
membranes facilitates the delivery of the peptides to this confined
environment, as some peptide is already locally present.
Ultimately, the membrane can act as a ‘‘catalyst’’ to the binding
reaction between the gp41 and the peptides, as it has been
postulated in other receptor-ligand scenarios in the membrane
environment [25]. Thus, for this case, the higher potency of T-
1249 in relation to enfuvirtide seems to correlate with its higher
membranes binding to the blood cells, particularly the lympho-
cytic fraction, where the preferential target cells are included.
Then, its membrane binding capacity is possibly one of the
factors that explain their relative potency (Fig. 6B). In terms of its
structure and sequence, both peptides have the LBD sequence
that accounts almost totally for enfuvirtide membrane binding.
Nevertheless, T-1249 should have some other structural charac-
Figure 6. Proposed mode of action of enfuvirtide and T-1249 in circulation with blood cells. A) Sequence alignment of enfuvirtide and T-
1249 with native gp41 (PDB code: 1ENV), showing the pocket binding domain (PBD) in blue and the putative lipid binding domain (LBD) close to the
membrane proximal region in red. B) Peptides partition to the membranes of circulating blood cells creating a peptide-rich environment, when the
virus interact both with erythrocytes and lymphocytes. HIV associates with erythrocytes via DARC receptor or complement opsonized virus via CR1.
Exchanges of peptide between cells and virus and partition of peptide directly to the viral membrane can occur. When infecting the preferential CD4+
T cells, the membrane binding of peptide inhibitors should facilitate its interaction with the exposed conformation of gp41, preventing the 6-helix
bundle formation. If the virus is internalized and fuses with the cell membrane at the endosome level, as recently described [27], the partition of the
peptides to the membranes ensures that a considerable amount of peptides enters upon endocytosis in order to be available during the intracellular
fusion event.
doi:10.1371/journal.pone.0009830.g006
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teristic that account for its higher binding affinity. The PBD
region additionally present on T-1249 is also a hydrophobic
region and has 2 tryptophan residues (LBD has 3 Trp). This
could account for a weak membrane binding domain. However,
the membrane binding capacity of a C-peptide with an altered
heptad repeat sequence and containing a PBD but not a LBD
(PBD-4HR, similar do C34) is very poor, similar to a C-peptide
that does not have any of these domains [26]. We could speculate
that a possible, but not certain, synergistic action between the
PBD and LBD domains present on T-1249 to increase its
membranotropism. Another contributing factor could be the
increased helicity of T-1249 in solution compared to enfuvirtide
[12], a structural characteristic that favors insertion and stability
in the membrane. Summarizing, T-1249 would be more effective
due to: a) a LBD sequence motif, shared with enfuvirtide, that
allows the peptide to anchor to the membrane as a platform to
reach the target sequence in gp41 and explains part of its
membranotropism; b) a PBD sequence motif that accounts for an
enhanced gp41 binding and c) the higher overall affinity towards
cell membranes of T-1249 (especially cholesterol-rich domains)
not explained by the sum of the membrane binding effects of
PBD and LBD.
Recently, a novel discovery about the HIV-1 entry into host
cells challenged the current knowledge of viral-cell membrane
fusion at the cell surface. Miyauchi et al. [27] showed that HIV-1
tends to prefer an endocytic route of entry and that fusion
preferentially occurs at the endosomes. This would elicit
protection to HIV from fusion inhibitors, as the surface exposition
of the gp41 extended conformation is reduced. Hence, the
capability of peptide fusion inhibitors to partition to the membrane
and remain there while the virus is internalized, together with a
cell membrane patch, can prove to be a decisive factor concerning
their inclusion on the endosome, leading to increased antiretro-
viral efficacy and potency.
The relevance of peptide binding to erythrocytes is not to be
diminished. In fact, HIV can be found associated with erythrocytes
in vivo [28] and binds to erythrocyte membrane in vitro [29]. The
virus can bind to erythrocytes via the DARC (Duffy Antigen
Receptor for Chemokines) [30,31] or via the complement receptor
1 (CR-1), that binds C3b or C3bi opsonized virus [32,33].
Moreover, erythrocytes can mediate trans-infection of these bound
viruses to other immune system cells that circulate in the blood
and reside in the spleen [30,32]. Interestingly, depending on which
complement proteins are opsonizing the virus, they can direct the
virus through various immune system cells that express different
complement receptors, creating a dynamic circulation of the virus
and facilitating its spreading through the body [34]. Therefore, we
can speculate that by contacting with erythrocytes with pre-bound
fusion inhibitor peptides, the virus itself can take peptide in its own
membrane (Fig. 6B). In fact, Aloia et al. [35] found the lipid
composition of the erythrocyte membrane to be similar to the HIV
membrane itself; thus, peptide-viral membrane interaction seems
to be very feasible. This peptide-membrane interaction can occur
also for other circulating cells.
In a therapeutic context, several factors can influence the
availability of the antiretroviral peptides in circulation. The drug is
distributed to different components of the blood, namely, dissolved
in the plasma, bound to plasma proteins (namely, albumin) and, as
we established with this study, bound to cell membranes. The
membrane-bound fraction would enhance the availability towards
the molecular target in the virus, as explained earlier in this
section, opposing to the fraction bound to plasma proteins, a factor
that enhances peptide clearance. In conclusion, the dynamics
between the peptide interaction among the different cell
populations and with the virus, along with emerging new
perspectives of HIV entry are complex factors that should the
taken in consideration when rationally designing the next
generation of fusion inhibitor peptides.
Materials and Methods
Isolation and labeling of human erythrocytes and PBMC
Human blood samples were obtained from healthy volunteer
donors at the public blood bank Instituto Portugueˆs do Sangue
(Lisbon, Portugal), with their informed written consent. These
samples were obtained under an institutional agreement between
IPS Lisboa and Instituto de Bioquı´mica from Faculdade de
Medicina da Universidade de Lisboa. This study was approved by
the Ethics Committee of Faculdade de Medicina da Universidade
de Lisboa. Donors were asked to give up to 10 mL of blood for
research purposes additionally to their common blood donation of
450 mL to the blood bank. The blood collection was made
anonymously as the data treatment resulting from the experiences
made with these samples. The samples were drawn to K3EDTA
anticoagulant tubes (Vacuette, Greiner Bio-one, Kremsmu¨nster,
Austria). For erythrocytes, the blood samples were centrifuged at
1200 g during 10 min to remove plasma and buffy-coat. The
erythrocytes were washed at least two times with working buffer
(HEPES 10 mM pH 7.4, in NaCl 150 mM, both from Sigma, St.
Louis, MO, USA). For labeling, they were prepared at 1%
hematocrit in working buffer supplemented with 0.05% (m/V)
Pluronic F-127 (Sigma) and di-8-ANEPPS 10 mM (Molecular
Probes, Invitrogen, Carlsbad, CA, USA). PBMC were isolated by
density gradient using Ficoll-Paque Plus (GE Healthcare, Little
Chalfont, UK), accordingly to manufacturer’s instructions. Cells
were counted in Cell-Dyn 1600 analyzer (Abbott, Abbott Park, IL,
USA) and were prepared at 3000 cells/mL in Pluronic supple-
mented buffer with di-8-ANEPPS 3.3 mM. The suspensions of
erythrocytes or PBMC with probe were incubated at room
temperature with gentle agitation for 1 h. Unbound di-8-ANEPPS
was removed by two wash cycles, with centrifugations at 1500 g for
5 min.
Preparation and labeling of lipid vesicles
Large unilamellar vesicles (LUV) with ,100 nm diameter,
composed of pure POPC (Avanti Polar Lipids, Alabaster, AL,
USA) or POPC with 33% mol cholesterol (Sigma), were obtained
by extrusion of multi-lamellar vesicles (MLV) as described
elsewhere [36]. Briefly, a chloroform dissolved lipid was dried in
round-bottom flasks to obtain a film. MLV were obtained by
dissolving the film in working buffer and subjecting to 8 freeze-
thaw cycles. The suspension was extruded, first through a
polycarbonate filter with 400 nm pores, followed by passages
trough 100 nm pores filters in a custom made extruder. For
cholesterol enriched vesicles, the extruder was heated by a water
bath. Lipid vesicles suspensions with 500 mM of total lipid were
incubated overnight with di-8-ANEPPS 10 mM, to ensure
maximum incorporation of the probe.
Fusion inhibitor peptides
The HIV-fusion inhibitors enfuvirtide (T-20) and T-1249 (kind
gifts of Roche, Palo Alto, CA, USA) were prepared in working
buffer at maximum stock concentration of 250 mM. These
peptides were incubated at different concentrations with labeled
erythrocytes (0.02% hematocrit), PBMC (100 cells/mL) or lipid
vesicles (200 mM of total lipid) during 1 h for cells or 90 min for
vesicles, with gentle agitation before measurements.
HIV Inhibitors Membranotropism
PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9830
98
Microscopy imaging
Erythrocyte microscopy images were obtained in a laser
scanning confocal microscope Zeiss LSM 5 Live (Jena, Germany)
using a water immersion objective Zeiss C-Apochromat 206 (1.20
numerical aperture). PBMC images were obtained in a Zeiss
LSM510 Meta using an oil immersion objective Zeiss Plan-
Apochromat 636 (1.4 numerical aperture). Di-8-ANEPPS was
excited by a 488 nm laser (LP 505 filter for erythrocytes, BP 575–
615 for PBMC). For the PBMC, Hoescht dye (Molecular Probes,
Invitrogen) was also used for nucleus labeling, excited by a 405 nm
laser (LP 420 filter).
Membrane dipole potential assessed by di-8-ANEPPS
The membrane probe di-8-ANEPPS assesses dipole potential by
shifting its excitation spectrum. Differential spectra for detecting
these shifts are obtained by subtracting the excitation spectrum of
labeled cells in the presence of peptide from the spectrum in its
absence. Before subtraction the spectra were normalized to the
integrated areas to reflect only spectral shifts. The differential
spectra are waveform shaped, which amplitude directly correlates
with the peak shifting magnitude, and hence, with the dipole
potential variation. Blue-shifts will result in differential spectra in
which a maximum comes at a lower wavelength than the
maximum, and the opposite for red-shifts.
To qualitatively define a value for the spectral shift and hence,
the dipole potential, a ratio was established from fluorescence
intensities at two wavelengths on the sides of excitation spectrum
peak [15,37]. We chose them by taking the corresponding
wavelength values for the minimum and the maximum of the
differential spectra, defining the ratio R for this case as I455 nm/
I525 nm (I, fluorescence intensity). It was already established that an
increase in the membrane dipole potential leads to a blue-shift in
the membrane incorporated di-8-ANEPPS and, consequently, to
an increase in the ratio [15,37]. We also made a simple test for
erythrocytes by adding 6-ketocholestanol (Sigma), an agent that
increases dipole potential, and we observed the expected behavior
of di-8-ANEPPS.
The variation of R with the peptide concentration was analyzed
by a single binding site model [17], following equation 1, with the
R values normalized for R0, the value at zero peptide
concentration. Rmin defines the asymptotic minimum value of R
and Kd is the dissociation constant.
R=R0~1z
Rmin=R0 Peptide½ �
Kdz Peptide½ � ðEq:1Þ
Fluorescence spectroscopy measurements
All the fluorescence spectroscopy measurements were made in a
Varian Cary Eclipse (Mulgrave, Australia) fluorescence spectro-
photometer. Membrane-bound di-8-ANEPPS excitation spectra
and ratios were taken with emission at 670 nm in order to avoid
membrane fluidity effects, as previously tested for lipid vesicles
[38]. We also tested if this was observed in labeled erythrocytes
(data not shown). The R values were measured through
temperatures from 15uC to 50uC, with emissions at 580, 600
and 670 nm. The slope was lower for 670 nm, meaning a lower
interference of fluidity effect at this wavelength. Excitation and
emission slits for all measurements were 5 nm and 10 nm,
respectively.
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Sifuvirtide is a gp41 based peptide that inhibits HIV-1 fusion with the host cells and is currently under
clinical trials. Previous studies showed that sifuvirtide partitions preferably to saturated phosphatidyl-
choline lipid membranes, instead of ﬂuid-phase lipid vesicles. We extended the study to the interaction
of the peptide with circulating blood cells, by using the dipole potential sensitive probe di-8-ANEPPS.
Sifuvirtide decreased the dipole potential of erythrocyte and lymphocyte membranes in a concentration
dependent manner, demonstrating its interaction. Also, the lipid selectivity of the peptide towards more
rigid phosphatidylcholines was conﬁrmed based on the dipole potential variations. Overall, the interac-
tion of the peptide with the cell membranes is a contribution of different lipid preferences that presum-
ably directs the peptide towards raft-like domains where the receptors are located, facilitating the reach
of the peptide to its molecular target, the gp41 in its pre-fusion conformation.
 2010 Elsevier Inc. All rights reserved.
1. Introduction
The search for new antiretroviral drugs has been an ongoing ef-
fort in order to manage HIV pathogenesis, leading to AIDS in hu-
mans. With the evolving technology, the paradigm has shifted to
rationally designed drugs, tailored for a speciﬁc target of the viral
life cycle [1]. HIV-1 fusion inhibitor peptides have been the object
of intense research in the recent years as a consequence of the suc-
cessful approval for clinical use of enfuvirtide (formerly T-20) [2].
Sifuvirtide is a second generation HIV-1 fusion inhibitor that is
currently undergoing phase II clinical trials [3,4]. As previous HIV-
1-fusion inhibitors, this peptide is based on the C-terminal heptad
repeat (CHR) region of gp41, in order to bind to the N-terminal
heptad repeat (NHR) region of gp41 and inhibit its pre-fusion con-
formation. Sifuvirtide was designed to increase the stability of the
a-helix and to cover the deep pocket binding region of gp41 [3].
It shares some features with C34, another peptide that covers only
the deep pocket region, differing from it in 16 out of 36 residues.
Contrary to enfuvirtide, sifuvirtide lacks the region close to the
membrane proximal region, which presumably accounts for lipid
binding characteristics. T-1249, another second generation fusion
inhibitor [5,6], has both the pocket (PBD) and lipid (LBD) binding
domains.
Enfuvirtide and T-1249 were previously reported to partition to
lipid model membranes [7,8] and blood cell membranes [9], a char-
acteristic that correlated with antiviral efﬁcacy, as T-1249, a more
potent drug, has more afﬁnity towards membranes than enfuvir-
tide. These peptides face a limited spatial and temporal window
in which gp41 is susceptible in its pre-fusion conformation; there-
fore, a local concentration of peptide in the membrane environ-
ment makes the peptide delivery more efﬁcient than via aqueous
diffusion only. However, sifuvirtide was found not to partition to-
wards POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)
and POPC/cholesterol membranes, preferring instead more rigid
choline phospholipids (DPPC, 1,2-dipalmitoyl-sn-glycero-3-phos-
phocholine) [10,11], which mimic more rigid lipid domains en-
riched in receptors at the cell membrane context. These are also
the preferred sites of action for the HIV-1 gp41 fusion peptide
[12,13]. Moreover, the viral envelope membrane is enriched in sat-
urated phosphatidylcholines (PC), relative to the host cell, with
DPPC constituting up to 20% of total PC [14].
We aimed to explore the membranotropism of sifuvirtide to-
wards circulating blood cells (erythrocytes and peripheral blood
mononuclear cells, PBMC) by monitoring its interaction using a
membrane ﬂuorescent probe. This probe, di-8-ANEPPS (4-[2-[6-
(dioctylamino)-2-naphthalenyl]ethenyl]-1-(3-sulfopropyl)-pyridi-
nium), is sensitive to alterations on the membrane dipole potential,
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which occur when molecules containing dipoles, such as this pep-
tide, adsorb or insert into the lipid bilayer [15–18]. The membrane-
incorporated di-8-ANEPPS reports dipole potential changes due to
a shift in its excitation spectrum. The spectral shift is proportional
to the magnitude of the potential change. This makes ﬂuorescence
differential ratiometric measurements an appropriate approach to
quantify these changes [17].
2. Materials and methods
Human blood samples were collected from healthy blood do-
nors, with their previous written informed consent, following a
protocol established with the Portuguese Blood Institute (Lisbon),
approved by the Ethics Committee of the Faculty of Medicine of
the University of Lisbon. Erythrocytes and PBMC were isolated
and labeled with di-8-ANEPPS (Invitrogen, Carlsbad, CA, USA) as
previously described [9]. Brieﬂy, erythrocytes were isolated by re-
peated centrifugation and washing with isotonic buffer and incu-
bated at 1% hematocrit with 10 lM di-8-ANEPPS and buffer
supplemented with 0.05% (m/V) Pluronic F-127 (Sigma, St. Louis,
MO, USA). PBMC were isolated by density gradient using Ficoll-Pa-
que Plus (GE Healthcare, Litlle Chalfont, UK) and incubated at
3000 cells/lL in Pluronic-supplemented buffer with 3.3 lM di-8-
ANEPPS. Incubations lasted for 1 h and unbound probe was washed
by centrifugation. Large unilamellar vesicles (LUV) with 100 nm
diameter, composed of pure POPC (Avanti Polar Lipids, Alabaster,
AL, USA), POPC with 33% mol cholesterol (Sigma) and DPPC (Avanti
Polar Lipids), were obtained by extrusion of multi-lamellar vesicles
(MLV) as described elsewhere [9,19]. Lipid vesicles suspensions
with 500 lM of total lipid were incubated overnight with di-8-
ANEPPS 10 lM, to ensure maximum incorporation of the probe.
Sifuvirtide (a kind gift of FusoGen, Tianjin, PR China) was incubated
at different concentrations with labeled erythrocytes (0.02%
hematocrit), PBMC (100 cells/lL) or lipid vesicles (200 lM of total
lipid) during 1 h for cells or 90 min for vesicles, with gentle agita-
tion before measurements. These incubations times were checked
to be adequate for an equilibrium to be reached. All the ﬂuores-
cence spectroscopy measurements were made in a Varian Cary
Eclipse (Mulgrave, Australia) ﬂuorescence spectrophotometer.
Membrane-bound di-8-ANEPPS excitation spectra and ratios were
taken with emission at 670 nm in order to avoid membrane ﬂuidity
effects [9,20]. Excitation and emission slits for all measurements
were 5 nm and 10 nm, respectively.
All the experiments were done in HEPES isotonic buffer (HEPES
10 mM, NaCl 150 mM) at pH 7.4 and at room temperature (25 C).
3. Results
In order to qualitatively evaluate sifuvirtide–membrane inter-
action, these two types of cell populations were incubated with
three concentrations of sifuvirtide and the differential spectra were
obtained (Fig. 1). The shape of these graphs indicates that there is a
decrease in the dipole potential due to the presence of the peptide.
Moreover, the amplitude, which is proportional to the spectral shift
of the probe, is dependent on the peptide concentration.
To further investigate this dependence, we deﬁned the ratio R of
ﬂuorescence intensities (I) at the two excitation wavelengths of
maximum signal variation I455 nm/I525 nm (both measurements with
emission at 670 nm) of cell membrane-bound di-8-ANEPPS, which
is proportional to the dipole potential (Fig. 2A). The effect of the
peptide concentration is identical for the two cell types.
The decrease in the dipole potential is almost linear with con-
centration, at variance with the hyperbolic-like variation previ-
ously observed for enfuvirtide and T-1249 (Fig. 3) [9]. This
denotes that the overall afﬁnity is much lower compared to those
two other fusion inhibitors. High concentrations were needed in
order to decrease the dipole potential in a comparable way to T-
1249 and enfuvirtide. Nevertheless, a clear membranotropic
behavior is observed.
We also assessed the dipole potential variation for membrane
model systems of deﬁned composition (Fig. 2B). For that we used
large unilamelar vesicles (LUVs) labeled with the same probe, di-
8-ANEPPS. To model a standard mammalian membrane we used
POPC to form zwitterionic and ﬂuid phase bilayers on the liquid
disordered state (ld). Lipid raft-like domains, on the liquid ordered
state (lo) were mimicked by POPC:cholesterol (2:1) LUV. Also, we
used pure DPPC, a totally saturated, gel phase-forming phospho-
lipid, to which sifuvirtide has preference [10]. The results agreed
with the previous study using tryptophan intrinsic ﬂuorescence,
in which the extension of the interaction varied following the trend
POPC < POPC:cholesterol < DPPC.
4. Discussion
The overall membranotropism of sifuvirtide is lower regarding
blood cell membranes or even lipid vesicles (depending on the
composition) in relation to enfuvirtide and T-1249. The primary
explanation for this relates to the portion of the sequence of
gp41 CHR that the peptide is based on. Sifuvirtide, like C34, lacks
the lipid-binding domain present in enfuvirtide and T-1249, which
reduces its membrane afﬁnity. In fact, C34 (and also sifuvirtide)
has a very low binding to POPC lipid vesicles, as measured by mic-
rocalorimetry [3]. However, regarding the blood cells, we mea-
sured an overall afﬁnity that is the sum of the contributions of a
complex mixture of components present on their membranes.
Apparently, there is no clear distinction between the interaction
of sifuvirtide with erythrocytes and PBMC (Fig. 2A). Different levels
of membrane interaction could be expected, considering the dis-
tinct lipid compositions of these two cell types that differ mainly
in cholesterol composition. However, just for the sake of compari-
son with the model lipids used in this work, erythrocytes have
nearly doubled cholesterol content, while having half of the DPPC
content when compared to PBMC [21]; therefore, both factors
may eventually level up.
Sifuvirtide prefers more rigid phosphatidylcholines-rich lipid
domains and this speciﬁc targeting can potentially direct the pep-
tide to the saturated PC-enriched viral envelope membranes and,
probably, also to the raft-like regions of host cells, which are richer
in membrane receptors, including CD4, constituting a preferential
site for HIV binding. Moreover, the fusion peptide directs the virus
to these receptor-harboring platforms [12,13].
The atypical shape of the dipole potential variation as a function
of the fusion-inhibitor concentration, both for cell membranes and
biomembrane model systems, should be the result of the combined
effects of the different lipids present on them, and hence, different
preferences that are difﬁcult to dissect in the cell membrane con-
text. However, by comparing the maximum extent of binding for
the lipid vesicles and the cell membranes, one can conclude that
the heterogeneity of the latter is an adjuvant to the binding of this
peptide, as it performs much better than simple POPC and
POPC:cholesterol lipid mixtures. Yet, atomic force microscopy re-
sults show that this is not related to the effect of membrane do-
main interfaces [11]. Negative inﬂexions on the R vs.
concentration curves close to a sifuvirtide concentration of
60 lM are especially evident on the studies with LUVs, but can also
be noticed on the measurements with erythrocytes. This effect can
be explained by the previously reported oligomerization of sifuvir-
tide in solution, occurring above 60 lM [10]. However, the forma-
tion of sifuvirtide larger aggregates, detectable by dynamic light
scattering, only occurs at concentrations above 600 lM [10].
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The results presented in this report using erythrocytes and
PMBC show that the membrane-association of sifuvirtide is poten-
tially relevant in the biological context. The results obtained with
vesicles show a weak and interfacial adsorption, which is consis-
tent with the results now presented for cells. Sifuvirtide interacts
with membranes, but not as extensively as enfuvirtide or T-1249.
This can be related to the so-called ‘‘membrane catalysis’’ hypoth-
esis, where one of the effect of membranes is to increase the local
Fig. 1. Probe response to the presence of sifuvirtide in labeled blood cells membranes. Difference spectra of suspended cells with membrane-bound di-8-ANEPPS incubated
with different concentrations of sifuvirtide, for erythrocytes (red blood cells, RBC; left) and PBMC (right) to assess the extent of excitation spectra shift. These were obtained
by subtracting the normalized excitation spectra (to the integrated areas) of labeled cells in the presence of peptide from the spectrum in its absence. The shape and
amplitude variation denotes a sifuvirtide concentration-dependent decrease in the dipole potential.
Fig. 2. Interaction of sifuvirtide with cell membranes and biomembrane model systems. (A) Variation of the di-8-ANEPPS excitation ratio Rnorm with sifuvirtide concentration
for erythrocytes and PBMC. N = 6 for erythrocytes and PBMC (blood samples from different donors). (B) Dipole potential variation for labeled LUV with deﬁned lipid
composition of POPC, POPC:cholesterol 2:1 and DPPC at 200 lM total lipid (N = 2). Ratio values were normalized for the initial value in the absence of sifuvirtide. Plotted
values represent mean ± SEM.
Fig. 3. Comparison with enfuvirtide and T-1249. The binding proﬁle of sifuvirtide is shown here compared with previously obtained results for enfuvirtide and T-1249 [9], for
erythrocytes (A) and PBMC (B), under the same experimental conditions. Ratio values were normalized for the initial value in the absence of peptide. Plotted values represent
mean ± SEM.
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concentration of ligands in the vicinity of their targets [22]. A pos-
sible model for the relevance of the interaction of sifuvirtide with
blood cells, based on information available on the literature, com-
plemented by the present ﬁndings, is presented in Fig. 4. The virus
was previously demonstrated to associate to the erythrocyte sur-
face, allowing trans-infection to permissive cells [23–26], high-
lighting an importance in the context of drug distribution and
delivery of sifuvirtide to the viral envelope, where it can also ad-
sorb (the viral envelope is a DPPC- and cholesterol-rich bilayer).
When the virus infects the preferential target cells, CD4+ lympho-
cytes, the accumulation of sifuvirtide in the cell surface domains is
a factor that could enhance the inhibition of HIV gp41-mediated
fusion and entry.
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Abstract
Recently, the covalent binding of a cholesterol moiety to a classical HIV-1 fusion inhibitor peptide, C34, was shown to
potentiate its antiviral activity. Our purpose was to evaluate the interaction of cholesterol-conjugated and native C34 with
membrane model systems and human blood cells to understand the effects of this derivatization. Lipid vesicles and
monolayers with defined compositions were used as model membranes. C34-cholesterol partitions more to fluid phase
membranes that mimic biological membranes. Importantly, there is a preference of the conjugate for liquid ordered
membranes, rich in cholesterol and/or sphingomyelin, as observed both from partition and surface pressure studies. In
human erythrocytes and peripheral blood mononuclear cells (PBMC), C34-cholesterol significantly decreases the membrane
dipole potential. In PBMC, the conjugate was 14- and 115-fold more membranotropic than T-1249 and enfuvirtide,
respectively. C34 or cholesterol alone did not show significant membrane activity. The enhanced interaction of C34-
cholesterol with biological membranes correlates with its higher antiviral potency. Higher partitions for lipid-raft like
compositions direct the drug to the receptor-rich domains where membrane fusion is likely to occur. This intermediary
membrane binding step may facilitate the drug delivery to gp41 in its pre-fusion state.
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Introduction
The development of new drugs against the human immunode-
ficiency virus type 1 (HIV-1) has been the focus of intense research
since its discovery [1]. The virus fusion with the cell membrane
and the consequent entry into the host cell is a critical moment of
its life cycle. Efficiently blocking this process prevents all the
subsequent intracellular steps. Most importantly, the integration of
the viral genome, which can stay silent for years, does not occur.
Despite this promising approach, only two HIV entry inhibitors
are available in the market: maraviroc, an inhibitor of envelope
binding to the CCR5 co-receptor [2], and enfuvirtide, a fusion
inhibitor peptide targeting gp41 in its pre fusion conformation [3].
Enfuvirtide, due to its peptide nature, has to be administered
subcutaneously and is more sensitive to degradation while in
circulation. It is important to overcome these limitations as peptide
drugs can also have the advantage to be potentially less toxic.
Several HIV-1 fusion inhibitor peptides have been developed
and studied in vitro [4–6]. The rationale for the development of
these peptides is based on the structural rearrangements of gp41
after the binding of gp120 to CD4 and a co-receptor (CCR5 or
CXCR4). The two heptad repeats fold into each other creating a
hairpin structure (also named 6-helix bundle, due to the formation
of a homotrimer of heterodimers) that brings the two membranes
together and promotes the formation of the fusion pore used for
the entry of the viral content into the target cell [7]. Most of these
peptides were derived from the C-terminal heptad repeat (CHR)
region of gp41, and hence bind to the opposite domain in order to
prevent bundle formation. The rational design of higher efficacy
peptides compared to the native sequence from gp41 CHR
include rearrangements and substitutions in order to improve
intrinsic characteristics such as solubility, helical stability, oligo-
merization, lipophilicity and resistance to proteolysis [4].
In our previous works, we emphasized the importance of the
lipophilicity and membrane interaction properties of the fusion
inhibitor peptides enfuvirtide, T-1249 and sifuvirtide [8–10]. The
fact that these peptides can partition to the membranes and to the
microdomains, where receptors are preferentially located, facili-
tates the interaction with gp41 in its exposed conformation. This
intermediate is temporally and spatially constrained; thus, a pre-
concentration effect in the membrane can be a strategy to
overcome this poorly accessible target.
Previously, the peptide C34, a classical fusion inhibitor used also
as a template for the structural characterization of gp41 [7], was
conjugated with a cholesterol moiety in order to obtain higher
efficacy and lifetime in vivo [11]. C34-cholesterol (with cholesterol
covalently bound to the C-terminus of the peptide; also known as
L’644) was shown to be 50-fold more potent than C34 alone in
terms of IC50 (HXB2 strain). Moreover, in a mouse model, the
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conjugated peptide was still detected 24 h after injection and with
higher concentration, when compared with the unconjugated
peptide, which was undetectable after 6 h [11]. In another recent
work, a comparative pre-clinical evaluation of four fusion
inhibitors (C34, T1249, enfuvirtide and C34-cholesterol) as
potential microbicides showed that C34-cholesterol exhibits the
highest anti HIV-1 activity as well as an extended window of
activity. Moreover, C34-cholesterol is able to inhibit both wild
type and reverse transcriptase inhibitors-resistant isolates [12].
The conjugation approach to improve fusion inhibitor peptides,
such as by attaching acyl chains of various sizes [13–15] or human
serum albumin [16,17], has been tried before; however, none has
reached beyond pre-clinical tests. C34-cholesterol is a promising
candidate [12].
In this article, we aimed at characterizing the interaction of C34
and C34-cholesterol with biomembranes to elucidate the peptide-
membrane interaction and possible relations with the efficiency of
these drugs. Our approach first covered a detailed study of the
peptide partition towards biomembrane model systems, namely
large unilamellar vesicles (LUV), by following the intrinsic
fluorescence changes of the peptide tryptophan residues, located
at the N-terminal region, when it adsorb or penetrate in the lipid
environment. This methodology allows testing a diversity of lipid
compositions, in order to dissect the role of the different lipid
types. Insertion of the fusion inhibitors in lipid monolayers was
also evaluated on a Langmuir-Blodgett trough. Finally, we studied
the interaction with membranes of human blood cells, in an ex vivo
setting. In this case, we used a lipophilic fluorescent probe (di-8-
ANEPPS) that is sensitive to the membrane dipole potential and
can report interactions of molecules that disturb the membrane
order.
Experimental Section
Reagents
C34 (WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL)
was obtained from the NIH AIDS Research and Reference
Reagent Program (Division of AIDS, NIAID, NIH). C34-
cholesterol (L’644) was a kind gift from the International
Partnership for Microbicides (licensed by Merck) and its sequence
is C34-GSGC-Cholesterol. 5NS (5-doxyl-stearic acid) and 16NS
(16-doxyl-stearic acid) were from Aldrich (Milwaukee, WI, USA).
L-Tryptophan, acrylamide, HEPES and NaCl were from Merck
(Darmstadt, Germany). POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine), DPPC (1,2-dipalmitoyl-sn-glycero-3-phospho-
choline), POPG (1-palmitoyl-2-oleoyl-sn-glycero-3-[phospho-rac-
(1-glycerol)]), DHSM (N-dodecanoyl-sphinganine-1-phosphocho-
line), SM (egg sphingomyelin), POPE (1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphoethanolamine) and POPS (1-palmitoyl-2-oleoyl-
sn-glycero-3-phospho-L-serine) were purchased from Avanti Polar
Lipids (Alabaster, AL, USA), while cholesterol (Chol) were from
Sigma (St. Louis, MO, USA).
Fluorescence Spectroscopy Measurements
C34 and C34-cholesterol peptides contain tryptophan residues,
which make fluorescence techniques suitable tools to probe these
molecules. The working buffer used throughout the studies was
HEPES 10 mM pH 7.4 in NaCl 150 mM. C34 (150 mM) and Trp
(500 mM) stock solutions were prepared in buffer. C34-cholesterol
(500 mM) stock solutions were prepared in DMSO. Large
unilamellar vesicles (LUV) were prepared by extrusion methods,
as described elsewhere [18,19].
Membrane partition and fluorescence quenching studies using
acrylamide were carried out in a Varian Cary Eclipse fluorescence
spectrophotometer (Mulgrave, Australia) and time-resolved fluo-
rescence spectroscopy studies in a LifeSpec II Fluorescence
Lifetime spectrometer (Edinburgh Instruments).
The fluorescence spectral characterization of C34, C34-
cholesterol and Trp was performed with an excitation wavelength
of 280 nm, except for 5NS, 16NS and acrylamide quenching
experiments, where the excitation was performed at 290 nm to
minimize the relative quencher/fluorophore light-absorption
ratios. For the quenching experiments, fluorescence emission was
collected at a fixed wavelength of 350 nm and for the partition
studies integrated spectra from 310 to 450 nm were used. Typical
spectral bandwidths were 5 nm for excitation and 10 nm for
emission. Excitation and emission spectra were corrected for
wavelength-dependent instrumental factors [20]. During the
quenching and partition experiments, emission was also corrected
for successive dilutions, scatter [21] and simultaneous light
absorptions of quencher and fluorophore. All the fluorescence
measurements in this study were performed at room temperature
(approximately 25uC).
Partition Coefficient Determination
Membrane partition studies were performed by successive
additions to a 5 mM C34 or C34-cholesterol solution of small
amounts of LUV suspensions with different lipid compositions,
including: POPC, POPC:Chol (2:1 and 1:1), DPPC, POPC:-
Chol:SM (1:1:1 and 2:2:1), POPC:SM (2:1), POPC:POPG (5:1),
POPC:DHSM (1:0.06), and HIV membrane-like mixture with
and without DHSM (POPC 5.3%, DPPC 3.5%, cholesterol
45.3%, SM 18.2%, POPE 19.3% and POPS 8.4% [22]), with a
10 min incubation time between each addition. The partition
coefficients (Kp) were calculated using the equation [23]:
I
IW
~
1zKpcL
IL
IW
L½ �
1zKpcL L½ �
ð1Þ
where IW and IL are the fluorescence intensities in aqueous
solution and in lipid, respectively, cL is the molar volume of the
lipid [24,25], and [L] its concentration.
Surface Pressure
Changes on the surface pressure of lipid monolayers induced by
C34, C34-cholesterol, enfuvirtide and T-1249 were measured in a
Langmuir-Blodgett trough NIMA ST900 (Coventry, UK), at
constant temperature (2560.5uC). The surface of a HEPES buffer
solution contained in a Teflon trough of fixed area was
exhaustively cleaned by surface aspiration. Then, a solution of
lipids in chloroform was spread on this surface, reaching a surface
pressure of 20.561 mN/m. Peptide solutions were injected in the
subphase and the changes on the surface pressure were followed
during the necessary time to reach a constant value. The surface
pressure of an air2water interface upon injecting the largest
concentration of each peptide used throughout the studies was
always below 15 mN/m (data not shown). For this reason, the
lowest initial surface pressure of the lipid monolayers before the
addition of the peptides to the subphase was above that value. In
this condition, the changes in surface pressure observed upon the
injection of the peptide can be attributed to an effect of the peptide
on the monolayer interfacial tension.
The dissociation constant (Kd) was calculated from the
adsorption Langmuir isotherm:
C34-Cholesterol Membrane Interactions
PLOS ONE | www.plosone.org 2 April 2013 | Volume 8 | Issue 4 | e60302
114
DP~
DPmax peptide½ �
Kdz peptide½ � ð2Þ
where DP are the changes of surface pressure, DPmax is the
maximum change of pressure achieved and [peptide] is the peptide
concentration.
Acrylamide Quenching
The fluorescence quenching of 5 mMC34 or C34-cholesterol by
acrylamide (0260 mM) [8] was studied in buffer and in the
presence of POPC or DPPC 3 mM LUV, by successive additions
of small volumes of the quencher stock solution. For every
addition, a minimal 10 min incubation time was allowed before
measurement. Quenching data were analyzed by using the
Stern2Volmer equation [23]:
I0
I
~1zKSV: Q½ � ð3Þ
where I and I0 are the fluorescence intensity of the sample in the
presence and absence of quencher, respectively, KSV is the
Stern2Volmer constant and [Q] the concentration of quencher.
5NS and 16NS Quenching
Fluorescence quenching assays with the lipophilic probes 5NS
and 16NS were performed by time-resolved fluorescence spec-
troscopy. These assays were carried out at the same peptide and
lipid concentrations used for the acrylamide quenching, by
successive additions of small amounts of these quenchers (in
ethanol) to samples of peptide in POPC and POPC:Chol (2:1),
keeping the ethanol concentration below 2% (v/v) [26]. The
effective lipophilic quencher concentration in the membrane was
calculated from the partition coefficient of both quenchers to the
lipid bilayers [27]. For every addition, a minimal 10 min
incubation time was allowed before measurement. Quenching
data were analyzed by using the Stern2Volmer equation (eq. 1),
or the Lehrer equation [27,28] when a negative deviation to the
Stern–Volmer relationship is observed:
I0
I
~
1zKSV Q½ �
1zKSV Q½ �ð Þ 1{fbð Þzfb ð4Þ
where fb is the fraction of light arising from the fluorophores
accessible to the quencher.
In the case of dynamic quenching, the relationship I0/I= t0/t is
valid; thus, time-resolved quenching data can be analyzed by using
the same equations (eq. 3 and 4).
Membrane Dipole Potential Assessed by di-8-ANEPPS
Human blood samples were obtained from healthy volunteers,
with their previous written informed consent, at the Instituto
Portugueˆs do Sangue (Lisbon, Portugal). This study was approved
by the ethics committee of the Faculdade de Medicina da
Universidade de Lisboa. Isolation of erythrocytes and PBMC and
labeling of these cells with di-8-ANEPPS (Invitrogen, Carlsbad,
CA, USA) were performed as described before [9,29]. For
erythrocytes isolation, blood samples were centrifuged at 12006
g during 10 min, plasma and buffy-coat were removed, and
remaining erythrocytes were washed twice in working buffer. They
were incubated at 1% hematocrit in buffer supplemented with
0.05% (m/v) Pluronic F-127 (Sigma) and di-8-ANEPPS 10 mM.
PBMC were isolated by density gradient using Ficoll-Paque Plus
(GE Healthcare, Little Chalfont, UK) and counted in a Neubauer
improved hemocytometer. They were incubated at 3000 cells/mL
in Pluronic-supplemented buffer with 3.3 mM di-8-ANEPPS. Cells
were incubated with the fluorescent probe during 1 h, with gentle
agitation, and unbound probe was washed with Pluronic-free
buffer on two centrifugation cycles. C34, C34-cholesterol (in
DMSO stock solution) or cholesterol (in DMSO:ethanol 1:1 stock
solution) were incubated with erythrocytes at 0.02% hematocrit
and with PBMC at 100 cells/mL during 1 h, with gentle agitation,
before the fluorescence measurements. For lipid vesicles labeling,
suspensions with 500 mM of total lipid were incubated overnight
with di-8-ANEPPS 10 mM, to ensure maximum incorporation of
the probe. The maximum concentration of DMSO or
DMSO:ethanol in the suspensions was 2.4% (v/v) at 6 mM of
peptide or cholesterol. Excitation spectra and the ratio of
intensities at the excitation wavelengths of 455 and 525 nm
(R= I455/I525) were obtained with emission set at 670 nm to avoid
membrane fluidity-related artifacts [30,31]. Excitation and emis-
sion slits for these measurements were set to 5 and 10 nm,
respectively. The variation of R with the peptide concentration
was analyzed by a single binding site model [32]:
R
R0
~1z
Rmin=R0 peptide½ �
Kdz peptide½ � ð5Þ
with the R values normalized for R0, the value in the absence of
peptide. Rmin defines the asymptotic minimum value of R and Kd is
the dissociation constant.
Data Analysis
Fitting of the equations mentioned in this article to the
experimental data was done by non-linear regression using
Graphpad Prism 5. Error bars on data presentation represent
the standard error of mean (SEM).
Results
Membrane Partition
UV-visible absorption and fluorescence spectra in buffer of C34
are comparable to those of Trp in aqueous solution (Fig. 1);
however, C34-cholesterol presents a blue shift, indicating that
there is a change in the Trp surrounding environment in this
conjugate.
As shown in Fig. 2, there is an increase in the fluorescence
intensity of C34-cholesterol in the presence of LUV. The partition
coefficient between the lipid and aqueous phases, Kp, was
determined by fitting eq. 1 to the fluorescence intensity data, in
order to quantify the extent of interaction of the peptides to the
LUV (Table 1). For POPC, a lipid with packing density and
fluidity properties similar to biological membranes, a Kp value of
1.576103 was obtained, showing a significant interaction. When
gel phase DPPC membranes were tested, a decreased Kp was
found, probably due to the higher bilayer rigidity. In cholesterol-
rich membranes (POPC:Chol, POPC:Chol:SM 2:2:1 and HIV-
like mixture) a significant increase in the partition was observed,
when compared with pure POPC, also with a decrease on IL.
Mixtures with cholesterol and SM mimic membrane microdo-
mains usually named lipid rafts [33]. The same variation on IL
occurred for the addition of SM or DHSM (an unusual
sphingolipid which does not contain a 4,5-trans double bond in
its sphinganine backbone, significantly enriched in HIV-1
membranes [22]). The HIV-like mixture had the highest partition,
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hinting to an importance of the viral membrane in capturing the
drug besides the cell membrane.
In the case of C34, except for DPPC, no significant changes in
the fluorescence intensity were observed in the presence of
membranes (Fig. 2A), indicating an absence of significant peptide-
membrane interactions.
Surface Pressure Perturbation of Monolayers
Despite the negligible partition and quenching results, adsorp-
tion of C34 to the membrane surface cannot be discarded, as it
may leave the Trp residues exposed to the bulk aqueous
environment, with unchanged quantum yield (i.e., not contributing
for Kp calculation) [10]. In order to discard that situation, surface
pressure measurements on POPC monolayer were carried out,
using a low initial surface pressure (20.5 mN/m). Usually, the
adsorption and penetration of molecules is favored at low surface
density (loosely packed lipid monolayers), whereas high surface
pressure (compact lipid packing) hinders the adsorption and
penetration in the lipid monolayers [34]. As shown in Fig. 3A, C34
is not able to induce any significant change in the surface pressure,
in contrast to C34-cholesterol.
We also measured the changes in surface pressures induced by
enfuvirtide and T-1249, yielding similar results to C34-cholesterol
(Fig. 3A). In contrast, with POPC:Chol (2:1) or POPC:Chol:SM
(1:1:1) monolayers, C34-cholesterol was able to induce larger
changes than the other inhibitors (Figure 3B,C). Kd and DPmax
values were determined by fitting eq. 2, in order to quantify the
interaction of each peptide with the Langmuir monolayers
(Table 2).
Direct comparison between the three peptides is difficult since
they have different membrane binding domains. Therefore, they
are not expected to modify the same way the surface tension of the
membrane. However, comparing the same peptide for different
lipids, we observe that C34-cholesterol presents an increased
affinity to cholesterol rich membranes: an approximate ten-fold
increase for POPC:Chol (2:1) and around six-fold for POPC:-
Chol:SM (1:1:1), when compared to pure POPC. This is in good
agreement with data obtained from partition studies. In the case of
enfuvirtide, no significant changes in the affinity were observed
among each membrane composition tested, with just a slight
decrease in the affinity for POPC:Chol, in a good agreement with
previously published data [35]. Finally, T-1249 presented lower
affinity for POPC:Chol, when compared with the other two
compositions.
When the interaction kinetics were tested, a faster variation was
observed for C34-cholesterol (Figure 3D). Control experiments
were carried out using DMSO without C34-cholesterol and no
significant changes were observed.
Localization in the Lipid Bilayer
In order to test the accessibility of the fluorophores to the
aqueous environment, the fluorescence quenching of the Trp
residues of the peptide by acrylamide was studied. Linear Stern-
Volmer plots were obtained in the absence of lipid (Fig. 4) and the
quenching for C34-cholesterol is less efficient than C34, indicating
that the fluorophore in the conjugate is less exposed to the
surrounding aqueous medium. The cholesterol moiety may create
hydrophobic pockets due to the formation of micro-aggregates,
leading to this difference in the quenching in aqueous solution.
Stern2Volmer plots and Ksv constants in the presence of 3 mM of
lipid and 5 mM of C34 or C34-cholesterol were obtained in order
to complement the partition assays (Fig. 4). For C34-cholesterol,
both assays with lipids yielded Ksv values lower than the obtained
in their absence (7.2360.15 mM21 in solution, 5.5860.14 mM21
with DPPC and 5.1660.11 mM21 with POPC). In contrast, for
C34 only, DPPC was able to reduce the Ksv value from
Figure 1. Characteristics of C34 and C34-cholesterol. (A) Schematic representation of HIV-1 gp41 main domains, depicting the relative
position of the fusion peptide (FP), N-terminal heptad repeat domain (NHR), C-terminal heptad repeat domain (CHR) and transmembrane region (TM).
The sequence of C34 was aligned with enfuvirtide, T-1249 and sifuvirtide, showing the pocket binding domain (PBD) and the lipid binding domain
(LBD). Hydrophobic residues are represented in blue, non-charged polar residues in green, and charged polar residues in red. (B) Normalized
fluorescence excitation (dashed line) and emission (solid line) spectra of 5 mM C34, C34-cholesterol or Trp in aqueous solution.
doi:10.1371/journal.pone.0060302.g001
Table 1. Partition coefficients.
Lipid Mixture Kp IL/Iw
POPC 15746261 1.8860.05
DPPC 331644 2.9860.16
POPC:Chol 2:1 34546718 1.2560.01
POPC:Chol:SM 2:2:1 40506885 1.2460.01
POPC:Chol 1:1 46126436 1.3260.01
POPC:DHSM (6%) 7556232 1.7260.09
HIV-like mixture 808461190 1.1460.004
HIV-like mixture with DHSM 17586688 1.1560.002
Parameters obtained from the fitting of the fluorescence data of the partition
assays of C34-cholesterol 5 mM using eq. 1. All measures were made at least in
triplicate. Values are presented as mean 6 standard error of mean (SEM).
doi:10.1371/journal.pone.0060302.t001
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13.660.01 mM21 in solution to 11.560.39 mM21 in DPPC
vesicles. These reductions on the Stern2Volmer constant indicate
that the interaction with the membrane occurs with the
fluorophores partially exposed to the aqueous environment.
Fluorescence quenching measurements were also used to
evaluate the depth of insertion of Trp residues of the peptides
inserted in POPC or POPC:Chol (2:1) vesicles. Stearic acid
molecules derivatized with doxyl (quencher) groups either at
carbon 5 (5NS) or 16 (16NS) were used. 5NS is a better quencher
for molecules inserted in the membrane in a shallow position, close
to the lipid-water interface, while 16NS is better for molecules
buried deeply in the membrane [36]. Fig. 5A and B shows the
Stern-Volmer plot obtained for C34-cholesterol on POPC or
POPC:Chol (2:1), respectively, using the effective concentration of
5NS and 16NS in the bilayer matrix. For POPC, the Ksv with 5NS
was higher (4.4360.41 mM21, calculated with the Lehrer
equation) than for 16NS (1.3860.052 mM21, calculated with
the linear Stern-Volmer equation). In the case of POPC:Chol
(2:1), Ksv for 5NS was also higher (9.2360.67 mM
21, with the
Lehrer equation) than 16NS (6.9460.44 mM21, with the Lehrer
equation). Fluorescence lifetime quenching data enabled the
application of the SIMEXDA method [36] to obtain the depth
of insertion of the Trp residues of C34-cholesterol (Fig. 5C). A
similar mean shallow location, close to the membrane interface,
was observed for both lipid membranes. However, in the presence
of cholesterol, the depth distribution is narrower, and the location
more superficial (more exposed to the aqueous media), in a good
agreement with acrylamide quenching data. The location distri-
bution of C34-cholesterol does not differ much from the
determined previously for enfuvirtide or T-1249 [10,35]. As
expected, no changes in the fluorescence intensity were detected in
the presence of 5NS or 16NS for C34 (data not shown).
Interaction with Blood Cell Membranes
After the characterization using membrane-model systems, we
studied this peptide-membrane interaction in biological settings.
We used isolated human erythrocytes and PBMC, labeled with
the fluorescent probe di-8-ANEPPS, which is sensitive to the
membrane dipole potential [30]. If the peptides interact by
inserting or adsorbing on the membrane, it is expected that they
change the membrane order to some extent, inducing variations
in its dipole potential. These changes can be reported by di-8-
ANEPPS excitation spectrum shifts [30,37], becoming easier to
assess in differential spectra (Fig. 6A–C). The fluorescence red
shift indicates a decrease in the membrane dipole potential in a
peptide concentration-dependent manner. In order to quantify
this interaction, we measured the ratio R of the intensities at the
excitation wavelengths 455 and 525 nm (with emission at
670 nm) for a range of peptide concentrations. R is a
quantitative descriptor of spectral shifts and, hence, of the
relative variation of dipole potential. The membrane dipole
potential significantly decreased in the presence of C34-
cholesterol (Fig. 6 D–F), in sharp contrast to the unconjugated
C34 peptide that had almost no effect. This shows that, in
agreement with the model membrane studies, C34 does not
have tendency to interact with cell membranes, while C34-
cholesterol does. Affinity constants derived from the dipole
potential variation curves indicate a much higher affinity when
compared with the previously studied HIV fusion inhibitor
peptides enfuvirtide and T-1249 (Table 3).
For the sake of comparison with the data obtained for blood cell
membranes, and in order to validate the comparison with previous
data, we also labeled lipid vesicles with di-8-ANEPPS (Fig. 6A, D).
Lipid vesicles were composed of POPC, POPC:Chol 2:1 and
POPC:Chol 1:1. In a good agreement with the partition and
pressure data, we found that the increase of the cholesterol
percentage on the membrane also increased the interaction of
C34-cholesterol. Additions of DMSO, cholesterol or C34 were
also tested as control and no changes on the dipole potential were
observed (data not shown).
Discussion
In previous works, we showed that the interaction of HIV fusion
inhibitor peptides with membranes (using lipid membrane models
Figure 2. Partition of the peptides to lipid vesicles. Evaluation of Trp fluorescence variations of 5 mM C34 (A) or C34-cholesterol (B) upon
titration with large unilamellar vesicles (LUV), performed by successive additions of POPC, POPC:Chol 2:1, DPPC or HIV-like mixture LUV suspension.
Dashed lines are fittings of eq. 1 to the experimental data.
doi:10.1371/journal.pone.0060302.g002
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and blood cells) is a key aspect of their mechanism of action. The
membranotropic properties of a peptide can increase its local
concentration at the membrane and boost the efficiency of the
drug [8–10,29,35,38]. In this context, we studied the membrane
interactions of the C34 peptide, in comparison with its cholesterol
conjugated version, C34-cholesterol, in order to understand the
Figure 3. Interaction of the fusion inhibitor peptides with lipid monolayers. (A2C) Changes in surface pressure as a function of HIV-1
fusion inhibitor addition to pure POPC (A), POPC:Chol 2:1 (B) or POPC:Chol:SM 1:1:1 (C) monolayers. Dashed lines are fittings of eq. 2 to the
experimental data. (D) Changes in surface pressure as a function of time after addition of HIV fusion inhibitors to achieve a final concentration of
31 nM on a POPC:Chol 2:1 monolayer. All assays were carried out at 25uC, using an initial pressure of 21.560.5 mN/m. Each point is the average of at
least triplicates of independent samples. Error bars represent the standard error of mean (SEM).
doi:10.1371/journal.pone.0060302.g003
Table 2. Dissociation constants, Kd, and DPmax determined from surface pressure changes.
C34-cholesterol Enfuvirtide T1249
Kd
(nM)
DPmax
(mN/m)
Kd
(nM)
DPmax
(mN/m)
Kd
(nM)
DPmax
(mN/m)
POPC 59615 3.560.3 3163.7 3.160.1 1260.6 3.360.02
POPC:Chol (2:1) 5.361.4 2.560.05 4166.8 1.460.06 6563.5 1.960.03
POPC:Chol:SM (1:1:1) 9.261.3 2.660.02 2764.6 1.660.03 1361.1 1.860.02
Parameters obtained from the fitting of the surface pressure data from Fig. 3 using eq. 2. All measures were made at least in triplicate. Values are presented as mean 6
standard error of mean (SEM).
doi:10.1371/journal.pone.0060302.t002
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molecular basis of the dramatically increased antiviral efficiency of
the conjugate [11].
This study demonstrates the membrane-binding ability of C34-
cholesterol. Overall the results obtained from partition, surface
pressure, quenching and dipole potential show that the addition of
the cholesterol moiety to the C-terminus of C34 renders the
peptide membranotropic. The partition coefficients for POPC
obtained for this conjugated peptide are of the same order as the
previously determined for enfuvirtide and T-1249 (Table 1). In
contrast, C34 shows no partition for membranes of this lipid.
Enfuvirtide and C34 share a common CHR sequence as a
structural domain; however, C34 lacks a putative lipid-binding
domain (LBD) that is Trp rich, which may explain its low
membrane partition (Fig. 1A) [39]. This is also the case of the
LBD-lacking fusion inhibitor peptide sifuvirtide, which also
presents residual binding to POPC vesicles and the same
preference for DPPC membranes (on the gel phase) [8,29]. When
the interactions with cholesterol-rich membranes were studied, in
contrast with the result previously obtained for enfuvirtide [35],
membrane partition of C34-cholesterol still takes place and with a
relatively high Kp (Table 1). A similar behavior was found for lipid
raft-mimicking membranes (POPC:Chol:SM).
In order to interpret results on POPC:Chol binary mixtures,
their phase diagram at 25uC needs to be considered [33]. In the
case of pure POPC, the membrane is in the liquid disordered
phase (Ld). For POPC:Chol 2:1 there is a phase coexistence
between liquid ordered (Lo) and liquid disordered (Ld) phases,
while for POPC:Chol 1:1 only Lo phase occurs (but close to the
Figure 4. Accessibility of the peptide to the aqueous medium. Fluorescence quenching by acrylamide of C34 (A) and C34-cholesterol (B) in
the presence (filled symbols) and absence (empty circles) of lipid vesicles (5 mM peptide and 3 mM total lipid). Lipid compositions tested were pure
POPC, POPC:Chol 2:1 and pure DPPC. Dashed lines are fittings of the Stern-Volmer equation (eq. 3) to the experimental data.
doi:10.1371/journal.pone.0060302.g004
Figure 5. Localization of C34-cholesterol in the bilayer. (A–B) Stern-Volmer plots for the quenching of C34-cholesterol fluorescence by 5NS or
16NS in POPC (A) and POPC:Chol 2:1 (B) LUV, using time-resolved fluorescence measurements. Each point is the average of three independent
measures. The dashed lines are fittings of the Lehrer equation (eq. 4) to the experimental data, except for 16NS in POPC (eq. 3). (C) Depth of insertion
of C34-cholesterol Trp residues in the membrane using SIMEXDA method [36], yielding an average location 16.8 A˚ away from the center of the bilayer
for POPC and 18.0 A˚ for POPC:Chol 2:1. Distributions’ half-width at half-height were 8.9 A˚ for POPC and 6.5 A˚ for POPC:Chol.
doi:10.1371/journal.pone.0060302.g005
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boundary between Lo/Ld coexistence). Our partition data indicate
that C34-cholesterol preferentially partitions to the Lo phase,
displaying a Kp three-fold higher than for the Ld phase (pure
POPC), and an intermediate behavior when both Ld and Lo
phases coexist. Additionally, using di-8-ANEPPS labeled LUV
(Fig. 6A, D), we showed that the interaction of the conjugated
peptide increases with the amount of cholesterol present in the
POPC:Chol binary mixture, suggesting again a preference for
cholesterol-rich membranes.
Surface pressure measurements (Fig. 3) showed a higher
membrane affinity of C34-cholesterol towards cholesterol and
SM-rich membranes, when compared to pure POPC. Taking into
account that C34 was unable to induce any change in any of the
tested monolayers (data not show) these experiments also showed
that the cholesterol moiety boosts the adsorption of C34
specifically on cholesterol-rich membranes. In comparison, en-
fuvirtide showed much less distinction between the three mixtures
tested. Furthermore, regarding the kinetics of the interactions of
the three HIV fusion inhibitors in POPC:Chol monolayers
(Fig. 3D), we found that C34-cholesterol also exhibit a faster
binding kinetic, which could only be assigned to the ‘‘membrane
anchoring’’ cholesterol moiety.
This preference of the drug for cholesterol and ‘‘lipid raft-like’’
mixtures is very relevant regarding inhibiting HIV entry. The
most important receptors for HIV entry, CD4 and CCR5, were
shown to be associated with lipid raft microdomains and DRM
(detergent resistant membranes) and this association is important
for the binding of the virus to cells [40]. Several studies also
demonstrated that depleting cholesterol from the host cells greatly
Table 3. Antiviral activity and cell membrane interaction
parameters compared of HIV-1 fusion inhibitors.
C34-cholesterol T-1249 Enfuvirtide (T-20)
IC90
(nM)*
JRFL 0.36 8.3 20
NL4-3 0.09 2.6 6.1
Kd (mM) Erythrocytes 0.5860.049 4.1660.13
{ 35.461.33{
PBMC 0.5460.052 7.7160.61{ 62.2610.2{
*[11];
{[9].
doi:10.1371/journal.pone.0060302.t003
Figure 6. Peptide interactions with di-8-ANEPPS labeled LUV and cell membranes. (A–C) Differential spectra of di-8-ANEPPS bound to LUV
(A) erythrocytes (B) and PBMC (C) membranes in the presence of C34-cholesterol and in its absence. Spectra were obtained by subtracting the
excitation spectrum (normalized to the integrated areas) of labeled cells in the presence of peptide from the spectrum in the absence of the
respective peptide. The shift to the red (decrease in dipole potential) is peptide concentration-dependent. For LUV, spectra traces represent C34-
cholesterol 4 mM, in the presence of different lipid compositions: POPC, POPC:Chol 2:1 and POPC:Chol 1:1. For cells, spectra traces represent different
C34-cholesterol concentrations: 0 mM, 0.25 mM, 1 mM and 5 mM. (D) Binding profiles of C34-cholesterol to LUV of POPC, POPC:Chol 2:1 and POPC:Chol
1:1, by plotting the di-8-ANEPPS excitation ratio, R (I455/I525, normalized to the initial value), as a function of the peptide concentration. DMSO,
cholesterol and C34 (unconjugated) were also tested, as controls, and no significant changes on the dipole potential were observed (data not shown).
(E–F) Binding profiles of C34-cholesterol, C34 and cholesterol to erythrocytes (E) and PBMC (F) cell membranes. Controls for DMSO (empty circles)
and DMSO:ethanol (empty square) were also performed. Dashed curves represent the fitting to the single binding site equation (eq. 5). Affinity
parameters for the cells are indicated in Table 3. Error bars represent SEM, with n= 5 for C34-cholesterol curves in cells and n= 3 for the control curves
and LUV.
doi:10.1371/journal.pone.0060302.g006
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inhibits HIV infection [40–42]. Moreover, the substitution of the
virion-associated cholesterol by the raft-inhibiting sterol analogues
4-cholestenone and coprostanol was shown to reduce infectivity, in
contrast to other raft promoting sterols [43]. Overall, lipid rafts are
considered to be essential for the virus entry process [44]. The
preferential partition of C34-cholesterol to those domains would
make the drug more available at the site where membrane fusion
occurs.
Recently, the lipid composition of HIV-1 membrane, consti-
tuting its lipidome, has been precisely determined [22]. That
allowed us to study lipid vesicles with compositions mimicking the
virus envelope. The high C34-cholesterol partition observed for
the HIV membrane-like mixture of lipids indicates that the viral
membrane itself can also extensively capture and carry the
conjugate drug on its surface, enhancing its availability at the
required site of action. However, this interaction seems to be
sensitive to the presence of DHSM, a lipid found to be unusually
enriched at the viral membrane, when compared to the host cell
membrane [22]. When present, DHSM decreases C34-cholesterol
partition (Table 1). It is tempting to speculate that, in a context of
virus and host cell engagement; this may be a factor that shifts the
equilibrium of partition towards the cell membranes, where it
anchors in the right direction to interact with the transiently
exposed gp41 NHR domain.
Regarding the location of C34-cholesterol at the membrane
level, our data show that the Trp residues of the peptide insert in
the external leaflet of the bilayer, at a shallow position. Previously,
the Trp-rich regions of enfuvirtide and T-1249 were also shown to
insert superficially in lipid bilayers [10,35]. As the peptide is
conjugated with cholesterol in a defined position, the peptide
should adopt a consistent orientation, with the C-terminus
anchored to the membrane by the cholesterol moiety (Fig. 1A).
This is the proper orientation to align in an anti-parallel fashion
with the NHR domain of gp41 when it extends towards the target
membrane. The N-terminus, where the Trp residues are located,
may interact freely with the nearby lipids, but cannot insert deep
in the membrane.
In order to have a better understanding of what may happen in
the bloodstream, we also studied the interaction of the peptides
with human erythrocytes and mononuclear leukocytes. These
peptide drugs must be injected, as oral administration is not
feasible. HIV-1 is known to associate to the surface of erythrocytes
in circulation [45–47], while PBMC are among the virus main
targets. C34-cholesterol decreases the membrane dipole potential
of the two cell types, indicating that an interaction is occurring
(Fig. 6). In agreement with the partition data, C34 alone also does
not interact with cell membranes. The same concentration of
cholesterol alone is not sufficient to induce a detectable membrane
potential change [48], indicating that the potential change is
induced essentially by the peptide component of the conjugate.
However this change only occurs in the conjugate, emphasizing
the role of cholesterol in inducing the membrane partition of the
peptide to cell membranes.
Quantitatively, C34-cholesterol was found to have approxi-
mately 115 or 14 times more affinity towards PBMC membranes
than enfuvirtide or T-1249, respectively. Furthermore, the cell
membrane affinities of the different fusion inhibitor peptides (C34-
cholesterol.T-1249. enfuvirtide) correlate with the antiviral
potency against HIV-1 (Table 3). Regarding the comparison with
the Kp values determined with lipid vesicles, this is not
straightforward, as the results obtained for the different compo-
sitions tested indicate that the process is lipid composition-
dependent. Moreover, the partition is based on tryptophan
fluorescence, which regards only the peptide part of the conjugate.
Figure 7. Putative mode of action of HIV-1 fusion inhibitor C34-cholesterol. In aqueous solution, the conjugate may form micro-aggregates
when membranes are not present, due to its cholesterol moiety. The drug was demonstrated to partition to cell membranes and virus-like
membranes. A preference towards cholesterol and SM-rich compositions was identified. These lipids are characteristic of the membrane
microdomains designated as lipid rafts, which usually contain the receptors involved in HIV entry. C34-cholesterol anchors to the membrane via its
cholesterol moiety and also, with a putative weaker binding, via its Trp (W)-rich N-terminal domain. In the context of HIV-1 gp41 engagement with
the target cell, a confined space exits between the two membranes. Enrichment in DHSM in the viral membrane decreases the peptide partition,
possibly shifting membrane partition equilibrium to the host cell membrane. The drug concentrated in the lipid raft environment may reach its target
(gp41) more efficiently than through simple diffusion in aqueous solution. Moreover the anchoring promoted by the cholesterol at the C-terminus
brings the peptide into contact in the correct orientation to compete with NHR binding site. This way, gp41 mediated fusion may be inhibited,
blocking viral content entry into the cell.
doi:10.1371/journal.pone.0060302.g007
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However, if we focus on cholesterol-containing mixtures, C34-
cholesterol has the highest partition, contrasting with enfuvirtide,
with negligible interaction [35]. T-1249 should fall in between,
considering its partition to cholesterol-poor domains and ability to
adsorb on cholesterol-rich domains [10].
These findings, relating membrane binding to improved
antiviral potency of the peptides, indicate that this is a major
factor to take into account when rationally designing HIV fusion
inhibitor peptides. We demonstrated that C34-cholesterol has
membranotropic behavior towards lipid vesicles and strongly
interacts with circulating blood cells membranes. HIV fusion
inhibitors have a restricted temporal and spatial window of
opportunity to bind to their molecular target: the NHR region of
gp41 in its extended conformation, when the virus and target cell
are closely engaged. This makes aqueous diffusion of the peptide
to its target less efficient. It has also been demonstrated that the
forces governing protein–protein interactions in a membrane
environment are different from those in solution [49]. The ability
that these peptides have to bind to cell membranes facilitates the
delivery of the peptides to this confined environment, as some
peptide is already locally present (Figure 7). In this context, C34-
cholesterol should be able to concentrate at the cell surface and
also on the viral membrane. In agreement with this, previous
results with cells after 48 h of treatment with C34-cholesterol
showed the persistence of antiviral activity of residual peptide not
cleared by washing steps [11], supporting the idea that cell
membranes could work as C34-cholesterol reservoir. Importantly,
the concentration effect would be higher on the lipid rafts, where
the HIV receptors are present and fusion is more likely to occur
[40,44]. This persistent antiviral activity may be ideal for this drug
to be applied as a topical microbicide, for example as vaginal gel,
to prevent infection [12]. C34-cholesterol was generally the most
active inhibitor when tested in the context of human mucosal
tissue explants (colorectal, penile and cervical), when compared to
C34, enfuvirtide and T-1249 [12]. The first microbicides
formulations against HIV were based on unspecific polyanions
to present viral attachment to the cell surface; however, they
largely failed in clinical trials [50]. Only recently a trial using a
tenofovir gel (a reverse transcriptase inhibitor) showed 39%
reduction on HIV-1 infection [51]. Using an entry inhibitor such
as C34-cholesterol could prevent the viral entry in the first
encountered immunological cells of the mucosa, blocking the virus
at the earliest stage of infection.
Ultimately, the membrane may act as a ‘‘catalyst’’ to the
binding reaction between gp41 and the peptide inhibitors, as it has
been postulated in other receptor-ligand scenarios in membrane
environments [38]. Thus, in this case, the marked increase in
antiviral efficiency of C34-cholesterol in relation to C34 (and other
fusion inhibitors) correlates with its higher affinity towards model
and blood cells membranes.
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Overview 
This section presents the experiments to determine the major GAG structural 
requirements that enable the binding to HIV-1 envelope gp120. We use surface 
plasmon resonance, an optical based label-free technique to determine biological 
interactions at the molecular level. Different types of GAG, with different 
sequence, size and sulfation patterns, were chosen to probe this interaction. 
Protection strategies for the immobilization of the proteins were also tried. 
These studies were done at IMIM, in Barcelona, Spain, with the assistance of 
Prof. Ricardo Gutiérrez-Gallego. They are presented as an unpublished manuscript 
currently submitted to a peer-reviewed journal. 
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Structural requirements of glycosaminoglycans for the 
interaction with HIV-1 envelope glycoprotein gp120 
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Heparan sulfate proteoglycans are known to 
assist HIV-1 entry into host cells, mediated by 
the viral envelope glycoprotein gp120. We 
aimed to determine the general structural 
features of glycosaminoglycans that enable 
their binding to gp120 by surface plasmon 
resonance. Binding was found to be dependent 
on sequence type, size and sulfation patterns. 
HIV-1 gp120 prefers heparin and heparan 
sulfate (with at least 16 monomers in 
extension) over chondroitin and dermatan. 
Sulfate groups were essential to promote this 
interaction. These results advance the 
understanding of the molecular level 
requirements for the mechanism of virus 
attachment and cell entry. 
Introduction 
Human immunodeficiency virus type 1 
(HIV-1) envelope glycoproteins (gp120 and 
gp41) are the prime mediators of the virus 
capability to bind and enter into host CD4+ cells. 
These viral glycoproteins are required for 
engagement with the target cell receptors CD4 
and co-receptors CCR5 or CXCR4 and, as an 
enveloped virus, to drive the fusion between the 
viral and cell membranes [1, 2]. However, 
additional mediators at the cell surface help the 
virus to approach and attach to the target cells, 
before CD4 interaction [3]. These attachment 
mediators include adhesion molecules, lectins, 
heparan sulfate proteoglycans (HSPG), and the 
glycolipid GalCer (galactosylceramide). HSPG 
are proteins (either membrane-bound or 
secreted) with attached glycosaminoglycan 
(GAG) chains [4]. These GAG are linear 
polysaccharides consisting of repeating 
disaccharide units of hexosamine and uronic 
acid, which are often sulfated and/or acetylated. 
Syndecans are a transmembrane form of HSPG 
that have an extended ectodomain, with the 
heparan sulfate (HS) chains mainly attached in a 
distal position from the membrane [4]. HS is the 
major GAG of cell surface proteoglycans. 
Chondroitin and dermatan sulfate are mainly 
associated to the proteoglycans from the 
extracellular matrix and important constituents 
of blood vessels, heart valves, bone, cartilage, 
tendons and skin [5].  
In vitro studies of glycosaminoglycan-
protein interactions usually rely on the soluble 
heparin as GAG model. Heparin is a highly 
sulfated form of heparan that is produced by 
mast cells to act as adjuvant in anti-coagulation 
[5]. Heparin and HS have been shown to bind 
HIV-1 gp120 [6, 7] and the essential residues for 
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this interaction were identified, included in the 
V2 and V3 loops, in the C-terminal domain and 
in the CD4-induced co-receptor binding site [8-
10]. Cells treated with heparitinase [11] or 
knocked out for GAG production [12] have 
much lower levels of viral attachment and 
infection than their wt counterparts. Syndecans 
have also been implicated in attachment and 
trans-infection to T lymphocytes [13]. 
Moreover, syndecans present in macrophages 
are crucial for HIV-1 attachment, as they 
compensate for the lower CD4 levels of these 
cells, when compared to CD4+ T cells [14]. 
Syndecan-3 was also identified as a specific 
attachment site during HIV-1 infection of 
dendritic cells [15]. Overall, the ubiquitously 
present proteoglycans, especially in the 
epithelial, endothelial cells and dendritic cells, 
can efficiently capture HIV virions, protect them 
and facilitate trans-infections to T lymphocytes, 
enhancing viral spreading and pathogenesis [16]. 
In this work, we explored the interaction of 
HIV-1 gp120 with distinct glycosaminoglycans, 
differing in their type/composition, sulfation 
pattern and size. We screened these molecules 
for gp120 binding via surface plasmon resonance 
(SPR), a technique that allows label-free 
characterization of molecular interactions, in 
order to understand the general structural 
requirements for the glycosaminoglycan-HIV-1 
envelope binding that may contribute to the 
design of more efficient HIV-binding blockers. 
Materials and Methods 
High grade heparin from porcine mucosa, 
heparin oligosaccharides (dp4, dp8, dp12, dp16, 
dp20 and dp30, with dp stating the monomer 
number), selectively desulfated heparins (2-O-
desulfated, 6-O-desulfated, N-desulfated and N-
desulfated re-N-acetylated), heparan and 
dermatan sulfate from porcine mucosa and K5 
polysaccharide were all from Iduron 
(Manchester, UK). Chondroitin sulfate from 
shark cartilage and bovine serum albumin (BSA) 
were from Sigma (St. Louis, MO, USA). Refer to 
Table 1 for molecular weights. 
Recombinant HIV-1 BaL gp120 envelope 
glycoprotein (produced in HEK-293), in 
monomeric form, was obtained from the NIH 
AIDS Research and Reference Reagent Program 
(Division of AIDS, NIAID, NIH; Germantown, 
MD, USA). 
Biacore CM5 sensorchips, amine coupling 
kit (containing 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide 
hydrochloride (EDC), N-hydroxysuccinimide 
(NHS) and 1 M ethanolamine-HCl pH 8.5) and 
HBS-EP running buffer (10 mM HEPES pH 7.4, 
150 mM NaCl, 3 mM EDTA, 0.005% v/v 
surfactant P20) were from Biacore GE 
Healthcare Life Sciences (Uppsala, Sweden). All 
the experiments were performed using a Biacore 
3000 SPR instrument (GE Healthcare). 
BSA or recombinant HIV-1 gp120 were 
immobilized in CM5 sensorchips via amine 
coupling. The chip surface was activated with 
freshly prepared 1:1 mixture of EDC and NHS 
(50 μL), followed by injection of 50 μg/mL of 
protein in acetate buffer pH 4.8 (60 μL) and 
blocking of the remaining active surface with 1 
M ethanolamine-HCl pH 8.5 (60 μL). The flow 
was kept at 5 μL/min during the immobilization 
procedures. 
To assess the influence of gp120 positive 
charges distribution, we employed two other 
immobilization methods that required pre-
incubation of the proteins with p-nitrocatechol 
sulfate (pNCS, Sigma) or suramin (Tocris 
Bioscience, Bristol, UK), at room temperature. 
The pre-incubation of gp120 with pNCs was 
done at 50 μg/ml protein concentration, with a 
protein:pNCS 1:10 molar ratio, for 25 min, and 
the immobilization with acetate buffer pH 4.0. 
For suramin, the concentration of protein was 
doubled to 100 μg/mL and the molar ratio for 
incubation was 1:5 (protein:suramin), for 1 h, 
with following immobilization done at pH 4.0. 
Binding experiments were performed in the 
running buffer HBS-EP. 
Results 
Measuring the binding of proteins to 
glycosaminoglycans in SPR systems usually relies 
on the immobilization of biotinylated GAG 
(usually heparin) at the sensor surface via 
streptavidin linking and flowing the protein as 
analyte. This is because the heterogeneity of 
molecular masses and optical properties of GAG 
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in solution may not render the most adequate 
changes in order to be detected by the SPR 
sensor. However, since our objective was to test a 
diverse panel of different GAG under equivalent 
conditions, it was more appropriate to use them 
as analytes against the HIV-1 envelope 
glycoprotein. This strategy poses the analytical 
disadvantage of lower quality sensorgrams (in 
comparison to the reverse situation), which are 
required for detailed kinetic studies using SPR. 
Hence, in this work, we focused on the 
qualitative comparison of the binding degrees 
between each of the tested GAG. 
In order to establish the requirements for 
GAG binding to HIV-1 gp120, we selected a 
panel of soluble GAG regarding their type 
(monomer sequence), desulfation pattern and 
oligomer size. We initially selected four GAG, 
namely heparin, heparan, chondroitin and 
dermatan sulfate, which differ in their 
disaccharide unit sequence, as well as in their 
distinct functions and locations in the human 
body. To assess the importance of the sulfate 
groups in the backbone of the GAG, we used 
heparins selectively desulfated in the position 2-
O or 6-O, and an N-desulfated re-N-acetylated 
GAG. For a totally nonsulfated control, we used 
the K5 polysaccharide from Escherichia coli, a 
nonsulfated analogue of HS. Furthermore, we 
also tested different sizes of heparin 
olygosaccharides, ranging from dp4 to dp30. 
Immobilization of HIV-1 gp120 BaL via 
amine coupling on carboxymethylated dextran 
surfaces was readily achieved, with 
immobilization levels around 1.6 × 104 RU. 
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Figure 1 – Sensorgrams of glycosaminoglycans binding to immobilized HIV-1 gp120 BaL. All the soluble
GAG were divided in three categories and tested against two independent chips with different proteins lots (chip
I and II). Immobilized BSA was used as a control surface and all the traces were subtracted for this control. (A-C)
For chip I, GAG were used at 20 μM and flown at 10 μL/min; immobilization levels were 19,835 RU for BSA and
16,103 RU for gp120. (D-F) For chip II, GAG were used at 50 μM and flown at 40 μL/min; immobilization levels
were 15,094 RU for BSA and 16,482 RU for gp120. Plots are representative of duplicates. 
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Heparin, which is known to bind gp120 [6], was 
consistently the best binder to gp120 among the 
soluble GAG tested. Regarding the different 
types of GAG  (Fig. 1A,D), HS followed heparin 
in affinity, while dermatan and chondroitin had 
lower binding. Comparing heparin with its 
selectively desulfated counterparts and the 
nonsulfated K5 (Fig. 1B,E), it can be observed 
that all the desulfated forms have considerably 
lower (almost residual) binding to gp120. 
However, the distinction between them is not 
clear. The binding of heparin is also size-
dependent (Fig. 1C,F), with higher molecular 
masses having higher binding degree in the 
association phase. The binding was weak below 
dp16, indicating that 16 monomers is the 
minimum needed for a significant binding. 
The direct immobilization of gp120 on the 
CM5 chip is directed by the electrostatic 
attraction to the negatively charged 
carboxymethylated surface (at pH > 3), before 
the covalent reaction occurs. To understand if 
any positively charged patches on the surface of 
gp120 were hidden following the immobilization 
procedure, we undertook a protection strategy 
by incubating with sulfated compounds prior to 
the immobilization. For this, we used the 
monosulfated small molecular p-nitrocatechol 
sulfate and the intermediate size hexasulfated 
suramin. The immobilization levels obtained 
when the gp120 was pre-incubated with the 
sulfated compounds was around 1.1 × 104 RU. A 
significant reduction is observed, when 
compared with the levels of the unprotected ones 
(1.6 × 104 RU), indicating that these compounds 
decrease the exposure of the glycoprotein 
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Figure 2 – Sensorgrams of glycosaminoglycans binding to HIV-1 gp120 BaL, pre-protected with sulfated
compounds upon immobilization. The protein was incubated with p-nitrochatechol sulfate (A-C) or suramin
(D-F), as described in the text, before being injected for immobilization. GAG were used at 20 μM and flown at 20
μL/min. Traces are subtracted for the control surface (BSA for suramin chip and activated/deactivated surface for
pNCS chip). Immobilization levels for pNCS chip was 11,400 RU for gp120 and for suramin chip was 11,305 RU
for gp120 and 9,970 RU for BSA. Plots are representative of duplicates. 
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positive patches, hence the attraction to the 
surface and thus the immobilization efficiency. 
However, the GAG interactions in the protected 
immobilized gp120 did not show significant 
differences (Fig. 2). Heparin was again the GAG 
type that bound with higher affinity, followed by 
heparan (based only on the association rate). 
Dermatan and chondroitin affinities seem also to 
depend on the type of protection applied. 
Desulfated heparins (Fig. 2B,E) bind at much 
lower degree than heparin itself, as previously 
observed in Fig. 1. In the case of suramin-treated 
gp120 (Fig. 2E), the binding of desulfated GAG 
is residual. However, for pNCS-treated gp120 
(Fig. 2B), the levels of binding, although low, are 
significant, with 2-O-desulfated heparin having 
the highest affinity among them and K5 the 
lowest. Size dependent binding is retained also 
after protection, with the binding threshold 
maintained at dp16 (Fig. 2C, F). 
Discussion 
In this study we sought to qualitatively rank 
different glycosaminoglycans for their binding to 
HIV-1 gp120, under identical circumstances, 
using surface plasmon resonance. Despite the 
analytical challenge of monitoring directly the 
binding of compounds with low direct impact on 
the dielectric constants of the solutes, by running 
different GAG on immobilized gp120, we 
observe that the binding was dependent on GAG 
type (sequence), desulfation pattern and size. 
Heparin was the best binder for gp120. It is also 
the most sulfated GAG among the tested panel 
and the best characterized GAG binding partner 
to gp120 [6, 7]. Regarding the types of GAG, HS 
followed heparin in affinity, with dermatan and 
chondroitin possessing lower binding. 
Distinction between dermatan and chondroitin 
depended also on the protection of gp120 upon 
immobilization, but chondroitin usually showed 
higher RU levels in the dissociation phase. We 
can rank the binding as heparin > heparan > 
chondroitin ≈ dermatan (refer to the summary 
of the binding results in Table 1). This is 
consistent with the studies showing the ability of 
syndecans to capture HIV, since HS is the main 
GAG in those proteoglycans [13]. Chondroitin 
and dermatan sulfates are less relevant in the 
context of HIV infection as their locations and 
functions tend to be more at the level of the 
extracellular matrix [5]. 
Table 1 – Molecular weights of the glycosaminoglycans and their interaction with gp120. 
GAG Family GAG Designation Mean Mw a 
Binding to 
gp120 
Sequence 
distinct GAG 
Heparin 15000 +++ 
Heparan sulfate 22000 ++ 
Dermatan sulfate 41400 + 
Chondroitin sulfate 30000 + 
Heparin 
oligomers 
Heparin dp4 1340 - 
Heparin dp8 2680 - 
Heparin dp12 4020 + 
Heparin dp16 5360 + 
Heparin dp20 6700 ++ 
Heparin dp30 >9000 ++ 
Desulfated GAG 
2-O-desulfated heparin  15000 - 
6-O-desulfated heparin 15000 - 
N-desulfated heparin 15000 - 
N-desulfated re-N-acetylated heparin 15000 - 
K5 polysaccharide 30000 - 
aSome values are estimates provided by the supplier. 
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Desulfated heparins presented residual 
binding, with little distinction achieved among 
them. The totally unsulfated K5 had the lowest 
absolute binding level. This confirms the crucial 
role of the GAG sulfate groups for their proper 
function and binding abilities, especially towards 
our protein of study, gp120. Desulfated heparins, 
especially O-desulfated, were previously shown 
not to have an inhibitory effect on HIV 
replication in vitro, similarly to what happened 
to heparin after desulfation [17]. 
The binding of heparin was also clearly 
dependent on the size of the oligomers, which 
can be interpreted both in terms of number and 
spatial distribution of the sulfate groups. The 
binding of dp12 and smaller oligomers was 
poorly detected, indicating that dp16 is the 
minimum size required for efficient binding. 
This size-dependency seems an actual biological 
differentiation, rather than experimental 
limitation, as the read-out for the species above 
dp16 are clear and proportional to size, whereas 
below this threshold value the read-outs are in 
the noise level. In the protected gp120 
immobilization, despite a weak binding below 
dp16, the instrument can still differentiate 
among the different GAG. The length of HS 
chains in syndecans and other HSPG is subject 
to great variability [18, 19]. As such, a direct 
comparison between the minimum binding size 
determined by us and the lengths of the actual 
HSPG is difficult. However, the virions should 
bind more efficiently to those displaying longer 
and more sulfated chains. When gp120 interacts 
with CD4, the co-receptor binding site is 
exposed, which is also a known heparin binding 
domain [8]. For that case, the minimum size for 
binding was determined to be dp10 [8]. 
The binding we measure here is refer directly 
to gp120 in its monomeric form. At the viral 
envelope, gp120 forms trimers. Hence, increased 
sizes of GAG chain may present avidity effects 
towards the envelope, that is, the chain may span 
more than one gp120 monomer. As such, 
binding to the viral envelope in an in vivo setting 
should be more stable. The avidity effect may 
also be a concern when measuring binding of 
long GAG chains (in the case of dp30 and 
unfractionated heparin) to the immobilized 
gp120 monomer, as one chain may bind more 
than one protein. 
New strategies targeting this HIV-
proteoglycan interaction are starting to appear: a 
syndecan-Fc hybrid molecule showed potent 
antiviral activity and prevented trans-infection 
[20] and a synthetic CD4-mimetic peptide linked 
to an HS or an HS peptidomimetic chain also 
inhibited HIV-1 attachment and entry [21, 22]. 
These new inhibitors diversify the range of 
possible microbicides, increasing the probability 
of finding drug candidates with higher clinical 
potential. 
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Overview 
In this section we evolve our studies from peptides and proteins to actual 
viruses. We set up an experimental strategy to observe individual viruses fusing 
with supported lipid bilayers of defined lipid composition. VSV G protein was 
pseudotyped to a retrovirus core and double labeled in the membrane and in the 
nucleocapsid for fluorescence microscopy. Full fusion was observed by the 
dispersion of the membrane dye and disappearance of the fluorescent capsid 
signal, which allowed fusion kinetics to be evaluated. Anionic lipids were essential 
to promote these VSV G mediated viral fusion. 
This work was done at Emory Childen’s Center of Emory University, in 
Atlanta, USA, with the supervision of Prof. Gregory Melikyan. 
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Background: Regulation of virus entry by host lipids is poorly understood.
Results: Imaging of low pH-mediated fusion between single vesicular stomatitis pseudoviruses and lipid bilayers revealed a
striking reliance on anionic lipids.
Conclusion: The dependence of fusion on late endosome-resident anionic lipids suggests a new means for regulating the virus
entry sites.
Significance: Reliance on specific lipids for fusion may shed light on future antiviral strategies.
Viral glycoproteins mediate fusion between viral and cellular
membranes upon binding to cognate receptors and/or experi-
encing low pH. Although activation of viral glycoproteins is
thought to be necessary and sufficient for fusion, accumulating
evidence suggests that additional cellular factors, including lip-
ids, can modulate the fusion process. Understanding the role of
lipids in virus entry via endocytosis is impeded by poor accessi-
bility and the highly diverse nature of endosomes. Here we
imaged fusionof single retroviral particles pseudotypedwith the
vesicular stomatitis virus (VSV) G protein with dextran-sup-
ported lipid bilayers. Incorporation of diffusible fluorescent
labels into the viral membrane and the viral interior enabled
detection of the lipid mixing (hemifusion) and content transfer
(full fusion) steps of VSV G-mediated fusion at low pH.
Although single virus fusion with supported bilayers made of
zwitterionic lipids could not be detected, inclusion of anionic
lipids, phosphatidylserine, and bis(monoacylglycero)phosphate
(BMP), greatly enhanced the efficiency of hemifusion and per-
mitted full fusion. Importantly, lipid mixing always preceded
the opening of a fusion pore, demonstrating that VSV G-medi-
ated fusion proceeds through a long-lived hemifusion interme-
diate. Kinetic analysis of lipid and content transfer showed that
the lags between lipid and content mixing defining the lifetime
of a hemifusion intermediate were significantly shorter for
BMP-containing compared with PS-containing bilayers. The
strong fusion-enhancing effect of BMP, a late endosome-resi-
dent lipid, is consistent with themodel that VSV initiates fusion
in early endosomes but releases its core into the cytosol after
reaching late endosomal compartments.
Entry of enveloped viruses into a host cell is a complex, mul-
tistep process mediated by viral glycoproteins, which are acti-
vated upon encountering cellular receptor(s) and/or low pH (1,
2). Generally, the entry of enveloped viruses proceeds through
attachment to a host cell, binding to cognate receptor(s), and
either fusion of the viral membrane with the cell plasma mem-
brane or virus internalization and low pH-dependent fusion
with endosomes (3). Recent evidence suggests that viruses that
do not rely on low pH can also enter through endocytic path-
ways (4–7). Viral envelope glycoproteins are thought to medi-
ate energetically unfavorable membrane fusion events by
releasing the energy stored in their native structure upon
refolding into a thermodynamically favorable conformation
(8–11). Despite the highly diverse structures of viral fusion gly-
coprotein, they are categorized into three classes on the basis of
their structural and biochemical properties (2, 12).
VSV2 G protein is a class III viral fusion protein that is well
characterized both structurally and functionally (13–15). Inter-
estingly, pH-induced conformational changes in VSV G are
reversible, as the protein assumes the native conformation
upon returning to neutral pH in the absence of a target mem-
brane (16–18). This unusual feature ofVSVG indicates that the
difference between free energies of the initial “metastable” and
final “stable” conformations is not large and that, therefore,
little energy can be released by this protein to drive membrane
fusion (19). These considerations warrant further studies of
VSVG-mediated fusion to gain critical insights into the univer-
sal principles by which viral proteins promote membrane
merger.
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Despite extensive efforts, the host cell receptor(s) for VSV
entry has not been unambiguously identified. Phosphatidylser-
ine (PS) has been shown to promote VSV fusion and entry into
cells (20–23). However, this lipid is unlikely to be the primary
VSV receptor because VSV binding and infection do not corre-
late with the level of PS in the plasma membrane, and blocking
PS with annexin V does not inhibit VSV infection (24). More-
over, the fact that VSV can merge with lipid vesicles made of
phosphatidylcholine at low pH (21, 25) indicates the lack of
reliance on a proteinaceous receptor or a specific lipid. On the
other hand, lipid composition is known to modulate the kinet-
ics and efficiency of viral fusion (26) and could, therefore, play a
role in the regulation of G protein-mediated fusion. Recent
studies highlight the importance of an endosome-specific
anionic lipid, bis(monoacylglycero)phosphate (BMP), also
referred to as lysobisphosphatidic acid (27), in promoting
fusion of unrelated viruses entering cells via endocytosis (28–
31). For instance, dengue virus fusion with liposomes and with
cell membranes has been shown to depend on anionic lipids,
including BMP (30), which is one of the major lipid species in
late endosomes and multivesicular bodies (27, 32). BMP is
thought to facilitate cellular entry of different pathogens by
regulating back-fusion between intralumenal vesicles and the
limiting membrane of an endosome (33, 34). Interestingly, a
BMP-dependent back-fusion process has also been implicated
in the VSV nucleocapsid release into the cytosol following virus
fusion with intralumenal vesicles (28, 29). However, this two-
step VSV entry model is not universally accepted because this
virus appears to quickly fuse with early endosomes prior to
entry into multivesicular bodies (35, 36).
Single virus trafficking in host cells is an increasingly popular
tool to study the viral entry process (37). However, real-time
detection of fusion events that culminate in the viral content
release is technically challenging and, therefore, less common
(4, 38–40). Themain advantage of these approaches is the abil-
ity to study events at a single virus level, which allows distin-
guishing specific subpopulations of particles or characteristics
hidden in bulk assay data.
Although single virus imaging in live cells provides impor-
tant insights into the entry process, the complexity of vesicular
trafficking and the heterogeneity of endosomal compartments
impede mechanistic studies of viral fusion. Dissecting the viral
entry processes in a controlled environment can shed light on
the mechanism of fusion and on the host factors required for
completion of this reaction. A powerful approach to address
these questions is to reconstitute viral fusion in model systems
such as liposomes and supported lipid bilayers (SLB). Recent
advances in imaging of membrane fusion using supported lipid
bilayers or tethered single liposomes have brought new mech-
anistic insights into themembranemergermediated by cellular
fusion proteins (41–43) and viral glycoproteins (44–46). Rapid
pH-dependent hemifusion/fusion of single influenza and Sind-
bis viruses with SLBwas observed bymonitoring redistribution
of a lipophilic dye incorporated into the viral membrane (hemi-
fusion) (46) or by visualizing the transfer of both viral mem-
brane and content markers (full fusion) (44, 45).
Here, we report the direct visualization of VSV G-pseu-
dotyped particle (VSVpp) fusion with dextran-supported lipid
bilayers. We took advantage of the murine leukemia virus
(MLV) pseudotyping system, which allows incorporation of a
releasable fluorescent protein marker into the virus (5) and of a
membrane dye into the viral envelope. This labeling strategy
permitted the detection of both lipid mixing (hemifusion) and
content release (full fusion) steps of the VSVpp fusion process.
Imaging of single VSVpp revealed that both hemifusion and
fusionwith supported bilayersweremarkedly promoted by ani-
onic lipids, POPS, or BMP. Although BMP-containing bilayers
supported faster conversion of hemifusion to full fusion com-
pared with POPS bilayers, similar probabilities of fusion and
identical effective sizes of nascent fusion pores were consistent
with the lack of requirement for a specific lipid for productive
VSV entry. The strong fusion-stimulating effect of BMP indi-
cates, however, that this endosome-resident lipid may modu-
late the outcome of low pH-induced VSV fusion with intracel-
lular compartments.
EXPERIMENTAL PROCEDURES
Virus Production—Fluorescently labeled pseudoviruses were
produced inHEK293T/17 cells using PolyFect transfection rea-
gent (Qiagen, Valencia, CA). Cells grown on 10-cm dishes were
transfected with 2 g MLV-Gag-Pol, 1 g MLV-Gag-mKO, 3
g pMLV-LTR-LacZ, and 3g of pMDG-VSV-G. Twenty-four
hours post-transfection, cells were labeled with 10 M 1,1-
dioctadecyl-3,3,3,3-tetramethylindodicarbocyanine (DiD) for
4 h in aCO2 incubator at 37 °C.Cellswerewashed, coveredwith
6ml of fresh phenol red-free growthmedium, and incubated for
an additional 24 h. Virus-containingmediumwas collected 48 h
post-transfection, passed through a 0.45 M filter, aliquoted,
and stored at80 °C. The infectious titer was determined by a
-galactosidase assay in TZM-bl cells (47). Vectors expressing
MLV-Gag-pol and MLV-LTR LacZ (48) were provided by Dr.
WaltherMothes (Yale University). The pMDG-VSV-G expres-
sion vector was provided by Dr. John Young (Salk Institute).
The construction of theMLV-Gag-mKo expression vector was
described in Ref. 5.
Preparation of Small Unilamellar Vesicles—1-palmitoyl-
2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-
2-oleoyl-sn-glycero-3-phospho-L-serine (POPS), BMP (S,R
isomer) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-
N-(carboxyfluorescein) (CF-PE) were purchased from Avanti
Polar Lipids (Alabaster, AL). Cholesterol (Chol) was from
Sigma. Lipids weremixed in chloroform and dried to a thin film
in a round-bottom glass flask under an argon stream. Traces of
solvent were removed by placing the flask in a vacuum chamber
for at least 3 h. The lipid film was hydrated in PBS buffer (Cell-
gro, Mediatech, Inc., Manassas, VA) to make a final lipid con-
centration of 1 mM. The lipid suspension was subjected to sev-
eral freeze/thaw cycles and sonicated with a probe sonicator
(VWR, Radnor, PA) on ice to avoid sample heating. The
obtained lipid suspension was cleared by centrifugation at
10,000 g for 5 min.
Coverslip Cleaning and Functionalization with Dextran—
Glass coverslips (no. 1.5, 22 22mm, Corning, NY) were thor-
oughly cleaned using the following steps: 1) immersion into hot
2% Hellmanex (Hellma Analytics, Mu¨llheim, Germany) for 30
min, 2) sonication in Hellmanex for 15 min while warm, 3)
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rinsing extensively with Milli-Q water, 4) immersion into Pira-
nha solution (3:1 concentrated sulfuric acid/hydrogen peroxide
30% without stabilizer) for 30 min, 5) rinsing extensively with
Milli-Q water, 6) sonication inMilli-Q water for 10 min, and 7)
rinsing extensively with Milli-Q water. The cleaned coverslips
were dried in an oven for 1 h at100 °C.
Dextran functionalization was carried out as described pre-
viously (45). Briefly, cleaned coverslips were immersed in 0.2%
(3-glycidyloxypropyl)trimethoxysilane (Sigma) in isopropanol
for 5min under gentle agitation. After rinsingwith pure isopro-
panol, the coverslips were cured for 1 h at80 °C. A 30% (w/v)
dextran (Mr 5 105, Sigma-Fluka) solution was prepared using
Milli-Q water, and air bubbles were removed in a vacuum
chamber. The coverslips were carefully covered with dextran
solution (1 ml) and incubated in a humidified chamber for
24 h. Excess dextran was rinsed off by dipping repeatedly in
water and leaving the coverslips in water for 2 days. The cover-
slips were dried in an oven for 1 h at 80 °C and stored in a
vacuum desiccator.
Microfluidic Chamber Design and Fluorescence Micros-
copy—The microfluidic polydimethylsiloxane (PDMS) cham-
ber was fabricated using both standard photolithography and
soft lithography. To prepare the soft mold for the microfluidic
channels, a negative photoresist (MicoChem, SU-8) was spin-
coated and patterned on a 4-inch silicon wafer. The patterned
wafers were silanized using hexamethyldisilazane so that the
cured PDMS could be easily peeled off from the soft mold.
PDMS mixed at a 10:1 ratio (w/w) of polymer to curing agent
was then poured onto the silanized wafer and cured at 60 °C for
about 24 h. The cured device was then peeled off from the
wafer. The PDMS pieces were then rinsed thoroughly with
deionized water and set to dry at 60 °C in an oven.
The 25 25-mm PDMS block had two 10-mm grooves that
were 1 mmwide and 75 m deep. Small holes were punched at
each end of the grooves, and polytetrafluoroethylene tubing
(microbore 0.03-inch (0.76-mm) diameter) was inserted into
the holes (Fig. 1,A and B). The PDMS block was adhered to top
of a dextran-functionalized coverslip, thus creating two flow
channels between the PDMS block and the coverslip. Tight
adhesion of the polymer to the glass surface was sufficient to
seal the channels. This approach was similar to a method
described previously for SLB formation in microfluidic cells
(49).
All imaging experiments were carried out at room tempera-
ture using a confocal laser scanning microscope Zeiss LSM 780
and oil immersion Plan-Neofluar 40/1.3 numerical aperture
objective. The laser lines used to excite fluorophores were 488
(CF-PE), 561 (mKO), and 633 nm (DiD). The PDMS block with
coverslip was affixed to a microscope stage and connected to a
peristaltic pump (Fig. 1A). Solution flow during the imaging
experiments was adjusted to48 l/min.
Supported Lipid Bilayer Formation—SLBwere formed by the
vesicle fusion method (50). Small unilamellar vesicle suspen-
sions with 0.1 mM of total lipids in PBS were injected into both
microfluidic channels. After incubation for 30 min, the excess
of liposomes was removed by flowing PBS for 5 min. The com-
positions used for the SLB were POPC:Chol:CF-PE, 84.5:15:0.5
mol %; POPC:Chol:POPS:CF-PE, 64.5:15:20:0.5 mol %; and
POPC:Chol:BMP:CF-PE, 64.5:15:20:0.5 mol %. These mixtures
are designated throughout the text as POPC, POPS, and BMP,
respectively. Small amounts of the fluorescent lipidCF-PEwere
included for three reasons: to assess the uniformity of SLBs, to
test whether lipids would diffuse freely in SLBs by performing
FRAP experiments (see below), and to determine the exact time
of the pH drop upon perfusion with acidic buffers (similar to
Ref. 45).
FRAP Assay—SLB obtained by spontaneous rupture/fusion
of small unilamellar vesicles over the hydrated dextran layer of
the glass coverslip were usually uniform, as observed by the
fluorescence of CF-PE incorporated in the lipids mixtures.
Next, SLB were tested for fluidity using FRAP (51). Briefly, a
circular region of interest (radius 8 m) was photobleached
using a brief pulse of the 488-nm line of an argon laser set at
100% power. The fluorescence recovery wasmonitored by low-
intensity laser excitation for at least 5 min. The fluorescence of
a distant circular region of interest (ROI) served as a reference
signal.
Intensity profiles for the bleached and reference ROIs were
analyzed using ImageJ software. The fluorescence recovery
trace was double-normalized to take into account a possible
inadvertent bleaching effect upon image acquisition
Fnorm 
FRef pre
FRef t

FFRAP t
FFRAP pre
(Eq. 1)
where FRef is the mean fluorescence intensity of the reference
ROI, FFRAP is the intensity of the bleached ROI, t is the time
after photobleaching, and pre stands for the mean intensity
before photobleaching.
The normalized traces of the bleached ROI were fitted using
a diffusion model for a circular spot (52)
FFRAPnorm t a0 a1  e


2t tbleach  I0 2t tbleach
 I1 2t tbleach    w
2
D
(Eq. 2)
where tbleach is the time of bleaching,  is the characteristic
diffusion time, w is the radius of the ROI, D is the diffusion
coefficient, and In(x) are modified Bessel functions. Nonlinear
fit of the data was performed in GraphPad Prism version 5.
The results of the FRAP assay for each type of lipid mixture
used are shown in Fig. 1D, and the corresponding diffusion
coefficients are in the figure legend. Diffusion coefficients
around 1 m2/s, corresponding to free lipid diffusion in bilay-
ers, were deemed acceptable for virus fusion experiments. Sys-
tematic verification of the bilayer fluidity is important because a
fraction of bilayers did not exhibit fluorescence recovery after
photobleaching (see also Ref. 49).
Imaging of VSVpp Fusion—All experiments were performed
at room temperature. For each imaging experiment, a sample of
5 l of the virus stock solution was diluted in 100l of PBS and
vortexed briefly. Approximately 90 l of viral suspension was
continuously flowing into a channel. Viruses adhered to the
bilayer reasonably well, permitting subsequent washing with
BPS for 1–2 min to remove unbound viruses. Next, image
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acquisition was started, and perfusion with an MES (pH 5.5)
buffer (144 mM NaCl, 2 mM CaCl2, 30 mM MES) was initiated.
This acidic buffer quenched the CF-PE fluorescence, marking
the exact time of the pH change (similar to an approach intro-
duced in Ref. 45). Imageswere acquiredwith 2-s intervals for 11
min. At the end of the acquisition, the flow channel was cleaned
by flowing 1 ml of 70% ethanol at a higher flow rate before
removing the chamber from the microscope.
Image Analysis—Hemifusion and fusion events were initially
identified by visual inspection of image sequences. Next, dou-
ble-labeled (DiD and mKO) viral particles were detected, and
their mean fluorescence intensities over time were measured
using Speckle TrackerJ, a recent freely available ImageJ plug-in
(53). The program identified fluorescent particles and tracked
them until the fluorescence intensity/particle size decreased
below a defined threshold. DiD-only labeled particles (likely
dye aggregates) were excluded from the analysis. Virus hemifu-
sion was defined as DiD redistribution into SLBs without the
loss of mKO, whereas full fusion was defined as release of DiD
followed by loss of the content marker. The mean fluorescence
intensity profiles for eachmarker (CF-PE, DiD, andmKO)were
obtained using small circular regions encompassing the parti-
cles. Analysis of these profiles yielded the following key events
used for kinetic analysis. The pH drop was assessed by decay of
the CF-PE signal; the onset of lipid mixing was defined as the
onset of DiD dequenching or, when dequenching was weak, by
the onset of fluorescence decay because of DiD dilution; the
onset of content release was detected by mKO fluorescence
decrease; and completion of content release was defined as the
time point at which the mKO signal reached the background
level. The non-parametric Mann-Whitney rank sum test was
used to evaluate the differences among the kinetic parameters
for bilayers of different composition.
RESULTS
Direct Visualization of Single VSVpp Hemifusion and Fusion
Events—The microfluidic PDMS chamber allowed for an easy
solution change and for a quick formation of supported lipid
bilayers, as described under “Experimental Procedures” (Fig. 1,
A and B). After testing the SLB fluidity by FRAP (Fig. 1D), dou-
ble-labeled VSV pseudoviruses were drawn into the chamber
and allowed to attach to the bilayer for 5 min. VSVpp readily
adhered to bilayers and remained relatively immobile through-
out the experiments despite the solution changes. The same
volume of diluted viral stockwas passed through a flow channel
in each experiment, resulting in adhesion of 60–100 particles/
FIGURE1.Schematic representationof singlevirus fusionexperiments.A, schematic drawingof themicrofluidic chambermountedonamicroscope stage.
B, sketch of themicrofluidic PDMS block (top view) that was attached to the glass coverslip to form two channels where the SLB were formed. C, single VSVpp
fusion triggered by low pH detected by double fluorescent labeling with Gag-mKO (green) and DiD (red). VSV G-mediated lipid mixing is manifested in radial
diffusion of DiD into the SLB. After pore formation, the fluorescent content marker is released into the dextran layer underneath the bilayer and disappears
because of diffusion. D, FRAP assay to measure the fluidity of supported lipid bilayers. The recovery of CF-PE fluorescence after photobleaching of a defined
circular region (w 8.02m)was followedover time. Plotted values aremeanswith error bars from95%confidence intervals (n 5). Recovery datawere fitted
with equation 1. The resultingmean S.E. diffusion coefficients for CF-PE were 0.946 0.022m2/s in POPC, 0.904 0.026m2/s in POPS, and 1.16 0.035
m2/s in BMP bilayers.
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image field. VSVpp were colabeled with the membrane dye,
DiD, and the viral content marker, the MLV-Gag polyprotein
tagged with mKO (monomeric Kusabira Orange, Ref. 54), as
described inRef. 5. TheGag-mKOmarker is cleaved uponMLV
maturation, producing the nucleocapsid-mKO (NC-mKO)
fragment, which is not associated with the viral core and is,
therefore, readily released upon viral fusion (4, 5, 55). For low
pH-triggered fusion, mKO is a better marker thanGFP because
its resistance to quenching by low pH (pKa 5 (54)) minimizes
the possibility that the loss ofmKO signal is due to acidification
of the viral interior. This strategy allowed the detection of DiD
transfer into SLB as amarker for hemifusion aswell as detection
of the viral content release as a marker for full fusion (Fig. 1C).
VSVpp fusion with SLB was initiated by perfusion with an
acidic (pH 5.5) buffer. The exact time of acidificationwas deter-
mined on the basis of quenching of CF-PE fluorescence, simi-
larly to the approach described in Ref. 45. Shortly after acidifi-
cation, radial diffusion of DiD into a bilayer, away from the viral
particles, was observed for a fraction of the virions (Fig. 2).
Typical fluorescence intensity profiles for fusion events are
shown in Fig. 2, A and B, and Fig. 3. The DiD signal usually
increased because of fluorescence dequenching and then
decayed upon spreading into the supported bilayer. These lipid
mixing events reflecting virus-SLB hemifusion were not
observed at neutral pH. Following the lipid mixing events, a
fraction of particles lost their content marker, NC-mKO.
Because themKO signal fromneighboring particles that had no
change in DiD fluorescence remained stable, the loss of the
mKO signal following the hemifusion step signified the viral
content release through a fusion pore (Fig. 2, D–E, and supple-
mentalmovie 1). The existence of a hydrated dextran layer sup-
porting the membrane provided sufficient space to accommo-
date the viral content marker and to permit its diffusion away
from a particle. The four sequential events (acidification of the
flow channel, onset of lipidmixing, as well as the onset and time
of completion of content release) aremarked by vertical lines in
Fig. 2, A and B. These four parameters were used to compare
the kinetics of VSVpp fusion with SLB of a different lipid com-
position (see examples in Fig. 3).
Anionic Lipids Are Essential for VSVG-mediatedHemifusion
and Fusion—The total number of double-labeled VSVpp
attached to POPS and BMPmembranes was comparable, but a
FIGURE2. Imaging singleVSVpseudovirus fusion.A, exampleof fluorescence intensity profiles for a singleVSVpp-SLB fusionevent (POPS). ThedropofCF-PE
signal (blue) marks the acidification of the image area to pH 5.5. Key events used for kinetic analysis are marked by vertical lines representing the time of
acidification (blue), onset of lipid mixing (red), onset of content release (green), and end of content release (light green). B, intensity profiles for a single fusion
event with BMP bilayers exhibiting a slow mKO release. The slight reduction in the mKO signal upon acidification reflects a spectral bleed-through from the
CF-PE signal which was fully quenched by low pH. C, intensity profiles for a virus undergoing hemifusion (decay of the DiD signal without loss of the mKO
signal). D and E, images of full VSVpp fusion events with POPS (D) and BMP (E) bilayers. The double-labeled pseudoviruses (yellow) released DiD (red) into the
SLB by radial diffusion, followedby disappearance of green puncta because of release of NC-mKO. The first images in each panel are taken before acidification,
the second and third images show the dequenching and spread of DiDwhile themKO signal remains steady, and the last imageswere taken after completion
of fusion (mKO release). F, example of a hemifusion event with BMP bilayer that did not culminate in full fusion. Here the mKO signal remained steady
throughout the experiment.White numbers (D–F) indicate timeafter acidification in seconds. The image fields are 1212m.Thewhite arrow is pointed at the
central particle of interest that will undergo fusion.
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larger number of pseudoviruses adhered to POPC-basedmem-
branes lacking anionic lipids (see legend for Fig. 4A). However,
despite the larger number of adhered particles, POPC bilayers
did not support complete VSVpp fusion, and only 2.5% of dou-
ble-labeled particles exhibited lipid mixing (hemifusion) with
these bilayers (Fig. 4A). In sharp contrast, 31.1% and 41.5% of
VSV pseudoviruses released DiD into POPS and BMP bilayers,
respectively (Fig. 4A). BMPmore potently facilitated lipid mix-
ing than an equal amount of POPS. Under our experimental
conditions, double-labeled particles released their lipid mark-
ersmuchmore frequently than their contents. Complete fusion
was detected for 6.6% of particles following their hemifusion
with POPS bilayers and for 5.1% particles adhered to BMP
bilayers. In other words, a significant fraction of viruses under-
went hemifusion but did not form a fusion pore large enough to
allow NC-mKO escape into the dextran layer underneath SLB
(Figs. 1C and 2, C and F, and supplemental movie 2). Hemifu-
sion always preceded full fusion. The fluorescence signal from
FIGURE 3.Mean fluorescence intensity profiles of representative single virus fusion events with POPS (A–D) and BMP (E–H) bilayers.MFIs of arbitrary
circular regions encompassing individual particles areplotted.Red traces show theDiD signal,green traces show themKO, andblue traces show theCF-PE signal
(the pH indicator). Note that quenching of the CF-PE fluorescence upon acidification was often associated with a concomitant reduction in the mKO signal
because of a spectral bleed-through. These initial changes in the mKO signal were ignored.
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double-labeled particles that did not exhibit lipid or content
mixing was stable over the course of the experiment, demon-
strating that inadvertent photobleaching of fluorophores was
negligible (supplemental Fig. 1). In conclusion, 20 mol % of
POPS or BMP greatly enhanced the efficiency of VSVpp hemi-
fusion and, importantly, enabled complete fusion compared
with the basal lipid mixture lacking anionic lipids (Fig. 4A).
BMPShortens the LagTime between LipidMixing and Fusion
Pore Formation—As indicated above, lipid mixing events were
rare for POPC bilayers lacking anionic lipids. This is in contrast
with POPS or BMP bilayers supporting amuch greater number
of lipid mixing events. To further assess the role of anionic
lipids in VSVpp fusion, we analyzed the distribution of delay
times from the pH drop to the onset of lipid mixing (Fig. 4B).
After acidification, VSVpp hemifusion with POPS and BMP
bilayers occurred with the half-times of 44 s and 55 s, respec-
tively (Fig. 4B). The difference in lag times to the onset of lipid
mixingwith BMP and POPS bilayers was not statistically signif-
icant (p  0.93). These results suggest that although anionic
lipids promote VSVpp hemifusion, this process does not
require a specific lipid. It thus appears that the enhanced
VSVpp fusion with bilayers containing anionic lipids is due to
an electrostatic effect.
The kinetics of VSVpp fusion were analyzed in more detail
using the following parameters illustrated in Figs. 2 and 5: 1)
time to the onset of lipid mixing/hemifusion, 2) time to the
onset of content release, 3) lag time between lipid mixing and
content release for a given particle, and 4) the time from the
onset to completion of theNC-mKO release as ameasure of the
relative size of a fusion pore. All full fusion events were pre-
ceded by lipidmixing (Figs. 2 and 3), demonstrating thatVSVpp
fusion proceeded through a relatively long-lived hemifusion
intermediate. This analysis revealed that the distribution of the
times fromacidification to content releasewas slightly faster for
BMPbilayers than for POPS bilayers, but the differencewas not
statically significant (Fig. 5, A and B). Importantly, the lag time
between lipid mixing and content release was significantly
shorter for BMP when compared with POPS bilayers (Fig. 5, A
and B). These results indicate that BMP can accelerate the con-
version of a hemifusion intermediate into a functional fusion
pore. Although POPS supports the efficient formation of fusion
pores, this process is slower than with BMP bilayers.
We next asked whether the effective sizes of VSV G-medi-
ated fusion pores are lipid-dependent. By analyzing the mKO
release profiles for individual events on the basis of the fluores-
cence signal decay (Fig. 3), we found that the time required for
complete release of NC-mKO varied. In many cases the mKO
signal dropped virtually instantaneously (e.g. Figs. 2A and 3, A,
C, and F), but there were also particles exhibiting a slow
decrease of the signal (e.g. Figs. 2B and 3,D andE). Thus, VSVG
formed fusion pores of different initial sizes. To assess whether
lipids can alter the time between the onset and the end of the
mKO signal decrease, we compared the VSVpp fusion with
POPS and BMP bilayers and found that the distributions of this
parameterwere identical (Fig. 5C). These findings argue against
a specific effect of anionic lipids on the apparent size of a fusion
pore.
Another prominent feature of the VSV G-mediated fusion
was the stepwise release of the mKO marker (Fig. 3, A and H).
The two-step release of the viral content likely reflected the
pore flickering. The transient halting of content release is likely
due to pore closure or shrinkage, whereas resumption of release
reflects subsequent pore dilation (56, 57). Thus, fusion pores
formed by VSV G in supported bilayers exhibited dynamic
features similar to those formed by other viral proteins (38, 56,
58, 59).
DISCUSSION
In this study, we successfully reconstituted VSVG-mediated
membrane fusion in a minimal model system that enabled
time-resolved imaging of single lipid mixing and content
release events. The ability tomediated fusion with lipid bilayers
at low pH implies that VSV G does not strictly require a pro-
teinaceous receptor to induce fusion. On the other hand,
VSVpp fusion was markedly augmented by anionic lipids,
POPS, or BMP. Only bilayers containing POPS or BMP sup-
ported complete VSVpp fusion, whereas a POPC-based mix-
ture supported only limited lipid mixing activity. Our results
FIGURE 4. Analyses of the extent and kinetics of VSV pseudovirus fusion. A, the relative frequencies of fusion outcomes (no fusion, hemifusion, and full
fusion) are shown for fusion of double-labeled VSVpp with SLBs of different lipid compositions. Hemifusion is defined as dequenching/loss of the DiD signal
without the content release, whereas fusion is defined as the loss of both membrane and content markers (DiD and mKO, respectively). The total number of
membrane-bound particles immediately after the pH drop was 398 for POPC, 257 for POPS, and 275 for BMP bilayers using four independent image fields for
each lipid composition. B, distribution of the time elapsed between the pH drop (CF-PE fluorescence quenching) and the onset of lipid mixing for double-
labeled particles that underwent hemifusion or fusion. The difference in the lag times before the lipidmixing for POPS and BMPwas not significant (p 0.93),
but the differences between the hemifusion kinetics for these bilayers and POPC-based membranes were significant (p 0.006 for POPS and p 0.023 for
BMP). The hemifusion half-time (t50) was determined by fitting the datawith equationN (At)/(t50 t), whereA is the total number of events and t is the time.
The green and red dashed vertical lineswith corresponding numbers at the x axis correspond to the t50 values for BMP and POPS bilayers, respectively.
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are in full agreement with the previous report that BMP some-
what selectively facilitates VSV G-mediated lipid mixing with
liposomes (31). However, in that study, the beneficial effect of
BMP was observed in the background of 50% POPS, thus com-
plicating the evaluation of relative roles of these lipids inVSVpp
fusion.We found that, although BMP supportedmore efficient
lipid mixing and faster conversion from hemifusion to full
fusion than POPS, these differences were modest. In addition,
the average time required to complete the release of viral con-
tent, which is inversely proportional to the size of a fusion pore
(60), was identical for BMP and POPS bilayers. These findings
argue against POPS as the specific receptor for VSV and high-
light the potential direct role of BMP in entry of this virus.
The BMP content in late endosomes was reported to be as
high as 15% of total phospholipids, with the POPC:BMP molar
ratio3:1 (32) being close to the lipid composition of the SLB
used in our study. By contrast, late endosomalmembranes con-
tain only 5% of PS (32), which appears to be even lower that the
PS content of the plasma membrane (61, 62). Furthermore,
because VSV infection is not inhibited by the PS-binding pro-
tein annexin V (22), it is unlikely that the incoming VSV
encounters PS at the cell surface or during intracellular traffick-
ing. On the other hand, recent evidence suggests a role for BMP
in VSV entry from late endosomes (28). The observation that
lipid mixing between VSV and endosomes is not attenuated by
BMP depletion with specific antibodies (28) suggests that, sim-
ilarly to dengue virus (30), VSV may undergo hemifusion with
early endosomes. It is conceivable that complete fusion can be
delayed until VSV enters into late compartments enriched in
BMP (28). However, given the evidence that VSV enters from
early endosomes (36, 63), further studies are required to test
this model.
The relatively low probability of full fusion between VSVpp
and SLBs containing BMP or POPS may be due to incorpora-
tion of fewer G proteins compared with bona fideVSV (64, 65).
In addition, fusion with liposomes appears to occur at the base
of a bullet-shaped VSV particle (65), suggesting that the archi-
tecture of the virus and perhaps the interactions betweenG and
Mproteins regulate the fusion activity. Another explanation for
the poor fusion efficiency is that low pH and anionic lipids may
not be the only factors required for VSV fusion. Future studies
of single VSV fusion with lipid bilayers should distinguish
between these possibilities.
Regardless of the lipid composition of SLBs tested in this
study, hemifusion always preceded or full fusion. For some par-
ticles, the lag time from lipid mixing to the onset of content
release reached several minutes. These results agree with pre-
vious data on influenza (45), HIV-1 (55) and avian sarcoma and
leucosis virus (66) fusion and show that hemifusion is a true and
long-lived intermediate stage of VSVG-mediated fusion. Note,
however, that for 10% of single influenza virus fusion events
with SLB, viral content transfer preceded lipid mixing (45). No
explanation for this rather unusual phenotype has been offered
by the authors. In addition, our experiments detected transient
closing/shrinkage of fusion pores formed by VSVG, a phenom-
enon known as pore flickering (38, 56, 58, 59).
In conclusion, the SLB model offers a number of important
advantages for mechanistic studies of viral fusion at the single
particle level. Also, pseudotyping the MLV core with VSV G or
other viral glycoproteins provides a universal platform for
future mechanistic studies of single virus fusion. The virus
labeling and imaging strategies introduced in this study enable
detailed studies of the role of lipids at distinct intermediate
steps of VSVpp fusion: hemifusion and formation of a small
FIGURE 5. Kinetics of distinct steps of single VSV pseudovirus fusion. A
and B, distributions of the delay times from acidification to the onset of lipid
mixing (hemifusion, red circles) to the onset of content release (green circles)
as well as the lag times between hemifusion and fusion for a given particle
(blue circles) for bilayers containing POPS (A) and BMP (B). Only the lag time
between lipid and content transfer was significantly different between POPS
and BMP (p 0.045). C, distributions of the duration of mKO release (i.e. time
from the onset of mKO signal decrease to reaching the background fluores-
cence level) that reflect the relative diameter of fusion pores. The total num-
ber of full fusion eventswas 17 for the POPSmixture (red circles) and14 for the
BMP mixture (green circles). No fusion events were observed for the POPC-
based mixture lacking the anionic lipids.
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fusion pore. Future studies should help delineate the effects of
other anionic and neutral lipids, as well as lipid domains, in
regulation of membrane fusion mediated by VSV G and other
viral glycoproteins. It would also be interesting to assess the pH
dependence of VSVpp-SLB hemifusion and fusion. Of particu-
lar relevance are the efficiency and kinetics of viral fusion at a
higher pH, around 6.0, typical of early endosomes (67, 68).
Because the pH threshold of VSV fusion is only somewhat
higher than 6.0 (65, 69, 70), fusion experiments carried out at
this suboptimal pH can accentuate the stimulating effect of var-
ious lipids and cofactors compared with the optimal pH of 5.5
employed in this study.
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Supplementary Figure and Movie Legends 
Supplementary Figure 1. Mean fluorescence intensity (MFI) profiles of VSV G pseudoparticles that 
failed to undergo hemifusion or fusion at low pH. The relatively stable signals from single particles 
indicate that photobleaching occurred at a significantly lower (in some cases undetectable) rate than loss 
of fluorescence due to DiD or mKO release. Two representative traces are shown for each lipid 
composition: POPC (A-B), POPS (C-D) and BMP (E-F). Note that quenching of the CF-PE fluorescence 
upon acidification was often associated with concomitant reduction in the mKO signal due to a spectral 
bleed through. 
Supplementary Movie 1. Complete fusion of a VSV G pseudovirus with BMP-containing bilayers.
A pseudovirus co-labeled with DiD (red) and NC-mKO (green) is marked by a white arrow (see the 
corresponding Figure 2C showing a sub-area from this movie). The size of the area shown here is 30×30 
µm. DiD signal is in red and NC-mKO signal in green (the CF-PE fluorescence is not shown for clarity). 
The frame rate is 10 fps. 
Supplementary Movie 2. Hemifusion of a VSV G pseudovirus with BMP-containing bilayer. Images 
of a pseudovirus co-labeled with DiD (red) and NC-mKO (green) correspond to Figure 2D, but show a 
somewhat larger area (24×24 µm). The CF-PE signal is not shown for clarity. The frame rate is 10 fps. 
 
155
SUPPLEMENTARY FIGURE 1
156
 
157
 
 
 
 
 
 
 
 
 
 
 
 
 
Imaging of endosome acidification and 
single retrovirus trafficking and fusion 
 
V

 
159
Overview 
Visualizing the capture and intracellular voyage of a virus is a challenging task 
that has become possible with the improvements in microscopes, fluorescent dyes 
and fluorescent proteins technologies. In this chapter, we present a study that 
follows the ASLV internalization though the endosomes until it fuses, observed by 
the fluorescent capsid release. We engineered the virus to have a fluorescent 
protein pair mTFP1-eYFP in its envelope, which allowed quantitative imaging of 
the pH variations along the viral path. The results shed new light on the entry 
pathway of the virus and on endosome dynamics. 
This work was done at Emory Childen’s Center of Emory University, in 
Atlanta, USA, with the supervision of Prof. Gregory Melikyan. 
Article F 
Padilla-Parra S, Matos PM, Kondo N, Marin M, Santos NC, Melikyan GB. 
Quantitative imaging of endosome acidification and single retrovirus fusion with 
distinct pools of early endosomes. Proc. Natl. Acad. Sci. U.S.A. 109:17627-17632 
(2012). 
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Diverse enveloped viruses enter host cells through endocytosis and
fuse with endosomal membranes upon encountering acidic pH.
Currently, the pH dynamics in virus-carrying endosomes and the
relationship between acidiﬁcation and viral fusion are poorly char-
acterized. Here, we examined the entry of avian retrovirus that
requires two sequential stimuli—binding to a cognate receptor and
low pH—to undergo fusion. A genetically encoded sensor incorpo-
rated into the viral membrane was used to measure the pH in virus-
carrying endosomes. Acid-induced virus fusion was visualized as the
release of a ﬂuorescent viral content marker into the cytosol. The pH
values in early acidic endosomes transporting the virus ranged from
5.6 to 6.5 but were relatively stable over time for a given vesicle.
Analysis of viralmotility and luminal pH showed that cells expressing
the transmembrane isoform of the receptor (TVA950) preferentially
sorted the virus into slowly trafﬁcking, less acidic endosomes. In con-
trast, viruses internalized by cells expressing the GPI-anchored iso-
form (TVA800) were uniformly distributed between stationary and
mobile compartments. We found that the lag times between acidiﬁ-
cation and fusion were signiﬁcantly shorter and fusion pores were
larger in dynamic endosomes than inmore stationary compartments.
Despite the same average pH within mobile compartments of cells
expressing alternative receptor isoforms, TVA950 supported faster
fusion than TVA800 receptor. Collectively, our results suggest that
fusion steps downstream of the low-pH trigger are modulated by
properties of intracellular compartments harboring the virus.
confocal imaging | nano-pH-meter | single virus tracking | FRET
Many enveloped viruses use endocytosis and vesicular traf-ﬁcking to enter host cells, where acidiﬁcation of an endo-
somal lumen serves as a trigger for viral fusion (1, 2). Viral fusion
proteins are ﬁne-tuned to respond to different pH values. Those
that are activated at less acidic pH (∼6.0) are thought to mediate
fusion with early endosomes, whereas those with a lower pH
threshold (∼5.0) appear to direct the virus entry from late endo-
somes (1, 3). However, recent evidence implies that factors other
than low pH, such as speciﬁc endosome-resident lipids, can de-
termine the intracellular compartments fromwhich the viral capsid
is released into the cytosol (2, 4, 5). Progress in understanding the
complex regulation of virus–endosome fusion has been hindered
by poor accessibility of intracellular compartments and lack of
direct techniques for monitoring this process in situ.
Single-virus imaging is a powerful tool for gaining critical insights
into virus entry (reviewed in ref. 6), but detection of virus–endo-
some fusion (here deﬁned as the release of viral content into the
cytoplasm) is technically challenging (7, 8). To understand the re-
lationship between the pH trigger and virus–endosome fusion, it is
essential to visualize these events in real time. A ratiometricmethod
developed by the Zhuang group (9, 10) permits monitoring endo-
somal pH around single inﬂuenza viruses colabeled with pH-sensi-
tive and pH-insensitiveﬂuorescentmarkers.However, simultaneous
measurements of the pHdrop and the resulting virus fusion have not
been reported so far.
We previously developed tools to visualize virus uptake (11)
and to detect single retrovirus–endosome fusion (7, 8, 12) for
differently labeled viruses in separate experiments. Here, we
incorporated a FRET-based pH sensor into the membrane of the
avian sarcoma and leukosis virus (ASLV) and loaded virions with
a ﬂuorescent content marker. This technique permitted simul-
taneous measurements of the pH in virus-carrying endosomes
and the kinetics of postacidiﬁcation steps of fusion. Analyses of
acidiﬁcation and movement patterns of virus-carrying endo-
somes indicated that ASLV entered two distinct pools of endo-
somes: slow moving and generally less acidic or dynamic and
more acidic compartments. The rate of virus fusion depended on
the pH and endosome motility and on the ASLV receptor iso-
form. For the same pH value, the kinetics of fusion and sizes of
nascent fusion pores differed in cells expressing alternative iso-
forms of the ASLV receptor, which appear to target the virus
entry through distinct endocytic routes (13, 14). These ﬁndings
suggest that late steps of ASLV entry are modulated by prop-
erties of intracellular membranes.
Results
Genetically Engineered Sensor for Single Virus-Based pHMeasurements.
We previously visualized virus entry into acidic endosomes by in-
corporating a membrane-anchored ecliptic pHluorin (15) into the
viral membrane (7, 11). The nearly complete quenching of the
ecliptic pHluorin signal at pH below 6.2 marked the ASLV entry
into mildly acidic compartments but did not allow quantitative
measurements of endosomal pH. To enable simultaneous meas-
urements of endosomal pH and ASLV fusion, we used a modiﬁed
version of the FRET-based pH sensor, pHlameleon (16). The CFP
(donor) module of pHlameleon was replaced with the monomeric
teal ﬂuorescent protein, mTFP1 (Fig. 1A) (17). The higher pho-
tostability and brightness of mTFP1 compared with CFP make
this protein more suitable for single-virus imaging. The mTFP1-
eYFP tandem was appended to the N terminus of the trans-
membrane domain of human ICAM-1 (Fig. 1A), which is known
to incorporate selectively into retroviral particles (e.g., ref. 18). As
we have demonstrated previously (7, 11), coexpression of ICAM-
1–anchored ﬂuorescent proteins with viral structural proteins
results in efﬁcient labeling of the viral membrane. Labeled viruses
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were immobilized on poly-L-lysine–coated coverslips and imaged
using a Zeiss LSM780 confocal microscope in spectral mode (Fig.
1B). At basic pH, mTFP1 ﬂuorescence is weak because of efﬁ-
cient FRET between donor and acceptor eYFP (Fig. S1 and ref.
19). Low pHmarkedly reduces sensitized emission of eYFP (pKa
7.1) (20) by shifting its absorption peak (21) (Fig. 1 B and C)
and thereby increases the signal from relatively pH-insensitive
mTFP1 (pKa 4.3) (17).
To determine the relationship between the pH and emission
spectrum of the mTFP1-eYFP sensor, viruses were imaged in
solutions of different acidity (Fig. 1 B and C). To ensure that the
measured signal was from viruses, particles were colabeledwith the
content marker, murine leukemia virus (MLV) Gag-mKate2 (red
emission). Only puncta positive for all three labels, mTFP1, eYFP,
and mKate2, were analyzed, yielding the calibration curve that
related the mTFP1/eYFP emission ratio to the external pH (Fig.
1D). The observed spectral shift in the tandem protein ﬂuores-
cence enabled sensitive pH measurements in individual ASLV-
carrying endosomes within a physiologically relevant range. Nor-
mally, FRET measurements using sensitized emission require
corrections for direct excitation of the acceptor by the 458-nm laser
line and spectral bleed-through (donor photons detected in the
acceptor channel). However, for intramolecular FRET between
the tandem mTFP1-eYFP proteins, the donor/acceptor stoichi-
ometry and their emission ratio are ﬁxed, thus providing a reliable
direct measure of pH based on the emission ratio (17).
Imaging the pH Drop in a Single-Virus–Carrying Endosome and Viral
Content Release into the Cytosol. Subtype A ASLV envelope gly-
coprotein (EnvA) becomes competent to mediate low-pH–de-
pendent membrane fusion only after binding to the avian tumor
virus receptor A (TVA receptor) (22, 23). Both isoforms of
this receptor, the transmembrane (TVA950) and GPI-anchored
(TVA800) proteins (24), support ASLV fusion but appear to
direct the virus entry through different endocytic routes (13, 14).
To determine the timing and the strength of the pH trigger that
activates the receptor-primed ASLV entering through different
routes, we imaged fusion of triple-labeled pseudoviruses into cells
expressing either TVA800 or TVA950. Viruses were prebound to
cells under cold conditions, and their entry was initiated by raising
the temperature. ASLV internalization and delivery into acidic
endosomes resulted in diminution of the eYFP signal and con-
comitant increase of the mTFP1 ﬂuorescence (Fig. 2). These
changes could be seen readily as a white-to-purple shift in the virus
color (Fig. 2, a–b transitions). For most virions, endosomal pH
dropped fairly quickly (<20 s) and usually stabilized around pH 6.0
(Fig. 2 B and C and Fig. S2).
Low-pH–dependent ASLV fusion was detected based on the
loss of the viral content marker, nucleocapsid-mKate2, a product
of the MLV Gag-mKate2 cleavage occurring upon virus matura-
tion (Fig. 2) (25). We found that ∼20% of triple-labeled particles
fused with acidic endosomes, as evidenced by the quick loss of the
mKate2 signal following the pH drop (Fig. 2, b–c transitions). In
contrast to eYFP, the more acid-resistant mTFP1 signal persisted
under acidic conditions and thus continued to mark the viral
membrane after fusion took place. Similar acidiﬁcation and fusion
patterns were observed in cells expressing TVA950 and TVA800
(Fig. 2 B and C). Fusion was not detected in control experiments
performed in the presence of a fully inhibitory dose (0.1 mg/mL) of
the ASLV EnvA-derived R99 peptide (26). Thus we were able to
measure the pH dynamics in virus-carrying endosomes and detect
ASLV fusion in the same experiment.
Endosome Acidity and pH-Dependence of ASLV Fusion Are Not Affected
by TVA Isoforms. Analysis of the changes in ﬂuorescence of the
virus-borne pH-sensor showed that acidity of individual endo-
somes was fairly stable over time (Fig. S2). We did not detect
further acidiﬁcation of lumen for as long as we could reliably
measure the pH (usually up to 20 min, at which point most viruses
entered the autoﬂuorescent perinuclear area). Steady luminal pH
aided more precise determination of this parameter for each
vesicle by averaging the mTFP1/eYFP ratio signal (Fig. 2 B andC).
The time-averaged values of pH in virus-carrying endosomes were
broadly distributed (Fig. 3A, circles), and its mean value before
fusion was independent of the receptor isoform: 5.98 ± 0.16 (n =
39) for TVA800 and 5.99 ± 0.14 (n = 57) for TVA950 cells (Fig.
3A, diamonds). The fraction of fusion events as a function of pH
was distributed normally, with most events occurring between pH
5.8 and 6.1 (Fig. 3B, black and open bars).
Fig. 1. Construction of pH-sensing ASLV particles
and pHmeasurements. (A) Drawings of triple-labeled
ASLV viruses bearing a pH-sensor in their membranes
at different pH. The sensor consisted of a CFP (mTFP1)
attached to an eYFP by a short linker (shown re-
spectively as colored cylinders or boxes on the en-
larged diagram), which was in turn fused to the N
terminus of the ICAM-1 transmembrane domain. The
virus interior was labeled with the MLV Gag-mKate2
(red dots). (Left) At basic pH, mTFP1 is poorly ﬂuo-
rescent because of FRET, which is manifested in in-
tense sensitized eYFP emission. (Right) In an acidic
environment, eYFP ﬂuorescence is quenched (gray
cylinders or boxes), and FRET is disrupted, leading
to an increase in the mTFP1 signal. (B) The pH-de-
pendent spectral shift in the tandem protein emis-
sion. ASLV pseudoviruses colabeled with mTFP1-
eYFP-ICAM andGag-mKate2were allowed to adhere
to poly-L-lysine–coated coverslips andwere imaged at
room temperature in citrate/phosphate buffers ad-
justed to different pH values. Representative micro-
graphs takenatneutral pH (Left) and acidic pH (Right)
are shown alongwith the coloring chart. ThemKate2
ﬂuorescence is not included for visual clarity. (C) The
mTFP1-eYFP-ICAM emission spectra as a function of
pH. (D) The calibration curve obtained by plotting the
average ratio of the mTFP1 and eYFP signals from all
viruses in the image ﬁeld at different pH.
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The reduced number of fusion events at more acidic pH (Fig.
3B) apparently was caused by the lower abundance of virus car-
riers with luminal pH below 5.8. This notion was veriﬁed by
measuring the pH distribution around triple-labeled particles that
entered acidic compartments but failed to fuse (Fig. 3B): Only
a minor fraction of fusion-incompetent viruses were exposed to
pH <5.8. On the other hand, the low occurrence of fusion events
relative to the virus delivery into less acidic compartments (pH
>6.2) likely reﬂects suboptimal activation of receptor-primed
EnvA. This result is in agreement with the pH threshold of ∼6.2
obtained from ensemble measurements of ASLV fusion (27) and
from ASLV EnvA-mediated cell–cell fusion (28).
The mean pH in endosomes carrying nonfusogenic viruses was
6.10 ± 0.19 (n = 46) and 6.10 ± 0.22 (n = 43) in TVA800 and
TVA950 cells, respectively. These values were signiﬁcantly higher
(P < 0.022) than the average pH in endosomes transporting fu-
sion-competent viruses. Assuming that all endocytosed virions are
fusion competent, one can estimate the pH-dependence of fusion
by normalizing the number of viral content release events to the
number of internalized particles (from Fig. 3B) across the pH
range. ASLV fusion with TVA800 and TVA950 cells exhibited
similar pH-dependence (Fig. 3C), indicating that both receptor
isoforms efﬁciently primed EnvA for low-pH–induced fusion. The
obtained pH-dependence of ASLV–endosome fusion appeared
less steep than for EnvA-mediated cell–cell fusion, which reached
the maximal level below pH 5.7 (28; see also ref. 27).
ASLV Enters and Fuses with Distinct Populations of Endosomes. Vi-
sual inspection of fusion events showed that a fraction of viruses
entered acidic endosomes and released their content without
undergoing considerable displacement from their initial position
on the cell surface (Fig. 2B). In contrast, other particles moved
quickly before being exposed to low pH and undergoing fusion.
Because endosome acidiﬁcation is coupled to their retrograde
trafﬁcking (29), we explored the relationship between endosome
motility and luminal pH. Viruses/endosomes that moved faster
than an arbitrary threshold (set at 0.5 μm/s) for at least two
consecutive frames before or at the time of fusion were regarded
as “fast” (Fig. 3D and Fig. S3). This relatively fast and directional
movement is typical for trafﬁcking along microtubules (10).
Particles that did not reach the threshold velocity were desig-
nated “slow” In both cell lines, rapid movement correlated with
acidiﬁcation and usually occurred within 1 min from the pH drop
(Fig. S3C). Interestingly, the average pH was signiﬁcantly higher
in slow endosomes than in fast compartments. Fast and slow
endosomes in TVA800 cells exhibited average pH values of 6.04 ±
0.16 (n= 20) and 5.92± 0.15 (n= 19), respectively (P= 0.022) (Fig.
3A, squares). Likewise, slow endosomes in TVA950 cells were
less acidic than fast endosomes: 6.02 ± 0.15 (n = 35) vs. 5.93 ±
0.13 (n = 14) (P = 0.048). The differences in average pH and
different motion patterns of fast and slow endosomes suggest
these endosomes are distinct, perhaps corresponding to quickly
and slowly maturing pools of vesicles, respectively (9).
Velocity analysis for all triple-labeled particles, irrespective of
whether they underwent fusion, revealed that the number of
internalized ASLV was divided nearly evenly between fast and
slow endosomes in both TVA800 and TVA950 cells. However,
although the number of fusion events in TVA800 cells also was
equally distributed between the two populations of endosomes,
ASLV fused less frequently with fast endosomes in TVA950 cells
(Fig. 3E). If fusing and nonfusing viruses are sorted similarly by
TVA950 cells, the less frequent fusion with fast endosomes
Fig. 2. Measuring the pH drop in ASLV-carrying
endosomes and virus–endosome fusion. (A) Diagram of
ASLV colabeled with mTFP1-eYFP-ICAM and Gag-
mKate2 (a) and of the color changes associated with
virus entry into acidic endosomes (b) and fusion (c). (B
and C) Triple-labeledASLV pseudoviruses (appearing as
white puncta) were prebound to CV-1 cells expressing
either TVA950 (B) or TVA800 (C) in the cold, and fusion
was initiated by shifting to 37 °C. The mTFP1 ﬂuores-
cence is shown in blue, the sensitized eYFP emission in
green, and the mKate2 signal in red. Image panels
represent consecutive snapshots of viruses before in-
ternalization (marked “a”), immediately after entry in-
to acidic endosomes (purple puncta, “b”), and after
fusion, which results in the release of mKate2 (blue
puncta, “c”). White dashed lines in images B and C
outline the cell nucleus. The lower left panels in B and C
show the particle’s trajectory pseudocolored according
to the time from the onset of the experiment (see
corresponding Movies S1 and S2). The graphs show
the ﬂuorescence intensities of viral markers as a func-
tion of time obtained by single-particle tracking using
the mTFP1 channel. Endosomal pH (gray dots) and
smoothed pH data (black lines) are shown also. Vertical
gray dashed lines illustrate the lag time between acidi-
ﬁcation and fusion.
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would indicate that these compartments are less permissive of
fusion than slow endosomes.
To compare the fusion-permissiveness of fast and slow com-
partments, we assessed the effective sizes of fusion pores formed
by ASLV EnvA. Larger initial fusion pores usually correlate with
a more robust fusion process, consistent with the higher proba-
bility of ASLV fusion and faster release of the viral content (a
measure of the pore diameter) in TVA950 as compared with
TVA800 cells (7). We found that the decay of the mKate2 signal
as a result of fusion with TVA950 cells was faster than for
TVA800 cells (Fig. 3F). Thus, pores formed through the GPI-
anchored receptor were smaller, because they restricted the ef-
ﬂux of mKate2 from virions. The fact that larger, more robust
fusion pores were observed in mobile endosomes of TVA950
cells (Fig. 3F) argues against the possibility that these endosomes
are less permissive to fusion than stationary compartments.
Quickly Moving Endosomes Support Faster ASLV Fusion than Less
Mobile Compartments. Measurements of the lag times from shift-
ing to 37 °C to individual acidiﬁcation events showed that ASLV
entered acidic compartments in TVA950 cells earlier than in
TVA800 cells (Fig. S3D). This result was expected, based on our
previous ﬁndings that TVA800 internalized ASLV more slowly
than the transmembrane receptor (7, 14). In TVA800 cells, endo-
some acidiﬁcation occurred with the same time course, irrespective
of their motion pattern, whereas in TVA950 cells the lumen of fast
endosomes became acidic at earlier times than in slow compart-
ments (P = 0.023).
We next determined the true kinetics of acid-mediated ASLV
fusion with different endosomes by measuring the interval be-
tween the pH drop below pH 6.3 (Fig. 3C) and the onset of
mKate2 release, as illustrated in Fig. 2 B and C (vertical dashed
lines). The lag times to fusion with fast endosomes in both
TVA800 and TVA950 cells were considerably shorter than with
their respective slow endosomes (P = 0.012 and 0.001, re-
spectively) (Fig. 4A). In other words, the virus’ ability to undergo
quick fusion correlated with accelerated/directional movement
of carrier endosomes. In addition, fusion with mobile endosomes
was faster in TVA950 than in TVA800 cells (P = 0.012), whereas
the fusion rates with slow endosomes in the two cell lines were not
signiﬁcantly different (P = 0.151). These shorter lags to ASLV
fusion in fast endosomes in TVA950 cells are inconsistent with the
possibility that these compartments are less permissive to fusion
than slow endosomes.
Accelerated fusion with fast endosomes could be driven, at
least in part, by their lower luminal pH compared with slow
endosomes (Fig. 3A). However, the differences in the mean pH in
dynamic and stationary endosomes in TVA950 cells were of only
borderline signiﬁcance (Fig. 3A). More importantly, the waiting
times to fusion did not correlate strictly with luminal pH (Fig.
4B). For both TVA950 and TVA800 cells, lag times to fusion
exhibited relatively weak dependences on endosomal pH with
Fig. 3. Distribution of endosomal pH and pH-de-
pendence of ASLV fusion. (A) Distributions of pH in
virus-carrying endosomes in TVA800andTVA950 cells
from 10 independent experiments performed for
each cell line. Mean pH values (diamonds) and scat-
terplots of individual pH values (circles) are shown.
Also shown are the mean pH (squares) and scatter-
plots for mobile (“fast”) and less mobile (“slow”)
subpopulations of endosomes. Error bars indicate
SDs. (B) pH histograms for nonfusing (hatched and
gray bars) and fusing particles (black and open bars).
Solid and dashed lines are Gaussian ﬁts to data for
TVA800 and TVA950 cells, respectively; curve ﬁts for
fusion events are shown by black lines and for non-
fusing particles by gray lines. (C) The pH-dependence
of ASLV fusion with endosomes is shown as the ratio
of fused vs. inactiveparticles for TVA800 (black circles)
and TVA950 (open circles) cells. (D) Velocities as
a function of time are shown for 20 representative
fusion-competent virions in TVA950 cells before fu-
sion. Velocities below 0.5 μm/s (marked by a thick
dashed line) deﬁne slow endosomes. (E) Relative
frequencies of ASLV fusionwith fast (black segments)
and slow (open segments) endosomes of TVA800 and
TVA950 cells. (F) Decay times for the viral content
(mKate2) signal upon ASLV fusion. Twenty individual
ﬂuorescence traces for fast (open triangles) and slow
endosomes (open circles) in TVA950 cells and for fast
(black triangles) and slow (black circles) endosomes in
TVA800 cellswere averaged andplotted as a function
of time. Error bars indicate SEM. The corresponding
single exponential ﬁts are shown by solid lines. Pores
were signiﬁcantly larger in fast TVA950 endosomes
than in fast TVA800 endosomes (P = 0.001) or in slow
TVA950 endosomes (P = 0.032).
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a greater scatter observed at pH above 5.95. This pattern sug-
gests that, although low pH triggers fusion, other factors, such
as heterogeneity of viruses and of endosomal membranes, can
modulate postacidiﬁcation steps of this process. It appears that
endosomal compartments in TVA950 cells, but not in TVA800
cells, support the formation of a relatively long-lived (∼1 min)
hemifusion intermediate (7). The existence of such an in-
termediate is consistent with delays between acidiﬁcation and
content release (full fusion) observed in this work (Fig. 4).
Together, our ﬁndings are in line with the idea that endosomes
exhibiting distinct motion patterns vary in their propensity to
support ASLV fusion.
Because dynamic endosomes support faster ASLV and faster
release of the viral content in TVA950 than in TVA800 cells, it is
unlikely that dynamic compartments disfavor ASLV fusion. We
therefore reinterpreted the apparent probability of fusion obtained
by comparing the frequencies of fusing and nonfusing particles
across the pH range (Fig. 3E). It appears that, although nonfusing
particles are distributed evenly between the two populations of
endosomes, fusion-competent virions are sorted preferentially to
slow endosomes in TVA950 cells. Although fewer virions enter
fast endosomes, these compartments appear to support ASLV
fusion optimally.
Discussion
In this study, retroviruses tagged with a genetically encoded pH-
sensor and a ﬂuorescent content marker enabled simultaneous
measurements of the pH drop within virus-carrying vesicles and
the resulting virus–endosome fusion. From several FRET-based
sensors designed to measure endosomal pH (16, 30–32), we used
a derivative of pHlameleon (16) incorporated into the viral
membrane. Unlike other approaches, this strategy avoided chem-
ical modiﬁcations of the virus, which could compromise its ability
to undergo fusion. The ICAM-1–anchored pH sensors can be in-
corporated into retroviral particles pseudotyped with other viral
fusion proteins (11) and thus may be used for studies of entry of
other enveloped viruses.
The main limitation of single virus-based pH measurements is
the relatively weak signal from the tandem ﬂuorescent protein.
Although this sensor allowed pH measurements around single
viruses down to ∼5.2 in vitro (Fig. 1D), the ability to determine
the pH reliably in late endosomes was limited by cell auto-
ﬂuorescence. This problem can be alleviated by incorporating
a larger number of pHlameleon-based sensors into the viral
membrane and/or by implementing alternative labeling strate-
gies (32). Further improvements in sensitivity and temporal
resolution of pH measurements could shed light on biogenesis of
acidic compartments. The initial pH drop to ∼6.0 followed by
a stationary phase (Fig. 2 and Fig. S2) appears surprising, con-
sidering that endosome maturation is thought to be coupled to
gradual acidiﬁcation. However, to our knowledge, pH meas-
urements in a single maturing endosome have not been reported
(perhaps with the exception of refs. 9 and 10). Ensemble
measurements of endosomal pH are not likely to resolve the pH
proﬁle observed here for single endosomes.
Simultaneous measurements of endosomal pH and the release
of viral content into the cytosol afford a unique opportunity to
deﬁne the relationship between the strength of the fusion trigger
and the rate and efﬁciency of this process. A weak correlation
between endosomal pH and the lag before fusion (Fig. 4B)
implies that additional factors, such as the property of endo-
somal membranes, can modulate the fusion reaction. Indeed, the
ASLV fusion pores were larger (Fig. 3F) and the lag times to
fusion were shorter (Fig. 4A) in dynamic endosomes than in slow
endosomes of TVA950 cells. In contrast, nascent fusion pores
formed in either fast or slow endosomes of TVA800 cells were
not statistically different. A possible explanation is that, because
the GPI-anchored receptor internalizes the virus through a raft-
dependent pathway (14), particles trafﬁcked to distinct com-
partments may remain associated with raft-like subdomains that
are equally permissive to fusion.
Paradoxically, quick and robust ASLV fusion with fast endo-
somes in TVA950 cells (Figs. 3F and 4A) was observed relatively
infrequently as comparedwith respective compartments inTVA800
cells (Fig. 3E). This difference could result from differential sorting
of fusion-competent and -incompetent particles in TVA950 cells. If
fusogenic particles incorporate more Env glycoproteins than fu-
sion-incompetent ones, they could induce stronger signaling and
be sorted into a different endosome population than inactive
particles. The lack of selective sorting (and perhaps signaling) of
ASLV in TVA800 cells is consistent with its slow uptake occur-
ring at the rate of receptor-independent endocytosis in parental
CV-1 cells (7).
The possibility of selective sorting of fusion-competent, but not
inactive, ASLV into a subset of endosomes makes it difﬁcult to
evaluate the fusion efﬁciency simply by normalizing the number of
fusion events to the total number of internalizedparticles. Thus it is
possible that the real pH-dependence of ASLV–endosome fusion
is steeper than shown in Fig. 3C and is similar to EnvA-mediated
cell–cell fusion (28). The apparently selective ASLV entry into
slow endosomes in TVA950 cells is in contrast to sorting of the
inﬂuenza virus to mobile, quickly maturing endosomes (9). These
differences likely reﬂect the markedly lower pH optimum for in-
ﬂuenza fusion (pH 4.8–5.2) (33) compared with ASLV fusion (pH
∼5.5) (27, 28). Entry into quickly maturing endosomes likely
ensures faster delivery of inﬂuenza viruses into sufﬁciently acidic
compartments.
Accumulating evidence supports the notion that TVA950 and
TVA800 direct the ASLV entry through distinct routes (13, 14).
It currently is not known whether ASLV fuses with early endo-
somes in both cell lines; such fusion would suggest quick con-
vergence of different endocytic routes to early endosomes where
fusion takes place shortly after acidiﬁcation. Future studies with
cells expressing speciﬁc markers of early and late endosomes,
Rab5 and Rab7, should provide further insights into ASLV-
trafﬁcking pathways and reveal the identity of endosomes sup-
porting the fusion reaction.
Methods
Cell Lines, Plasmids, and Virus Preparation. Cell lines and reagents used in this
study, as well as pseudovirus production protocols, have been described
before (7, 8, 12). For details, see SI Methods.
Calibration of a Nano-pH-Meter. MLV-based pseudoparticles carrying ASLV
EnvA were colabeled with Gag-mKate2 (content marker) and mTFP1-eYFP-
ICAM (membrane marker). Viruses were adhered to poly-L-lysine–coated
Fig. 4. Kinetics of low-pH–triggered ASLV fusion with fast and slow endo-
somes. (A) The time intervals between the pH drop below 6.3 and the onset
of mKate2 release were determined for fusion events in TVA800 (ﬁlled
symbols) and TVA950 (open symbols) cells and were plotted separately for
fast and slow endosomes (triangles and circles, respectively). (B) Correlation
between endosomal pH and the delay between acidiﬁcation and fusion for
TVA800 (ﬁlled circles) and TVA950 (open circles) cells. Solid and dashed lines
are linear regressions for TVA800 and TVA950 data, respectively.
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eight-well coverslips (Nunc) and visualized using a Zeiss LSM780 confocal
microscope (Carl Zeiss Microsystems). To relate changes in the mTFP1/YFP-
sensitized emission to extraviral pH, viruses were exposed to a set of citrate/
phosphate buffers between pH 4.3 and 7.3 and were imaged using a 63×/
1.4 NA oil immersion objective. Fluorophores were excited with the 458-nm
line of an argon laser, and emission spectra between 468 and 600 nm were
acquired with a 32-channel GaAsP detector in the spectral mode. To mini-
mize the effect of photobleaching, the calibration curve was obtained from
nine separate experiments, each using a buffer of different acidity. The
ﬂuorescence ratios used for the calibration curve were obtained by sum-
ming the intensity of spectral images between 468–503 nm for the mTFP1
emission and 512–547 nm for the sensitized eYFP emission. This conﬁgu-
ration was preserved when carrying out measurements in live cells using
the same GaAsP detector. The ﬂuorescence signal from all viruses in the
image ﬁeld (usually around 100 particles) was integrated and plotted as
a function of wavelength. Background subtraction and a low-pass ﬁlter
were applied on all spectral images using ImageJ (National Institutes
of Health). The experimental points were ﬁtted, as described in ref. 16,
yielding the apparent pKa 5.95.
Imaging Virus Entry into Acidic Compartments and Fusion. CV-1 cells expressing
eitherTVA950orTVA800weregrowntonearconﬂuencyonglass-bottomed35-
mmPetridishes (MatTek) inphenol red-freemedium.Disheswereplacedon ice,
washed with cold HBSS, and centrifuged with ∼1.5 × 104 IU of pseudoviruses
colabeled with mTFP1-eYFP-ICAM and Gag-mKate2 at 2,100 × g (4 °C) for 20
min. Unboundviruseswere removedbywashing, and cellsweremounted onto
a microscope stage maintained at 37 °C. Virus internalization and fusion were
imaged using a Zeiss LSM 780 confocal microscope with a 63×/1.4 NA oil im-
mersion objective. mTFP1 andmKate2 were excited with the 458- and 561-nm
laser lines, respectively. Fluorescence emission was detected with the 32-
channel spectral detector. Theﬁrst 16 channels recorded themTFP1 signal, and
the remaining 16 channels acquired the sensitized eYFP emission signal. The
mKate2 ﬂuorescence was detected using a cooled photomultiplier tube.
Images were acquired for 35–40 min approximately every 8 s.
Single-virus tracking was performed with Imaris (BitPlane) or Volocity
(Perkin-Elmer). Changes in the average ﬂuorescence ratio of mTFP1 ﬂuores-
cence and of sensitized eYFP emission from internalized viruses were con-
verted to pH units using the calibration curve. Virus-carrying endosomes were
considered quickly moving (“fast”) if (i) the particle’s velocity exceeded
0.5 μm/s for at least three consecutive frames before virus fusion and (ii) in-
creased velocity was associated with directional movement toward the nu-
cleus. The endosomal pH distributions were compared using the two-tailed
Student t test, and distributions of waiting times for fusion were compared
using the Mann–Whitney rank sum test.
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SI Methods
Cell Lines and Plasmids. HEK293T/17 cells were obtained from the
AmericanTypeCultureCollection.CV-1 cells stably expressing the
avian tumor virus receptor A (TVA) receptor isoforms TVA800 or
TVA950 have been described previously (1). CV-1–derived cells
were grown in DMEM (Cellgro) supplemented with 10% (vol/vol)
Cosmic Calf Serum (HyClone Laboratories) and 100 U penicillin-
streptomycin (Gemini Bio-Products). HEK 293T/17 cells were
cultured in high-glucose DMEM supplemented with 10% FBS
(HyClone Laboratories), 100 U penicillin/streptomycin, and 0.5
mg/mL G418 sulfate (Cellgro). Vectors expressing murine leuke-
mia virus (MLV) Gag-Pol, Gag-GFP, and MLV LTR lacZ were
a gift from W. Mothes (Yale University, New Haven, CT). The
avian sarcoma and leukosis virus (ASLV)-A envelope glycoprotein
lacking cytoplasmic tail (EnvAΔCT) and MLV Gag-mKate2
plasmids have been described previously (2, 3).
Construction of mTFP1-ICAM and mTFP1-eYFP-ICAM was
done as follows. The mTFP1 gene fragment was ampliﬁed using
KODXtremeDNApolymerase (Novagen), mTFP1-eYFP plasmid
(a gift fromMaïté Coppey-Moisan, Université Paris Diderot, Paris)
(4) as a template, and the forward and reverse primers 5′-
TAAGCTTCTCGAG GTGAGCAAGGGCGAGGAGACCAC-
3′ and 5′-TGAATTCTTCTTGTACAGCTCGTCCATGCCGTC-
3′, respectively. The ampliﬁed fragment was inserted into
pCR4blunt-topo vector using a TOPO cloning kit (Invitrogen).
After verifying the sequence, the mTFP1 gene was puriﬁed and li-
gated into EcpH-TM vector by replacing the EcpH gene with
mTFP1 using HindIII and EcoRI restriction enzyme sites (corre-
sponding to the italicized regions in primers). Cloning of the
mTFP1-EYFP fragment into the EcpH-TM vector was done es-
sentially as described above, except that the reverse primer 5′-
TGAATTCTT CTTGTACAGCTCGTCCATGCCGAGAGTG-3′
was used for the ampliﬁcation of the mTFP1-EYFP fragment
by PCR.
Virus Production. ASLV EnvA-pseudotyped ﬂuorescent viruses
bearingmTFP1-ICAMormTFP1-eYFP-ICAMon the surface and
Gag-mKate2 as a content marker were produced as follows. ASLV
EnvAΔCT (3 μg), MLVGag-Pol (2 μg), pMLV-LTR-LacZ (3 μg),
MLVGag-mKate2 (1.2 μg), and mTFP1-ICAM or mTFP1-eYFP-
ICAM (3 μg) expression plasmids were mixed with 300 μL of
DMEM and 122 μL of Polyfect (Qiagen). The mixture was in-
cubated for 10 min at room temperature, diluted to 1 mL with
DMEM containing 10% FBS, and added onto HEK 293T cells
grown to ∼60% conﬂuency in a 100-mm dish. Twelve hours after
transfection, the medium was replaced with 6 mL of fresh warm
DMEM/10% FBS without phenol red. The plate was incubated
further for 34 h at 37 °C. The culture supernatant was collected,
passed through a 0.45-μm ﬁlter, aliquoted, and stored at −80 °C.
The virus titer was determined by the β-gal assay using TVA800
cells, as described previously (5).
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Fig. S1. Fluorescence lifetime imaging microscopy (FLIM) of FRET in the mTFP1-eYFP-ICAM sensor. FLIM measurements were performed using a Zeiss LSM780
confocal microscope equipped with an HPM-100–40 hybrid detector from Becker &. Time-correlated single-photon counting was performed using an SPC-830
(Becker & Hickl) acquisition card. A 63×/1.4 NA oil immersion objective was used for all measurements. Samples were excited with a Picosecond Laser Diode
Head (Becker & Hickl) tuned at 440 nm with the repetition frequency of 80 MHz. (A) ASLV pseudoviruses colabeled with Gag-mKate2 and mTFP1-ICAM-1
(donor alone) or mTFP1-eYFP-ICAM-1 (tandem ﬂuorescent protein) were allowed to adhere to poly-L-lysine–coated coverslips and were imaged at room
temperature in Hanks’ buffer. The average lifetime of mTFP1-ICAM-1 for the virus population was 2.4 ± 0.3 ns (Upper). The average lifetime of mTFP1 for
pseudoviruses bearing mTFP1-eYFP-ICAM-1 was shortened to 1.9 ± 0.3 ns because of FRET between mTFP1 (donor) and eYFP (acceptor) (Lower). (B) Decay of
the mTFP1 ﬂuorescence of a single virus labeled with mTFP1-ICAM-1 (blue trace) and of a virus labeled with tandem protein (green trace) conﬁrms FRET
between donor and acceptor. (C) Analysis of the average lifetimes for multiple viruses in the image ﬁeld. A clear blue shift of the mTFP1-eYFP-ICAM-1 lifetime
at neutral pH shows efﬁcient FRET.
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Fig. S2. ASLV entry into acidic endosomeswithout fusion. (A) Consecutive images of a representative pseudovirus (circled) colabeledwithmTFP1-eYFP-ICAM (blue
and green) and Gag-mKate2 (red) as it enters an acidic endosome (seen as transition fromwhite to purple). (Scale bar, 5 μm.) (B) Mean ﬂuorescence intensities of all
three ﬂuorophores are shown with respectively colored lines along with the calculated endosomal pH (gray circles and black line).
Fig. S3. Acidiﬁcation and motility analyses for representative particles fusing with TVA950 and TVA800 cells. (A and B) The pH changes (green dots) and the
mKate2 ﬂuorescence proﬁle for particles fusing with TVA950 (A) and TVA800 (B) cells. An additional axis on the right depicts particle velocity. Green solid lines
are the running averages of raw pH data. Note the postfusion acceleration of an endosome in a TVA950 cell (A, blue line), which contrasts with the quick
trafﬁcking of in a TVA800 cell (B). Thick dashed lines show the arbitrary threshold that separates slow-moving particles (speed <0.5 μm/s) from fast particles.
Fusion with a TVA800, but not with a TVA950 cell, is preceded by an increase in velocity above the threshold level for several consecutive image frames.
Snapshots of sequential acidiﬁcation and fusion steps are shown below the respective graphs. (Scale bar, 5 μm.) (C) Histograms of lag times between acidi-
ﬁcation and acceleration above 0.5 μm/s for TVA800 (black bars) and TVA950 (open bars) cells. The less mobile particles traveling in “slow” endosomes are
grouped, and their number is shown on the right. (D) Kinetics of endosome acidiﬁcation in TVA800 (black symbols) and TVA950 (open symbols) cells. The lag
times from the temperature increase to the drop in pH were measured, ranked, and plotted as cumulative distributions for slow- (circles) and fast-moving
(triangles) endosomes. Pooled data for fusing and nonfusing viruses are shown.
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Movie S1. Visualization of ASLV entry into acidic endosomes and fusion with TVA950 cells. ASLV pseudoviruses colabeled with mTFP1-eYFP-ICAM (colored
blue and green, respectively) and Gag-mKate2 (red) were prebound to CV-1 cells expressing TVA950 in the cold, and fusion was initiated by shifting to 37 °C.
The circled virus enters into an acidic endosome, as seen by the color shift from white to purple caused by eYFP quenching, and then undergoes fusion (seen as
purple-to-blue transition). The movie is played at 5 frames/s. See also corresponding Fig. 2B.
Movie S1
Movie S2. Visualization of ASLV entry into acidic endosomes and fusion with TVA800 cells. ASLV pseudoviruses colabeled with mTFP1-eYFP-ICAM (colored
blue and green, respectively) and Gag-mKate2 (red) were prebound to CV-1 cells expressing TVA800 in the cold, and fusion was initiated by shifting to 37 °C.
The circled virus enters into an acidic endosome, as seen by the color shift from white to purple caused by eYFP quenching, and then undergoes fusion (purple-
to-blue transition). The movie is played at ﬁve frames/s. See also corresponding Fig. 2C.
Movie S2
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This Thesis gathered different points of view regarding enveloped viruses 
attachment, fusion and entry steps of their lifecycles. Throughout this work, we 
diversified our objects of study from simple peptides, to glycoproteins, to whole 
viruses and cells. Moreover, we took advantage of membrane model systems from 
lipid vesicles to supported lipid bilayers. In terms of main techniques, we focused 
on optical based biophysical techniques, namely fluorescent spectroscopy, confocal 
microscopy and surface plasmon resonance. All of this came together and allowed 
us to achieved the following: i) establishment of the membranotropism towards 
lipid raft-like domains as a factor that influences the action of HIV-1 fusion 
inhibitor peptides; ii) elucidation that sequence type, size and sulfation pattern are 
determinants of HIV-1 gp120 interaction with glycosaminoglycans; iii) 
recognition of the importance of anionic lipids as an essential host factor that 
modulates the fusion of VSV; and iv) clarification on the entry pathways of ASLV 
via quantitative imaging of endosomal pH and fusion. 
HIV-1 fusion inhibitor peptides constitute a relatively recent family of 
antiviral drugs, with enfuvirtide being the only one in the market. However, 
emergence of viral strains resistant to enfuvirtide [189-191] urged the development 
and trials of new drugs of this type. As described in the Introduction section, many 
experimental peptide fusion inhibitors were developed with different rational 
designs behind them. Some required sequence modifications to overcome 
resistance, to increase helical content, stability or solubility while others have 
conjugated the peptides with other proteins and lipophilic moieties [192,193] 
[Book Chapter A]. We were able to study different generations of HIV-1 fusion 
inhibitor peptides, from the only one approved, enfuvirtide, to T-1249, sifuvirtide, 
C34 and C34-cholesterol. The final target for these peptides is the extended 
conformation of gp41, when it is bridging the cellular and viral membranes before 
their fusion. This target is only exposed transiently and confined in a limited space 
between the membranes. As such, we proposed that fusion inhibitor peptides 
binding to the surrounding cell and viral membranes to constitute an intermediate 
step on their mechanism of action. The concentration of peptide in the cell and 
viral membranes would make the peptide more available to bind gp41 near the 
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possible sites of fusion, potentiating its antiviral activity. In our studies, we 
observed that the mentioned peptides had different affinities towards membranes 
and that it was dependent on the lipid compositions used, for the case of model 
membranes. 
Enfuvirtide and T-1249 partition was first studied in model membranes. T-
1249 was able to adsorb to cholesterol rich lipid vesicles, contrary to enfuvirtide 
[69,81]. In our work with model membranes, we observed that C34-cholesterol 
had notorious partition towards cholesterol-rich and cholesterol/SM mixtures 
mimicking lipid rafts. The development of the assays for evaluating the binding to 
cell membranes by the potential sensitive probe di-8-ANEPPS, allowed the 
translation of these evaluations from model membranes to cells. The results for cell 
membrane binding were elucidative enough to establish an increasing degree of 
membranotropism that correlated with their antiviral potency, for the following 
peptides: enfuvirtide < T-1249 < C34-cholesterol. The same sequence also applies 
for partitions to lipid raft mimicking model membranes (Table 2). 
Table 2 – Summary of the relative antiviral potencies and membrane 
partition or binding for the studied HIV-1 fusion inhibitor peptides. 
Peptides Enfuvirtide T-1249 C34-cholesterol 
Sifuvirtide 
C34 
Antiviral potency + ++ +++ ++ 
Partition to raft-
mimicking model 
membranes 
+ ++ +++ 
Specific for rigid PC 
(DPPC) 
++ 
Binding to cell 
membranes + ++ +++ Low 
 
The case of sifuvirtide proved to be particular. Despite being of a later 
generation and more potent than enfuvirtide [53,55], it was found that it had 
residual partition towards fluid phase POPC vesicles, but was highly specific 
towards rigid phosphatidylcholines, mainly DPPC [84,85]. In terms of cell 
membranotropism, we observed some degree of binding, but lower than 
enfuvirtide. Rigid domains are also a characteristic of lipid rafts, and hence one 
can assume that sifuvirtide screens very specifically for such domains, despite its 
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overall partition towards cholesterol and sphingomyelin-rich membranes being 
low [84,85]. As such, the intermediate step of lipid raft binding before gp41 
binding should also be present at some extent for sifuvirtide. However, the higher 
potency of sifuvirtide compared to enfuvirtide should rely more on the sequence 
optimization that allows more stable binding to gp41 NHR [53]. 
Overall, targeting lipid raft binding for fusion inhibitor peptides is an 
important factor to take into account in the mode of action and potency of these 
drugs. 
The search for better fusion inhibitor peptides is an ongoing effort and 
rational design has been of key importance to enhance the properties of these 
drugs at several levels. There are three major drawbacks in the clinical use of 
enfuvirtide, the only HIV fusion inhibitor currently approved: i) administration by 
injection, ii) appearance of resistance and iii) cost. The improvements in potency 
and stability of the peptides should allow less frequent injections, with lower doses, 
as already happens for sifuvirtide [53] and others [194,195]. Similarly, sequence 
modification in the peptide design taking into account known resistance patterns 
for enfuvirtide will delay viral resistance [196]. Moreover, the mutations that the 
virus has to develop in order to escape the later generation inhibitors can greatly 
reduce viral fitness and delay disease progression [197-200]. Regarding the 
financial burden of fusion inhibitors therapy, the development and large scale 
production of more peptide drugs should help bring the costs down. It is 
noteworthy that peptides are still cheaper to produce than antibodies. 
The future of viral fusion inhibitors also lies on alternative therapy uses, 
mainly in combination therapy and in microbicide topical formulations [192]. 
Currently, the antiviral therapy is highly dependent on combinations of different 
types of drugs, constituting the HAART regimen (highly active antiretroviral 
therapy) [201]. As such, therapy regimens with future fusion inhibitor peptides 
should involve some kind of combination with other entry inhibitors and/or other 
intracellular acting antivirals. This has already been proven to be beneficial, mostly 
in vitro [202-206]. The success of fusion inhibitors may also be achieved through 
their use in topical formulations to prevent new infections (microbicides). As 
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mentioned before, studies in vitro and in animal models have shown promising 
results for gels containing T-1249 [50-52], sifuvirtide [58] or C34-cholesterol [60]. 
This is particularly interesting in the case of T-1249, which clinical trials for use as 
injected antiretroviral have been put on hold due to formulation problems [49]. Its 
new use as microbicide revives the potential of this drug to succeed clinically. 
The potential for fusion inhibitor peptides also spans to other enveloped 
viruses that rely on the conserved mechanism of the viral fusion proteins hairpin 
folding. In fact, the derivation of peptides from the sequence of fusion proteins can 
constitute a robust framework to rapidly develop antivirals for emerging viral 
diseases. Examples of fusion inhibitors for influenza virus and paramyxoviruses, 
particularly the emerging Nipah and Hendra viruses [73,207], have already been 
given in the Introduction section. The case of development of entry inhibitors, 
either peptides or small molecules, for respiratory syncytial virus is interesting 
since in this particular case a inhalation route can be used to deliver the drug 
directly in the respiratory system [208,209]. Sequencing the fusion protein of new 
viruses can give the necessary information to synthesize potential peptide 
inhibitors against them. 
The fusion inhibitors development is a great example of drug design that used 
the accumulated knowledge of fundamental molecular biology and biochemistry 
research on virus entry mechanisms. In that sense, we also pursued a study to 
evaluate the glycosaminoglycans characteristics that were essential for binding to 
HIV-1 envelope protein gp120. The importance of the GAGs in viral pathogenesis 
was clarified in the introduction section, as essential attachment helpers to the cell 
surface. Interaction with gp120 was dependent on sequence type, with preference 
for heparin and heparan sulfate, with minimum extension of 16 monomers and 
highly dependent on sulfate groups. We also applied the SPR methodology in an 
uncommon way. Usually glycosaminoglycans, mainly heparin, used as a model, 
are immobilized on the surface via biotin-streptavidin link, which limits the types 
of GAG one can use. We managed to (at least qualitatively) evaluate protein-GAG 
binding using several GAG types. Protection strategies such as the attempt to 
shield charges in the proteins to be immobilized using counteracting charged small 
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molecules are also uncommon. These findings help to understand the 
requirements for viral attachment via glycosaminoglycans, a step previous to virus 
fusion and entry. The relevance of this interaction is demonstrated by the recently 
developed drugs that make use of the binding sites in gp120 for heparan sulfate 
and block them, the previously mentioned syndecan-Fc hybrid and a CD4-
mimetic peptide linked to heparan sulfate [105,106]. 
Besides receptors that allow the virus to enter and fuse with the host cell, we 
explored the role of host lipids in the promotion of fusion mediated by VSV G 
protein. Visualization of single pseudovirus fusion was achieved on supported 
lipid bilayers with defined lipid compositions. Hemifusion and content release 
were temporally distinguished and proved that a long-lived hemifusion 
intermediate can exist for VSV G. We focused on comparing the fusion efficiencies 
and kinetics in the presence of anionic lipids (POPS and BMP) and the 
zwitterionic POPC. Anionic lipids were required for full fusion processes and 
greatly enhance hemifusion efficiency compared to POPC. BMP, an endosome 
resident lipid, also presented a shorter lag time between hemifusion and content 
release. As such, VSV can start to hemifuse in early endosomes but complete its 
fusion in late endosomes upon encounter of BMP-rich compartments. We 
reproduced fusion with minimal components: the virus, a planar membrane and 
low pH. However, the low full fusion efficiencies obtained should mean that other 
factors are as important as the lipids studied, including the elusive receptor either 
at the cell surface or in an intracellular compartment. Just after the publication of 
our VSV fusion studies on Article E, a paper came out identifying the receptor of 
low-density lipoprotein as the receptor for VSV [131]. That study shows strong 
evidence that VSV binding, internalization and infection depends on the LDLR. 
However, it is still not clear if the receptor has a direct role on the fusion process 
itself. The use of supported lipid bilayer containing such receptor should help to 
characterize its influence on viral fusion kinetics. 
The methodology we used on this VSV study is very recent and allows to 
study in detail, at the single particle level, the effect of the lipids in the fusion. This 
method was only previously used to characterize the kinetics of influenza fusion 
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[182,185]. However, in these studies, they used the intraviral aqueous dye 
sulforhodamine B to observe content leakage. We actually observe labeled 
nucleocapsid proteins being released, which can implicate that we only detect pore 
sizes that are large enough for viral proteins to be released. The full potential of 
this technique is yet to be achieved. Reconstitution of recombinant cellular 
receptors in the supported lipid bilayer should enable the study of receptor-
dependent viruses and how the binding differ from lipid-only bilayers. Ultimately, 
this technique can be applied to study all enveloped viruses entry mechanisms and 
enable a fine control of the different parameters that modulate viral entry: pH, 
cellular receptors and membrane lipids. Consequently, this would also allow 
detailed mechanistic insights into the effects of entry inhibitors. 
Fluorescent based single-particle imaging was also used to follow the entry 
pathways of ASLV in cells. In this study, a novel methodological approach was 
developed as we incorporated a FRET pair of fluorescent proteins in the virus 
envelope to quantify the pH of the surrounding environment. The distinct pKa 
values of mTFP1 and eYFP allowed ratiometric imaging to be calibrated in actual 
pH values. Acidification to around pH 6 triggered viral core release shortly after, as 
measured by the disappearance of Gag-mKate2 signal. The single particle tracking 
revealed sorting of the viruses to distinct populations of early endosomes and that 
the TVA950 receptor isoform supported faster fusion than TVA800. 
The ability of following single viruses in their trajectory inside the cell 
provides valuable information regarding their lifecycle and mechanisms of 
invasion. This technique may be also of broad interest to other viruses, which 
entry pathways are yet to be clarified. However, these tracking techniques still 
require laborious manual work to ensure the validity of what is being observed. 
Development of more robust automated methods of acquisition and analysis 
would help these experiments to go mainstream. Moreover, as better and brighter 
fluorescent probes are developed, and super resolution microscopies becomes 
increasingly available, more detailed views of viral infection processes should be 
uncovered. 
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Future perspectives 
The studies presented here pave the way for novel approaches to understand 
viral entry and its inhibition. 
The attachment of a cholesterol moiety to C34 proved to be a successful 
strategy to improve antiviral potency. C34 is an analogue of sifuvirtide, as both 
lack a putative LBD that renders them less membranotropic. Despite the fact that 
sifuvirtide may have similar activity comparing to C34, depending on the strain 
[210], a possible sifuvirtide-cholesterol conjugation should also be beneficial. 
Structurally, sifuvirtide is more stable than C34, due to its rational design. 
Providing it with a lipid anchor may render a highly potent and specific new drug. 
The new anti-HIV peptides to be developed should also account for a recently 
established aspect of HIV-1 entry: it was proved that HIV can use an endocytic 
pathway to enter cells [36,37]. In this scenario, fusion inhibitors should be able to 
be internalized together with the virus to act inside the endosomes. Partitioning to 
membranes, especially for peptides possessing a lipid anchor, may help these drugs 
to be internalized as the membranes invaginates. Indeed, a recent study already 
pointed that this occurs in the case of influenza virus, upon testing a cholesterol-
conjugated anti-influenza peptide [43]. In this regard, single virus fusion imaging 
in cells can be a valuable tool to assess such specific endosome level inhibition. 
The membranotropism evaluation of drugs, either from peptides or small 
molecules, can be a valuable tool to assess drug delivery to the right target. If 
intracellular, the drug needs to be capable of interacting with the membrane and 
crossing it. If it is a cell surface protein, its concentration at the membrane level 
may also boost the action of the drug, as it is exemplified for the fusion inhibitors. 
Moreover, crossing cellular barriers such as epithelia, endothelia or the blood-
brain barrier should also benefit from membrane crossing properties. These assays 
of membrane partition and membrane interaction, with model membranes and 
cells can be applied to early drug development stages, in order to assure they have 
such properties [211]. 
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VSV has long been used as a model for viral entry and fusion studies. 
However, all the requirements necessary for its entry are yet to be understood. 
More studies are necessary in this regards, and the single virus fusion technique 
presented here can bring more information. More detailed fusion kinetics data 
with varying pH, with varying concentrations of BMP and other important lipids, 
such as cholesterol, SM and PE, can inform on limiting steps of viral fusion. 
Moreover, now that we know the LDL receptor mediates at least the 
internalization of the virus, the performing of these further studies evaluating also 
the effect of the presence or absence of the receptor should clarify the precise roles 
of LDLR and if other receptors may eventually be necessary. This would help to 
improve our knowledge on the behavior of class III fusion proteins, the latest type 
to be classified. 
Single virus imaging with cells allowed a finer dissection of viral entry 
pathways for several viruses, but several questions still remain. The properties of 
the different populations of endosomes in which ASLV are sorted into poses a new 
question for the cell biology field. More comprehensive co-localization studies 
with different markers of early and late endosomes, and even other known 
intracellular compartments, should inform on viral trafficking sites. Herpes virus, 
in certain cases, apparently needs a double stimulus for fusion, binding to a 
receptor and low pH, as ASLV [11-14]. Engineering fluorescent herpes virus for 
single virus tracking may elucidate if it shares this rare mechanism of entry with 
ASLV, despite having different classes of fusion proteins  
Increasing the fundamental knowledge of virus entry is a necessity in today’s 
world of emerging viral diseases. Targeting the proteins responsible for the initial 
steps of viral invasion should be an effective method to control infections. I hope 
this Thesis has helped to advance the knowledge in this area and contribute to the 
scientific community as a whole. 
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